



# Effective Health Care Program

---

Comparative Effectiveness Review  
Number 66

## Treatment Strategies for Women With Coronary Artery Disease



Agency for Healthcare Research and Quality  
Advancing Excellence in Health Care • [www.ahrq.gov](http://www.ahrq.gov)

# *Comparative Effectiveness Review*

---

Number 66

## **Treatment Strategies for Women With Coronary Artery Disease**

**Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
540 Gaither Road  
Rockville, MD 20850  
[www.ahrq.gov](http://www.ahrq.gov)

**Contract No. 290-2007-10066-I**

**Prepared by:**

Duke Evidence-based Practice Center  
Durham, NC

**Investigators:**

Rowena J. Dolor M.D., M.H.S., Principal Investigator  
Chiara Melloni, M.D., M.H.S., Clinical Investigator  
Ranee Chatterjee, M.D., M.P.H., Clinical Investigator  
Nancy M. Allen LaPointe, Pharm.D., Clinical Investigator  
Judson B. Williams Jr., M.D., Clinical Investigator  
Remy R. Coeytaux, M.D., Ph.D., EPC Investigator  
Amanda J. McBroom, Ph.D., EPC Project Manager  
Michael D. Musty, EPC Project Coordinator  
Liz Wing, M.A., EPC Editor  
Gregory P. Samsa, Ph.D., EPC Statistician  
Manesh R. Patel M.D., Principal Investigator

**AHRQ Publication No. 12-EHC070-EF**  
**August 2012**

This report is based on research conducted by the Duke Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10066-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials that are clearly noted in the document. Further reproduction of those copyrighted materials is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact [EffectiveHealthCare@ahrq.hhs.gov](mailto:EffectiveHealthCare@ahrq.hhs.gov).

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.
---

**Suggested Citation:** Dolor RJ, Melloni C, Chatterjee R, Allen LaPointe NM, Williams JB Jr., Coeytaux RR, McBroom AJ, Musty MD, Wing L, Samsa GP, Patel MR. Treatment Strategies for Women With Coronary Artery Disease. Comparative Effectiveness Review No. 66. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 12-EHC070-EF Rockville, MD. Agency for Healthcare Research and Quality. August 2012. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

## Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting comparative effectiveness reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see [www.effectivehealthcare.ahrq.gov/reference/purpose.cfm](http://www.effectivehealthcare.ahrq.gov/reference/purpose.cfm).

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input from are essential to the Effective Health Care Program. Please visit the Web site ([www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov)) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

Carolyn M. Clancy, M.D.  
Director, Agency for Healthcare Research  
and Quality

Stephanie Chang M.D., M.P.H.  
Director, EPC Program  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.  
Director, Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Elisabeth U. Kato, M.D., M.R.P.  
Task Order Officer  
Center for Outcomes and Evidence  
Agency for Healthcare Research and Quality

## Acknowledgments

The authors thank Megan von Isenburg, M.L.S., for help with the literature search and retrieval, and Dr. Douglas McCrory for comments on the final draft of the report.

## Key Informants

Noel Bairey Merz, M.D.  
Professor of Medicine  
Director, Women's Heart Center  
Cedars-Sinai Medical Center  
Los Angeles, CA

Patricia Best, M.D.  
Assistant Professor of Medicine  
Mayo Clinic College of Medicine  
Rochester, MN

Javed Butler, M.D., M.P.H.  
Associate Professor of Medicine  
Emory University  
Atlanta, GA

Lily Chaput, M.D., M.P.H.  
Chief, California Heart Disease and Stroke  
Prevention Program  
Sacramento, CA

Brenda J. Clark  
Go Red for Women  
American Heart Association  
San Francisco, CA

Linda Humphrey, M.D., M.P.H.  
Clinical Director, Evidence-based Synthesis  
Program  
Portland Veterans Affairs Medical Center  
Portland, OR

Michael Lauer, M.D.  
Director, Division of Cardiovascular  
Sciences  
National Heart, Lung, and Blood Institute  
Bethesda, MD

Peter K. Smith, M.D.  
Chief, Cardiothoracic Surgery  
Duke University Medical Center  
Durham, NC

## Technical Expert Panel

Noel Bairey Merz, M.D.  
Director, Women's Heart Center  
Professor of Medicine  
Cedars-Sinai Medical Center  
Los Angeles, CA

Patricia Best, M.D.  
Assistant Professor of Medicine  
Mayo Clinic College of Medicine  
Rochester, MN

Javed Butler, M.D., M.P.H.  
Associate Professor of Medicine  
Emory University  
Atlanta, GA

Lily Chaput, M.D., M.P.H.  
Chief, California Heart Disease and Stroke  
Prevention Program  
Sacramento, CA

Nakela L. Cook, M.D., M.P.H.  
Division of Cardiology  
Washington Hospital Center  
Washington, DC

Linda Humphrey, M.D., M.P.H.  
Clinical Director, Evidence-based Synthesis  
Program  
Portland Veterans Affairs Medical Center  
Portland, OR

Frank V. Lefevre, M.D.  
Associate Professor  
Northwestern University Feinberg School of  
Medicine  
Chicago, IL

## Peer Reviewers

Indira Jevaji, M.D., M.S.L.  
Senior Medical Officer  
Office of Research on Women's Health  
Bethesda, MD

Michael Mack, M.D.  
Medical Director, Cardiovascular Services  
Medical City Dallas Hospital  
Dallas, TX

Lori Mosca, M.D., Ph.D., M.P.H.  
Professor of Medicine  
Director of Preventive Cardiology  
Columbia University Medical Center  
New York, NY

John Puskas, M.D., M.Sc.  
Associate Chief, Division of Cardiothoracic  
Surgery  
Emory University School of Medicine  
Atlanta, GA

William S. Weintraub, M.D.  
Chief of Cardiology  
Director, Christiana Center for Outcomes  
Research  
Christiana Care Health System  
Newark, DE

# Treatment Strategies for Women With Coronary Artery Disease

## Structured Abstract

**Objectives.** Although coronary artery disease (CAD) is the leading cause of death for women in the United States, treatment studies to date have primarily enrolled men and may not reflect the benefits and risks that women experience. Our systematic review of the medical literature assessed the comparative effectiveness of major treatment options for CAD specifically in women. The comparisons were (1) percutaneous coronary intervention (PCI) versus fibrinolysis/supportive pharmacologic therapy in ST elevation myocardial infarction (STEMI), (2) early invasive versus initial conservative management in non-ST elevation myocardial infarction (NSTEMI) or unstable angina, and (3) PCI versus coronary artery bypass surgery (CABG) versus optimal medical therapy in stable or unstable angina. The endpoints assessed were clinical outcomes, modifiers of effectiveness by demographic and clinical factors, and safety outcomes.

**Data Sources.** MEDLINE<sup>®</sup>, PubMed<sup>®</sup>, Embase<sup>®</sup>, and Cochrane Database of Systematic Reviews.

**Review Methods.** Randomized controlled trials published in English from January 1, 2001, to December 12, 2011, comparing the treatment options for CAD listed above and containing sex-specific outcomes. Clinical outcomes were classified as short term ( $\leq 30$  days), intermediate term (1 year), or long term ( $>1$  year). Random-effects meta-analysis was performed for studies with similar outcomes measured at similar time points.

**Results.** Twenty-eight comparative studies contributed evidence about effectiveness, modifiers of effectiveness, or safety for the comparisons described above. For women with STEMI, five studies showed a reduction in composite outcomes (primarily death/MI/stroke) at 30 days for PCI over fibrinolysis (odds ratio [OR] 0.50; 95% CI, 0.36 to 0.72; high strength of evidence [SOE]); there was insufficient evidence for assessing outcomes at 1 year. For women with NSTEMI or unstable angina, the included studies, although not showing statistical significance, suggested a benefit of early invasive over initial conservative management for the composite outcome of primarily death/MI at 6 months and 1 year (2 studies, OR 0.77; CI, 0.28 to 2.12; low SOE; 5 studies, OR 0.78; CI, 0.54 to 1.12; low SOE). Evidence, however, suggested a small benefit of initial conservative management at 5 years (2 studies, OR 1.05; CI, 0.81 to 1.35). Given the small suggested benefit at 5 years, the wide confidence interval crossing 1, and the trend favoring early invasive therapy suggested at earlier time points and across time points in men—we cannot support firm conclusions (insufficient SOE). For women with stable angina randomized to revascularization (PCI or CABG) or medical therapy, three studies showed a reduction in the composite outcome of death/MI/repeat revascularization at 5 years for revascularization with either PCI (OR 0.64; CI, 0.47 to 0.89; moderate SOE) or CABG (OR 0.56; CI, 0.32 to 0.96; low SOE). For stable and unstable angina trials comparing PCI with CABG, two studies suggested a nonsignificant benefit of PCI in mortality at 30 days (low SOE). At 1 year and beyond, although suggestive of a benefit of CABG in for the composite outcomes

of death/MI/stroke for women, this finding was not statistically significant and represented wide confidence intervals (low SOE at 1 year and at >2 years).

Five studies assessed modifiers of effectiveness in women due to demographic factors ( $\geq 65$  or  $\geq 80$  years of age) or clinical factors (risk stratification or diabetes). Strength of evidence for modifiers of effectiveness for STEMI, NSTEMI, and stable/unstable angina was insufficient.

Four studies assessed safety outcomes in women: two STEMI studies (PCI versus fibrinolysis) and two NSTEMI studies (PCI versus CABG) assessed transfusion rates, incidence of intracranial hemorrhage, and bleeding rates. Strength of evidence for safety outcomes for all the CAD presentations was insufficient.

**Conclusions.** From a limited number of studies reporting results for women separately from the total study population, our findings confirm current practice and evidence for care in one of the three areas evaluated. For women with STEMI, we found that an invasive approach with immediate PCI is superior to fibrinolysis for reducing cardiovascular events, which is similar to findings in previous meta-analyses combining results for both women and men. For women with NSTEMI or unstable angina, evidence suggested that an early invasive approach reduces cardiovascular events; however, it was not statistically significant. Previous meta-analyses of studies comparing early invasive with initial conservative strategies on a combined population of men and women showed a significant benefit of early invasive therapy. We also found that the few trials reporting sex-specific data on revascularization compared with optimal medical therapy for stable angina showed a greater benefit with revascularization for women, while the men in the study fared equally well with either treatment. In contrast, previous meta-analyses that combined results for men and women found similar outcomes for either treatment.

Limitations include a small number of trials with data for women available for meta-analysis, varying definitions of composite outcomes, and variable timing of followup. Future studies should collect and report clinical outcomes and harms in women by treatment strategy and at each followup time point—including subgroup data on important demographic and clinical factors that may modify clinical effectiveness—so that firmer conclusions can be reached about the risk and benefit of these therapies in women.



# Contents

<b>Executive Summary</b> .....	ES-1
<b>Introduction</b> .....	1
Background .....	1
Clinical Presentations of CAD .....	2
Treatment Options for Patients With CAD .....	3
Scope and Key Questions .....	5
<b>Methods</b> .....	7
Topic Development and Refinement .....	7
Analytic Framework .....	7
Literature Search Strategy .....	8
Sources Searched .....	8
Process for Study Selection .....	8
Screening for Inclusion and Exclusion .....	8
Data Extraction and Data Management .....	11
Individual Study Quality Assessment .....	11
Data Synthesis .....	12
Grading the Body of Evidence .....	12
Peer Review and Public Commentary .....	13
<b>Results</b> .....	14
Key Question 1: Women With STEMI (PCI Vs. Fibrinolysis) .....	15
Overview .....	15
Key Points .....	16
Detailed Synthesis .....	16
KQ 1a: Effectiveness of Interventions .....	20
KQ 1b: Modifiers of Effectiveness .....	22
KQ 1c: Safety Concerns .....	22
Key Question 2: Women With UA/NSTEMI (Early Invasive Vs. Initial Conservative Therapy) .....	23
Overview .....	23
Key Points .....	24
Detailed Synthesis .....	25
KQ 2a: Effectiveness of Interventions .....	31
KQ 2b: Modifiers of Effectiveness .....	34
KQ 2c: Safety Concerns .....	35
Key Question 3: Women With Stable or Unstable Angina .....	35
Overview .....	36
Strategy 1: Revascularization Versus Optimal Medical Therapy in Stable Angina .....	37
KQ 3a: Effectiveness of Interventions .....	41
KQ 3b: Modifiers of Effectiveness .....	43
KQ 3c: Safety Concerns .....	43
Strategy 2: PCI Versus CABG in Stable/Unstable Angina .....	44
KQ 3a: Effectiveness of Interventions .....	50
KQ 3b: Modifiers of Effectiveness .....	53
KQ 3c: Safety Concerns .....	53

<b>Summary and Discussion</b> .....	54
Key Findings and Strength of Evidence .....	54
Modifiers of Effectiveness .....	61
Safety Concerns .....	61
Discussion .....	61
Limitations of This Review .....	63
Conclusions .....	64
<b>Future Research</b> .....	66
Studies With Sufficient Representation of Women .....	66
Patient-Level Meta-Analysis .....	66
Reporting Sex by Treatment Results Separately .....	66
Reporting of Demographic and Clinical Factors That Influence Cardiovascular Outcomes .....	67
Reporting of Safety Concerns/Risks by Sex .....	67
<b>References</b> .....	68
<b>Abbreviations</b> .....	76

## Tables

Table A. Comparisons of Treatment Strategies for Women With CAD .....	ES-4
Table B. Summary of Inclusion and Exclusion Criteria .....	ES-9
Table C. Summary of Key Findings .....	ES-15
Table 1. Comparisons of Treatment Strategies for Women With CAD .....	4
Table 2. Summary of Inclusion and Exclusion Criteria .....	9
Table 3. KQ 1: Study Characteristics of RCTs Evaluating Women With STEMI .....	17
Table 4. KQ 1: Outcomes Reported in RCTs Evaluating Women With STEMI .....	19
Table 5. Sex Results for STEMI on Composite Outcomes (Short-Term) .....	20
Table 6. Sex Results for STEMI on Clinical Outcomes (Intermediate-Term) .....	21
Table 7. KQ 2: Study Characteristics of RCTs Evaluating Women With UA/NSTEMI .....	26
Table 8. Outcomes Reported in RCTs Evaluating Women With UA/NSTEMI .....	29
Table 9. Sex Results for UA/NSTEMI on Composite Outcomes (Short-Term) .....	31
Table 10. Sex Results for UA/NSTEMI on Composite Outcomes (Intermediate-Term) .....	32
Table 11. Sex Results for UA/NSTEMI on Composite Outcomes (Long-Term) .....	33
Table 12. KQ 3 Strategy 1: Study Characteristics of RCTs Evaluating Women With Stable Angina (PCI/CABG Vs. Optimal Medical Therapy) .....	38
Table 13. KQ 3 Strategy 1: Outcomes Reported in RCTs Evaluating Women With Stable Angina (PCI/CABG Vs. Optimal Medical Therapy) .....	40
Table 14. Sex Results for Stable Angina on Composite Outcomes (Long-Term) .....	41
Table 15. KQ 3 Strategy 2: Study Characteristics of RCTs Evaluating Women With Stable or Unstable Angina (PCI Vs. CABG) .....	45
Table 16. KQ 3 Strategy 2: Outcomes Reported in RCTs Evaluating Women With Stable or Unstable Angina (PCI Vs. CABG) .....	48
Table 17. Sex Results for Stable/Unstable Angina on Composite Outcomes (Short-Term) .....	50
Table 18. Sex Results for Stable/Unstable Angina on Composite Outcomes (Intermediate-Term) .....	51
Table 19. Sex Results for Stable/Unstable Angina on Composite Outcomes (Long-Term) .....	52
Table 20. Strength of Evidence by Effectiveness Outcome .....	55

## Figures

Figure A. Analytic Framework .....	ES-7
Figure B. Literature Flow Diagram .....	ES-13
Figure C. Number of Articles Reporting Data on Women by Year .....	ES-20
Figure 1. Analytic Framework .....	7
Figure 2. Literature Flow Diagram .....	14
Figure 3. STEMI Short-Term (30 Days) PCI Versus Fibrinolysis .....	21
Figure 4. UA/NSTEMI Short-Term (6 Months) Early Invasive Versus Initial Conservative.....	32
Figure 5. UA/NSTEMI Intermediate-Term (1 Year) Early Invasive Versus Initial Conservative .....	33
Figure 6. UA/NSTEMI Long-Term (5 Years) Early Invasive Versus Initial Conservative .....	34
Figure 7. Stable Angina, Revascularization (Primarily PCI) Versus Medical Therapy .....	42
Figure 8. Stable Angina, Revascularization (Primarily CABG) Versus Medical Therapy .....	42
Figure 9. Stable Angina, Revascularization (Combined) Versus Medical Therapy .....	43
Figure 10. Stable/Unstable Angina Short-Term (30 Days) PCI Versus CABG .....	50
Figure 11. Stable/Unstable Angina Intermediate-Term (1 Year) PCI Versus CABG .....	51
Figure 12. Stable/Unstable Angina Long-Term ( $\geq 2$ Years) PCI Versus CABG .....	53
Figure 13. Number of Articles Reporting Data on Women by Year .....	64

## Appendixes

Appendix A. Exact Search Strings
Appendix B. Data Abstraction Elements
Appendix C. List of Included Studies
Appendix D. Quality and Applicability of Included Studies
Appendix E. List of Excluded Studies
Appendix F. Summary Tables for Sex-Specific Clinical Outcomes
Appendix G. Summary Table for Modifiers of Effectiveness
Appendix H. Summary Table for Safety Concerns

# Executive Summary

## Background

Cardiovascular disease remains the leading cause of death among women in the United States.<sup>1</sup> More than 500,000 women die of cardiovascular disease each year, exceeding the number of deaths in men and the next seven causes of death in women combined. This translates into approximately one death every minute.<sup>1,2</sup> Coronary artery disease (CAD)—which includes coronary atherosclerotic disease, myocardial infarction (MI), acute coronary syndrome, and angina—is the most prevalent form of cardiovascular disease and is the largest subset of this mortality. An estimated 16.3 million Americans 20 years of age and older have CAD, and the overall CAD prevalence is 7 percent in adults in the United States (8.3% for men, 6.1% for women). The prevalence of CAD is higher in men than in women across different age groups until they reach 75 years of age, giving the perception that CAD is a male-specific disease.<sup>1</sup>

This report focuses on women because of the differences in clinical presentation and coronary anatomy, which affect the treatment options for CAD.<sup>3-5</sup> Currently available guidelines and systematic reviews provide specific treatment recommendations for women only among a subset of treatment options and overall assume that treatment options are equally effective for both sexes when gender data are not available. However, women have a worse prognosis than men for manifestations of CAD such as acute myocardial infarction, and some data suggest that women and men do not respond equally to the same treatments. Further, women are more likely than men to experience bleeding complications.<sup>6-9</sup>

In women, CAD is misdiagnosed or not treated as aggressively as in men or is underresearched.<sup>10-12</sup> Multiple factors<sup>13</sup> are likely to contribute to the lower use of evidence-based medicine (medical therapy and/or coronary revascularization) and the higher rate of cardiovascular complications among women with CAD.<sup>3</sup> These factors include:

- Cardiovascular disease affects women later in life.<sup>1,13-15</sup>
- At the time CAD is diagnosed, women are more likely to have comorbid factors such as diabetes mellitus, hypertension, hypercholesterolemia, peripheral vascular disease, and heart failure.<sup>10</sup>
- Women present with angina-equivalent symptoms such as dyspnea or atypical symptoms more often than men.<sup>16,17</sup>
- The coronary vessels in women tend to be smaller than those of men, which makes them more difficult to revascularize percutaneously and surgically,<sup>18</sup> and microvascular disease of the coronary arteries is more common in women than in men.<sup>19</sup>
- Women tend to have less extensive CAD and a higher proportion of nonobstructive CAD.<sup>20,21</sup>
- Delay in hospitalization, symptom pattern and recognition, and higher frequency of nonobstructive CAD ultimately results in delay in diagnosis and effective treatment.<sup>13,14,22,23</sup>
- Because of underrepresentation of women in randomized controlled trials (RCTs), a lack of solid data on cardiovascular disease in women leaves uncertainty about the risk–benefit ratio of treatment.<sup>24,25</sup>

Thus, a better understanding of the evidence for the effectiveness of medical treatment and revascularization therapies specifically in women is needed in order to reduce cardiovascular events in women.

## **Clinical Presentations of CAD**

Coronary artery disease is the presence of atherosclerosis in the epicardial coronary arteries. Atherosclerotic plaques may either rupture and cause acute ischemia or progressively narrow the coronary artery lumen, resulting in chronic stable angina. Acute myocardial ischemia occurs when an atheromatous plaque ruptures or splits. The reasons for why a specific plaque ruptures when it does are unclear but probably relate to plaque morphology, plaque calcium content, and plaque softening due to an inflammatory process. Rupture exposes collagen and other thrombogenic material, which activates platelets and the coagulation cascade, resulting in an acute thrombus that interrupts coronary blood flow and causes some degree of myocardial ischemia. The consequences of acute ischemia depend on the location and degree of obstruction and range from reversible ischemia (unstable angina) through partial obstruction and tissue damage (non-ST elevation myocardial infarction [NSTEMI]) to complete epicardial occlusions leading to possible transmural infarction of the heart muscle (ST elevation myocardial infarction [STEMI]). The constellation of clinical symptoms that are compatible with acute myocardial ischemia is usually referred to as acute coronary syndrome.<sup>26,27</sup>

Angina resulting from progressive narrowing of the coronary arteries is the initial manifestation of ischemic heart disease in approximately one-half of patients.<sup>28</sup> Angina is a clinical syndrome characterized by discomfort in the chest, jaw, shoulder, back, or arm. It is typically aggravated by exertion or emotional stress and relieved by nitroglycerin. Angina usually occurs in patients with CAD that involves at least one large epicardial artery. However, angina can also occur in patients with valvular heart disease, hypertrophic cardiomyopathy, and uncontrolled hypertension. It can also be present in patients with normal coronary arteries and myocardial ischemia related to spasm or endothelial dysfunction. Most angina is a sign of significant CAD—defined angiographically as a stenosis with greater than 70 percent diameter in at least one major epicardial artery segment or with greater than 50 percent diameter in the left main coronary artery. However, some angina is caused by stenotic lesions of lesser diameters, which have much less prognostic significance.<sup>28</sup>

Unstable angina (UA) is defined as angina with at least one of three features: (1) it occurs at rest or with minimal exertion, (2) it is severe and of recent onset (within the past 4 to 6 weeks), and/or (3) it occurs in a crescendo pattern (i.e., more severe, more prolonged, or more frequent than previously experienced). UA and NSTEMI have a fairly similar pathophysiology, mortality rate, and management strategy when compared with STEMI; therefore they are often grouped together as UA/NSTEMI in clinical guidelines and trial populations. Chronic stable angina is classified as pain that classically occurs with moderate to severe exertion, is milder in nature, and is relieved with rest or sublingual nitroglycerin.

## **Treatment Options for Patients With CAD**

### **Optimal Medical Therapy**

All patients with CAD—regardless of clinical presentation—should receive aggressive management of risk factors for progression of atherosclerosis (smoking, hypertension, hyperlipidemia, and diabetes) combined with pharmacological treatment (antiplatelets,

antianginals, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and lipid-lowering drugs).<sup>29</sup> Optimal medical therapy of CAD comprises the combinations of these treatments to reduce future cardiovascular events for all the clinical presentations outlined in the previous section. However, patients may not be able to receive optimal medical therapy if they have allergies to, or adverse effects from, individual medications (e.g., aspirin, beta blockers, or cholesterol-lowering drugs) or the combination of medications. Also, the definition of optimal medical therapy continues to evolve as new drugs are developed and as studies are conducted to assess the optimal blood pressure, blood sugar, and lipid goals needed to reduce future cardiovascular events. For medical therapy to be optimized, patients should be prescribed appropriate therapy to reach their therapeutic goal. The effectiveness of medical therapy is also affected by how adherent the patient is to the prescribed therapy.

## **Coronary Revascularization**

Coronary revascularization falls broadly into two categories: coronary artery bypass grafting (CABG) and catheter-based percutaneous coronary intervention (PCI). Together, these coronary revascularization techniques are among the most common major medical procedures performed in North America and Europe. Since the introduction of bypass surgery in 1967 and PCI in 1977, it has become clear that both strategies can contribute to the effective treatment of patients with CAD. CABG and PCI (with or without stents) are alternative approaches in coronary revascularization, so their comparative effectiveness in terms of patient outcomes has been of great interest. The comparative effectiveness of CABG and PCI is an open question primarily for those patients for whom either procedure would be technically feasible or whose CAD is neither too limited nor too extensive.

CABG is generally preferred for patients with very high CAD burden—often described as left main CAD or severe triple-vessel disease with reduced left ventricular function—because CABG has previously been shown in RCTs to improve survival when compared with medical therapy. In contrast, PCI is generally preferred for patients with milder CAD burden—described as single- or double-vessel disease—when symptoms warrant coronary revascularization, in light of its lower procedural risk and evidence that PCI reduces angina and myocardial ischemia in this subset of patients. Uncertainty exists about the choice between PCI and CABG for patients with moderate CAD burden; namely, patients with disease of the proximal left anterior descending artery and less extensive forms of triple-vessel CAD. Most RCTs of PCI and CABG have been conducted in this middle segment of the patient population with CAD. The major advantage of PCI is its relative ease of use and avoidance of general anesthesia, thoracotomy, extracorporeal circulation, central nervous system complications, and prolonged convalescence. Repeat PCI can be performed more easily than repeat bypass surgery, and revascularization can be achieved more quickly in emergency situations. The disadvantages of PCI are early restenosis and the inability to relieve many totally occluded arteries or vessels with extensive atherosclerotic disease. CABG has the advantages of greater durability (graft patency rates exceeding 90% at 10 years with arterial conduits) and more complete revascularization regardless of the morphology of the obstructing atherosclerotic lesion.<sup>30</sup>

Therefore, patients and clinicians have two or more major treatment approaches to consider for each presentation of CAD. In general, these fall into less invasive (i.e., more medical) approaches and more invasive approaches. Table A summarizes the major treatment options for each clinical scenario described in the sections that follow.

**Table A. Comparisons of treatment strategies for women with CAD**

CAD Presentation	Treatment Choices
STEMI	PCI vs. fibrinolysis PCI vs. conservative/supportive medical management
NSTEMI/unstable angina	Early invasive management (with PCI or CABG) vs. initial conservative management
Stable/unstable angina	PCI vs. CABG vs. optimal medical therapy

CABG = coronary artery bypass grafting; CAD = coronary artery disease; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST elevation myocardial infarction

## STEMI

Treatment for patients with ST-segment elevation is well established. Patients with STEMI are candidates for reperfusion therapy (either pharmacological or catheter-based) to restore blood flow promptly in the occluded epicardial infarct-related artery. Pharmacological therapy consists of fibrinolysis or conservative/supportive therapy with facilitated antithrombotic medications.<sup>27</sup> Multiple randomized trials have demonstrated the benefit of PCI in reducing major cardiovascular adverse events when compared with fibrinolysis or conservative therapy; therefore, immediate revascularization with PCI is the preferred strategy when patients have close access to a catheterization facility. Otherwise, fibrinolysis is recommended (in facilities without access) since it also has been shown to improve cardiovascular outcomes. In older or unstable patients, the use of fibrinolytics can increase bleeding complications; therefore, trials comparing conservative medical therapy to PCI have been performed. In general, patients with STEMI are not treated with CABG (unless emergent from PCI complications) but do receive optimal medical therapy.

## UA/NSTEMI

Patients with UA/NSTEMI are not candidates for immediate pharmacological reperfusion. The optimal management of UA/NSTEMI has the twin goals of the immediate relief of ischemia and the prevention of serious adverse outcomes (i.e., death or MI). Optimal management is best accomplished with an approach that includes anti-ischemic therapy, antithrombotic therapy, ongoing risk stratification, and in some cases the use of invasive procedures. In addition to aggressive medical therapy, two treatment pathways have emerged for treating patients without ST-segment elevation.<sup>26</sup> An initial conservative strategy (also referred to as selective invasive management) calls for proceeding with an invasive evaluation only for those patients whose medical therapy fails (refractory angina or angina at rest or with minimal activity despite vigorous medical therapy) or in whom objective evidence of ischemia (dynamic electrocardiographic changes, high-risk stress test) is identified. An early invasive strategy triages patients to undergo an invasive diagnostic evaluation without first getting a noninvasive stress test or having medical treatment fail. Patients treated with an early invasive strategy generally will undergo coronary angiography within 4 to 24 hours of admission; however, these patients also are treated with the usual UA/NSTEMI medications, including appropriate anti-ischemic, antiplatelet, and anticoagulant therapy. Several RCTs have demonstrated improved clinical outcomes in patients with an invasive strategy, leading to guideline recommendations for invasive approaches to treat patients with NSTEMI and high-risk acute coronary syndrome. Patients with UA/NSTEMI also receive optimal medical therapy.

## Angina

The treatment of stable angina has two major purposes. The first is to prevent MI and death and thereby increase the quantity of life. The second is to reduce symptoms of angina and occurrence of ischemia, which should improve the quality of life.<sup>28</sup> All patients with stable angina are candidates for optimal medical therapy and may be candidates for PCI or CABG based on findings from coronary angiography and if symptoms persist despite optimal medical therapy.

## Objectives of This Review

Although CAD is the leading cause of death for women in the United States, treatment studies to date have primarily enrolled men and may not reflect the benefits and risks that women experience. We conducted this systematic review of the medical literature to assess the comparative effectiveness of the major treatment options for CAD specifically in women, evaluating these comparisons:

1. PCI versus fibrinolysis or PCI versus conservative/supportive medical management in women with STEMI
2. Early invasive versus initial conservative management in women with UA/NSTEMI
3. PCI versus CABG versus optimal medical therapy in women with stable or unstable angina

The endpoints assessed were clinical outcomes, modifiers of effectiveness by demographic and clinical factors, and safety outcomes. The following Key Questions (KQs) were considered in this review:

**KQ 1.** In women presenting with ST elevation myocardial infarction (STEMI):

- a. What is the effectiveness of percutaneous coronary intervention (PCI) versus fibrinolysis/supportive therapy on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects)?
- b. Is there evidence that the comparative effectiveness of PCI versus fibrinolysis/supportive therapy varies based on characteristics such as:
  - Age, race, or other demographic and socioeconomic risk factors?
  - Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
  - Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or coronary artery bypass graft surgery [CABG] revascularization procedure)?
  - Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?
- c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

**KQ 2.** In women presenting with unstable angina or non-ST elevation myocardial infarction (UA/NSTEMI):

- a. What is the effectiveness of early invasive (PCI or CABG) versus initial conservative therapy on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, graft failure, angina relief, quality of life, or cognitive effects)?



- b. Is there evidence that the comparative effectiveness of early invasive versus initial conservative therapy varies based on characteristics such as:
  - Age, race, or other demographic and socioeconomic risk factors?
  - Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
  - Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or CABG revascularization procedure)?
  - Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?
- c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?


**KQ 3.** In women presenting with stable or unstable angina:

- a. What is the effectiveness of the following treatment strategies on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, graft failure, angina relief, quality of life, or cognitive effects)?
  - Revascularization (PCI or CABG) versus optimal medical therapy in women with stable angina
  - PCI versus CABG in women with stable or unstable angina
- b. Is there evidence that the comparative effectiveness of revascularization versus optimal medical therapy varies based on characteristics such as:
  - Age, race, or other demographic and socioeconomic risk factors?
  - Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
  - Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or CABG revascularization procedure)?
  - CABG-specific factors such as type of surgery performed, cardiopulmonary bypass mode (normothermic versus hypothermic), on-pump versus off-pump, type of cardioplegia used (blood versus crystalloid), or use of saphenous vein grafts, single or bilateral internal mammary artery grafts, or other types of bypass grafts?
  - Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?
- c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

## Analytic Framework

Figure A shows the analytic framework for the systematic review of treatment strategies for women with CAD.

**Figure A. Analytic framework**



CABG = coronary artery bypass graft; CAD = coronary artery disease; KQ = Key Question; MACE = major adverse cardiovascular events; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST elevation myocardial infarction

## Methods

### Input From Stakeholders

During the topic refinement stage, the KQs were refined with the help of an eight-person Key Informant group representing clinicians (cardiology, primary care, cardiac surgery), patients, scientific experts, and Federal agencies. We solicited input from the Task Order Officer and an eight-person Technical Expert Panel (TEP) with experts knowledgeable in CAD, PCI, and CABG throughout our evidence review and followed, based on an a priori research protocol, the Effective Health Care Program’s Methods Guide for Effectiveness and Comparative Effectiveness Reviews<sup>31</sup> (hereafter referred to as the Methods Guide) for literature search strategies, inclusion/exclusion of studies, abstract screening, data abstraction and management, assessment of methodological quality of individual studies, data synthesis, and grading of evidence for each KQ. All Key Informant and TEP participants were screened for conflicts of interest, and any potential conflicts were balanced or mitigated.

### Data Sources and Selection

We included studies published in English from January 1, 2001, through December 12, 2011. Search strategies were specific to each database in order to retrieve the articles most relevant to the KQs. Our search strategy used the National Library of Medicine’s medical subject headings (MeSH) keyword nomenclature developed for MEDLINE<sup>®</sup> and adapted for use in other databases. In consultation with our research librarians, we used PubMed<sup>®</sup>, Embase<sup>®</sup>, the

Cochrane Database of Systematic Reviews, and the Cochrane Central Registry of Controlled Trials for our literature search. We also searched the grey literature of study registries and conference abstracts for relevant articles from completed RCTs. Grey literature databases included Clinicaltrials.gov; metaRegister of Controlled Trials; ClinicalStudyResults.org; WHO: International Clinical Trials Registry Platform Search Portal; and ProQuest COS Conference Papers Index. The exact search strings used in our strategy are given in Appendix A of the full report. The reference lists of articles applicable to the relevant KQs of two previous Agency for Healthcare Research and Quality (AHRQ) reports related to this topic<sup>32,33</sup> and from identified systematic reviews and meta-analyses were manually hand-searched and cross-referenced against our library, and additional manuscripts were retrieved. All citations were imported into an electronic bibliographic database (EndNote<sup>®</sup> Version X4; Thomson Reuters, Philadelphia, PA).

We developed a list of article inclusion and exclusion criteria for the KQs (Table B). This review focused on randomized controlled studies, since this is the strongest study design for evaluating treatment effectiveness and since observational studies contain potential biases (e.g., patient selection bias, intervention bias) that could affect the clinical outcome. The TEP approved this approach given that the number of abstracts identified in PubMed exceeded 5,000. This review focused on comparisons of treatment strategies; therefore, differences in specific drugs or devices were not investigated and were considered beyond the scope. Using the prespecified inclusion and exclusion criteria, titles and abstracts were examined independently by two reviewers for potential relevance to the KQs. Articles included by any reviewer underwent full-text screening. At the full-text screening stage, two independent reviewers read each article to determine if it met eligibility criteria. At the full-text review stage, paired researchers independently reviewed the articles and indicated a decision to “include” or “exclude” the article for data abstraction. When the paired reviewers arrived at different decisions about whether to include or exclude an article, they reconciled the difference through a third-party arbitrator. Articles meeting our eligibility criteria were included for data abstraction. Relevant review articles, meta-analyses, and methods articles were flagged for manual searching and cross-referencing against the library of citations identified through electronic database searching.

## **Data Extraction and Quality Assessment**

The investigative team created forms for abstracting the data elements for the KQs. The abstraction forms were pilot tested with a sample of included articles to ensure that all relevant data elements were captured and that there was consistency and reproducibility between abstractors for accuracy. Based on their clinical and methodological expertise, two researchers were assigned to abstract data from the eligible articles pertaining to the research questions. One researcher abstracted the data, and the second overread the article and the accompanying abstraction form to check for accuracy and completeness. Disagreements were resolved by consensus or by obtaining a third reviewer’s opinion if consensus was not reached by the first two researchers. Guidance documents were drafted and given to the researchers as reference material to perform data abstraction, thus aiding in both reproducibility and standardization of data collection.

**Table B. Summary of inclusion and exclusion criteria**

Study Characteristic	Inclusion Criteria	Exclusion Criteria
Population	Adult women (≥18 years of age) with CAD and angiographically proven single- or multiple-vessel disease including STEMI, NSTEMI, and stable angina	<p>Study population was composed entirely of patients without CAD, or the population also included patients with CAD but results were not reported separately for the subgroup with CAD</p> <p>Study did not include women, or results were not reported by sex</p> <p>All subjects under age 18, or some subjects under age 18, but results were not broken down by age</p> <p>Study did not report any of the primary or secondary outcomes of interest</p>
Interventions and comparators	<p>Article reported original data for any of the interventions compared with another treatment category; or a related methodology paper of an included article</p> <p>Optimal medical therapy alone</p> <p>PCI (bare-metal and drug-eluting stents) with optimal medical therapy</p> <p>CABG with optimal medical therapy</p>	<p>Intervention comparisons within the same treatment category such as:</p> <p>Medical therapy with medical therapy (e.g., one type of fibrinolysis drug compared with another fibrinolysis drug)</p> <p>PCI with PCI (e.g., bare-metal stent compared with drug-eluting stent)</p> <p>CABG with CABG (e.g., open sternotomy compared with minimally invasive CABG)</p>
Outcomes and effect modifiers	<p>Primary outcomes: major adverse cardiovascular events such as death, nonfatal myocardial infarction, stroke, and repeat revascularization</p> <p>Other clinical outcomes: heart failure, repeat hospitalization, length of hospital stay, unstable angina, graft failure, angina relief, quality of life, cognitive effects</p> <p>Adverse effects of interventions: adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections</p>	<p>Outcomes of women not reported separately from total population</p> <p>Study did not report any of the primary or secondary outcomes of interest</p>

**Table B. Summary of inclusion and exclusion criteria (continued)**

Study Characteristic	Inclusion Criteria	Exclusion Criteria
Outcomes and effect modifiers (continued)	<p>Effect modifiers—individual characteristics including the following:</p> <p>Age, race, or other demographic and socioeconomic risk factors</p> <p>Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease</p> <p>Angiographic-specific factors such as access site (radial or femoral), number of diseased vessels, vessel territory stenoses, left ventricular function, or prior PCI or CABG revascularization procedure</p> <p>CABG-specific factors such as type of surgery performed (traditional or robot-assisted), cardiopulmonary bypass mode (normothermic versus hypothermic), on-pump versus off-pump, type of cardioplegia used (blood versus crystalloid), or use of saphenous vein grafts, single or bilateral internal mammary artery grafts, or other types of bypass grafts</p> <p>Hospital characteristics (hospital patient volume, setting, guideline-based treatment protocols)</p>	Outcomes of women not reported separately from total population
Timing	Short-term (≤30 days), intermediate-term (1 year), or long-term (>1 year)	None
Setting	Inpatient or outpatient, primarily primary care and cardiology clinics	None
Study design	Randomized controlled trial (strongest study design for evaluating treatment effectiveness)	<p>Observational (retrospective or prospective cohort) studies, due to potential biases that could affect the clinical outcome (e.g., patient selection bias, intervention bias)</p> <p>Not a clinical study (e.g., editorial, nonsystematic review, letter to the editor, case series). Systematic reviews and meta-analyses were excluded from abstraction but hand-searched as potential sources of additional material if relevant to the topic.</p>
Publication languages	English only	Given the high volume of English-language publications (including the majority of known important studies), non-English articles were excluded

CABG = coronary artery bypass grafting; CAD = coronary artery disease; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST elevation myocardial infarction

To aid in both reproducibility and standardization of data collection, researchers received data abstraction instructions directly on each form created specifically for this project with the DistillerSR data synthesis software program (Evidence Partners Inc., Manotick, ON, Canada).

We designed the data abstraction forms for this project to collect the data required to evaluate the specified eligibility criteria for inclusion in this review as well as to collect demographics and outcomes. The safety outcomes abstracted included adverse drug reactions, radiation exposure, access-site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, and infections—the more common adverse events resulting from medical therapy and revascularization. Data on the total population and women and men subgroups were collected. Appendix B of the full report lists the elements used in the data abstraction form. Appendix C contains a bibliography of all studies included in this review, organized alphabetically by author. When appropriate, methods articles providing additional detail were considered when abstracting data for an included study. If a methods article was used as a source for information in the abstraction of a study, it was included in the review and is listed in the bibliography in Appendix C.

Study quality was assessed on the basis of the reported methods and results and performed by two reviewers. We evaluated the quality of individual studies using the approach described in the Methods Guide.<sup>31</sup> To evaluate methodological quality, we applied criteria for RCTs that were derived from the core elements described in the Methods Guide. To indicate the summary judgment of the quality of the individual studies, we used the summary ratings of Good, Fair, and Poor based on the study's adherence to well-accepted standard methodologies and adequate reporting.

We used data abstracted on the population studied, the intervention and comparator, the outcomes measured, settings, and timing of assessments to identify specific issues that may have limited the applicability of individual studies or a body of evidence as recommended in the Methods Guide.<sup>31</sup> We used these data to evaluate the applicability to clinical practice, paying special attention to study eligibility criteria, demographic features of the enrolled population (e.g., age, race/ethnicity, sex) in comparison with the target population, version or characteristics of the intervention used in comparison with therapies currently in use (e.g., specific components of treatments considered to be “optimal medical therapy,” plus advancements in PCI or CABG techniques that have changed over time), and clinical relevance and timing of the outcome measures. We summarized issues of applicability qualitatively. Appendix D of the full report summarizes our assessment of the quality and applicability for each included study.

## **Data Synthesis and Analysis**

We synthesized the primary literature by continuous data (e.g., age, event rates) and categorical data (e.g., race/ethnicity, presence of coronary disease risk factors). We determined the feasibility of completing a quantitative synthesis (i.e., meta-analysis). The feasibility of a meta-analysis depended on the volume of relevant literature (two or more studies), and clinical and methodological homogeneity of the studies. When a meta-analysis was appropriate, we used random-effects models to quantitatively synthesize the available evidence (Review Manager software Version 5.1.; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). We tested for heterogeneity while recognizing that the ability of statistical methods to detect heterogeneity may be limited. When feasible, we used similar composite outcomes in the meta-analysis for two reasons: (1) a majority of studies reported a composite outcome (e.g., death/MI/stroke/revascularization) as their primary endpoint and (2) many of the studies reported results for women for the primary composite outcome but not for each individual (secondary) outcome. We presented summary odds ratio estimates, standard errors, and confidence intervals for women and men separately to show any similarity or differences.

The majority of outcomes within this report were binary or categorical; therefore, we summarized these outcomes by proportions. We summarized inherently continuous variables, such as age, by mean, median, and standard deviation.

## **Grading the Body of Evidence**


The strength of evidence for each KQ was assessed by using the approach described in the Methods Guide.<sup>31</sup> The evidence was evaluated by using the four required domains: risk of bias (low, medium, or high), consistency (consistent, inconsistent, or unknown/not applicable), directness (direct or indirect), and precision (precise or imprecise). Additionally, when appropriate, the studies were evaluated for the presence of confounders that would diminish an observed effect, the strength of association (magnitude of effect), and publication bias. The strength of evidence was assigned an overall grade of high, moderate, low, or insufficient according to the following four-level scale:

- b. **High**—High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
- c. **Moderate**—Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
- d. **Low**—Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.
- e. **Insufficient**—Evidence either is unavailable or does not permit estimation of effect.

## **Results**

The flow of articles through the literature search and screening process is depicted in Figure B. Of the 13,073 citations identified by our searches, 5,369 were duplicates. Manual searching identified an additional 173 citations for a total of 7,877 citations. After applying inclusion/exclusion criteria at the title/abstract level, 619 full-text articles were retrieved and screened. Of these, 547 articles were excluded at the full-text screening stage, with 72 articles (representing 28 studies) remaining for data abstraction. Appendix E of the full report provides a complete list of articles excluded at the full-text screening stage, with reasons for exclusion.

**Figure B. Literature flow diagram**



CABG = coronary artery bypass graft; CAD = coronary artery disease; KQ = Key Question; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; RCT = randomized controlled trial; STEMI = ST elevation myocardial infarction

## Summary of Key Findings

Our search identified 28 comparative studies (72 articles, including methodology and secondary analysis papers). Of the 28 studies, 24 were good quality and 4 were fair quality for their overall reporting of methodology and analysis. A total of 35,597 patients included 10,126 (28%) women. We grouped these by CAD presentation and type of comparison:

- a. KQ 1: seven studies (six good quality, one fair) comparing PCI with fibrinolysis/supportive (five fibrinolysis, two supportive) in patients with STEMI
- b. KQ 2: seven studies (six good quality, one fair) comparing early invasive (PCI or CABG) with initial conservative in patients with UA/NSTEMI
- c. KQ 3: 5 studies (all good quality) comparing revascularization (PCI or CABG) with optimal medical therapy in patients with stable angina (Strategy 1) and 10 studies (8 good quality, 2 fair) comparing PCI with CABG in patients with either stable or unstable angina (Strategy 2). There were a total of 14 studies with 1 study containing data for both comparative strategies.



Table C summarizes the key findings for each KQ, including the modifiers of effectiveness and safety concerns, and provides a grade for the strength of supporting evidence. Detailed reporting of the risk of bias, consistency, directness, precision, and limits to applicability are described in the Summary and Discussion section of the full report.

## Discussion

The findings from this systematic review on the treatment strategies for women across the spectrum of CAD presentations highlight areas for future research and for informing clinical practice. First, this review underscores the significant need for clinical researchers to provide study findings with women-specific data on the primary and secondary clinical outcomes. Overall, we were able to find only 28 relevant studies with data on either shorter term or longer term outcomes in women with CAD treated with invasive or conservative medical therapies. In addition, the representation of women enrolled in these trials was low. Melloni et al.<sup>25</sup> found similarly low rates with sex-specific results discussed in only 31 percent of the 156 primary trial publications cited by the American Heart Association's 2007 women's prevention guidelines. In addition, they found that enrollment of women in randomized clinical trials had increased over time (18% in 1970 to 34% in 2006) but remained low relative to their overall representation in disease populations (e.g., 25% women representation in RCTs of CAD compared with 46% women representation in the CAD population).

Second, our findings confirm current practice and evidence for care in one of the three areas evaluated. For women patients with STEMI, we found that an invasive approach with immediate PCI is superior to fibrinolysis in reducing cardiovascular events in women. These findings are similar to a meta-analysis<sup>34</sup> of 23 randomized trials comparing PCI with fibrinolysis for acute MI in combined populations of men and women. However, for patients with NSTEMI treated with an early invasive approach compared with a conservative or selective invasive approach, this review did not find statistically significant evidence about the benefit of an early invasive approach in reducing cardiovascular events in women—although our findings did suggest a benefit of early invasive therapy. In contrast, the meta-analysis for trials of early invasive versus conservative strategies in the overall population showed a statistically significant benefit of early invasive therapy.<sup>35</sup> The results from this review suggest that such a benefit may also be true in women, but the confidence intervals are too wide to support a firm conclusion.

In addition, for medical therapy alone versus revascularization plus medical therapy for patients with stable angina or high CAD burden, the findings from the current analysis suggest a benefit of revascularization in women. These findings should be viewed with caution because they are based on a limited number of studies with data on 704 (17%) women; these analyses often have both PCI and CABG together in the revascularization group, and the overall findings from these studies do not show a significant benefit beyond angina or symptom reduction for revascularization. In these studies, it is possible that women who present later in life with CAD, and with higher CAD burden, may be obtaining a greater benefit with revascularization, and the findings from this analysis should prompt further research in this area and again encourage researchers to provide data specific on women. In contrast, previous meta-analyses that combined results for men and women found similar outcomes for either treatment. The higher proportion of men enrolled in these trials (83%) may have led to the masking of the women's results by the men's results within a pooled analysis.

**Table C. Summary of key findings**

Key Question	Strength of Evidence	Conclusions
<p><b>KQ 1: Women with STEMI (PCI vs. fibrinolysis/supportive therapy)</b></p>	<p><u>Effectiveness of intervention</u>                      1. High (women and men) for short-term (30-day) composite outcomes                      2. Insufficient (women and men) for intermediate-term (1-year) composite outcomes</p> <p><u>Modifiers of effectiveness</u>                      Insufficient</p> <p><u>Safety concerns</u>                      Insufficient</p>	<p>7 studies (6 good quality, 1 fair) compared PCI with or without supportive therapy with fibrinolysis or other routine medical care for women with STEMI and contributed evidence about the comparative effectiveness, modifiers of effectiveness, or safety for these interventions. These studies included a total of 4,527 patients, of which 1,174 (26%) were women.</p> <ul style="list-style-type: none"> <li>• <u>Effectiveness of interventions:</u> A meta-analysis of 5 studies (all good quality) reporting 30-day composite outcomes (primarily death/MI/stroke) showed that PCI was better than fibrinolysis in women (OR, 0.50; 95% CI, 0.36 to 0.72) and men (OR, 0.54; CI, 0.42 to 0.70). However, there was insufficient evidence for assessing outcomes at 1 year.</li> <li>• <u>Modifiers of effectiveness:</u> 2 studies (1 good quality, 1 fair) reported subgroup analyses of demographic or clinical factors in women and included a total of 395 patients, of which 167 (32%) were women. 1 good-quality study evaluated the comparative effectiveness of PCI vs. fibrinolysis in patients &lt;65 years of age and ≥65 and found no differences in in-hospital mortality among the treatment groups. 1 fair-quality study evaluated patients ≥80 years of age with STEMI. The study was limited by a small overall size, and it did not find significant differences in outcomes in patients ≥80 years with STEMI undergoing PCI compared with usual (supportive) medical care.</li> <li>• <u>Safety concerns:</u> 2 good-quality studies reported safety concerns in women with STEMI and included a total of 1,532 patients, of which 367 (24%) were women. 1 study reported a lower nadir hematocrit in women receiving PCI vs. fibrinolysis but no statistically significant differences in the requirement for blood transfusion. Another study reported the proportion of women with intracranial hemorrhage in women who received PCI vs. accelerated t-PA (0% vs. 4.1%). No studies systematically reported radiation exposure, contrast reactions, access site complications, or stent thrombosis in women with STEMI undergoing PCI.</li> </ul>

**Table C. Summary of key findings (continued)**

Key Question	Strength of Evidence	Conclusions
<p><b>KQ 2: Women with UA/NSTEMI (early invasive vs. initial conservative)</b></p>	<p><u>Effectiveness of interventions</u>                      1. Low (women) and high (men) for short-term (6-month) composite outcomes                      2. Low (women and men) for intermediate-term (1-year) composite outcomes                      3. Insufficient (women) and low (men) for long-term (5-year) composite outcomes</p> <p><u>Modifiers of effectiveness</u>                      Insufficient</p> <p><u>Safety concerns</u>                      Insufficient</p>	<p>7 studies (6 good quality, 1 fair) compared early invasive (revascularization via PCI or CABG) with initial conservative therapy for women with UA/NSTEMI and contributed evidence about the comparative effectiveness, modifiers of effectiveness, or safety for these interventions. These studies included a total of 17,930 patients, of which 6,084 (34%) were women.</p> <ul style="list-style-type: none"> <li>• <u>Effectiveness of interventions:</u> A meta-analysis of 2 good-quality studies reporting 6-month composite outcomes (death/MI) suggested a benefit of early invasive compared with initial conservative therapy in women (OR, 0.77; 95% CI, 0.28 to 2.12) that, however, was not statistically significant; early invasive therapy was superior to initial conservative therapy in men at 6 months (OR, 0.65; CI, 0.52 to 0.82; p=0.0002). At 1 year, a meta-analysis of 5 good-quality studies showed that the composite outcome (primarily death/MI) suggested a similar benefit in women who received early invasive therapy (OR, 0.78; CI, 0.54 to 1.12) as well as in men (OR, 0.88; CI, 0.64 to 1.20); however, this was not statistically significant. A meta-analysis of 2 good-quality studies with 5-year followup between early invasive and initial conservative therapy for the composite outcome of death/MI in both sexes suggested a small benefit of initial conservative therapy in women (1.05; CI, 0.81 to 1.35) while suggesting a benefit of early invasive therapy in men (0.91; CI, 0.53 to 1.56). Given the small suggested benefit at 5 years in women, the wide confidence interval crossing 1, and the trend favoring early invasive therapy suggested at earlier time points and across time points in men — we cannot support firm conclusions.</li> <li>• <u>Modifiers of effectiveness:</u> 2 good-quality studies comparing initial conservative medical therapy with early invasive therapy with PCI reported a subgroup analysis by risk stratification and included a total of 4,030 patients, of which 1,439 (36%) were women. These studies revealed conflicting results—one showed no difference in treatment outcomes in the intermediate- and high-risk groups; the other showed a higher event rate in women in the groups with moderate-to-high risk for thrombolysis in myocardial infarction.</li> <li>• <u>Safety concerns:</u> 1 good-quality study (2,220 total patients, 757 [34%] women) reported the harms associated with treatment of UA/NSTEMI by sex group but not the rates of events by treatment group. Bleeding in women undergoing PTCA was higher compared with men (adjusted OR, 3.6; 95% CI, 1.6 to 8.3). However, bleeding related to CABG was similar in women and men, with rates of 12.6 and 15%, respectively. No studies systematically reported radiation exposure, contrast reactions, access site complications, stent thrombosis, or infection in women with UA/NSTEMI comparing early invasive with initial conservative therapy.</li> </ul>

**Table C. Summary of key findings (continued)**

Key Question	Strength of Evidence	Conclusions
<p><b>KQ 3: Strategy 1—women with stable angina (revascularization vs. optimal medical therapy)</b></p>	<p><u>Effectiveness of interventions</u></p> <p>1. With the PCI strategy: Moderate (women) and low (men) for long-term (4- to 5-year) composite outcomes</p> <p>2. With the CABG strategy: Low (women and men) for long-term (4- to 5-year) composite outcomes</p> <p>3. With both types of revascularization: Moderate (women) and low (men) for long-term (4- to 5-year) composite outcomes</p>	<p>5 studies (all good quality) compared revascularization (PCI or CABG) with optimal medical therapy for women with stable angina and contributed evidence about the comparative effectiveness, modifiers of effectiveness, or safety for these interventions. These studies included a total of 6,851 patients, of which 1,285 (19%) were women.</p> <ul style="list-style-type: none"> <li>• <u>Effectiveness of interventions:</u> A meta-analysis of 3 good-quality studies with long-term followup on the composite outcomes (death/MI/revascularization) comparing PCI or CABG with optimal medical therapy showed that revascularization was significantly better than optimal medical therapy in women with stable angina (OR, 0.64; 95% CI, 0.47 to 0.89; p=0.008 for PCI strategy trials; OR, 0.56; CI, 0.32 to 0.96; p=0.04 for CABG strategy trials; and OR, 0.59; CI, 0.43 to 0.81; p=0.001 for either PCI or CABG). However, for men with stable angina, the analysis suggested a small benefit for optimal medical therapy when compared with PCI (OR, 1.03; CI, 0.79 to 1.33). This suggested small benefit however has a wide confidence interval crossing 1 and is not supported by additional time periods or by the evidence in women. Analyses suggested a benefit of CABG (OR, 0.62; CI, 0.31 to 1.24) or either PCI or CABG (OR, 0.71; CI, 0.49 to 1.02) in men with stable angina. These findings were not statistically significant and had very wide confidence intervals.</li> </ul>

**Table C. Summary of key findings (continued)**

Key Question	Strength of Evidence	Conclusions
<p><b>KQ 3: Strategy 2—women with stable/unstable angina (PCI vs. CABG)</b></p>	<p><u>Effectiveness of interventions</u></p> <ol style="list-style-type: none"> <li>1. Low (women and men) for short-term (30-day) composite outcomes</li> <li>2. Low (women and men) for intermediate-term (1-year) composite outcomes</li> <li>3. Low (women) and high (men) for long-term (&gt;2-year) composite outcomes</li> </ol> <p><u>Modifiers of effectiveness</u></p> <p>Insufficient</p> <p><u>Safety concerns</u></p> <p>Insufficient</p>	<p>10 studies (8 good quality, 2 fair) compared PCI with CABG in women with stable/unstable angina and contributed evidence about the comparative effectiveness, modifiers of effectiveness, or safety for these interventions. These studies included a total of 6,289 patients, of which 1583 (25%) were women.</p> <ul style="list-style-type: none"> <li>• <u>Effectiveness of interventions:</u> A meta-analysis of 2 good-quality studies reporting a 30-day death outcome showed no statistically significant difference between PCI and CABG in either men or women. The summary odds ratio in women was 0.68 (95% CI, 0.24 to 1.93) and in men was 1.36 (CI, 0.44 to 4.24). The odds ratios suggest a possible sex effect, with PCI showing more benefit in women and CABG showing more benefit in men, but the confidence intervals are too wide to support firm conclusions. For 1-year composite outcomes (death/MI/stroke), a meta-analysis of 2 good-quality studies showed lower events in the CABG group for both sexes, but this benefit was not statistically significant. The summary odds ratio in women was 1.30 (CI, 0.69 to 2.45) and in men was 1.19 (CI, 0.84 to 1.70). For long-term (&gt;2 years) composite outcomes (death/MI/stroke), a meta-analysis of 4 good-quality studies suggested lower events in the CABG group in women (OR, 1.17; CI, 0.90 to 1.54) although again this did not reach statistical significance; however in men, CABG was significantly better than PCI in lowering cardiovascular events (OR, 1.63; CI, 1.20 to 2.23; p=0.002).</li> <li>• <u>Modifiers of effectiveness:</u> 1 good-quality study evaluated the comparative effectiveness of PCI vs. CABG in diabetic patients with stable/unstable angina. The survival rate at 7 years was similar in diabetic women from both treatment groups. However in diabetic men, those treated with CABG had higher survival than those treated with PCI.</li> <li>• <u>Safety concerns:</u> 1 good-quality study reported harms associated with PCI compared with CABG among women with UA/NSTEMI and found that bleeding associated with PCI was higher in women compared with men (OR, 29.4; 95% CI, 5.3 to 500; p=0.001). No studies systematically reported radiation exposure, contrast reactions, access site complications, stent thrombosis or infection, in women with UA/NSTEMI undergoing PCI or CABG.</li> </ul>

CABG = coronary artery bypass grafting; CI = confidence interval; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; SOE = strength of evidence; STEMI = ST elevation myocardial infarction; t-PA = tissue plasminogen activator; UA = unstable angina

Our stakeholder group advised us to assess the effectiveness of these therapies by sex on multiple important clinical outcomes such as nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects. A majority of sex-specific reporting was on the composite outcome of major cardiovascular adverse events (death, MI, or revascularization). Individual outcomes by sex were rarely reported, especially on heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects.

Based on the small number of studies that looked at demographic and clinical factors that influence response to treatment strategies in women, there was insufficient evidence that clinicians can use to determine if age, race/ethnicity, socioeconomic status, coronary risk factors, angiographic-specific factors, CABG-specific factors, or hospital-level characteristics should be taken into consideration when deciding a treatment strategy for women with CAD. Unfortunately, more studies are needed that evaluate the subgroups and various demographic and clinical characteristics to fully understand this evidence gap.

In addition, the safety concerns or harms of these treatment strategies are underreported for women enrolled in RCTs. It appears that the bleeding risk may be higher in women receiving fibrinolysis or PCI. Careful consideration should be given to the dose, timing, and duration of antiplatelet, antithrombotic, and anticoagulant therapies administered to women.


## **Limitations of the Review Process**

With 28 studies meeting the inclusion criteria, this systematic review has several limitations. First, our search focused on comparative RCTs—the highest quality of evidence for determining the efficacy of different treatment modalities on cardiovascular outcomes. While this was adequate for evaluating the evidence to support the clinical outcomes by treatment strategy and by CAD presentation for the overall population, there were very few RCTs that reported subgroup analyses by demographic or clinical characteristics and also very few RCTs that reported the harms or risks of therapy. Most studies that reported results applicable to modifiers of effectiveness or safety did this for the overall population and did not separate the effects by sex. We are aware that there are several observational and noncomparator studies of each of the treatment modalities that address these issues in women. Because of the problems with confounding from observational studies and the difficulty of constructing reliable comparisons among single-arm studies, we did not include observational or noncomparator studies in our review.

Second, the sample size and low representation of women in most of the comparator studies may affect the study authors' ability to analyze the results by sex, therefore reducing the number of studies reporting these findings separately (i.e., reporting bias). We excluded 355 articles due to lack of sex-specific reporting of the study results, which resulted in low numbers of studies available for analysis for each clinical presentation (STEMI, UA/NSTEMI, stable angina). Of these 355 articles, 116 were associated with the same 28 studies included in our review, but they did not report data on women separately. The remaining 239 articles were associated with 173 studies that did not report data on women. Figure C presents a graph of the number of articles reporting data on women per year. The percentage ranges from 0 percent (in 1992 and 1993) to 75 percent in 1995. On average, 17 percent of the articles comparing treatment strategies for CAD reported sex-specific outcomes. Of note, many articles included a multivariate analysis that included sex as a covariate in the model; the majority found no evidence of a sex effect. The result of a multivariable model is insufficient for incorporating into a meta-analysis; thus these

were excluded from the review. Reporting bias in these publications therefore resulted in selection bias in this review.

**Figure C. Number of articles reporting data on women by year**



Third, the strength of our meta-analysis is limited by the different definitions of the primary composite outcome and by the timing (short term and long term) of those clinical endpoints. We used our best judgment in choosing which composite outcomes (e.g., death/MI/stroke and death/MI/stroke/revascularization) and time points (e.g., in hospital and 30 days) to combine in the meta-analysis.

A final limitation is the change in PCI techniques and definition of optimal medical therapy over time. Most of the studies involved balloon angioplasty or bare-metal stents. The current era of drug-eluting stents and the use of dual antiplatelet therapy may be underrepresented. Nevertheless, the findings represent the best available evidence. While the treatment options continue to evolve over time, these older therapies (bare-metal stents, balloon angioplasty) are still being used in clinical practice, and therefore we did not downgrade the strength of evidence based on the availability of newer technologies. Medication adherence to beta blockers, angiotensin-converting enzyme inhibitors, aspirin, antiplatelet agents, and lipid-lowering agents were not reported in the studies included in this review. There was also variable reporting on the implementation of optimal medical therapy.

Many of these studies were multicenter, international RCTs with multiple countries represented. The generalizability of those studies to the United States may be of concern; however, the practice of revascularization and prescription of medical therapies are not dramatically different.

## Conclusions

From a limited number of studies reporting results for women separately from the total study population, our findings confirm current practice and evidence for care in one of the three areas evaluated.

1. For women with STEMI, we found that an invasive approach with immediate PCI is superior to fibrinolysis for reducing cardiovascular events, which is similar to findings in previous meta-analyses combining results for both women and men.
2. For women with NSTEMI or unstable angina, we found that, although not statistically significant, the evidence suggests a benefit of an early invasive approach in reducing cardiovascular events, whereas previous meta-analyses of studies comparing early invasive with initial conservative strategies on a combined population of men and women showed a statistically significant benefit of early invasive therapy.
3. For women with stable angina, the few trials reporting sex-specific data on revascularization compared with optimal medical therapy showed a greater benefit with revascularization for women, while the men in the study fared equally well with either treatment. In contrast, previous meta-analyses that combined results for men and women found similar outcomes for either treatment.

## Implications for Future Research

This comprehensive review of the comparative effectiveness of treatment modalities for women with CAD identified numerous gaps in evidence that would be suitable for future research and for improving the reporting of women findings of cardiovascular therapies in the published literature.

## Studies With Sufficient Representation of Women

Sex subgroup analyses are often limited by the number of men or women in each treatment group to allow for adequate power to detect a statistically significant difference in outcome. While we were able to find RCTs that reported risk ratios in women, the enrollment numbers were insufficient to have adequate power to detect a difference, thus resulting in large confidence intervals that often crossed the null effect, with a potential type II error. To better understand the clinical outcomes of women treated by medical therapy or revascularization, trials should be either (1) women-only enrollment or (2) of large enough sample size with stratification of randomization by sex to allow for meaningful sex-based analyses. In order to assess sex differences in treatment modalities and their impact on clinical outcomes, a sufficient sample size is required in order to have adequate statistical power for subgroup analyses.

## Patient-Level Meta-Analysis

Given the small representation of women in these RCTs, the heterogeneity of clinical outcomes (e.g., definition of composite outcome) and different measurement time points (e.g., 30 days or 6 weeks for short-term outcomes), we are aware that our group-level meta-analysis may be inadequate (when too few studies are available) to address the comparative effectiveness of medical therapy and revascularization. Therefore, patient-level analysis of trials comparing similar interventions for the same CAD presentation may be more appropriate for assessing the sex differences as well as for conducting subgroup analyses on demographic and clinical factors that influence treatment outcomes, or for evaluating safety concerns/harms of these treatment



strategies. Subgroup analyses across trials can be done similarly to a previous AHRQ report on the comparative effectiveness of PCI and CABG, which included an addendum study that pooled individual patient data from 10 randomized trials to compare the effectiveness of CABG with PCI according to patients' baseline clinical characteristics (e.g., age, diabetes, sex, individual cardiac risk factors, angioplasty versus bare metal stents).<sup>32,36,37</sup>

## **Reporting Sex by Treatment Results Separately**

Our review excluded trials that looked for a sex effect yet failed to provide results of women and men by treatment arm. An example is a trial that did a multivariate analysis to assess factors that influenced clinical outcomes and included male (or female) sex in the model, with a finding that it was nonsignificant or significant. We did not contact the corresponding authors of the articles that did not report sex results separately. It would aid future comparisons of treatment modalities if study authors were to report the primary data for women and men separately either within the article itself or in an online supplementary appendix. The 2010 report by the Institute of Medicine on Women's Health Research recommended that funding agencies ensure adequate participation of women and reporting of sex-specific analyses in health research.<sup>38</sup>

## **Reporting of Demographic and Clinical Factors That Influence Cardiovascular Outcomes**

We found a few studies that conducted subgroup analyses of age, diabetes, and risk stratification in women populations. We did not find any data specific to women on race/ethnicity, socioeconomic factors, chronic kidney disease, angiographic-specific factors, or CABG-specific factors that were listed in KQ 2. Knowing the influence of these factors on cardiovascular outcomes is important for determining the proper treatment strategy and prognosis of women patients who present with various risk factors and comorbidities.

## **Reporting of Safety Concerns/Risks by Sex**

Medical therapy can result in adverse drug reactions, and use of fibrinolytics can result in bleeding or intracranial hemorrhage. PCI can cause access site complications, radiation exposure, contrast-related anaphylaxis, bleeding, and stent thrombosis. CABG can result in wound infections, renal dysfunction, and bleeding. Most studies reported the bleeding risk of revascularization strategies but not the other safety concerns. Systematic reporting of adverse events in publications—in total and by sex—should continue to clarify which treatment modalities are safe for use in clinical practice.

To summarize, these evidence gaps could be addressed in various ways. First, more primary research with adequate representation of women for any of the three CAD clinical presentations could be conducted to achieve adequate statistical power for a sex-based analysis. Second, authors of the comparative trials that were excluded for not reporting sex-based results could be contacted to provide results of women and men by treatment arm, and the group-level meta-analysis could be repeated with a larger number of trials. Alternatively, these authors could be contacted to provide compatible (deidentified) datasets that could be combined for a patient-level analysis to assess the comparative effectiveness, modifiers of effectiveness, and risks of the various treatment strategies available. Finally, the use of observational cohorts from electronic health records could inform the real-world effectiveness of the treatment strategies chosen by clinicians and patients in a nonrandom fashion.

## Glossary

AHRQ	Agency for Healthcare Research and Quality
CABG	coronary artery bypass graft
CAD	coronary artery disease
CI	confidence interval
KQ	Key Question
MACE	major adverse cardiovascular events
MI	myocardial infarction
NSTEMI	non-ST elevation myocardial infarction
OR	odds ratio
PCI	percutaneous coronary intervention
RCT	randomized controlled trial
SOE	strength of evidence
STEMI	ST elevation myocardial infarction
TEP	Technical Expert Panel
t-PA	tissue plasminogen activator
UA	unstable angina

## References

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association. *Circulation*. 2012;125(1):e2-e220. PMID: 22179539.
2. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation*. 2007;115(11):1481-501. PMID: 17309915.
3. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. *J Am Coll Cardiol*. 2009;54(17):1561-75. PMID: 19833255.
4. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. *N Engl J Med*. 1999;341(4):226-32. PMID: 10413734.
5. Berger JS, Elliott L, Gallup D, et al. Sex differences in mortality following acute coronary syndromes. *JAMA*. 2009;302(8):874-82. PMID: 19706861.
6. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. *Circulation*. 2005;111(5):682-96. PMID: 15687114.
7. Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. *Circulation*. 2006;114(13):1380-7. PMID: 16982940.
8. Pepine CJ. Ischemic heart disease in women: facts and wishful thinking. *J Am Coll Cardiol*. 2004;43(10):1727-30. PMID: 15145090.

9. Vaccarino V, Abramson JL, Veledar E, et al. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. *Circulation*. 2002;105(10):1176-81. PMID: 11889010.
10. Mikhail GW. Coronary heart disease in women. *BMJ*. 2005;331(7515):467-8. PMID: 16141136.
11. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. *N Engl J Med*. 1999;341(4):217-25. PMID: 10413733.
12. Daly C, Clemens F, Lopez Sendon JL, et al. Gender differences in the management and clinical outcome of stable angina. *Circulation*. 2006;113(4):490-8. PMID: 16449728.
13. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol*. 2005;45(6):832-7. PMID: 15766815.
14. Anand SS, Xie CC, Mehta S, et al. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. *J Am Coll Cardiol*. 2005;46(10):1845-51. PMID: 16286169.
15. Vaccarino V, Rathore SS, Wenger NK, et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. *N Engl J Med*. 2005;353(7):671-82. PMID: 16107620.
16. Milner KA, Funk M, Richards S, et al. Gender differences in symptom presentation associated with coronary heart disease. *Am J Cardiol*. 1999;84(4):396-9. PMID: 10468075.
17. Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference? *Am Heart J*. 2004;148(1):27-33. PMID: 15215788.
18. Klein J, Karawan A, Abeles-Raviv N, et al. Is there a gender difference in risk profile, attendance, and beneficial effects of a multidisciplinary cardiac rehabilitation program? *J Am Coll Cardiol*. 2002;39(Supplement 1):1088-1137. PMID:
19. Kaski J. Cardiac syndrome X. In: Wenger NK and Collins P, eds. *Women and heart disease*. 2nd ed. London: Informa Healthcare. 2005:205-216. PMID:
20. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. *Eur Heart J*. 2004;25(18):1641-50. PMID: 15351164.
21. Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. *J Am Coll Cardiol*. 1997;30(1):141-8. PMID: 9207635.
22. Kreamsoulas C, Natarajan MK, Khatun R, et al. Identifying women with severe angiographic coronary disease. *J Intern Med*. 2010;268(1):66-74. PMID: 20210841.
23. Wenger NK. Angina in women. *Curr Cardiol Rep*. 2010;12(4):307-14. PMID: 20425162.
24. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. *JAMA*. 2001;286(6):708-13. PMID: 11495621.
25. Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. *Circ Cardiovasc Qual Outcomes*. 2010;3(2):135-42. PMID: 20160159.

26. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non ST-elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*. 2007;116(7):e148-304. PMID: 17679616.
27. Kushner FG, Hand M, Smith SC, Jr., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2009;120(22):2271-306. PMID: 19923169.
28. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). *Circulation* 2003;107(1):149-58. PMID: 12515758.
29. Sibley C, Rivera J, Blumenthal RS. 'ABCDE' makes an effective prevention tool. *Cardiology Today: approach translates guidelines into a comprehensive management plan for the primary and secondary prevention of CVD [commentary]*. 2007 Jun 1. [www.cardiologytoday.com/view.aspx?rid=39071](http://www.cardiologytoday.com/view.aspx?rid=39071).
30. Lansky AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. *Circulation*. 2005;111(7):940-53. PMID: 15687113.
31. Agency for Healthcare Research and Quality. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0*. Rockville, MD: Agency for Healthcare Research and Quality. Draft Posted October 2007. [www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318](http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318).
32. Bravata DM, McDonald KM, Gienger AL, et al. Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease. Comparative Effectiveness Review No. 9. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract No. 290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. October 2007. [www.effectivehealthcare.ahrq.gov/ehc/products/15/55/CER\\_PCI\\_CABGMainReport.pdf](http://www.effectivehealthcare.ahrq.gov/ehc/products/15/55/CER_PCI_CABGMainReport.pdf). PMID: 20704052.
33. Grady D, Chaput L, Kristof M. Results of systematic review of research on diagnosis and treatment of coronary heart disease in women. *Evid Rep Technol Assess (Summ)*. 2003(80):1-4. PMID: 12827897.
34. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet*. 2003;361(9351):13-20. PMID: 12517460.
35. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA*. 2005;293(23):2908-17. PMID: 15956636.

36. Hlatky MA, Boothroyd DB, Bravata DM, et al. Addendum to Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Interventions for Multivessel Disease. Comparative Effectiveness Review No. 9 Addendum. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract No. 290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. February 2010. [www.effectivehealthcare.ahrq.gov/ehc/products/15/421/CER9%20Addendum%20Final.pdf](http://www.effectivehealthcare.ahrq.gov/ehc/products/15/421/CER9%20Addendum%20Final.pdf).
37. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet*. 2009;373(9670):1190-7. PMID: 19303634.
38. Women's Health Research: Progress, Pitfalls, and Promise. Institute of Medicine of the National Academies, Consensus Report. 2010. [www.iom.edu/Reports/2010/Womens-Health-Research-Progress-Pitfalls-and-Promise.aspx](http://www.iom.edu/Reports/2010/Womens-Health-Research-Progress-Pitfalls-and-Promise.aspx).

# Introduction

## Background

Cardiovascular disease remains the leading cause of death among women in the United States.<sup>1</sup> More than 500,000 women die of cardiovascular disease each year, exceeding the number of deaths in men and the next seven causes of death in women combined. This translates into approximately one death every minute.<sup>1,2</sup> Coronary artery disease (CAD)—which includes coronary atherosclerotic disease, myocardial infarction, acute coronary syndrome, and angina—is the most prevalent form of cardiovascular disease and is the largest subset of this mortality. An estimated 16.3 million Americans 20 years of age and older have CAD, and the overall CAD prevalence is 7 percent in adults in the United States (8.3% for men, 6.1% for women). The prevalence of CAD is higher in men than in women across different age groups until they reach 75 years of age, thus giving the perception that CAD is a male-specific disease.<sup>1</sup>

The morbidity associated with this disease is also considerable. The estimated annual incidence of myocardial infarction is 610,000 new heart attacks; the average age at first myocardial infarction is 64.5 years for men and 70.3 for women. Many more individuals are hospitalized for unstable angina and for evaluation and treatment of stable chest pain syndromes. Recent data have shown a decrease in mortality rate in women, but reductions are well behind those obtained in men and are mainly in older women—still leaving the greater discrepancy in mortality rate limited to younger patients.<sup>3-5</sup>

This report focuses on women because of the differences in clinical presentation and coronary anatomy, which affect the treatment options for CAD.<sup>6-8</sup> Currently available guidelines and systematic reviews provide specific treatment recommendations for women only among a subset of treatment options and overall assume that treatment options are equally effective for both sexes when gender data are not available. However, women have a worse prognosis than men for manifestations of CAD such as acute myocardial infarction, and some data suggest that women and men do not respond equally to the same treatments. Further, women are more likely than men to experience bleeding complications.<sup>9-12</sup>

In women, CAD is misdiagnosed or not treated as aggressively as in men or is underresearched.<sup>4,13,14</sup> Multiple factors<sup>15</sup> are likely to contribute to the lower use of evidence-based medicine (medical therapy and/or coronary revascularization) and the higher rate of cardiovascular complications among women with CAD.<sup>6</sup> These factors include:

- Cardiovascular disease affects women later in life.<sup>1,15-17</sup>
- At the time CAD is diagnosed, women are more likely to have comorbid factors such as diabetes mellitus, hypertension, hypercholesterolemia, peripheral vascular disease, and heart failure.<sup>13</sup>
- Women present with angina-equivalent symptoms such as dyspnea or atypical symptoms more often than men.<sup>18,19</sup>
- The coronary vessels in women tend to be smaller than those of men, which makes them more difficult to revascularize percutaneously and surgically,<sup>20</sup> and microvascular disease of the coronary arteries is more common in women than in men.<sup>21</sup>
- Women tend to have less extensive CAD and a higher proportion of nonobstructive CAD.<sup>22,23</sup>

- Delay in hospitalization, symptom pattern and recognition, and higher frequency of nonobstructive CAD ultimately results in delay in diagnosis and effective treatment.<sup>15,16,24,25</sup>
- Because of underrepresentation of women in RCTs, a lack of solid data on cardiovascular disease in women leaves uncertainty about the risk-benefit ratio of treatment.<sup>26,27</sup>

Thus, a better understanding of the evidence for the effectiveness of medical treatment and revascularization therapies specifically in women is needed in order to reduce cardiovascular events in women.

## Clinical Presentations of CAD

Coronary artery disease is the presence of atherosclerosis in the epicardial coronary arteries. Atherosclerotic plaques may either rupture and cause acute ischemia or progressively narrow the coronary artery lumen, resulting in chronic stable angina. Acute myocardial ischemia occurs when an atheromatous plaque ruptures or splits. The reasons for why a specific plaque ruptures when it does are unclear but probably relate to plaque morphology, plaque calcium content, and plaque softening due to an inflammatory process. Rupture exposes collagen and other thrombogenic material, which activates platelets and the coagulation cascade, resulting in an acute thrombus that interrupts coronary blood flow and causes some degree of myocardial ischemia. The consequences of acute ischemia depend on the location and degree of obstruction and range from reversible ischemia (unstable angina) through partial obstruction and tissue damage (non-ST elevation myocardial infarction [NSTEMI]) to complete epicardial occlusions leading to possible transmural infarction of the heart muscle (ST elevation myocardial infarction [STEMI]). The constellation of clinical symptoms that are compatible with acute myocardial ischemia is usually referred to as acute coronary syndrome.<sup>28,29</sup>

Angina resulting from progressive narrowing of the coronary arteries is the initial manifestation of ischemic heart disease in approximately one-half of patients.<sup>30</sup> Angina is a clinical syndrome characterized by discomfort in the chest, jaw, shoulder, back, or arm. It is typically aggravated by exertion or emotional stress and relieved by nitroglycerin. Angina usually occurs in patients with CAD that involves at least one large epicardial artery. However, angina can also occur in patients with valvular heart disease, hypertrophic cardiomyopathy, and uncontrolled hypertension. It can also be present in patients with normal coronary arteries and myocardial ischemia related to spasm or endothelial dysfunction. Most angina is a sign of significant CAD—defined angiographically as a stenosis with greater than 70 percent diameter in at least one major epicardial artery segment or with greater than 50 percent diameter in the left main coronary artery. However, some angina is caused by stenotic lesions of lesser diameters, which have much less prognostic significance.<sup>30</sup>

Unstable angina (UA) is defined as angina with at least one of three features: (1) it occurs at rest or with minimal exertion, (2) it is severe and of recent onset (within the past 4 to 6 weeks), and/or (3) it occurs in a crescendo pattern (i.e., more severe, more prolonged, or more frequent than previously experienced). UA and NSTEMI have a fairly similar pathophysiology, mortality rate, and management strategy when compared with STEMI; therefore they are often grouped together as UA/NSTEMI in clinical guidelines and trial populations. Chronic stable angina is classified as pain that typically occurs with moderate to severe exertion, is milder in nature, and relieved with rest or sublingual nitroglycerin.

## **Treatment Options for Patients With CAD**

### **Optimal Medical Therapy**

All patients with CAD—regardless of clinical presentation—should receive aggressive management of risk factors for progression of atherosclerosis (smoking, hypertension, hyperlipidemia, and diabetes) combined with pharmacological treatment (antiplatelets, antianginals, beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and lipid-lowering drugs).<sup>31</sup> Optimal medical therapy of CAD comprises the combinations of these treatments to reduce future cardiovascular events for all the clinical presentations outlined in the previous section. However, patients may not be able to receive optimal medical therapy if they have allergies to, or adverse effects from, individual medications (e.g., aspirin, beta blockers, or cholesterol-lowering drugs) or the combination of medications. Also, the definition of optimal medical therapy continues to evolve as new drugs are developed and as studies are conducted to assess the optimal blood pressure, blood sugar, and lipid goals needed to reduce future cardiovascular events. For medical therapy to be optimized, patients should be prescribed appropriate therapy to reach their therapeutic goal. The effectiveness of medical therapy is also affected by how adherent the patient is to the prescribed therapy.

### **Coronary Revascularization**

Coronary revascularization falls broadly into two categories: coronary artery bypass grafting (CABG) and catheter-based percutaneous coronary intervention (PCI). Together, these coronary revascularization techniques are among the most common major medical procedures performed in North America and Europe. Since the introduction of bypass surgery in 1967 and PCI in 1977, it has become clear that both strategies can contribute to the effective treatment of patients with CAD. CABG and PCI (with or without stents) are alternative approaches in coronary revascularization, so their comparative effectiveness in terms of patient outcomes has been of great interest. The comparative effectiveness of CABG and PCI is an open question primarily for those patients for whom either procedure would be technically feasible or whose CAD is neither too limited nor too extensive.

CABG is generally preferred for patients with very high CAD burden—often described as left main CAD or severe triple-vessel disease with reduced left ventricular function—because CABG has previously been shown in randomized controlled trials (RCTs) to improve survival when compared with medical therapy. In contrast, PCI is generally preferred for patients with milder CAD burden—described as single- or double-vessel disease—when symptoms warrant coronary revascularization, in light of its lower procedural risk and evidence that PCI reduces angina and myocardial ischemia in this subset of patients. Uncertainty exists about the choice between PCI or CABG for patients with moderate CAD burden; namely, patients with disease of the proximal left anterior descending artery and less extensive forms of triple-vessel CAD. Most RCTs of PCI and CABG have been conducted in this middle segment of the patient population with CAD. The major advantage of PCI is its relative ease of use and avoidance of general anesthesia, thoracotomy, extracorporeal circulation, central nervous system complications, and prolonged convalescence. Repeat PCI can be performed more easily than repeat bypass surgery, and revascularization can be achieved more quickly in emergency situations. The disadvantages of PCI are early restenosis and the inability to relieve many totally occluded arteries or vessels with extensive atherosclerotic disease. CABG has the advantages of greater durability (graft



patency rates exceeding 90% at 10 years with arterial conduits) and more complete revascularization regardless of the morphology of the obstructing atherosclerotic lesion.<sup>32</sup>

Therefore, patients and clinicians have two or more major treatment approaches to consider for each presentation of CAD. In general, these fall into less invasive (i.e., more medical) approaches and more invasive approaches. Table 1 summarizes the major treatment options for each clinical scenario described in the sections that follow.

**Table 1. Comparisons of treatment strategies for women with CAD**

CAD Presentation	Treatment Choices
STEMI	PCI vs. fibrinolysis PCI vs. conservative/supportive medical management
NSTEMI/unstable angina	Early invasive management (with PCI or CABG) vs. initial conservative management
Stable/unstable angina	PCI vs. CABG vs. optimal medical therapy

CABG = coronary artery bypass grafting; CAD = coronary artery disease; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST elevation myocardial infarction

## STEMI

Treatment for patients with ST-segment elevation is well established. Patients with STEMI are candidates for reperfusion therapy (either pharmacological or catheter based) to restore blood flow promptly in the occluded epicardial infarct-related artery. Pharmacological therapy consists of fibrinolysis or conservative/supportive therapy with facilitated antithrombotic medications.<sup>29</sup> Multiple randomized trials have demonstrated the benefit of PCI in reducing major cardiovascular adverse events when compared with fibrinolysis or conservative therapy; therefore, immediate revascularization with PCI is the preferred strategy when patients have close access to a catheterization facility. Otherwise, fibrinolysis is recommended (in facilities without access) since it also has been shown to improve cardiovascular outcomes. In older or unstable patients, the use of fibrinolytics can increase bleeding complications; therefore trials comparing conservative medical therapy with PCI have been performed. In general, patients with STEMI are not treated with CABG (unless emergent from PCI complications) but do receive optimal medical therapy.

## UA/NSTEMI

Patients with UA/NSTEMI are not candidates for immediate pharmacological reperfusion. The optimal management of UA/NSTEMI has the twin goals of the immediate relief of ischemia and the prevention of serious adverse outcomes (i.e., death or MI). Optimal management is best accomplished with an approach that includes anti-ischemic therapy, antithrombotic therapy, ongoing risk stratification, and in some cases the use of invasive procedures. In addition to aggressive medical therapy, two treatment pathways have emerged for treating patients without ST-segment elevation.<sup>28</sup> An initial conservative strategy (also referred to as selective invasive management) calls for proceeding with an invasive evaluation only for those patients whose medical therapy fails (refractory angina or angina at rest or with minimal activity despite vigorous medical therapy) or in whom objective evidence of ischemia (dynamic electrocardiographic changes, high-risk stress test) is identified. The early invasive strategy triages patients to undergo an invasive diagnostic evaluation without first getting a noninvasive stress test or having medical treatment fail. Patients treated with an early invasive strategy generally will undergo coronary angiography within 4 to 24 hours of admission; however, these

patients also are treated with the usual UA/NSTEMI medications, including appropriate anti-ischemic, antiplatelet, and anticoagulant therapy. Several RCTs have demonstrated improved clinical outcomes in patients with an invasive strategy, leading to guideline recommendations for invasive approaches to treat patients with NSTEMI and high-risk acute coronary syndrome. Patients with UA/NSTEMI also receive optimal medical therapy.

## Angina

The treatment of stable angina has two major purposes. The first is to prevent MI and death and thereby increase the quantity of life. The second is to reduce symptoms of angina and occurrence of ischemia, which should improve the quality of life.<sup>30</sup> All patients with stable angina are candidates for optimal medical therapy and may be candidates for PCI or CABG based on findings from coronary angiography and if symptoms persist despite optimal medical therapy.

## Scope and Key Questions

Although CAD is the leading cause of death for women in the United States, treatment studies to date have primarily enrolled men and may not reflect the benefits and risks that women experience. We conducted a systematic review of the medical literature to assess the comparative effectiveness of the major treatment options for CAD specifically in women, evaluating these comparisons:

1. PCI versus fibrinolysis or PCI versus conservative/supportive medical management in women with STEMI
2. Early invasive versus initial conservative management in women with UA/NSTEMI
3. PCI versus CABG versus optimal medical therapy in women with stable or unstable angina

The endpoints assessed were clinical outcomes, modifiers of effectiveness by demographic and clinical factors, and safety outcomes. The following Key Questions (KQs) were considered in this review:

**KQ 1.** In women presenting with ST elevation myocardial infarction (STEMI):

- a. What is the effectiveness of percutaneous coronary intervention (PCI) versus fibrinolysis/supportive therapy on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects)?
- b. Is there evidence that the comparative effectiveness of PCI versus fibrinolysis/supportive therapy varies based on characteristics such as:
  - Age, race, or other demographic and socioeconomic risk factors?
  - Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
  - Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or coronary artery bypass graft surgery [CABG] revascularization procedure)?
  - Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?
- c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

**KQ 2.** In women presenting with unstable angina or non-ST elevation myocardial infarction (UA/NSTEMI):

- a. What is the effectiveness of early invasive (PCI or CABG) versus initial conservative therapy on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, graft failure, angina relief, quality of life, or cognitive effects)?
- b. Is there evidence that the comparative effectiveness of early invasive versus initial conservative therapy varies based on characteristics such as:
  - Age, race, or other demographic and socioeconomic risk factors?
  - Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
  - Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or CABG revascularization procedure)?
  - Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?
- c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

**KQ 3.** In women presenting with stable or unstable angina:

- a. What is the effectiveness of the following treatment strategies on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, graft failure, angina relief, quality of life, or cognitive effects)?
  - Revascularization (PCI or CABG) versus optimal medical therapy in women with stable angina
  - PCI versus CABG in women with stable or unstable angina
- b. Is there evidence that the comparative effectiveness of revascularization versus optimal medical therapy varies based on characteristics such as:
  - Age, race, or other demographic and socioeconomic risk factors?
  - Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
  - Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or CABG revascularization procedure)?
  - CABG-specific factors such as type of surgery performed, cardiopulmonary bypass mode (normothermic versus hypothermic), on-pump versus off-pump, type of cardioplegia used (blood versus crystalloid), or use of saphenous vein grafts, single or bilateral internal mammary artery grafts, or other types of bypass grafts?
  - Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?
- c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

# Methods


## Topic Development and Refinement

During the topic refinement stage, the Key Questions (KQs) were refined with the help of an eight-person Key Informant group representing clinicians (cardiology, primary care, cardiac surgery), patients, scientific experts, and Federal agencies. We solicited input from the Task Order Officer and an eight-person Technical Expert Panel (TEP) with experts knowledgeable in CAD, PCI, and CABG throughout our evidence review and followed, based on an a priori research protocol, the Effective Health Care Program’s Methods Guide for Effectiveness and Comparative Effectiveness Reviews<sup>33</sup> (hereafter referred to as Methods Guide) for literature search strategies, inclusion/exclusion of studies, abstract screening, data abstraction and management, assessment of methodological quality of individual studies, data synthesis, and grading of evidence for each KQ. All Key Informant and TEP participants were screened for conflicts of interest, and any potential conflicts were balanced or mitigated.

## Analytic Framework

Figure 1 shows the analytic framework for the systematic review of the comparative effectiveness of treatment strategies for women with CAD.

**Figure 1. Analytic framework**



CABG = coronary artery bypass graft; CAD = coronary artery disease; KQ = Key Question; MACE = major adverse cardiovascular events; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST elevation myocardial infarction

# Literature Search Strategy

## Sources Searched

We included studies published in English from January 1, 2001, through December 12, 2011. Search strategies were specific to each database in order to retrieve the articles most relevant to the KQs. Our search strategy used the National Library of Medicine's medical subject headings (MeSH) keyword nomenclature developed for MEDLINE<sup>®</sup> and adapted for use in other databases. In consultation with our research librarians, we used PubMed<sup>®</sup>, Embase<sup>®</sup>, the Cochrane Database of Systematic Reviews, and the Cochrane Central Registry of Controlled Trials for our literature search. We also searched the grey literature of study registries and conference abstracts for relevant articles from completed RCTs. Grey literature databases included Clinicaltrials.gov; metaRegister of Controlled Trials; ClinicalStudyResults.org; WHO: International Clinical Trials Registry Platform Search Portal; and ProQuest COS Conference Papers Index. The exact search strings used in our strategy are given in Appendix A. The reference list of articles applicable to the relevant KQs of two previous AHRQ reports related to this topic<sup>34,35</sup> and from identified systematic reviews and meta-analyses was manually hand-searched and cross-referenced against our library, and additional manuscripts were retrieved. All citations were imported into an electronic bibliographic database (EndNote<sup>®</sup> Version X4; Thomson Reuters, Philadelphia, PA).

## Process for Study Selection

### Screening for Inclusion and Exclusion

We developed a list of article inclusion and exclusion criteria for the KQs (Table 2). This review focused on randomized controlled studies since this is the strongest study design for evaluating treatment effectiveness and since observational studies contain potential biases (e.g., patient selection bias, intervention bias) that could affect the clinical outcome. The TEP approved this approach given that the number of abstracts identified in PubMed exceeded 5,000. This review focused on comparisons of treatment strategies; therefore, differences in specific drugs or devices were not investigated and were considered beyond the scope. Using the prespecified inclusion and exclusion criteria, titles and abstracts were examined independently by two reviewers for potential relevance to the KQs. Articles included by any reviewer underwent full-text screening. At the full-text screening stage, two independent reviewers read each article to determine if it met eligibility criteria. At the full-text review stage, paired researchers independently reviewed the articles and indicated a decision to “include” or “exclude” the article for data abstraction. When the paired reviewers arrived at different decisions about whether to include or exclude an article, they reconciled the difference through a third-party arbitrator. Articles meeting our eligibility criteria were included for data abstraction. Relevant review articles, meta-analyses, and methods articles were flagged for manual searching and cross-referencing against the library of citations identified through electronic database searching.

**Table 2. Summary of inclusion and exclusion criteria**

Study Characteristic	Inclusion Criteria	Exclusion Criteria
Population	<p>Adult women (<math>\geq 18</math> years of age) with CAD and angiographically proven single- or multiple-vessel disease including STEMI, NSTEMI, and stable angina</p>	<ul style="list-style-type: none"> <li>• Study population was composed entirely of patients without CAD, or the population also included patients with CAD but results were not reported separately for the subgroup with CAD</li> <li>• Study did not include women, or results were not reported by sex</li> <li>• All subjects under age 18, or some subjects under age 18, but results were not broken down by age</li> <li>• Study did not report any of the primary or secondary outcomes of interest</li> </ul>
Interventions and comparators	<p>Article reported original data for any of the interventions compared with another treatment category; or a related methodology paper of an included article</p> <ul style="list-style-type: none"> <li>• Optimal medical therapy alone</li> <li>• PCI (bare-metal and drug-eluting stents) with optimal medical therapy</li> <li>• CABG with optimal medical therapy</li> </ul>	<p>Intervention comparisons within the same treatment category such as:</p> <ul style="list-style-type: none"> <li>• Medical therapy with medical therapy (e.g., one type of fibrinolysis drug compared with another fibrinolysis drug)</li> <li>• PCI with PCI (e.g., bare-metal stent compared with drug-eluting stent)</li> <li>• CABG with CABG (e.g., open sternotomy compared with minimally invasive CABG)</li> </ul>
Outcomes and effect modifiers	<ul style="list-style-type: none"> <li>• Primary outcomes: major adverse cardiovascular events such as death, nonfatal myocardial infarction, stroke, and repeat revascularization</li> <li>• Other clinical outcomes: heart failure, repeat hospitalization, length of hospital stay, unstable angina, graft failure, angina relief, quality of life, cognitive effects</li> <li>• Adverse effects of interventions: adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections</li> </ul>	<ul style="list-style-type: none"> <li>• Outcomes of women not reported separately from total population</li> <li>• Study did not report any of the primary or secondary outcomes of interest</li> </ul>

**Table 2. Summary of inclusion and exclusion criteria (continued)**

Study Characteristic	Inclusion Criteria	Exclusion Criteria
Outcomes and effect modifiers (continued)	Effect modifiers—individual characteristics including the following: <ul style="list-style-type: none"> <li>• Age, race, or other demographic and socioeconomic risk factors</li> <li>• Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease</li> <li>• Angiographic-specific factors such as access site (radial or femoral), number of diseased vessels, vessel territory stenoses, left ventricular function, or prior PCI or CABG revascularization procedure</li> <li>• CABG-specific factors such as type of surgery performed (traditional or robot-assisted), cardiopulmonary bypass mode (normothermic vs. hypothermic), on-pump vs. off-pump, type of cardioplegia used (blood vs. crystalloid), or use of saphenous vein grafts, single or bilateral internal mammary artery grafts, or other types of bypass grafts</li> <li>• Hospital characteristics (hospital patient volume, setting, guideline-based treatment protocols)</li> </ul>	Outcomes of women not reported separately from total population
Timing	Short-term ( $\leq 30$ days), intermediate-term (1 year), or long-term ( $> 1$ year)	None
Setting	Inpatient or outpatient, primarily primary care and cardiology clinics	None
Study design	Randomized controlled trial (strongest study design for evaluating treatment effectiveness)	<ul style="list-style-type: none"> <li>• Observational (retrospective or prospective cohort) studies, due to potential biases that could affect the clinical outcome (e.g., patient selection bias, intervention bias)</li> <li>• Not a clinical study (e.g., editorial, nonsystematic review, letter to the editor, case series). Systematic reviews and meta-analyses were excluded from abstraction but hand-searched as potential sources of additional material if relevant to the topic.</li> </ul>
Publication languages	English only	Given the high volume of English-language publications (including the majority of known important studies), non-English articles were excluded

CABG = coronary artery bypass grafting; CAD = coronary artery disease; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST elevation myocardial infarction

## Data Extraction and Data Management

The investigative team created forms for abstracting the data elements for the KQs. The abstraction forms were pilot tested with a sample of included articles to ensure that all relevant data elements were captured and that there was consistency and reproducibility between abstractors for accuracy. Based on their clinical and methodological expertise, two researchers were assigned to abstract data from the eligible articles pertaining to the research questions. One researcher abstracted the data, and the second overread the article and the accompanying abstraction form to check for accuracy and completeness. Disagreements were resolved by consensus or by obtaining a third reviewer's opinion if consensus was not reached by the first two researchers. Guidance documents were drafted and given to the researchers as reference material to perform data abstraction, thus aiding in both reproducibility and standardization of data collection.

To aid in both reproducibility and standardization of data collection, researchers received data abstraction instructions directly on each form created specifically for this project with the DistillerSR data synthesis software program (Evidence Partners Inc., Manotick, ON, Canada). We designed the data abstraction forms for this project to collect the data required to evaluate the specified eligibility criteria for inclusion in this review as well as to collect demographics and outcomes. The safety outcomes abstracted included adverse drug reactions, radiation exposure, access-site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, and infections—which are the more common adverse events resulting from medical therapy and revascularization.

Appendix B lists the elements used in the data abstraction form. Appendix C contains a bibliography of all studies included in this review, organized alphabetically by author. When appropriate, methods articles providing additional detail were considered when abstracting data for an included study. If a methods article was used as a source for information in the abstraction of a study, it was included in the review and is listed in the bibliography in Appendix C.

## Individual Study Quality Assessment

Study quality was assessed on the basis of the reported methods and results and performed by two reviewers. We evaluated the quality of individual studies using the approach described in the Methods Guide.<sup>33</sup> To evaluate methodological quality, we applied criteria for RCTs that were derived from the core elements described in the Methods Guide. To indicate the summary judgment of the quality of the individual studies, we used the summary ratings of Good, Fair, and Poor based on the study's adherence to well-accepted standard methodologies and adequate reporting.

We used data abstracted on the population studied, the intervention and comparator, the outcomes measured, settings, and timing of assessments to identify specific issues that may have limited the applicability of individual studies or a body of evidence as recommended in the Methods Guide.<sup>33</sup> We used these data to evaluate the applicability to clinical practice, paying special attention to study eligibility criteria, demographic features of the enrolled population (e.g., age, race/ethnicity, sex) in comparison with the target population, version or characteristics of the intervention used in comparison with therapies currently in use (e.g., specific components of treatments considered to be “optimal medical therapy,” plus advancements in PCI or CABG techniques that have changed over time), and clinical relevance and timing of the outcome



measures. We summarized issues of applicability qualitatively. Appendix D summarizes our assessment of the quality and applicability for each included study.

## Data Synthesis

We synthesized the primary literature by continuous (e.g., age, event rates) and categorical data (e.g., race/ethnicity, presence of coronary disease risk factors). We determined the feasibility of completing a quantitative synthesis (i.e., meta-analysis). The feasibility of a meta-analysis depended on the volume of relevant literature (2 or more studies), and clinical and methodological homogeneity of the studies. When a meta-analysis was appropriate, we used random-effects models to quantitatively synthesize the available evidence (Review Manager software Version 5.1.; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). We tested for heterogeneity while recognizing that the ability of statistical methods to detect heterogeneity may be limited. When feasible, we used similar composite outcomes in the meta-analysis for two reasons: (1) a majority of studies reported a composite outcome (e.g., death, MI/ stroke/ revascularization) as their primary endpoint and (2) many of the studies reported results for women for the primary composite outcome but not for each individual (secondary) outcome. We presented summary odds ratio estimates, standard errors, and confidence intervals.

The majority of outcomes within this report were binary or categorical; therefore, we summarized these outcomes by proportions. We summarized inherently continuous variables, such as age, by mean, median, and standard deviation.

## Grading the Body of Evidence

The strength of evidence for each KQ was assessed by using the approach described in the Methods Guide.<sup>33</sup> The evidence was evaluated by using the four required domains: risk of bias (low, medium, or high), consistency (consistent, inconsistent, or unknown/not applicable), directness (direct or indirect), and precision (precise or imprecise). All the studies were randomized controlled trials and most were of good quality, resulting in a low risk of bias. To rate consistency, we looked at the test of heterogeneity and the  $I^2$  value; any significant test of heterogeneity or  $I^2$  value greater than 50 percent was rated as inconsistent. To rate directness, we looked at the composite outcome used in the meta-analysis; any inclusion of softer endpoints (e.g., revascularization or heart failure) in the composite outcome, or differences in the composite endpoint between studies, was rated as indirect. To rate precision, we looked at the effect sizes used in the power calculations of the trials to determine a clinically meaningful reduction in odds. For a negative finding, a confidence interval narrow enough to exclude a less than 30 percent reduction (or increase) was rated as precise. Additionally, when appropriate, the studies were evaluated for the presence of confounders that would diminish an observed effect, the strength of association (magnitude of effect), and publication bias.

The strength of evidence was assigned an overall grade of High, Moderate, Low, or insufficient according to the following four-level scale:

- High—High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
- Moderate—Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.

- Low—Low confidence that the evidence reflects the true effect. Further research is likely to change the confidence in the estimate of effect and is likely to change the estimate.
- Insufficient—Evidence either is unavailable or does not permit estimation of effect.


## **Peer Review and Public Commentary**

The peer review process was our principal external quality-monitoring device. Nominations for peer reviewers were solicited from several sources, including the TEP and interested Federal agencies. The list of nominees was forwarded to AHRQ for vetting and approval. A list of reviewers submitting comments on the draft report is included in the Preface.

## Results

The flow of articles through the literature search and screening process is depicted in Figure 2. Of the 13,073 citations identified by our searches, 5,369 were duplicates. Manual searching identified an additional 173 citations for a total of 7,877 citations. After applying inclusion/exclusion criteria at the title/abstract level, 619 full-text articles were retrieved and screened. Of these, 547 articles were excluded at the full-text screening stage, with 72 articles (representing 28 studies) remaining for data abstraction. Appendix E provides a complete list of articles excluded at the full-text screening stage, with reasons for exclusion.

**Figure 2. Literature flow diagram**



CABG = coronary artery bypass graft; CAD = coronary artery disease; KQ = Key Question; NSTEMI = non-ST elevation myocardial infarction; PCI = percutaneous coronary intervention; RCT = randomized controlled trial; STEMI = ST elevation myocardial infarction

## Key Question 1: Women With STEMI (PCI Vs. Fibrinolysis)

In women presenting with ST elevation myocardial infarction (STEMI):

a. What is the effectiveness of percutaneous coronary intervention (PCI) versus fibrinolysis/supportive therapy on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects)?

b. Is there evidence that the comparative effectiveness of PCI versus fibrinolysis/supportive therapy varies based on characteristics such as:

- Age, race, or other demographic and socioeconomic risk factors?
- Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
- Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or coronary artery bypass graft surgery [CABG] revascularization procedure)?
- Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?

c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

## Overview

STEMI is caused by the complete occlusion of an epicardial artery, leading to possible transmural infarction of the heart muscle. Treatment for patients with STEMI consists of reperfusion therapy (either pharmacological or catheter-based) to restore blood flow promptly in the occluded epicardial infarct-related artery. Pharmacological therapy consists of fibrinolysis or facilitated antithrombotic medications.<sup>29</sup> In general, patients with STEMI are not treated with CABG (unless emergent from PCI complications) but do receive optimal medical therapy in addition to treatment directed at removing the clot. Studies assessing the effectiveness of immediate PCI compared with fibrinolytics or immediate PCI compared with conservative/supportive therapy were evaluated for KQ 1.

## Key Points

- **Description of included studies:** Seven studies (6 good quality, 1 fair) evaluated PCI with or without supportive pharmacologic therapy versus fibrinolysis or other routine medical care for women with STEMI and included a total of 4,527 patients, of which 1,174 (26%) were women.
- **Effectiveness of interventions:** A meta-analysis of five studies (all good quality) reporting 30-day composite outcomes (primarily death/MI/stroke) showed that PCI was better than fibrinolysis in women (OR 0.50; 95% CI, 0.36 to 0.72) and men (OR 0.54; CI, 0.42 to 0.70). Strength of evidence favoring PCI over fibrinolysis was high at 30-day followup. However, there was insufficient evidence for assessing outcomes at 1 year. These findings also are limited in that all the studies were conducted with either balloon angioplasty or bare-metal stents. The current use of drug-eluting stents may lead to different practice patterns and, potentially, increase the effectiveness of PCI. Individual outcomes by sex were rarely reported for heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects.
- **Modifiers of effectiveness:** Two studies (1 good quality, 1 fair) reported subgroup analyses of demographic or clinical factors in women and included a total of 395 patients, of which 167 (32%) were women. Both studies assessed the influence of age on in-hospital mortality or composite clinical outcomes (death/heart failure/MI/stroke) and showed no age-related differences in PCI compared with optimal medical therapy. Therefore, there was insufficient evidence of the comparative effectiveness of treatment strategies among subgroups of women with STEMI, which precludes any meaningful conclusions.
- **Safety concerns:** Two good-quality studies reported safety concerns in women with STEMI and included a total of 1,532 patients, of which 367 (24%) were women. One study reported a lower nadir hematocrit in women receiving PCI versus fibrinolysis but no statistically significant differences in the requirement for blood transfusion. Another study reported the proportion of women with intracranial hemorrhage who received PCI versus accelerated tissue plasminogen activator (t-PA) (0% vs. 4.1%). No studies systematically collected radiation exposure, contrast reactions, access site complications, or stent thrombosis in women with STEMI undergoing PCI. Strength of evidence for safety concerns in STEMI studies was insufficient.

## Detailed Synthesis

We identified seven studies<sup>36-42</sup> that evaluated PCI with or without supportive pharmacologic therapy versus fibrinolysis or other routine medical care for women with STEMI. Of these seven studies, six were good quality, and one was fair quality. Table 3 presents a general description of these seven studies, including the study name, author, year, and related articles (i.e., study design and secondary papers); treatment comparisons evaluated; study population; and overall quality rating. Table 4 summarizes the women-specific outcomes (composite and individual) reported in these studies. Appendix F contains summary tables with sex-specific clinical outcomes for all followup time points.

**Table 3. KQ 1: Study characteristics of RCTs evaluating women with STEMI**

Study Author/Year Related Articles	Description of Study	# Subjects	Quality
<p>CARESS-in-AMI Di Mario et al., 2008<sup>36</sup></p> <p>and</p> <p>Di Mario et al., 2004<sup>43</sup></p>	<p><b>Title:</b> Immediate angioplasty vs. standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomized, multicentre trial</p> <p><b>Comparator:</b> Immediate PCI with fibrinolysis (reteplase) vs. fibrinolysis (reteplase) with rescue PCI</p> <p><b>Components of medical therapy:</b> Clopidogrel (300 mg bolus on arrival, then 75 mg once daily 1 to 12 months after stent implantation). Beta blockers, angiotensin-converting enzyme inhibitors, and statins were administered to all patients unless contraindicated.</p>	<p>Total: 600 Women: 128 (21%)</p>	<p>Good</p>
<p>DANAMI-2 Andersen et al., 2003<sup>37</sup></p> <p>and</p> <p>Mortensen et al., 2007<sup>44</sup> Nielsen et al., 2010<sup>45</sup> Busk et al., 2009<sup>46</sup> Busk et al., 2008<sup>47</sup></p>	<p><b>Title:</b> A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction</p> <p><b>Comparator:</b> PCI vs. fibrinolysis (accelerated t-PA)</p> <p><b>Components of medical therapy:</b> Aspirin 300 mg, IV beta-blocker (20 mg of metoprolol), IV unfractionated heparin (5000 U bolus, then 1000 U/hr).</p>	<p>Total: 1,572 Women: 417 (27%)</p>	<p>Good</p>
<p>Dobrzycki et al., 2007<sup>40</sup></p>	<p><b>Title:</b> Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals</p> <p><b>Comparator:</b> Transfer with tirofiban for primary PCI vs. onsite fibrinolysis (streptokinase)</p> <p><b>Components of medical therapy:</b> Aspirin 325 mg daily. Additional treatment was administered at the discretion of the physician.</p>	<p>Total: 401 Women: 105 (26%)</p>	<p>Good</p>
<p>GUSTO II-B Tamis-Holland et al., 2004<sup>39</sup></p>	<p><b>Title:</b> Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy</p> <p><b>Comparator:</b> PCI vs. fibrinolysis (accelerated t-PA)</p> <p><b>Components of medical therapy:</b> Not reported.</p>	<p>Total: 1,137 Women: 260 (23%)</p>	<p>Good</p>

**Table 3. KQ 1: Study characteristics of RCTs evaluating women with STEMI (continued)**

Study Author/Year Related Articles	Description of Study	# Subjects	Quality
Minai et al., 2002 <sup>41</sup>	<p><b>Title:</b> Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial</p> <p><b>Comparator:</b> PCI vs. optimal medical therapy (without fibrinolysis)</p> <p><b>Components of medical therapy:</b> IV heparin; IV nitroglycerin (0.5 mg/min/kg) for 24 hours after admission. Aspirin, other cardiovascular medications (calcium channel blockers, beta-blockers, and angiotensin-converting enzyme inhibitors administered at the discretion of the physician.</p>	Total: 120 Women: 60 (50%)	Fair
PAMI Stone et al., 1995 <sup>42</sup>	<p><b>Title:</b> Comparison of in-hospital outcome in men with outcome in women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction</p> <p><b>Comparator:</b> PCI vs. fibrinolysis (t-PA)</p> <p><b>Components of optimal medical therapy:</b> IV unfractionated heparin for 3 - 5 days, Nitroglycerin for at least 24 hours, followed by topic or oral nitrates. Aspirin 325 mg/daily, diltiazem 30 to 60 mg x 4 times a day; use of beta-blockers and IV lidocaine was left to investigator discretion.</p>	Total: 395 Women: 107 (27%)	Good
SHOCK Hochman et al., 2001 <sup>38</sup>  and  Hochman et al., 2006 <sup>48</sup> Hochman et al., 1999 <sup>49</sup> Hochman et al., 1999 <sup>50</sup>	<p><b>Title:</b> One-year survival following early revascularization for cardiogenic shock</p> <p><b>Comparator:</b> Early invasive revascularization (PCI or CABG within 6 hours) vs. initial medical stabilization (thrombolysis, IABP)</p> <p><b>Components of optimal medical therapy:</b> Aspirin, IV unfractionated heparin, as recommended by AHA/ACC guidelines and at discretion of local investigator.</p>	Total: 302 Women: 97 (32%)	Good

CABG = coronary artery bypass graft; IABP = intra-aortic balloon pump; IV = intravenous; PCI = percutaneous coronary intervention; RCT = randomized controlled trial; STEMI = ST elevation myocardial infarction; t-PA = tissue plasminogen activator

**Table 4. KQ 1: Outcomes reported in RCTs evaluating women with STEMI**

Study	Composite Outcome <sup>a</sup> (Timing)	Death <sup>a</sup> (Timing)	MI (Timing)	Stroke (Timing)	Revascularization (Timing)	Other (Timing)
	Anticipated Effect Size					
CARESS-in-AMI <sup>36,43</sup>	<i>Total mortality/reinfarction/refractory MI</i> (30 days)  Powered to detect >50% RRR					
DANAMI-2 <sup>37,44-47</sup>	<i>Total mortality/nonfatal MI/stroke</i> (30 days, 3 years; median 7.8 years)  Powered to detect 40% RRR	Yes (30 days, 3 years)				Angina (30 days, 1 year)  SF-36 (30 days, 1 year)
Dobrzycki et al. <sup>40</sup>	Total mortality/nonfatal MI/stroke (30 days, 1 year)  Powered to detect 50% RRR	Yes (30 days, 1 year)				
GUSTO II-B <sup>39</sup>	<i>Total mortality/nonfatal MI/nonfatal disabling stroke</i> (30 days)  Powered to detect 40% RRR	Yes (30 days)	Yes (30 days)	Yes (30 days)		Intracranial hemorrhage (30 days)
Minai et al. <sup>41</sup>	Total mortality/heart failure/repeat MI/stroke (3 years)  Primary outcome & effect size not specified					
PAMI <sup>42</sup>	<i>Death/reinfarction</i> (in hospital)  Powered to detect 50% RRR	Yes (in hospital)	Yes (in hospital)	Yes (in hospital)		Recurrent ischemia (in hospital)  Length of stay (in hospital)
SHOCK <sup>38,48-50</sup>	Powered to detect 25% RRR				Yes (1 year)	

MI = myocardial infarction; RRR = relative risk reduction; STEMI = ST elevation myocardial infarction

<sup>a</sup>Primary outcome in italics.



## KQ 1a: Effectiveness of Interventions

A meta-analysis was performed on studies with similar composite outcomes measured at similar time points. This meta-analysis was divided into followup intervals of short term ( $\leq 30$  days) and long term ( $\geq 1$  year). The SHOCK study,<sup>38</sup> evaluating early revascularization versus medical stabilization, did not report 1-year data by sex, except for noting the lack of a treatment-by-sex interaction, and therefore was not included in the meta-analysis. Similarly, in the Minai study<sup>41</sup> evaluating PCI versus no PCI, 3-year data reported no sex effect in a multivariate analysis; however, since the data were not reported by sex, this study also was excluded from the meta-analysis.

### Short-Term Followup Studies

Five studies—CARESS-in-AMI,<sup>36</sup> DANAMI-2,<sup>37</sup> Dobrzycki,<sup>40</sup> GUSTO II-B,<sup>39</sup> and PAMI<sup>42</sup>—were included in the meta-analysis based on comparable composite outcomes (primarily death/MI/stroke) and followup time points of 30 days or in-hospital. The published results from Dobrzycki et al. were inverted to change the reference arm to fibrinolysis. The PAMI study event rates by treatment group and sex were converted into odds ratios. Table 5 presents the outcomes, odds ratios, and confidence intervals for the meta-analysis.


**Table 5. Sex results for STEMI on composite outcomes (short-term)**

Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
CARESS-in-AMI (immediate PCI with reteplase vs. reteplase with rescue PCI)	Death/MI/refractory ischemia (30 days)	0.40 (0.12 to 1.31)	0.39 (0.18 to 0.85)	0.40 (0.21 to 0.76)
DANAMI-2 (immediate PCI vs. accelerated t-PA )	Death/MI/stroke (30 days)	0.47 (0.27 to 0.81)	0.59 (0.39 to 0.90)	0.55 (0.38 to 0.76)
Dobrzycki (transfer for primary PCI vs. onsite streptokinase )	Death/MI/stroke (30 days)	0.49 (0.20 to 1.18)	0.56 (0.26 to 1.18)	0.51 (0.29 to 0.91)
GUSTO II-B (PCI vs. accelerated t-PA)	Death/MI/stroke (30 days)	0.69 (0.36 to 1.32)	0.56 (0.35 to 0.91)	0.67 (0.47 to 0.97)
PAMI (PCI vs.t-PA )	Death/MI (in-hospital)	0.30 (0.08 to 1.16)	0.47 (0.18 to 1.19)	0.40 (0.18 to 0.85)

CI = confidence interval; MI = myocardial infarction; PCI = percutaneous coronary intervention; t-PA = tissue plasminogen activator

Forest plots for the random-effects model are shown in Figure 3. The summary odds ratio in women was 0.50 (95% CI, 0.36 to 0.72) and in men was 0.54 (CI, 0.42 to 0.70). The test for heterogeneity was nonsignificant. These results show that PCI was better than fibrinolysis in reducing death/MI/stroke in both sexes ( $p=0.0001$  women,  $p<0.00001$  men) at 30 days.

**Figure 3. STEMI short-term (30 days) PCI versus fibrinolysis**



## Intermediate-Term Followup Studies

Two studies—DANAMI-2<sup>44</sup> and Dobrzycki<sup>40</sup>—reported sex-specific clinical outcomes at 1 year. Table 6 presents the outcomes, odds ratios, and confidence intervals for PCI compared with fibrinolysis by sex. Due to the heterogeneous clinical outcomes, a meta-analysis was not conducted.

**Table 6. Sex results for STEMI on clinical outcomes (intermediate-term)**

Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
DANAMI-2 (immediate PCI vs. accelerated t-PA)	Angina	0.86 (0.50 to 1.49)	0.86 (0.61 to 1.20)	NR
Dobrzycki (transfer for primary PCI vs. onsite streptokinase)	Death/MI/stroke	0.40 (0.17 to 0.94)	0.62 (0.35 to 1.09)	0.53 (0.33 to 0.84)

CI = confidence interval; NR = not reported; PCI = percutaneous coronary intervention; t-PA = tissue plasminogen activator

## PCI Versus Fibrinolysis in High-Risk Groups

We identified two studies that evaluated a PCI or CABG strategy versus conservative/supportive medical therapy in high-risk groups.<sup>38,41</sup> These studies were not included in the meta-analysis since the actual results by sex were not reported in the manuscript; instead both papers report the results of a multivariate analysis with sex as a covariate in the model. The SHOCK study<sup>38</sup> was considered good quality and evaluated patients with cardiogenic shock and STEMI with a strategy of PCI or CABG within 6 hours versus initial medical stabilization that included fibrinolysis or insertion of an intra-aortic balloon pump (IABP). This study found that the early revascularization strategy was associated with a lower relative risk of death when compared with medical stabilization (risk ratio 0.72; 95% CI, 0.54 to 0.95). Analysis by sex did

not identify any significant interaction by treatment arm. The study by Minai et al.<sup>41</sup> was considered fair quality and evaluated PCI versus routine medical therapy without reperfusion in patients 80 years of age and older. There was no difference in the number of patients with the composite outcome of death/heart failure/repeat MI/stroke at 3 years between the treatment arms. No analysis by sex was done; however, in a multivariate analysis to evaluate factors associated with the composite outcome, sex was not found to be significantly associated with the outcome in the overall study population. This study was limited by the small sample size of 120 patients enrolled.

### **KQ 1b: Modifiers of Effectiveness**

Two studies<sup>41,42</sup> evaluating women with STEMI assessed the characteristics of interest and included a total of 515 patients, of which 167 (32%) were women. The PAMI study<sup>42</sup> was considered good quality and evaluated patients randomized to PCI versus fibrinolysis with t-PA. No difference was found in in-hospital mortality among women receiving PCI versus t-PA who were under 65 years of age (0% vs. 4%; p=0.42) nor among women 65 and older (5.9% vs. 21.9%; p=0.58).

The study by Minai et al.<sup>41</sup> evaluated PCI versus routine medical therapy without reperfusion in patients 80 years of age and older. The results are noted above. Appendix G contains a summary table with study data related to modifiers of effectiveness (subgroup analyses).

### **KQ 1c: Safety Concerns**

Two good-quality studies reported safety concerns in women with STEMI and included a total of 1,532 patients, of which 367 (24%) were women. In the PAMI study<sup>42</sup> evaluating PCI versus t-PA in STEMI patients, the mean nadir hematocrit in women with PCI was  $30 \pm 5$  percent versus  $33 \pm 5$  percent in women with t-PA (p=0.0002). However, there was no statistically significant difference in the requirement for blood transfusion in women with PCI versus t-PA (18% vs. 8.8%; p=0.16). In the GUSTO II-B study<sup>39</sup> the proportion of women with intracranial hemorrhage was reported in women who received PCI versus accelerated t-PA (0% vs. 4.1%), but statistical analysis for this comparison was not done. Appendix H contains a summary table with study data related to safety concerns (harms).

## Key Question 2: Women With UA/NSTEMI (Early Invasive Vs. Initial Conservative Therapy)

In women presenting with unstable angina or non-ST elevation myocardial infarction (UA/NSTEMI):

- a. What is the effectiveness of early invasive (PCI or CABG) versus initial conservative therapy on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, graft failure, angina relief, quality of life, or cognitive effects)?
- b. Is there evidence that the comparative effectiveness of early invasive versus initial conservative therapy varies based on characteristics such as:
  - Age, race, or other demographic and socioeconomic risk factors?
  - Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
  - Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or CABG revascularization procedure)?
  - Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?
- c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

## Overview

Unstable angina is caused by reversible ischemia of the epicardial arteries, whereas NSTEMI is caused by the partial obstruction of the epicardial arteries and results in myocardial tissue damage. Patients with UA/NSTEMI are not candidates for immediate pharmacological reperfusion (i.e., fibrinolysis). The optimal management of UA/NSTEMI has the twin goals of immediate relief of ischemia and the prevention of serious adverse outcomes (i.e., death or MI). Optimal management is best accomplished with aggressive medical therapy that includes anti-ischemic therapy, antithrombotic therapy, ongoing risk stratification, and in some cases the use of invasive procedures.

Following initiation of aggressive medical therapy, two treatment pathways have emerged for treating patients without ST-segment elevation.<sup>28</sup> An “initial conservative strategy” calls for proceeding with an invasive evaluation only for those patients whose medical therapy fails (refractory angina or angina at rest or with minimal activity despite vigorous medical therapy) or in whom objective evidence of ischemia (dynamic electrocardiographic changes, high-risk stress

test) is identified. The early invasive strategy triages patients to undergo an invasive diagnostic evaluation without first having a noninvasive stress test or having medical treatment fail. Patients treated with an early invasive strategy generally will undergo coronary angiography within 4 to 24 hours of admission; however, these patients also are treated with the usual UA/NSTEMI medications, including appropriate anti-ischemic, antiplatelet, and anticoagulant therapy. Therefore, studies assessing the effectiveness of early invasive versus initial conservative therapy were evaluated for KQ 2.

## Key Points

- **Description of included studies:** Seven studies (6 good quality, 1 fair) compared early invasive therapy (PCI or CABG) with initial conservative therapy for women with UA/NSTEMI and included a total of 17,930 patients, of which 6,084 (34%) were women.
- **Effectiveness of interventions:** A meta-analysis of two good-quality studies reporting 6-month composite outcomes (death/MI) suggested a benefit of early invasive compared with initial conservative therapy in women (OR 0.77; 95% CI, 0.28 to 2.12), but early invasive therapy was superior to initial conservative therapy in men (OR 0.65; CI, 0.52 to 0.82;  $p=0.0002$ ). At 1 year, a meta-analysis of five good-quality studies showed that composite outcomes (primarily death or MI) suggested a benefit for women who received early invasive therapy (OR 0.78; CI, 0.54 to 1.12) as well as for men (OR 0.88; CI, 0.64 to 1.20); however this benefit was not statistically significant. Finally, a meta-analysis of two good-quality studies with 5-year followup comparing early invasive and initial conservative therapy for the composite outcome of death or MI did not reach statistical significance in either sex. The summary odds ratio in women was 1.05 (CI, 0.81 to 1.35) and in men was 0.91 (CI, 0.53 to 1.56). The long-term analysis is limited by the low number of studies. Strength of evidence favoring an early invasive approach was low for women and high for men at 6-month followup; low for women and men at 1-year followup; and insufficient for women and low for men at 5-year followup. Similar to the STEMI studies, individual outcomes by sex were rarely reported for heart failure, repeat hospitalization, length of hospital stay, quality of life, or cognitive effects.
- **Modifiers of effectiveness:** Two good-quality studies comparing early invasive treatment with PCI with initial conservative treatment reported a subgroup analysis by risk stratification and included a total of 4,030 patients, of which 1,439 (36%) were women. These studies revealed conflicting results—one showed no difference in treatment outcomes in the intermediate- and high-risk groups; the other showed a higher event rate in women in the groups with moderate-to-high risk for thrombolysis in myocardial infarction (TIMI). Strength of evidence for modifiers of effectiveness for early invasive versus initial conservative treatments was insufficient.
- **Safety concerns:** One good-quality study (2,220 total patients, 757 women, 34% women) reported the harms associated with treatment of UA/NSTEMI by sex group but not the rates of events by treatment group. Bleeding in women undergoing PTCA was higher compared with men (adjusted OR 3.6; 95% CI, 1.6 to 8.3).<sup>51</sup> However, bleeding related to CABG was similar in women and men with rates of 12.6 and 15 percent respectively. No studies systematically reported radiation exposure, contrast reactions, access site complications, stent thrombosis or infection, in women with UA/NSTEMI comparing initial conservative with early invasive therapy. Strength of evidence for safety concerns in these populations was insufficient.

## Detailed Synthesis

We identified seven studies<sup>22,52-57</sup> that evaluated the effect of early invasive therapy compared with initial conservative therapy for UA/NSTEMI and reported results by sex. Of these seven studies, six were good quality, and one was fair. Table 7 presents a general description of these seven studies, including the study name, author, year, and related articles (i.e., study design and secondary papers); treatment comparisons evaluated; study population; and overall quality rating. Table 8 summarizes the women-specific outcomes (composite and individual) reported in these studies. Appendix F contains summary tables with sex-specific clinical outcomes for all followup time points.

**Table 7. KQ 2: Study characteristics of RCTs evaluating women with UA/NSTEMI**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
<p>FRISC II Lagerqvist et al., 2001<sup>52</sup></p> <p>and</p> <p>Lagerqvist et al., 2006<sup>58</sup> Wallentin et al., 2000<sup>59</sup> Anonymous, 1999<sup>60</sup></p>	<p><b>Title:</b> Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators</p> <p><b>Comparator:</b> Early invasive treatment with revascularization (PCI, type not specified, for 1- or 2-vessel CAD; CABG for 3-vessel CAD or left main disease) vs. initial conservative strategy</p> <p><b>Components of optimal medical therapy:</b> Aspirin 300 to 600 mg (initial), then 75 to 320 mg daily. Beta blockade (unless contraindicated). Organic nitrates and calcium antagonists as needed. Lowering of cholesterol with statins, angiotensin converting-enzyme inhibitors for left-ventricular dysfunction, and aggressive antidiabetic treatment were recommended according to modern treatment guidelines.</p>	<p>Total: 2,457 Women: 749 (30%)</p>	<p>Good</p>
<p>GUSTO IV-ACS Ottervanger et al., 2004<sup>53</sup></p>	<p><b>Title:</b> Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS</p> <p><b>Comparator:</b> Early invasive management vs. initial conservative treatment within 30 days. A total of 2265 (30%) patients underwent revascularization: 789 patients CABG, 1450 patients PCI, and 26 both CABG and PCI. Type of PCI was not specified.</p> <p><b>Components of optimal medical therapy:</b> Aspirin for 30 days if not contraindicated. IV unfractionated heparin as bolus and infusion for 48 hours or low molecular weight heparin (dalteparin) subcutaneously every 12 hours for 5 to 7 days or until a revascularisation procedure or discharge. Continuation of antithrombin therapy with unfractionated or low molecular weight heparin was left at the discretion of the investigator.</p>	<p>Total: 7,800 Women: 2,896 (37%)</p>	<p>Good</p>

**Table 7. KQ 2: Study characteristics of RCTs evaluating women with UA/NSTEMI (continued)**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
ICTUS de Winter et al., 2005 <sup>56</sup>  and  Damman et al., 2010 <sup>61</sup>	<p><b>Title:</b> Early invasive vs. selectively invasive management for acute coronary syndromes</p> <p><b>Comparator:</b> Early invasive therapy with revascularization vs. selective invasive strategy (initial conservative)</p> <p><b>Components of optimal medical therapy:</b> Aspirin (300 mg at randomization then 75 mg daily); enoxaparin (1 mg/kg twice daily subcutaneously for 48 hours), Clopidogrel (300 mg immediately, followed by 75 mg daily) in combination with aspirin was recommended after the drug was approved in 2002 for the indication of acute coronary syndromes; intensive lipid-lowering therapy, preferably 80 mg of atorvastatin daily or the equivalent.</p>	Total: 1,200 Women: 320 (27%)	Good
RITA-2 Anonymous, 1997 <sup>54</sup>	<p><b>Title:</b> Coronary angioplasty vs. medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants</p> <p><b>Comparator:</b> Early invasive therapy with PCI (primarily PTCA, but stent could be used if PTCA failed) vs. initial conservative</p> <p><b>Components of optimal medical therapy:</b> Aspirin, unless contraindicated. Antianginal medication for symptom relief. Beta-adrenoceptor blocker with a calcium antagonist and/or long-acting nitrate in maximally tolerated doses. Lipid-lowering drugs prescribed at the discretion of the supervising clinician.</p>	Total: 1,018 Women: 183 (8%)	Fair
RITA-3 Clayton et al., 2004 <sup>22</sup>  and  Fox et al., 2002 <sup>62</sup>	<p><b>Title:</b> Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST elevation myocardial infarction? The impact of gender in the RITA-3 trial</p> <p><b>Comparator:</b> Early invasive with PCI (type at discretion of investigator) vs. initial conservative</p> <p><b>Components of optimal medical therapy:</b> Aspirin; enoxaparin 1 mg/kg twice daily subcutaneously for 2 to 8 days. Antianginal treatment chosen by the supervising clinician, including a beta-blocker unless contraindicated.</p>	Total: 1,810 Women: 682 (38%)	Good



**Table 7. KQ 2: Study characteristics of RCTs evaluating women with UA/NSTEMI (continued)**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
<p>TACTICS TIMI-18 Cannon et al., 2001<sup>55</sup></p> <p>and</p> <p>Glaser et al., 2002<sup>51</sup> Cannon et al., 1998<sup>63</sup></p>	<p><b>Title:</b> Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban</p> <p><b>Comparator:</b> Early invasive with PCI (type not specified) vs. initial conservative</p> <p><b>Components of optimal medical therapy:</b> Aspirin 325 mg daily (unless contraindicated); IV unfractionated heparin (5000 U bolus, then 1000 U/hour for 48 hours); tirofiban (loading dose 0.4 <math>\mu</math> g/kg per minute for a period of 30 minutes, then 0.1 <math>\mu</math> g/kg/min for 48 hours or until revascularization, and for at least 12 hours after PCI; beta blockers (82%), nitrates (94%), and lipid-lowering agents (52%).</p>	<p>Total: 2,220 Women: 757 (34%)</p>	<p>Good</p>
<p>TIMI III-B Anonymous, 1994<sup>57</sup></p> <p>and</p> <p>Anderson et al., 1995<sup>64</sup></p>	<p><b>Title:</b> Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial</p> <p><b>Comparator:</b> Early invasive with PCI (type not specified) vs. initial conservative</p> <p><b>Components of optimal medical therapy:</b> Anti-ischemic therapy consisting of a beta-blocker (metoprolol 50 mg p.o. q 12 hours), a calcium antagonist (diltiazem 30 mg p.o. q 6 hours), and a long-acting nitrate (isosorbide dinitrate 10 mg p.o. q 8 hours) or larger doses and supplemented by sublingual nitroglycerin pm. IV heparin. Aspirin 325 mg daily was given on the second day and continued for 1 year.</p>	<p>Total: 1,425 Women: 497 (35%)</p>	<p>Good</p>

CABG = coronary artery bypass graft; PCI = percutaneous coronary intervention; NSTEMI = non-ST elevation myocardial infarction; PTCA: percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial; UA = unstable angina

**Table 8. Outcomes reported in RCTs evaluating women with UA/NSTEMI**

Study	Composite Outcome <sup>a</sup> (Timing)	Death (Timing)	MI (Timing)	Stroke (Timing)	Revascularization (Timing)	Other (Timing)
	Anticipated Effect Size					
FRISC II <sup>52,58-60</sup>	<i>Death/MI or both</i> (6 months, 1 year, 5 years)  Powered to detect 32% difference					
GUSTO IV-ACS <sup>53</sup>	Not reported by sex  Powered to detect 25% reduction in primary endpoint of death/MI	Yes (1 year)				
ICTUS <sup>56,61</sup>	<i>Death/MI/rehospitalization for angina</i> (1 year)  Death/spontaneous MI (5 years)  Powered to detect 25% RRR					
RITA-2 <sup>54</sup>	<i>Death/MI</i> (median followup of 2.7 years)  Powered to detect 15% difference					Angina grade 2+ (6 months)  Exercise time (6 months)
RITA-3 <sup>22,62</sup>	<i>Death/MI</i> (1 year)  Death/MI/refractory angina (4 months, 1 year)  Powered to detect 33% RRR	Yes (1 year)				

**Table 8. Outcomes reported in RCTs evaluating women with UA/NSTEMI (continued)**

Study	Composite Outcome <sup>a</sup> (Timing)  Anticipated Effect Size	Death (Timing)	MI (Timing)	Stroke (Timing)	Revascularization (Timing)	Other (Timing)
TACTICS TIMI-18 <sup>51,55,63</sup>	<i>Death/MI/rehospitalization for acute coronary syndrome</i> (6 months)  Death/MI (6 months)  Powered to detect 25% difference	Yes (6 months)				
TIMI III-B <sup>57,64</sup>	<i>Death/MI/failed symptom-limited exercise treadmill test</i> (6 weeks)  Death/MI (6 weeks, 1 year)  Powered to detect 30% RRR					

MI = myocardial infarction; RRR = relative risk reduction; NSTEMI = non-ST elevation myocardial infarction; UA = unstable angina

<sup>a</sup>Primary outcome in italics.

## KQ 2a: Effectiveness of Interventions

A meta-analysis was performed on studies with similar composite outcomes measured at similar time points. This meta-analysis was divided into followup intervals of short term (6 months), intermediate term (1 year) and long term (5 years).

### Short-Term Followup Studies

Two studies reporting 6-month outcomes—FRISC II<sup>60</sup> and TACTICS TIMI-18<sup>51</sup>—were included in the meta-analysis. The TIMI III-B study<sup>57</sup> (good quality) reported a shorter followup time point of 6 weeks and therefore was not included in this meta-analysis. In TIMI III-B, the proportion of women with the composite outcome of death/MI at 6 weeks was 6.1 percent in the early invasive arm and 8.9 percent in the initial conservative arm ( $p=0.24$ ). The proportion of men with the same composite outcome was 7.8 percent and 7.3 percent, respectively ( $p=0.73$ ). The RITA-2 study<sup>54</sup> (fair quality) reported outcomes for angina grade 2+ or exercise time and likewise was not included in the meta-analysis. In RITA-2, the proportion of women with angina graded 2 or higher at 6 months was 22.8 percent for the early invasive arm, and 39.8 percent for the initial conservative arm. In men, the proportion with angina graded 2 or higher was 20.5 percent and 31.4 percent, respectively. For the TACTICS TIMI-18 study, we used the adjusted odds ratio for the composite outcome of death/MI. Table 9 presents the outcomes, odds ratios, and confidence intervals for the meta-analysis.


**Table 9. Sex results for UA/NSTEMI on composite outcomes (short-term)**

Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
FRISC II (early invasive vs. initial conservative)	Death/MI	1.26 (0.80 to 1.97)	0.64 (0.49 to 0.84)	0.78 (0.62 to 0.98)
TACTICS TIMI-18 (early invasive vs. initial conservative)	Death/MI	0.45 (0.24 to 0.88)	0.68 (0.0.43 to 1.05)	0.74 (0.54 to 1.00)

CI = confidence interval; MI = myocardial infarction; PCI = percutaneous coronary intervention

Forest plots for the random-effects model are shown in Figure 4. The summary odds ratio in women was 0.77 (95% CI, 0.28 to 2.12) and in men was 0.65 (CI, 0.52 to 0.82). The test for heterogeneity was significant in women ( $p=0.01$ ), but it was nonsignificant in men. These results for short-term outcomes suggested a non-statistically significant benefit of early invasive compared with initial conservative therapy in women but demonstrated that early invasive was superior to initial conservative therapy in men ( $p=0.0002$ ). The two trials resulted in conflicting conclusions in women versus men, despite having similar results for the overall population.

**Figure 4. UA/NSTEMI short-term (6 months) early invasive versus initial conservative**



## Intermediate-Term Followup Studies

Five studies with 1-year data—FRISC II,<sup>59</sup> GUSTO IV-ACS,<sup>53</sup> ICTUS,<sup>56</sup> RITA-3,<sup>22</sup> and TIMI III-B<sup>64</sup>—were included in the meta-analysis. For the RITA-3 study, the adjusted odds ratio for the composite outcome of death/MI was selected for this analysis. For the ICTUS and TIMI III-B studies, event rates were converted to odds ratios. Table 10 presents the outcomes, odds ratios, and confidence intervals for the meta-analysis.


**Table 10. Sex results for UA/NSTEMI on composite outcomes (intermediate-term)**

Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
FRISC II (early invasive vs. initial conservative)	Death/MI	0.61 (0.47 to 0.79)	1.18 (0.79 to 1.76)	0.74 (0.60 to 0.92)
GUSTO IV-ACS (revascularization in 30 days vs. initial conservative)	Death	0.53 (0.28 to 1.00)	0.55 (0.35 to 0.85)	0.53 (0.37 to 0.77)
ICTUS (early invasive vs. selective invasive)	Death/MI/rehospitalization for angina	0.97 (0.59 to 1.60)	1.12 (0.81 to 1.56)	1.07 (0.87 to 1.33)
RITA-3 (early invasive vs. initial conservative)	Death/MI	1.79 (0.95 to 3.35)	0.63 (0.41 to 0.98)	0.91 (0.67 to 1.25)
TIMI III-B (early invasive vs. initial conservative)	Death/MI	0.60 (0.38 to 0.93)	1.07 (0.67 to 1.70)	0.88 (0.64 to 1.21)

CI = confidence interval; MI = myocardial infarction

Forest plots for the random-effects model are shown in Figure 5. The summary odds ratio in women was 0.78 (95% CI, 0.54 to 1.12) and in men was 0.88 (CI, 0.64 to 1.20). The test for heterogeneity was significant in women (p=0.01) and men (p=0.02). These results show trends favoring early invasive therapy in 1-year outcomes although these benefits were not statistically significant in either women or men.

**Figure 5. UA/NSTEMI intermediate-term (1 year) early invasive versus initial conservative**



## Long-Term Followup Studies

Two studies with 5-year, long-term data were included in the analysis: FRISC II<sup>58</sup> and ICTUS.<sup>61</sup> Table 11 presents the outcomes, odds ratios, and confidence intervals for the meta-analysis.


**Table 11. Sex results for UA/NSTEMI on composite outcomes (long-term)**

Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
FRISC II (early invasive vs. initial conservative)	Death/MI	1.12 (0.83 to 1.50)	0.70 (0.59 to 0.86)	0.81 (0.69 to 0.95)
ICTUS (early invasive vs. selective invasive)	Death/MI	0.87 (0.53 to 1.43)	1.22 (0.87 to 1.71)	1.29 (1.00 to 1.66)

CI = confidence interval; MI = myocardial infarction

Forest plots for the random-effects model are shown in Figure 6. The summary odds ratio in women was 1.05 (95% CI, 0.81 to 1.35) and in men was 0.91 (CI, 0.53 to 1.56). The test for heterogeneity was significant in men (p=0.005) but not in women. Although these results demonstrate a slight trend favoring initial conservative therapy in women, given the small suggested benefit at 5 years, the wide confidence interval crossing 1, and the trend favoring early invasive therapy suggested at earlier time points and across time points in men — we cannot support firm conclusions. There was no evidence of a sex effect. The analysis is limited by the low number of studies.

**Figure 6. UA/NSTEMI long-term (5 years) early invasive versus initial conservative**



Some of the analyses above showed heterogeneity in clinical outcomes between the FRISC II and ICTUS studies. The major heterogeneity in these studies arises from the rates and threshold of invasive treatment in the conservative arm. In the FRISC II study, more conservative strategies were used, thus leading to lower rates of invasive treatment in the conservative groups. In the ICTUS study, the selective invasive group was more liberal with the rates of invasive therapy and almost as high as the invasive arms of the other studies, thus explaining some of the potential differences in the results.

## KQ 2b: Modifiers of Effectiveness

We identified two good-quality studies<sup>22,55</sup> examining the effect of early invasive therapy compared with initial conservative therapy in women by subgroup; these included a total of 4030 patients, of which 1439 (36%) were women. The TACTICS TIMI-18 study<sup>55</sup> found that there was no significant benefit to the treatment of women with intermediate-risk (3 to 4) or high-risk (5 to 7) TIMI scores on the primary composite outcome of death/MI/rehospitalization for acute coronary syndrome with early invasive therapy (OR 0.72; 95% CI, 0.45 to 1.16) compared with initial conservative therapy (OR 0.56; CI, 0.23 to 1.32).<sup>51</sup> There also was no significant benefit of early invasive therapy on the primary composite outcome for those presenting with ST-segment changes (OR 0.66; CI, 0.38 to 1.15). However, there did seem to be a reduced risk of the primary composite outcome among women who had an elevated troponin level and who underwent early invasive treatment compared with conservative treatment (OR 0.56; CI, 0.32 to 0.97). Men with ST-segment changes and elevated troponin levels also seemed to benefit from early invasive therapy but not those in intermediate- or high-risk groups based on TIMI risk scores.<sup>51</sup>

The RITA-3 study<sup>22</sup> also examined the effect of early invasive therapy compared with initial conservative therapy in women by subgroup based on risk, which was derived from components of the TIMI risk score and a couple other aspects of the participants' presentation at randomization, including aspirin use and angina severity. This study, unlike the TACTICS TIMI-

18 study, found a higher event rate among women in moderate- and high-risk groups who underwent early invasive therapy compared with initial conservative therapy, with event rates of 13.4 percent versus 3.4 percent for those in the moderate-risk group and 11.7 percent versus 8.2 percent for those in the higher risk group. Men with moderate and higher risk had lower event rates if they were in the early invasive arm compared with the initial conservative arm, with 5.4 percent versus 9.4 percent for those in the moderate-risk group and 10.3 percent versus 17.9 percent for those in the higher risk group. This study also examined the effect of intervention group by body mass index group and found no effect of body mass index on treatment effect in either women or men.<sup>22</sup> Appendix G contains a summary table with study data related to modifiers of effectiveness (subgroup analyses).

## **KQ 2c: Safety Concerns**

We identified one good-quality study<sup>55</sup> (2,220 total patients, 757 women, 34% women) that reported the harms associated with treatment of UA/NSTEMI by sex group but not the rates of events by treatment group. The TACTICS TIMI-18 study, comparing early invasive therapy with initial conservative therapy, found that bleeding in women undergoing PTCA was higher than in men (adjusted OR 3.6; 95% CI, 1.6 to 8.3).<sup>51</sup> They found, however, that the bleeding related to CABG was similar in women and men with rates of 12.6 and 15 percent, respectively. Appendix H contains a summary table with study data related to safety concerns (harms).

### **Key Question 3: Women With Stable or Unstable Angina**

In women with stable or unstable angina:

a. What is the effectiveness of the following treatment strategies on clinical outcomes (nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, graft failure, angina relief, quality of life, or cognitive effects)?

Strategy 1. Revascularization (PCI or CABG) versus optimal medical therapy in women with stable angina

Strategy 2. PCI versus CABG in women with stable or unstable angina

b. Is there evidence that the comparative effectiveness of revascularization versus optimal medical therapy varies based on characteristics such as:

- Age, race, or other demographic and socioeconomic risk factors?
- Coronary disease risk factors such as diabetes, chronic kidney disease, or other comorbid disease?
- Angiographic-specific factors (number of diseased vessels, vessel territory stenoses, left ventricular function, access site, or prior PCI or CABG revascularization procedure)?



- CABG-specific factors such as type of surgery performed, cardiopulmonary bypass mode (normothermic versus hypothermic), on-pump versus off-pump, type of cardioplegia used (blood versus crystalloid), or use of saphenous vein grafts, single or bilateral internal mammary artery grafts, or other types of bypass grafts?
- Hospital characteristics (hospital volume, setting, guideline-based treatment protocols)?

c. What are the significant safety concerns associated with each treatment strategy (i.e., adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, bleeding, infections)?

## Overview

Angina resulting from progressive narrowing of the coronary arteries is the initial manifestation of ischemic heart disease in approximately 50 percent of patients.<sup>30</sup> Most angina is a sign of significant CAD, defined angiographically as a stenosis with  $\geq 70$  percent diameter in at least one major epicardial artery segment or with  $\geq 50$  percent diameter in the left main coronary artery. However, some angina is caused by stenotic lesions of lesser diameters, which have much less prognostic significance.<sup>30</sup>

Chronic stable angina is classified as pain that classically occurs with moderate to severe exertion, is milder in nature, and relieved with rest or sublingual nitroglycerin. Unstable angina (UA) is defined as angina with at least one of three features: (1) it occurs at rest or with minimal exertion, (2) it is severe and of recent onset (within the past 4 to 6 weeks), and/or (3) it occurs in a crescendo pattern (i.e., more severe, more prolonged, or more frequent than previously experienced). UA and NSTEMI have a fairly similar pathophysiology, mortality rate, and management strategy when compared with STEMI; therefore they are often grouped together as UA/NSTEMI in clinical guidelines and trial populations.

The treatment of angina has two major purposes. The first is to prevent MI and death and thereby increase the quantity of life. The second is to reduce symptoms of angina and occurrence of ischemia, which should improve the quality of life.<sup>30</sup> All patients with stable or unstable angina are candidates for optimal medical therapy and also may be candidates for PCI or CABG based on findings from coronary angiography or if symptoms persist despite optimal medical therapy.

For KQ 3, we evaluated two sets of treatment strategies:

1. Revascularization (PCI or CABG) versus optimal medical therapy in women with stable angina
2. PCI versus CABG in women with either stable or unstable angina

# Strategy 1: Revascularization Versus Optimal Medical Therapy in Stable Angina

## Key Points

- **Description of included studies:** Five studies (all good quality) compared revascularization (PCI or CABG) with optimal medical therapy for women with stable angina and included a total of 6,851 patients, of which 1,285 (19%) were women.
- **Effectiveness of interventions:** A meta-analysis of three good-quality studies with long-term (4- to 5-year) followup on the composite outcomes (death/MI/revascularization) comparing PCI or CABG with optimal medical therapy showed that revascularization was significantly better than optimal medical therapy in women with stable angina (OR 0.64; 95% CI, 0.47 to 0.89;  $p=0.008$  for PCI strategy trials; OR 0.56 [CI, 0.32 to 0.96;  $p=0.04$ ] for CABG strategy trials; and OR 0.59 [CI, 0.43 to 0.81;  $p=0.001$ ] for either PCI or CABG). However, for men with stable angina, the analysis did not show statistically significant findings between revascularization and optimal medical therapy, though it demonstrated a trend favoring optimal medical therapy compared with PCI (OR 1.03; CI, 0.79 to 1.33 for PCI strategy trials). This suggested small benefit however has a wide confidence interval crossing 1 and is not supported by additional time periods or by the evidence in women. Conversely, evidence suggested that CABG or either PCI or CABG reduced outcomes compared with optimal medical therapy in men (OR 0.62; CI, 0.31 to 1.24 for CABG strategy trials; and OR 0.71; CI, 0.49 to 1.02 for either PCI or CABG)—again these findings were not statistically significant. Strength of evidence favoring revascularization for women was moderate in the PCI strategy, low in the CABG strategy, and moderate for both types of revascularization combined. In men, the strength of evidence was low for the PCI, CABG, and combined revascularization strategies.
- **Modifiers of effectiveness:** No studies were identified that evaluated women presenting with stable angina; therefore data are insufficient.
- **Safety concerns:** No studies were identified that evaluated women presenting with stable angina; therefore data are insufficient.

## Detailed Synthesis

We identified five studies<sup>65-69</sup> that reported outcomes for women with stable angina. Of these five studies, all were good quality. Two studies compared PCI with optimal medical therapy,<sup>65,66</sup> one compared CABG with optimal medical therapy,<sup>67</sup> and one compared medical management with transmyocardial revascularization (TMR).<sup>69</sup> Table 12 presents a general description of these five studies, including the study name, author, year, and related articles (i.e., study design and secondary papers); treatment comparisons evaluated; study population; and overall quality rating. Table 13 summarizes the women-specific outcomes (composite and individual) reported in these studies. Appendix F contains summary tables with sex-specific clinical outcomes for all followup time points.

**Table 12. KQ 3 Strategy 1: Study characteristics of RCTs evaluating women with stable angina (PCI/CABG vs. optimal medical therapy)**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
<p>Allen et al., 2004<sup>69</sup> and Allen et al., 1999<sup>70</sup></p>	<p><b>Title:</b> Transmyocardial revascularization: 5-year follow-up of a prospective randomized multicenter trial</p> <p><b>Comparator:</b> Surgical revascularization (CABG with transmyocardial revascularization) vs. optimal medical therapy</p> <p><b>Components of optimal medical therapy:</b> Not reported.</p>	<p>Total: 222 Women: 61 (27%)</p>	<p>Good</p>
<p>COURAGE Boden et al., 2007<sup>65</sup> and Mancini et al., 2009<sup>71</sup> Boden et al., 2006<sup>72</sup></p>	<p><b>Title:</b> Optimal medical therapy with or without PCI for stable coronary disease</p> <p><b>Comparator:</b> PCI (type not specified) or CABG if PCI failed vs. optimal medical therapy</p> <p><b>Components of optimal medical therapy:</b> Aspirin (81 to 325 mg per day) or 75 mg of clopidogrel per day, if aspirin intolerance was present. Metoprolol, amlodipine, and isosorbide mononitrate, alone or in combination, along with either lisinopril or losartan; aggressive therapy to lower low-density lipoprotein cholesterol levels (simvastatin alone or in combination with ezetimibe) with a target level of 60 to 85 mg per deciliter (1.55 to 2.20 mmol per liter).</p>	<p>Total: 2,287 Women: 338 (15%)</p>	<p>Good</p>
<p>MASS II Hueb et al., 2010<sup>68</sup> and Hueb et al., 2004<sup>73</sup> Hueb et al., 2007<sup>74</sup></p>	<p><b>Title:</b> Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease</p> <p><b>Comparator:</b> PCI vs. optimal medical therapy; CABG vs. optimal medical therapy</p> <p><b>Components of optimal medical therapy:</b> Nitrates, aspirin, beta blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, or a combination of these drugs unless contraindicated. Lipid-lowering agents, particularly statins, were also prescribed, along with a low-fat diet, on an individual basis.</p>	<p>Total: 611 Women: 196 (32%)</p>	<p>Good</p>

**Table 12. KQ 3 Strategy 1: Study characteristics of RCTs evaluating women with stable angina (PCI/CABG vs. optimal medical therapy) (continued)**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
<p>OAT Hochman et al., 2006<sup>66</sup></p> <p>and</p> <p>Hochman et al., 2005<sup>75,76</sup></p>	<p><b>Title:</b> Coronary intervention for persistent occlusion after myocardial infarction</p> <p><b>Comparator:</b> PCI (or CABG if PCI failed) vs. optimal medical therapy</p> <p><b>Components of optimal medical therapy:</b> Aspirin, anticoagulation if indicated, angiotensin-converting enzyme inhibition, beta blockade, and lipid-lowering therapy, unless contraindicated. Thienopyridine therapy was initiated before PCI and continued for 2 to 4 weeks after stenting. After reports of the efficacy of prolonged treatment with a thienopyridine after MI, the recommendation was changed to 1 year in both study groups.</p>	<p>Total: 2,166 Women: 476 (22%)</p>	<p>Good</p>
<p>STICH Velazquez et al., 2011<sup>67</sup></p> <p>and</p> <p>Velazquez et al., 2007<sup>77</sup></p>	<p><b>Title:</b> Coronary-artery bypass surgery in patients with left ventricular dysfunction</p> <p><b>Comparator:</b> CABG vs. optimal medical therapy</p> <p><b>Components of optimal medical therapy:</b> Unless contraindicated, optimal medical therapy included angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or both; beta blocker; aldosterone antagonist; and antiplatelet agents adjusted to optimal doses within 30 days after randomization. Statin, diuretic, and digitalis use was individualized to patient-specific indications. The use of implantable defibrillators was encouraged as part of medical therapy and was used in compliance with standard guidelines.</p>	<p>Total: 1,212 Women: 148 (12%)</p>	<p>Good</p>

CABG = coronary artery bypass graft; CAD = coronary artery disease; MI = myocardial infarction; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty

**Table 13. KQ 3 Strategy 1: Outcomes reported in RCTs evaluating women with stable angina (PCI/CABG vs. optimal medical therapy)**

Study	Composite Outcome <sup>a</sup> (Timing)  Anticipated Effect Size	Death <sup>a</sup> (Timing)	MI (Timing)	CVA (Timing)	Revascularization (Timing)	Other <sup>a</sup> (Timing)
Allen et al. <sup>69,70</sup>	Effect size not reported	Yes (5.7 years)				<i>Angina relief</i> (5.7 years)
COURAGE <sup>65,71,72</sup>	<i>Death/MI</i> (median 4.6 years)  Powered to detect 22% RRR					
MASS II <sup>68,73,74</sup>	<i>Death/MI/angina requiring revascularization</i> (10 years)  Powered to detect 2-fold difference					
OAT <sup>66,75,76</sup>	<i>Death/MI/heart failure</i> (4 years, 7 years)  Powered to detect 25% reduction					
STICH <sup>67,77</sup>	Powered to detect 25% reduction in mortality	Yes (5 years)				

CABG = coronary artery bypass grafting; CVA = cerebrovascular accident; MI = myocardial infarction; PCI = percutaneous coronary intervention; RRR = relative risk reduction

<sup>a</sup>Primary outcome in italics.

## KQ 3a: Effectiveness of Interventions

### Long-Term Followup Studies

Three studies were included in a meta-analysis: COURAGE,<sup>65</sup> MASS II,<sup>68</sup> and STICH.<sup>67</sup> These studies had similar followup times (4 to 5 years, except a 10-year followup in the MASS II study) and comparable outcomes (composite, death). No results were available for the short- or intermediate-term outcomes. The TMR study by Allen et al.<sup>69</sup> was excluded since the results were reported in a different fashion (i.e., whether sex had an impact on outcome for the TMR patients) and could not be incorporated into the meta-analysis. The OAT study<sup>66</sup> was excluded from the meta-analysis since the study subjects were enrolled  $\geq 7$  days after an acute MI with revascularization or medical therapy for an occluded artery; the patient population was deemed to be quite different from those enrolled in the other studies. The MASS II study numbers were inverted to place PCI in the comparison group. Table 14 presents the outcomes, odds ratios, and confidence intervals for the meta-analyses.

**Table 14. Sex results for stable angina on composite outcomes (long-term)**


Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
COURAGE (PCI [or CABG if PCI failed] vs. optimal medical therapy)	Death/MI	0.65 (0.40 to 1.06)	1.15 (0.91 to 1.42)	1.05 (0.87 to 1.27)
MASS II (PCI vs. optimal medical therapy)	Death/MI/revascularization	0.64 (0.41 to 0.98)	0.88 (0.65 to 1.19)	0.79 (0.62 to 1.01)
MASS II (CABG vs. optimal medical therapy)	Death/MI/revascularization	0.43 (0.26 to 0.72)	0.43 (0.31 to 0.61)	0.43 (0.32 to 0.56)
STICH (CABG vs. optimal medical therapy)	Death	0.75 (0.42 to 1.31)	0.87 (0.72 to 1.06)	0.86 (0.72 to 1.04)

CI = confidence interval; CABG = coronary artery bypass graft; MI = myocardial infarction; PCI = percutaneous coronary intervention

Forest plots for the random-effects model are shown in Figures 7, 8, and 9. Separate analyses were created for (a) primarily PCI strategy, (b) primarily CABG strategy, and (c) either type of revascularization strategy compared with optimal medical therapy for the purposes of creating a sensitivity analysis given the subtle differences in patient populations and revascularization methods used in those studies.


The primarily PCI strategy (Figure 7) studies included COURAGE and MASS II (PCI). The summary odds ratio in women was 0.64 (95% CI, 0.47 to 0.89) and in men was 1.03 (CI, 0.79 to 1.33). The test for heterogeneity was not significant for women and men. The results showed that PCI reduced death/MI in women but not in men.

**Figure 7. Stable angina, revascularization (primarily PCI) versus medical therapy**




The primarily CABG strategy (Figure 8) studies included MASS II (CABG) and STICH. The summary odds ratio in women was 0.56 (CI, 0.32 to 0.96) and in men was 0.62 (CI, 0.31 to 1.24). The test for heterogeneity was not significant for women (p=0.15) but was significant for men (p=0.0004). These results show that CABG was significantly better in reducing cardiovascular events than optimal medical therapy was in women (effect size p=0.04) but not in men.

**Figure 8. Stable angina, revascularization (primarily CABG) versus medical therapy**



We then combined all studies utilizing both types of revascularization strategies (PCI or CABG)—COURAGE, MASS II, and STICH. Figure 9 shows the forest plot for the random-effects model using the MASS II (CABG) cohort. The summary odds ratio in women was 0.59 (CI, 0.43 to 0.81) and in men was 0.71 (CI, 0.49 to 1.02). The test for heterogeneity was not significant in women, but was significant in men. These results showed that revascularization was significantly better in reducing cardiovascular events than optimal medical therapy in women. Similar results were obtained if the model was run with the MASS II (PCI) cohort (figure not shown). For men, revascularization and optimal medical therapy were not statistically different.

**Figure 9. Stable angina, revascularization (combined) versus medical therapy**



### KQ 3b: Modifiers of Effectiveness

No studies were identified that evaluated women presenting with stable angina related to modifiers of the effectiveness of revascularization versus optimal medical therapy.

### KQ 3c: Safety Concerns

No studies were identified that evaluated women presenting with stable angina related to safety concerns for revascularization versus optimal medical therapy.



## Strategy 2: PCI Versus CABG in Stable/Unstable Angina

### Key Points

- **Description of included studies:** 10 studies (8 good quality, 2 fair) compared PCI with CABG in women with stable/unstable angina and included a total of 6,289 patients, of which 1,583 (25%) were women.
- **Effectiveness of interventions:** A meta-analysis of two good-quality studies reporting 30-day death rates showed no statistically significant difference between PCI and CABG and therefore did not support evidence of a sex effect. The summary odds ratio in women was 0.68 (95% CI, 0.24 to 1.93) and in men was 1.36 (CI, 0.44 to 4.24). These two studies did, however, suggest a potentially greater benefit with PCI in women and with CABG in men. The low number of studies and wide confidence intervals made this a less robust finding and one that should be interpreted with caution. For 1-year outcomes (death/MI/stroke), a meta-analysis of two good-quality studies suggested potentially better outcomes in the CABG group for both sexes however this findings was not statistically significant (CI crosses 1). The summary odds ratio in women was 1.30 (CI, 0.69 to 2.45) and in men was 1.19 (CI, 0.84 to 1.70). For long-term (>2 years) outcomes (death/MI/stroke), a meta-analysis of four good-quality studies although not statistically significant, suggested better outcomes in the CABG group in women (OR 1.17; CI, 0.90 to 1.54); however in men, CABG was significantly better than PCI (OR 1.63; CI, 1.20 to 2.23,  $p=0.002$ ). Strength of evidence favoring CABG over PCI was low for women and men at 30-day and 1-year followups, and low for women and high for men at  $\geq 2$ -year followup.
- **Modifiers of effectiveness:** One good-quality study (915 total patients, 249 [27%] women) evaluated the comparative effectiveness of PCI versus CABG in diabetic patients with stable/unstable angina. The survival rate at 7 years was similar in diabetic women from both treatment groups. However in diabetic men, those treated with CABG had higher survival than those who underwent PCI. Strength of evidence for modifiers of effectiveness for PCI versus CABG in stable/unstable angina was insufficient.
- **Safety concerns:** One good-quality study (1205 total patients, 283 [23%] women) reported harms associated with PCI compared with CABG among women with unstable angina or NSTEMI and found that bleeding associated with PCI was higher in women compared with men. Strength of evidence for safety concerns for PCI versus CABG in stable/unstable angina was insufficient.

### Detailed Synthesis

We identified 10 studies<sup>68,78-86</sup> that evaluated PCI versus CABG for women presenting with unstable angina or NSTEMI. Of these 10 studies, 8 were good quality, and 2 were fair quality. Table 15 presents a general description of these 10 studies, including the study name, author, year, and related articles (i.e., study design and secondary papers); treatment comparisons evaluated; study population; and overall quality rating. Table 16 summarizes the women-specific outcomes (composite and individual) reported in these studies. Appendix F contains summary tables with sex-specific clinical outcomes for all followup time points.

**Table 15. KQ 3 Strategy 2: Study characteristics of RCTs evaluating women with stable or unstable angina (PCI vs. CABG)**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
ARTS I Vaina et al., 2009 <sup>78</sup>  and  van den Brand, et al., 2002 <sup>87</sup> Serruys et al., 1999 <sup>88</sup> Voudris et al., 2006 <sup>89</sup> Anonymous, 1999 <sup>90</sup>	<p><b>Title:</b> Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II</p> <p><b>Comparator:</b> PCI (BMS) vs. CABG</p> <p><b>Components of medical therapy:</b> Not reported.</p>	Total: 1,205 Women: 283 (23%)	Good
BARI Jacobs et al., 1998 <sup>79</sup>  and  Gibbons et al., 2001 <sup>91</sup> Anonymous, 2007 <sup>92</sup> Lombardero et al., 2002 <sup>93</sup> Anonymous, 2000 <sup>94</sup> Hlatky et al., 1995 <sup>95</sup> Rogers et al., 1995 <sup>96</sup> Sutton-Tyrrell et al., 1998 <sup>97</sup> Mullany et al., 1999 <sup>98</sup> Anonymous, 1996 <sup>99</sup>	<p><b>Title:</b> Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI)</p> <p><b>Comparator:</b> PCI (type not specified) vs. CABG</p> <p><b>Components of medical therapy:</b> Not reported.</p>	Total: 915 Women: 249 (27%)	Good
CABRI Anonymous, 1995 <sup>80</sup>	<p><b>Title:</b> First-year results of CABRI (Coronary Angioplasty vs. Bypass Revascularisation Investigation)</p> <p><b>Comparator:</b> PCI (PTCA) vs. CABG</p> <p><b>Components of medical therapy:</b> Aspirin; fish oils and lipid-lowering agent were allowed; individual patient management followed the established practice at each participating center.</p>	Total: 1,054 Women: 234 (22%)	Good

**Table 15. KQ 3 Strategy 2: Study characteristics of RCTs evaluating women with stable or unstable angina (PCI vs. CABG) (continued)**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
CARDia Kapur et al., 2010 <sup>84</sup>  and  Kapur et al., 2005 <sup>100</sup>	<p><b>Title:</b> Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial</p> <p><b>Comparator:</b> PCI (BMS or DES) vs. CABG</p> <p><b>Components of medical therapy:</b> Glycoprotein IIb/IIIa, clopidogrel, and aspirin.</p>	Total: 510 Women: 132 (26%)	Good
EAST King et al., 2000 <sup>81</sup>  and  King et al., 1995 <sup>101</sup> King et al., 1994 <sup>102</sup> Zhao et al., 1996 <sup>103</sup>	<p><b>Title:</b> Eight-year mortality in the Emory Angioplasty vs. Surgery Trial (EAST)</p> <p><b>Comparator:</b> PCI (type not specified) vs. CABG</p> <p><b>Components of medical therapy:</b> Not reported.</p>	Total: 392 Women: 103 (26%)	Good
GABI Kaehler et al., 2005 <sup>86</sup>  and  Hamm et al., 1994 <sup>104</sup>	<p><b>Title:</b> 13-year follow-up of the German angioplasty bypass surgery investigation</p> <p><b>Comparator:</b> PCI (type not specified) vs. CABG</p> <p><b>Components of medical therapy:</b> Not reported (discretion of treating provider).</p>	Total: 359 Women: 66 (18%)	Good
MASS II Hueb et al., 2010 <sup>68</sup>  and  Hueb et al., 2004 <sup>73</sup> Hueb et al., 2007 <sup>74</sup>	<p><b>Title:</b> Ten-year followup survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease</p> <p><b>Comparator:</b> PCI (type not specified) vs. CABG</p> <p><b>Components of medical therapy:</b> Nitrates, aspirin, beta blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, or a combination of these drugs unless contraindicated. Lipid-lowering agents, particularly statins, were also prescribed, along with a low-fat diet, on an individual basis.</p>	Total: 611 Women: 196 (32%)	Good

**Table 15. KQ 3 Strategy 2: Study characteristics of RCTs evaluating women with stable or unstable angina (PCI vs. CABG) (continued)**

Study Author/Year Related Articles	Description of Study	# of Subjects	Quality
PRECOMBAT Park et al., 2011 <sup>85</sup>	<p><b>Title:</b> Randomized Trial of Stents versus Bypass Surgery for Left Main Coronary Artery Disease</p> <p><b>Comparator:</b> PCI (DES) vs. CABG</p> <p><b>Components of medical therapy:</b> Before or during PCI: aspirin plus clopidogrel (loading dose, 300 mg) or ticlopidine (loading dose, 500 mg). After PCI: 100 mg/day aspirin indefinitely and 75 mg/day clopidogrel or 250 mg/day ticlopidine for at least 6 months. Medications after CABG were selected according to the policy of the institution or physician.</p>	Total: 600 Women: 141 (24%)	Good
SOS Zhang et al., 2004 <sup>82</sup>  and  Zhang et al., 2003 <sup>105</sup> Stables et al., 1999 <sup>106</sup>	<p><b>Title:</b> Relative benefit of coronary artery bypass grafting vs. stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women vs. men (one-year results from the Stent or Surgery trial)</p> <p><b>Comparator:</b> PCI (BMS) vs. CABG</p> <p><b>Components of medical therapy:</b> Not reported.</p>	Total: 908 Women: 206 (23%)	Fair
SYNTAX Morice et al., 2010 <sup>83</sup>	<p><b>Title:</b> Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial</p> <p><b>Comparator:</b> PCI (type not specified) vs. CABG</p> <p><b>Components of medical therapy:</b> In the PCI arm, clopidogrel for 6 months, with aspirin therapy indefinitely.</p>	Total: 705 Women: 185 (26%)	Fair

BMS= bare-metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; DES = drug-eluting stent; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial

**Table 16. KQ 3 Strategy 2: Outcomes reported in RCTs evaluating women with stable or unstable angina (PCI vs. CABG)**

Study	Composite Outcome <sup>a</sup> (Timing)  Anticipated Effect Size	Death <sup>a</sup> (Timing)	MI (Timing)	CVA (Timing)	Revascularization (Timing)	Other (Timing)
ARTS I <sup>78,87-90</sup>	<p><i>Death/CVA/MI/CABG/repeat PCI</i> (30 days, 1 year, 3 years, 5 years)</p> <p>Death/CVA (30 days, 1 year, 3 years)</p> <p>Death/MI/CVA (30 days, 1 year, 3 years, 5 years)</p> <p>MI/CVA/PTCA (5 years)</p> <p>Powered to detect 7% difference in favor of CABG</p>	<p>Yes (30 days, 1 year, 3 years, 5 years)</p> <p>MACE-free survival (30 days, 1 year, 3 years)</p>	<p>Yes (30 days, 1 year, 3 years, 5 years)</p>	<p>Yes (5 years) (30 days, 1 year, 3 years, 5 years)</p>	<p>Yes (30 days, 1 year, 3 years, 5 years)</p>	<p>Quality of life (3 years)</p> <p>Bleeding (in hospital)</p>
BARI <sup>79,91-99</sup>	<p>Effect size not reported</p>	<p><i>Cumulative survival rate</i> (5 year, 7 years, 10 years)</p>	<p>Yes (in hospital)</p>		<p>Yes (10 years)</p>	<p>Angina status (4 years, 10 years)</p> <p>Congestive heart failure (in hospital)</p>
CABRI <sup>80</sup>	<p>Powered to detect 60% reduction in mortality in PCI group</p>	<p>Yes (1 year)</p>				<p>Angina (1 year)</p>
CARDia <sup>84,100</sup>	<p><i>Death/MI/stroke repeat revascularization</i> (1 year)</p> <p>Death/MI/CVA (1 year)</p> <p>Powered for OR of 0.69 in favor of PCI (upper CI 1.3)</p>					

**Table 16. KQ 3 Strategy 2: Outcomes reported in RCTs evaluating women with stable or unstable angina (PCI vs. CABG) (continued)**

Study	Composite Outcome <sup>a</sup> (Timing)  Anticipated Effect Size	Death <sup>a</sup> (Timing)	MI (Timing)	CVA (Timing)	Revascularization (Timing)	Other (Timing)
EAST <sup>81,101-103</sup>	Powered for 25% reduction	<i>Survival</i> (3 years, 8 years)				
GABI <sup>86,104</sup>	Powered for 15% difference in success rates as therapeutically equivalent	Yes (13 years)				Primary outcome was freedom from angina (not reported by sex)
MASS II <sup>68,73,74</sup>	Death/MI/angina requiring revascularization (10 years)  Powered to detect 2-fold difference					
PRECOMBAT <sup>85</sup>	<i>Death/MI/stroke/ischemia-driven target-vessel revascularization</i> (1 year, 2 years)  Powered to detect 7% difference					
SOS <sup>82,105,106</sup>	Powered for event rate of 5% in CABG arm and 10% in PCI arm				Primary outcome not reported by sex	Quality of life (6 months, 1 year)  Angina frequency (6 months, 1 year)  Physical limitation (6 months, 1 year)
SYNTAX <sup>83</sup>	<i>Death/MI/CVA/repeat revascularization</i> (1 year)  Powered for clinically relevant difference of 5%					

CABG = coronary artery bypass grafting; CVA = cerebrovascular accident; MACE = major adverse cardiovascular event; MI = myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; RRR = relative risk reduction

<sup>a</sup>Primary outcome in italics.

## KQ 3a: Effectiveness of Interventions

A meta-analysis of studies was performed on those with similar composite outcomes measured at similar time points. This meta-analysis was divided into followup intervals of short term ( $\leq 30$  days), intermediate term (1 year), and long term ( $\geq 2$  years).

### Short-Term Followup Studies

Two studies with short-term (30-day or in-hospital) outcomes—ARTS I<sup>78</sup> and BARI<sup>79</sup>—were included in the meta-analysis. For both studies, the reported event rates/percentages were converted into odds ratios. Table 17 presents the outcomes, odds ratios, and confidence intervals for the meta-analysis.


**Table 17. Sex results for stable/unstable angina on composite outcomes (short-term)**

Study (comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
ARTS I (PCI vs. CABG)	Death (30 days)	0.70 (0.19 to 2.51)	2.99 (0.60 to 14.91)	NR
BARI (PCI vs. CABG)	Death (in-hospital)	0.64 (0.11 to 3.86)	0.89 (0.34 to 2.31)	0.83 (0.36 to 1.93)

CI = confidence interval; CABG = coronary artery bypass graft; NR = not reported; PCI = percutaneous coronary intervention

Forest plots for the random-effects model are shown in Figure 10. The summary odds ratio in women was 0.68 (95% CI, 0.24 to 1.93) and in men was 1.36 (CI, 0.44 to 4.24). The test for heterogeneity was nonsignificant. The findings were not statistically significant for demonstrating a benefit in PCI and CABG, although the odds ratios suggested a possible sex effect, with PCI showing more benefit in women and CABG showing more benefit in men, but the confidence intervals are too wide to support firm conclusions.

**Figure 10. Stable/unstable angina short-term (30 days) PCI versus CABG**



## Intermediate-Term Followup Studies

Two studies with 1-year outcomes—ARTS I<sup>78</sup> and CARDia<sup>84</sup>—were included in the meta-analysis. In the SYNTAX study,<sup>83</sup> there was no difference in the primary composite outcome (death/MI/stroke, or repeat revascularization) at 1 year between patients undergoing CABG and PCI (13.6% vs. 15.8%). No sex data by treatment in this fair-quality study were provided, but being female was a significant predictor of 1-year major adverse cardiovascular events (OR 0.50; 95% CI, 0.27 to 0.91; p=0.02 [interaction effect not reported]). The SYNTAX study was excluded from the meta-analysis since it did not report subgroup results by sex. The PRECOMBAT study<sup>85</sup> did not report sex-specific data at 1 year, so this study was not included in this intermediate-term followup analysis (but data reported at 2 years are included in the long-term followup analysis below). Event data from the ARTS I study were transformed into risk ratios. Table 18 presents the outcomes, odds ratios, and confidence intervals for the meta-analysis.


**Table 18. Sex results for stable/unstable angina on composite outcomes (intermediate-term)**

Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
ARTS I (PCI vs. CABG)	Death/MI/stroke	1.05 (0.51 to 2.21)	1.27 (0.81 to 1.98)	NR
CARDia (PCI vs. CABG)	Death/MI/stroke	2.13 (0.68 to 6.68)	1.07 (0.59 to 1.93)	1.25 (0.75 to 2.09)

CI = confidence interval; CABG = coronary artery bypass graft; NR = not reported; PCI = percutaneous coronary intervention

Forest plots for the random effects model are shown in Figure 11. The summary odds ratio in women was 1.30 (95% CI, 0.69 to 2.45) and in men was 1.19 (CI, 0.84 to 1.70). The test for heterogeneity was nonsignificant. These results show lower events in the CABG group for both sexes, but this benefit was not statistically significant.

**Figure 11. Stable/unstable angina intermediate-term (1 year) PCI versus CABG**





## Long-Term Followup Studies

To assess the long-term effect at  $\geq 2$  years, four studies were included in the meta-analysis: ARTS I (3-year),<sup>78</sup> BARI (5-year),<sup>79</sup> MASS II (10-year),<sup>68</sup> and PRECOMBAT (2-year).<sup>85</sup> Results of the ARTS I and BARI studies were transformed into risk ratios. For the BARI study, the survival rates were converted into death rates. For women, the death rates for CABG and PCI were 24 percent of 240 and 26 percent of 249, respectively. For men, survival rates by treatment group were not reported. The MASS II results were inverted to hazard ratios  $<1$  favoring PCI and hazard ratios  $>1$  favoring CABG. The GABI study<sup>86</sup> was excluded from the meta-analysis because it did not present data by sex. The GABI study randomized 359 patients (66 women) with angina CCS class II-IV, under age 75, and coronary multiple-vessel disease requiring revascularization of at least 2 major coronary vessels to either PCI or CABG. The authors report that the hazard ratio for death following PCI or CABG was not different between men and women at the 13-year followup. Table 19 presents the outcomes, odds ratios, and confidence intervals for the meta-analysis.


**Table 19. Sex results for stable/unstable angina on composite outcomes (long-term)**

Study (Comparison)	Outcome	Women (95% CI)	Men (95% CI)	Overall (95% CI)
ARTS I (PCI vs. CABG)	Death/MI/CVA/revascularization	1.00 (0.57 to 1.76)	1.28 (0.88 to 1.86)	NR
BARI (PCI vs. CABG)	Death	1.11 (0.74 to 1.67)	NR	1.20 (0.92 to 1.59)
MASS II (PCI vs. CABG)	Death/MI/revascularization	1.47 (0.87 to 2.50)	2.04 (1.45 to 2.94)	1.89 (1.38 to 2.56)
PRECOMBAT (PCI vs. CABG)	Death/MI/CVA/revascularization	1.22 (0.48 to 3.08)	1.65 (0.88 to 3.07)	1.50 (0.90 to 2.52)

CI = confidence interval; CABG = coronary artery bypass graft; NR = not reported; PCI = percutaneous coronary intervention

Forest plots for the random effects model are shown in Figure 12. The summary odds ratio in women was 1.17 (95% CI, 0.90 to 1.54) and in men was 1.63 (CI, 1.20 to 2.23). The test for heterogeneity was nonsignificant. Similar to the intermediate-term outcomes, there was no definitive evidence of a sex effect. In men, CABG was significantly better than PCI ( $p=0.002$ ); in women, results suggest lower events in the CABG group, but it was not statistically significant ( $p=0.24$ ).

**Figure 12. Stable/unstable angina long-term (≥2 years) PCI versus CABG**



### KQ 3b: Modifiers of Effectiveness

We identified one good-quality study (915 total patients, 249 [27%] women) in which the long-term survival rate (7 years) in diabetic women was addressed. In the BARI study,<sup>79</sup> this subgroup analysis was not initially specified but was requested by the safety and monitoring board during the course of the trial on the basis of concurrent reports from another study. Survival rate at 7 years was significantly higher among diabetic patients (n=353) treated with CABG compared with those undergoing PCI (74.6% vs. 55.7%), a difference that remained significant in men (77.9% vs. 51.5%) but not in women (74.3% vs. 61.0%). Appendix G contains a summary table with study data related to modifiers of effectiveness (subgroup analyses).

### KQ 3c: Safety Concerns

We identified one good-quality study<sup>78</sup> (1,205 total patients, 283 [23%] women) that addressed significant safety concerns and, specifically, risk of major bleeding in women (n=283). The ARTS I study was designed to compare CABG with PCI combined with stent implantation for the treatment of patients with multiple-vessel disease. Major bleeding was higher in women undergoing PCI compared with men (7.2% vs. 0.2%, p<0.001) but not among those assigned to CABG (1.4% vs. 2.8%). After adjusting for baseline characteristics, major bleeding complications remained higher among women in the PCI group (OR 29.4; 95% CI, 5.3 to 500; p=0.001 women vs. men) compared with the CABG group (OR 1.5; CI, 0.4 to 10.1, p=0.58 women vs. men). Appendix H contains a summary table with study data related to safety concerns (harms).

## Summary and Discussion

For this report, we conducted a systematic review of the medical literature for the comparative effectiveness of optimal medical therapy, PCI, and CABG in women with CAD. CAD presentations included stable angina and acute coronary syndrome; i.e., STEMI, NSTEMI, and unstable angina. This review assessed the comparative effectiveness of the three treatment strategies on (1) clinical outcomes, (2) outcomes by modifiers such as demographic and clinical factors, and (3) safety outcomes.

Our search identified 28 comparative studies (72 articles, including methodology and secondary analysis papers). Of the 28 studies, 24 were good quality and 4 were fair quality for their overall reporting of methodology and analysis. A total of 35,597 patients included 10,126 (28%) women. We grouped these by CAD presentation and type of comparison:

- KQ 1: 7 studies (6 good quality, 1 fair) comparing PCI with fibrinolysis/supportive medical therapy (5 fibrinolysis, 2 supportive) in patients with STEMI
- KQ 2: 7 studies (6 good quality, 1 fair) comparing early invasive (PCI or CABG) with initial conservative in patients with UA/NSTEMI
- KQ 3: 5 studies (all good quality) comparing revascularization with optimal medical therapy in patients with stable angina (Strategy 1) and 10 studies (8 good quality, 2 fair) comparing PCI with CABG in patients with either stable or unstable angina (Strategy 2). There were a total of 14 studies with 1 study containing data for both comparative strategies.

## Key Findings and Strength of Evidence

The main findings of the treatment strategies for women with CAD are summarized in the following sections. Table 20 summarizes the strength of evidence (SOE) by effectiveness outcome for the KQs.

**Table 20. Strength of evidence by effectiveness outcome**

KQ: Presentation Comparison Outcome Time Point (Forest Plot #)	# Studies	N Total N Women (%)	Effect OR (95% CI)	Conclusions	Limitations to Applicability	Strength of Evidence
KQ 1a: STEMI PCI vs. fibrinolysis Death/MI/stroke 30 days (Figure 3)	5 <sup>36,37,39,40,42</sup>	Total: 4,105 Women: 1,017 (25%)	<u>Women</u> 0.50 (0.36 to 0.72); p=0.0001  <u>Men</u> 0.54 (0.42 to 0.70); p<0.00001	<u>Women</u> Favors PCI  <u>Men</u> Favors PCI	PCI consisted of balloon angioplasty or bare-metal stents	Study design/quality: RCT/good  <u>Women</u> Risk of bias : Low Consistency: Consistent Directness: Direct Precision: Precise <b>SOE: High</b>  <u>Men</u> Risk of bias: Low Consistency: Consistent Directness: Direct Precision: Precise <b>SOE: High</b>
KQ 1a: STEMI PCI vs. fibrinolysis 1 year (No figure)	2 <sup>40,44</sup>	Total: 1,973 Women: 523 (26%)	<u>Women</u> No summary estimate due to heterogeneous outcomes  <u>Men</u> No summary estimate due to heterogeneous outcomes	<u>Women</u> Insufficient  <u>Men</u> Insufficient	PCI consisted of balloon angioplasty or bare-metal stents	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: N/A Directness: N/A Precision: N/A <b>SOE: Insufficient</b>  <u>Men</u> Risk of bias: Low Consistency: N/A Directness: N/A Precision: N/A <b>SOE: Insufficient</b>

**Table 20. Strength of evidence by effectiveness outcome (continued)**

KQ: Presentation Comparison Outcome Time Point (Forest Plot #)	# Studies	N Total N Women (%)	Effect OR (95% CI)	Conclusions	Limitations to Applicability	Strength of Evidence
KQ 2a: UA/NSTEMI  Early invasive vs. initial conservative  Death/MI  6 months  (Figure 4)	2 <sup>51,60</sup>	Total: 4,677  Women: 1,506 (32%)	<u>Women</u> 0.77 (0.28 to 2.12)  <u>Men</u> 0.65 (0.52 to 0.82); p=0.0002	<u>Women</u> Trend favoring early invasive  <u>Men</u> Favors early invasive	FRISC II study had lower rates of invasive treatment in the initial conservative group.	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: Inconsistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>  <u>Men</u> Risk of bias: Low Consistency: Consistent Directness: Direct Precision: Precise <b>SOE: High</b>
KQ 2a: UA/NSTEMI  Early invasive vs. initial conservative  Death/MI/ rehospitalization  1 year  (Figure 5)	5 <sup>22,53,56,59</sup>	Total: 14,692  Women: 5,144 (35%)	<u>Women</u> 0.78 (0.54 to 1.12)  <u>Men</u> 0.88 (0.64 to 1.20)	<u>Women</u> Trend favoring early invasive  <u>Men</u> Trend favoring early invasive	FRISCII and RITA-3 studies had lower rates of invasive treatment in the initial conservative group. ICTUS allowed more liberal use of revascularization, therefore rates of invasive therapy were higher in initial conservative group.	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: Inconsistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>  <u>Men</u> Risk of bias: Low Consistency: Inconsistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>

**Table 20. Strength of evidence by effectiveness outcome (continued)**

KQ: Presentation Comparison Outcome Time Point (Forest Plot #)	# Studies	N Total N Women (%)	Effect OR (95% CI)	Conclusions	Limitations to Applicability	Strength of Evidence
<p>KQ 2a: UA/NSTEMI</p> <p>Early invasive vs. initial conservative</p> <p>Death/MI/rehospitalization</p> <p>5 years</p> <p>(Figure 6)</p>	<p>2<sup>58,61</sup></p>	<p>Total: 3,657</p> <p>Women: 1,069 (29%)</p>	<p><u>Women</u> 1.05 (0.81 to 1.35)</p> <p><u>Men</u> 0.91 (0.53 to 1.56)</p>	<p><u>Women</u> Slight trend favoring initial conservative therapy. Given the small suggested benefit at 5 years, the wide confidence interval crossing 1, and the trend favoring early invasive therapy suggested at earlier time points and across time points in men, we cannot support firm conclusions.</p> <p><u>Men</u> Trend favoring early invasive</p>	<p>At longer term followup, rate of PCI in initial conservative group approached that of early invasive group.</p>	<p>Study design/quality: RCT/good</p> <p><u>Women</u> Risk of bias: Low Consistency: Inconsistent Directness: Direct Precision: Imprecise <b>SOE: Insufficient</b></p> <p><u>Men</u> Risk of bias: Low Consistency: Inconsistent Directness: Direct Precision: Imprecise <b>SOE: Low</b></p>
<p>KQ 3a: Stable angina</p> <p>PCI vs. medical therapy</p> <p>Death/MI/revascularization</p> <p>4–5 years</p> <p>(Figure 7)</p>	<p>2<sup>65,68</sup></p>	<p>Total: 2,898</p> <p>Women: 556 (19%)</p>	<p><u>Women</u> 0.64 (0.47 to 0.89); p=0.008</p> <p><u>Men</u> 1.03 (0.79 to 1.33)</p>	<p><u>Women</u> Favors PCI</p> <p><u>Men</u> Slight trend favoring medical therapy. This suggested small benefit, however, has a wide confidence interval crossing 1 and is not supported by additional time points or by the evidence in women.</p>	<p>None</p>	<p>Study design/quality: RCT/good</p> <p><u>Women</u> Risk of bias: Low Consistency: Consistent Directness: Indirect Precision: Precise <b>SOE: Moderate</b></p> <p><u>Men</u> Risk of bias: Low Consistency: Inconsistent Directness: Indirect Precision: Imprecise <b>SOE: Low</b></p>

**Table 20. Strength of evidence by effectiveness outcome (continued)**

KQ: Presentation Comparison Outcome Time Point (Forest Plot #)	# Studies	N Total N Women (%)	Effect OR (95% CI)	Conclusions	Limitations to Applicability	Strength of Evidence
KQ 3a: Stable angina  CABG vs. medical therapy  Death/MI/ revascularization  4–5 years  (Figure 8)	2 <sup>67,68</sup>	Total: 1,823  Women: 344 (19%)	<u>Women</u> 0.56 (0.32 to 0.96); p=0.04  <u>Men</u> 0.62 (0.31 to 1.24)	<u>Women</u> Favors revascularization  <u>Men</u> Trend favoring revascularization	STICH study consisted of CABG in low EF patients.	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: Inconsistent Directness: Indirect Precision: Imprecise <b>SOE: Low</b>  <u>Men</u> Risk of bias: Low Consistency: Inconsistent Directness: Indirect Precision: Imprecise <b>SOE: Low</b>
KQ 3a: Stable angina  Revascularization (PCI or CABG) vs. medical therapy  Death/MI/ revascularization  4–5 years  (Figure 9)	3 <sup>65,67,68</sup>	Total: 4,110  Women: 704 (17%)	<u>Women</u> 0.59 (0.43 to 0.81); p=0.001  <u>Men</u> 0.71 (0.49 to 1.02)	<u>Women</u> Favors revascularization  <u>Men</u> Trend favoring revascularization	STICH study consisted of CABG in low EF patients.	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: Consistent Directness: Indirect Precision: Precise <b>SOE: Moderate</b>  <u>Men</u> Risk of bias: Low Consistency: Inconsistent Directness: Indirect Precision: Imprecise <b>SOE: Low</b>

**Table 20. Strength of evidence by effectiveness outcome (continued)**

KQ: Presentation Comparison Outcome Time Point (Forest Plot #)	# Studies	N Total N Women (%)	Effect OR (95% CI)	Conclusions	Limitations to Applicability	Strength of Evidence
KQ 3a: Stable/unstable angina  PCI vs. CABG  Death  30 days  (Figure 10)	2 <sup>78,79</sup>	Total: 2,120  Women: 530 (25%)	<u>Women</u> 0.68 (0.24 to 1.93)  <u>Men</u> 1.36 (0.44 to 4.24)	<u>Women</u> Trend favoring PCI  <u>Men</u> Trend favoring CABG	Type of PCI not specified in most studies.	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: Consistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>  <u>Men</u> Risk of bias: Low Consistency: Inconsistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>
KQ 3a: Stable/unstable angina  PCI vs. CABG  Death/MI/stroke  1 year  (Figure 11)	2 <sup>78,80,84</sup>	Total: 1,715  Women: 415 (24%)	<u>Women</u> 1.30 (0.69 to 2.45)  <u>Men</u> 1.19 (0.84 to 1.70)	<u>Women</u> Trend favoring CABG  <u>Men</u> Trend favoring CABG	Type of PCI not specified in most studies.	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: Consistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>  <u>Men</u> Risk of bias: Low Consistency: Consistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>



**Table 20. Strength of evidence by effectiveness outcome (continued)**

KQ: Presentation Comparison Outcome Time Point (Forest Plot #)	# Studies	N Total N Women (%)	Effect OR (95% CI)	Conclusions	Limitations to Applicability	Strength of Evidence
KQ 3a: Stable/unstable angina  PCI vs. CABG  Death/MI/stroke  ≥2 years  (Figure 12)	4 <sup>68,78,79,85</sup>	Total: 3,331  Women: 866 (26%)	<u>Women</u> 1.17 (0.90 to 1.54)  <u>Men</u> 1.63 (1.20 to 2.23); p=0.002	<u>Women</u> Trend favoring CABG  <u>Men</u> Favors CABG	Type of PCI not specified in most studies.	Study design/quality: RCT/good  <u>Women</u> Risk of bias: Low Consistency: Consistent Directness: Direct Precision: Imprecise <b>SOE: Low</b>  <u>Men</u> Risk of bias: Low Consistency: Consistent Directness: Direct Precision: Precise <b>SOE: High</b>

CABG = coronary artery bypass grafting; CI = confidence interval; MI = myocardial infarction; EF = ejection fraction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; RCT = randomized controlled trial; SOE = strength of evidence; STEMI = ST elevation myocardial infarction; UA = unstable angina

## Modifiers of Effectiveness

Five studies (four good, one fair quality) assessed variations in clinical outcomes in women due to demographic or clinical factors. One good-quality study evaluated the comparative effectiveness of PCI versus fibrinolysis in women under 65 years of age and women 65 and older and found no differences in in-hospital mortality among the treatment groups. One fair-quality study evaluated patients 80 years of age and older with STEMI. The study was limited by a small overall size, and it did not find significant differences in the composite outcome (death/heart failure/repeat MI/stroke) at 3 years in patients 80 years of age and older with STEMI undergoing PCI compared with conservative/supportive medical care.

Two good-quality UA/NSTEMI studies of early invasive versus initial conservative therapy showed conflicting results on risk stratification—one showed no difference in treatment outcomes in the intermediate- and high-risk groups (risk was derived from components of the TIMI risk score and a couple other aspects of the participants' presentation at randomization, including aspirin use and angina severity). The other study showed a higher event rate in women in the groups at moderate-to-high risk for thrombolysis in myocardial infarction (TIMI).

One good-quality stable/unstable angina study comparing PCI with CABG showed no difference in survival rate in diabetic women receiving CABG although survival was higher for diabetic men and the total diabetic population (total population results were influenced by the higher proportion of men enrolled in the study).

Of note, we did not find any data specific to women on race, socioeconomic factors, chronic kidney disease, angiographic-specific factors, or CABG-specific factors. Strength of evidence for modifiers of effectiveness for all treatment comparisons was insufficient.

## Safety Concerns

Four good-quality studies reported safety outcomes in women. Two good-quality STEMI studies comparing fibrinolysis with PCI showed no difference in transfusions and a higher incidence of intracranial hemorrhage in women who received accelerated t-PA versus PCI (4.1% vs. 0%), but statistical analysis for this comparison was not done. Two good-quality UA/NSTEMI studies showed higher in-hospital bleeding rates in women undergoing PCI (adjusted OR 3.6; 95% CI, 1.6 to 8.3) but not in those undergoing CABG. However, we did not find data specific to women on adverse drug reactions, radiation exposure, access site complications, renal dysfunction, anaphylaxis, arrhythmias, stent thrombosis, or infection. Strength of evidence for safety concerns for all treatment strategies was insufficient.

## Discussion

The findings from this systematic review on the treatment strategies for women across the spectrum of CAD presentations highlight areas for future research and for informing clinical practice. First, this review underscores the significant need for clinical researchers to provide study findings with women-specific data on the primary and secondary clinical outcomes. Overall, we were able to find only 28 relevant studies with data on either shorter term or longer term outcomes in women with CAD treated with invasive or conservative medical therapies. In addition, the representation of women enrolled in these trials was low. Melloni et al.<sup>27</sup> found similarly low rates with sex-specific results discussed in only 31 percent of the 156 primary trial publications cited by the American Heart Association's 2007 women's prevention guidelines. In

addition, they found that enrollment of women in randomized clinical trials had increased over time (18% in 1970 to 34% in 2006) but remained low relative to their overall representation in disease populations (e.g., 25% women representation in RCTs of CAD compared with 46% women representation in the CAD population).

Second, our findings confirm current practice and evidence for care in one of the three areas evaluated. For women patients with STEMI, we found that an invasive approach with immediate PCI is superior to fibrinolysis in reducing cardiovascular events. These findings are similar to a meta-analysis<sup>107</sup> of 23 randomized trials comparing PCI with fibrinolysis for acute MI in combined populations of men and women. However, for patients with NSTEMI treated with an early invasive approach compared with a conservative or selective invasive approach, this review, while finding a trend favoring early invasive strategies, does not demonstrate a statistically significant benefit of an early invasive approach in reducing cardiovascular events in women. In contrast, the overall meta-analysis for trials of early invasive versus conservative strategies including both men and women showed a benefit of early invasive therapy.<sup>108</sup> The results from this review suggest that such a benefit may also be true in women, but the confidence intervals are too wide to support a firm conclusion.

In addition, for medical therapy alone versus revascularization plus medical therapy for patients with stable angina or high CAD burden, the findings from the current analysis suggest a benefit of revascularization in women. These findings should be viewed with caution because they are based on a limited number of studies with data on 704 (17%) women; these analyses often have both PCI and CABG together in the revascularization group, and the overall findings from these studies do not show a significant benefit beyond angina or symptom reduction for revascularization. In these studies, it is possible that women who present later in life with CAD, and with higher CAD burden, may be obtaining a greater benefit with revascularization, and the findings from this analysis should prompt further research in this area and again encourage researchers to provide data specific on women. In contrast, previous meta-analyses that combined results for men and women found similar outcomes for either treatment. The higher proportion of men enrolled in these trials (83%) may have led to the masking of the women's results by the men's results within a pooled analysis.

Our stakeholder group advised us to assess the effectiveness of these therapies by sex on multiple important clinical outcomes, such as nonfatal MI, death, stroke, repeat revascularization, recurrent unstable angina, heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects. A majority of sex-specific reporting was on the composite outcome of major cardiovascular adverse events (death, MI, or revascularization). Individual outcomes by sex were rarely reported, especially on heart failure, repeat hospitalization, length of hospital stay, angina relief, quality of life, or cognitive effects.

Based on the small number of studies that looked at demographic and clinical factors that influence response to treatment strategies in women, there was insufficient evidence that clinicians can use to determine if age, race/ethnicity, socioeconomic status, coronary risk factors, angiographic-specific factors, CABG-specific factors, or hospital-level characteristics should be taken into consideration when deciding a treatment strategy for women with CAD. Unfortunately, more studies are needed that evaluate the subgroups and various demographic and clinical characteristics to fully understand this evidence gap.

In addition, the safety concerns or harms of these treatment strategies are underreported for women enrolled in RCTs. It appears that the bleeding risk may be higher in women receiving


fibrinolysis or PCI. Careful consideration should be given to the dose, timing, and duration of antiplatelet, antithrombotic, and anticoagulant therapies administered to women.

## Limitations of This Review

With 28 studies meeting the inclusion criteria, this systematic review has several limitations. First, our search focused on comparative RCTs—the highest quality of evidence for determining the efficacy of different treatment modalities on cardiovascular outcomes. While this was adequate for evaluating the evidence to support the clinical outcomes by treatment strategy and by CAD presentation for the overall population, there were very few RCTs that reported subgroup analyses by demographic or clinical characteristics and also very few RCTs that reported the harms or risks of therapy. Most studies that reported results applicable to modifiers of effectiveness or safety did this for the overall population and did not separate the effects by sex. We are aware that there are several observational or noncomparator studies of each of the treatment modalities that address these issues in women. Because of the problems with confounding from observational studies and the difficulty of constructing reliable comparisons among single-arm studies, we did not include observational or noncomparator studies in our review.

Second, the sample size and low representation of women in most of the comparator studies may affect the study authors' ability to analyze the results by sex, therefore reducing the number of studies reporting these findings separately (i.e., reporting bias). We excluded 355 articles due to lack of sex-specific reporting of the study results, which resulted in low numbers of studies available for analysis for each clinical presentation (STEMI, UA/NSTEMI, stable angina). Of these 355 articles, 116 were associated with the same 28 studies included in our review, but they did not report data on women separately. The remaining 239 articles were associated with 173 studies that did not report data on women. Figure 13 presents a graph of the number of articles reporting data on women per year. The percentage ranges from 0 percent (in 1992 and 1993) to 75 percent in 1995. On average, 17 percent of the articles comparing treatment strategies for CAD reported sex-specific outcomes. Of note, many articles included a multivariate analysis which included sex as a covariate in the model; the majority found no evidence of a gender effect. The result of a multivariable model is insufficient for incorporating into a meta-analysis, thus these were excluded from the review. Reporting bias in these publications therefore resulted in selection bias in this review.

**Figure 13. Number of articles reporting data on women by year**



Third, the strength of our meta-analysis is limited by the different definitions of the primary composite outcome and by the timing (short-term and long-term) of those clinical endpoints. We used our best judgment in choosing which composite outcomes (e.g., death/MI/stroke and death/MI/stroke/revascularization) and time points (e.g., in-hospital and 30 days) to combine in the meta-analysis.

A final limitation is the change in PCI techniques and definition of optimal medical therapy over time. Most of the studies involved balloon angioplasty or bare-metal stents. The current era of drug-eluting stents and the use of dual antiplatelet therapy may be underrepresented. Nevertheless, the findings represent the best available evidence. While the treatment options continue to evolve over time, these older therapies (bare-metal stents, balloon angioplasty) are still being used in clinical practice, and therefore we did not downgrade the strength of evidence based on the availability of newer technologies. Medication adherence to beta blockers, angiotensin-converting enzyme inhibitors, aspirin, antiplatelet agents, and lipid-lowering agents was not reported in the studies included in this review. There was also variable reporting on the implementation of optimal medical therapy.

Many of these studies were multicenter, international RCTs with multiple countries represented. The generalizability of those studies to the United States may be of concern; however, the practice of revascularization and prescription of medical therapies are not dramatically different.

## Conclusions

From a limited number of studies reporting results for women separately from the total study population, our findings confirm current practice and evidence for care in one of the three areas evaluated.

1. For women with STEMI, we found that an invasive approach with immediate PCI is superior to fibrinolysis for reducing cardiovascular events, which is similar to findings in previous meta-analyses combining results for both women and men.
2. For women with NSTEMI or unstable angina, we found evidence suggestive of a benefit of early invasive strategies for reducing cardiovascular events; however, this benefit was not statistically significant. Previous meta-analyses of studies comparing early invasive with initial conservative strategies on a combined population of men and women showed a significant benefit of early invasive therapy.
3. For women with stable angina, the few trials reporting sex-specific data on revascularization compared with optimal medical therapy showed a greater benefit with revascularization for women, while the men in the study fared equally well with either treatment. In contrast, previous meta-analyses that combined results for men and women found similar outcomes for either treatment.

## Future Research

This comprehensive review of the comparative effectiveness of treatment modalities for women with CAD identified numerous gaps in evidence that would be suitable for future research and for improving the reporting of women findings of cardiovascular therapies in the published literature.

### Studies With Sufficient Representation of Women

Sex subgroup analyses are often limited by the number of men or women in each treatment group to allow for adequate power to detect a statistically significant difference in outcome. While we were able to find RCTs that reported risk ratios in women, the enrollment numbers were insufficient to have adequate power to detect a difference, thus resulting in large confidence intervals that often crossed the null effect, with a potential type II error. To better understand the clinical outcomes of women treated by medical therapy or revascularization, trials should be either (1) women-only enrollment or (2) of large enough sample size with stratification of randomization by sex to allow for meaningful sex-based analyses. In order to assess sex differences in treatment modalities and their impact on clinical outcomes, a sufficient sample size is required in order to have adequate statistical power for subgroup analyses.

### Patient-Level Meta-Analysis

Given the small representation of women in these RCTs, the heterogeneity of clinical outcomes (e.g., definition of composite outcome) and different measurement time points (e.g., 30 days, 6 weeks for short-term outcomes), we are aware that our group-level meta-analysis may be inadequate (when too few studies are available) to address the comparative effectiveness of medical therapy and revascularization. Therefore, patient-level analysis of trials comparing similar interventions for the same CAD presentation may be more appropriate for assessing the sex differences as well as for conducting subgroup analyses on demographic and clinical factors that influence treatment outcomes, or for evaluating safety concerns/harms of these treatment strategies. Subgroup analyses across trials can be done similarly to a previous AHRQ report on the comparative effectiveness of PCI and CABG, which included an addendum study that pooled individual patient data from 10 randomized trials to compare the effectiveness of CABG with PCI according to patients' baseline clinical characteristics (e.g., age, diabetes, sex, individual cardiac risk factors, angioplasty versus bare metal stents).<sup>34,109,110</sup>

### Reporting Sex by Treatment Results Separately

Our review excluded trials that looked for a sex effect yet failed to provide results of women and men by treatment arm. An example is a trial that did a multivariate analysis to assess factors that influenced clinical outcomes and included male (or female) sex in the model, with a finding that it was nonsignificant or significant. We did not contact the corresponding authors of the articles that did not report sex results separately. It would aid future comparisons of treatment modalities if study authors were to report the primary data for women and men separately either within the article itself or in an online supplementary appendix. The 2010 report by the Institute of Medicine on Women's Health Research recommended that funding agencies ensure adequate participation of women and reporting of sex-specific analyses in health research.<sup>111</sup>

## **Reporting of Demographic and Clinical Factors That Influence Cardiovascular Outcomes**

We found a few studies that conducted subgroup analyses of age, diabetes, and risk stratification in women populations. We did not find any data specific to women on race, socioeconomic, chronic kidney disease, angiographic-specific factors, or CABG-specific factors that were listed in KQ 2. Knowing the influence of these factors on cardiovascular outcomes is important for determining the proper treatment strategy and prognosis of women patients who present with various risk factors and comorbidities.

## **Reporting of Safety Concerns/Risks by Sex**

Medical therapy can result in adverse drug reactions, and use of fibrinolytics can result in bleeding or intracranial hemorrhage. PCI can cause access site complications, radiation exposure, contrast-related anaphylaxis, bleeding, and stent thrombosis. CABG can result in wound infections, renal dysfunction, and bleeding. Most studies reported the bleeding risk of revascularization strategies but not the other safety concerns. Systematic reporting of adverse events in publications—in total and by sex—should continue to clarify which treatment modalities are safe for use in clinical practice.

To summarize, these evidence gaps could be addressed in various ways. First, more primary research with adequate representation of women for any of the three CAD clinical presentations could be conducted to achieve adequate statistical power for a sex-based analysis. Second, authors of the comparative trials that were excluded for not reporting sex-based results could be contacted to provide results of women and men by treatment arm, and the group-level meta-analysis could be repeated with a larger number of trials. Alternatively, these authors could be contacted to provide compatible (deidentified) datasets that could be combined for a patient-level analysis to assess the comparative effectiveness, modifiers of effectiveness, and risks of the various treatment strategies available. Finally, the use of observational cohorts from electronic health records could inform the real-world effectiveness of the treatment strategies chosen by clinicians and patients in a nonrandom fashion.



## References

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association. *Circulation*. 2012;125(1):e2-e220. PMID: 22179539.
2. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation*. 2007;115(11):1481-501. PMID: 17309915.
3. Vaccarino V, Horwitz RI, Meehan TP, et al. Sex differences in mortality after myocardial infarction: evidence for a sex-age interaction. *Arch Intern Med*. 1998;158(18):2054-62. PMID: 9778206.
4. Vaccarino V, Parsons L, Every NR, et al. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. *N Engl J Med*. 1999;341(4):217-25. PMID: 10413733.
5. Vaccarino V, Krumholz HM, Yarzebski J, et al. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. *Ann Intern Med*. 2001;134(3):173-81. PMID: 11177329.
6. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. *J Am Coll Cardiol*. 2009;54(17):1561-75. PMID: 19833255.
7. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIB Investigators. *N Engl J Med*. 1999;341(4):226-32. PMID: 10413734.
8. Berger JS, Elliott L, Gallup D, et al. Sex differences in mortality following acute coronary syndromes. *JAMA*. 2009;302(8):874-82. PMID: 19706861.
9. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. *Circulation*. 2005;111(5):682-96. PMID: 15687114.
10. Alexander KP, Chen AY, Newby LK, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. *Circulation*. 2006;114(13):1380-7. PMID: 16982940.
11. Pepine CJ. Ischemic heart disease in women: facts and wishful thinking. *J Am Coll Cardiol*. 2004;43(10):1727-30. PMID: 15145090.
12. Vaccarino V, Abramson JL, Veledar E, et al. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. *Circulation*. 2002;105(10):1176-81. PMID: 11889010.
13. Mikhail GW. Coronary heart disease in women. *BMJ*. 2005;331(7515):467-8. PMID: 16141136.
14. Daly C, Clemens F, Lopez Sendon JL, et al. Gender differences in the management and clinical outcome of stable angina. *Circulation*. 2006;113(4):490-8. PMID: 16449728.

15. Blomkalns AL, Chen AY, Hochman JS, et al. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol.* 2005;45(6):832-7. PMID: 15766815.
16. Anand SS, Xie CC, Mehta S, et al. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. *J Am Coll Cardiol.* 2005;46(10):1845-51. PMID: 16286169.
17. Vaccarino V, Rathore SS, Wenger NK, et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. *N Engl J Med.* 2005;353(7):671-82. PMID: 16107620.
18. Milner KA, Funk M, Richards S, et al. Gender differences in symptom presentation associated with coronary heart disease. *Am J Cardiol.* 1999;84(4):396-9. PMID: 10468075.
19. Patel H, Rosengren A, Ekman I. Symptoms in acute coronary syndromes: does sex make a difference? *Am Heart J.* 2004;148(1):27-33. PMID: 15215788.
20. Klein J, Karawan A, Abeles-Raviv N, et al. Is there a gender difference in risk profile, attendance, and beneficial effects of a multidisciplinary cardiac rehabilitation program? *Journal of the American College of Cardiology.* 2002;39(Supplement 1):1088-1137.
21. Kaski J. Cardiac syndrome X. In: Wenger NK and Collins P, eds. *Women and heart disease.* 2nd ed. London: Informa Healthcare. 2005:205-216.
22. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. *Eur Heart J.* 2004;25(18):1641-50. PMID: 15351164.
23. Hochman JS, McCabe CH, Stone PH, et al. Outcome and profile of women and men presenting with acute coronary syndromes: a report from TIMI IIIB. TIMI Investigators. Thrombolysis in Myocardial Infarction. *J Am Coll Cardiol.* 1997;30(1):141-8. PMID: 9207635.
24. Kreatsoulas C, Natarajan MK, Khatun R, et al. Identifying women with severe angiographic coronary disease. *J Intern Med.* 2010;268(1):66-74. PMID: 20210841.
25. Wenger NK. Angina in women. *Curr Cardiol Rep.* 2010;12(4):307-14. PMID: 20425162.
26. Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. *JAMA.* 2001;286(6):708-13. PMID: 11495621.
27. Melloni C, Berger JS, Wang TY, et al. Representation of women in randomized clinical trials of cardiovascular disease prevention. *Circ Cardiovasc Qual Outcomes.* 2010;3(2):135-42. PMID: 20160159.
28. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non ST-elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Circulation.* 2007;116(7):e148-304. PMID: 17679616.

29. Kushner FG, Hand M, Smith SC, Jr., et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2009;120(22):2271-306. PMID: 19923169.
30. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). *Circulation*. 2003;107(1):149-58. PMID: 12515758.
31. Sibley C, Rivera J, Blumenthal RS. 'ABCDE' makes an effective prevention tool. *Cardiology Today: approach translates guidelines into a comprehensive management plan for the primary and secondary prevention of CVD [commentary]*. 2007 Jun 1. [www.cardiologytoday.com/view.aspx?rid=39071](http://www.cardiologytoday.com/view.aspx?rid=39071).
32. Lansky AJ, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. *Circulation*. 2005;111(7):940-53. PMID: 15687113.
33. Agency for Healthcare Research and Quality. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews, Version 1.0*. Rockville, MD: Agency for Healthcare Research and Quality. Draft Posted October 2007. [www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318](http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=318).
34. Bravata DM, McDonald KM, Gienger AL, et al. Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease. Comparative Effectiveness Review No. 9. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract No. 290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. October 2007. [www.effectivehealthcare.ahrq.gov/products/15/55/CER\\_PCI\\_CABGMainReport.pdf](http://www.effectivehealthcare.ahrq.gov/products/15/55/CER_PCI_CABGMainReport.pdf). PMID: 20704052.
35. Grady D, Chaput L, Kristof M. Results of systematic review of research on diagnosis and treatment of coronary heart disease in women. *Evid Rep Technol Assess (Summ)*. 2003(80):1-4. PMID: 12827897.
36. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. *Lancet*. 2008;371(9612):559-68. PMID: 18280326.
37. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med*. 2003;349(8):733-42. PMID: 12930925.
38. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. *JAMA*. 2001;285(2):190-2. PMID: 11176812.
39. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. *Am Heart J*. 2004;147(1):133-9. PMID: 14691431.

40. Dobrzycki S, Kralisz P, Nowak K, et al. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals. *Eur Heart J.* 2007;28(20):2438-48. PMID: 17884846.
41. Minai K, Horie H, Takahashi M, et al. Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial. *Am Heart J.* 2002;143(3):497-505. PMID: 11868057.
42. Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol.* 1995;75(15):987-92. PMID: 7747700.
43. Di Mario C, Bolognese L, Maillard L, et al. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). *Am Heart J.* 2004;148(3):378-85. PMID: 15389222.
44. Mortensen OS, Bjorner JB, Newman B, et al. Gender differences in health-related quality of life following ST-elevation myocardial infarction: women and men do not benefit from primary percutaneous coronary intervention to the same degree. *Eur J Cardiovasc Prev Rehabil.* 2007;14(1):37-43. PMID: 17301625.
45. Nielsen PH, Maeng M, Busk M, et al. Primary angioplasty versus fibrinolysis in acute myocardial infarction: long-term follow-up in the Danish acute myocardial infarction 2 trial. *Circulation.* 2010;121(13):1484-91. PMID: 20308618.
46. Busk M, Maeng M, Kristensen SD, et al. Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial. *Am J Cardiol.* 2009;104(2):210-5. PMID: 19576349.
47. Busk M, Maeng M, Rasmussen K, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. *Eur Heart J.* 2008;29(10):1259-66. PMID: 17956874.
48. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. *JAMA.* 2006;295(21):2511-5. PMID: 16757723.
49. Hochman JS, Sleeper LA, Godfrey E, et al. SHould we emergently revascularize Occluded Coronaries for cardiogenic shockK: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group. *Am Heart J.* 1999;137(2):313-21. PMID: 9924166.
50. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med.* 1999;341(9):625-34. PMID: 10460813.
51. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA.* 2002;288(24):3124-9. PMID: 12495392.
52. Lagerqvist B, Safstrom K, Stahle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. *J Am Coll Cardiol.* 2001;38(1):41-8. PMID: 11451294.
53. Ottervanger JP, Armstrong P, Barnathan ES, et al. Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. *Eur Heart J.* 2004;25(17):1494-501. PMID: 15342168.
54. Anonymous. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet.* 1997;350(9076):461-8. PMID: 9274581.

55. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med.* 2001;344(25):1879-87. PMID: 11419424.
56. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. *N Engl J Med.* 2005;353(11):1095-104. PMID: 16162880.
57. Anonymous. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. *Thrombolysis in Myocardial Ischemia. Circulation.* 1994;89(4):1545-56. PMID: 8149520.
58. Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. *Lancet.* 2006;368(9540):998-1004. PMID: 16980115.
59. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. *Lancet.* 2000;355(9223):9-16. PMID: 10892758.
60. Anonymous. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. *Lancet.* 1999;354(9180):708-15. PMID: 10475181.
61. Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. *J Am Coll Cardiol.* 2010;55(9):858-64. PMID: 20045278.
62. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. *Randomized Intervention Trial of unstable Angina. Lancet.* 2002;360(9335):743-51. PMID: 12241831.
63. Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. *Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol.* 1998;82(6):731-6. PMID: 9761082.
64. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. *J Am Coll Cardiol.* 1995;26(7):1643-50. PMID: 7594098.
65. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med.* 2007;356(15):1503-16. PMID: 17387127.
66. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med.* 2006;355(23):2395-407. PMID: 17105759.
67. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. *N Engl J Med.* 2011. PMID: 21463150.
68. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation.* 2010;122(10):949-57. PMID: 20733102.

69. Allen KB, Dowling RD, Angell WW, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. *Ann Thorac Surg.* 2004;77(4):1228-34. PMID: 15063241.
70. Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. *N Engl J Med.* 1999;341(14):1029-36. PMID: 10502592.
71. Mancini GB, Bates ER, Maron DJ, et al. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. *Circ Cardiovasc Qual Outcomes.* 2009;2(4):320-7. PMID: 20031857.
72. Boden WE, O'Rourke R A, Teo KK, et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. *Am Heart J.* 2006;151(6):1173-9. PMID: 16781214.
73. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol.* 2004;43(10):1743-51. PMID: 15145093.
74. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation.* 2007;115(9):1082-9. PMID: 17339566.
75. Hochman JS, Lamas GA, Knatterud GL, et al. Design and methodology of the Occluded Artery Trial (OAT). *Am Heart J.* 2005;150(4):627-42. PMID: 16209957.
76. Hochman JS, Reynolds HR, Dzavik V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. *Circulation.* 2011;124(21):2320-2328. PMID: 22025606.
77. Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. *J Thorac Cardiovasc Surg.* 2007;134(6):1540-7. PMID: 18023680.
78. Vaina S, Voudris V, Morice MC, et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II. *EuroIntervention.* 2009;4(4):492-501. PMID: 19284072.
79. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). *Circulation.* 1998;98(13):1279-85. PMID: 9751675.
80. Anonymous. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. *Lancet.* 1995;346(8984):1179-84. PMID: 7475656.
81. King SB, 3rd, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). *J Am Coll Cardiol.* 2000;35(5):1116-21. PMID: 10758949.
82. Zhang Z, Weintraub WS, Mahoney EM, et al. Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). *Am J Cardiol.* 2004;93(4):404-9. PMID: 14969611.
83. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation.* 2010;121(24):2645-53. PMID: 20530001.

84. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol.* 2010;55(5):432-40. PMID: 20117456.
85. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. *N Engl J Med.* 2011(18):1718-27. PMID: 21463149
86. Kaehler J, Koester R, Billmann W, et al. 13-year follow-up of the German angioplasty bypass surgery investigation. *Eur Heart J.* 2005;26(20):2148-53. PMID: 15975991.
87. van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. *J Am Coll Cardiol.* 2002;39(4):559-64. PMID: 11849851.
88. Serruys PW, Unger F, van Hout BA, et al. The ARTS study (Arterial Revascularization Therapies Study). *Semin Interv Cardiol.* 1999;4(4):209-19. PMID: 10738354.
89. Voudris V, Ong AT, Serruys PW, et al. Sex differences and their impact on clinical outcome after percutaneous or surgical revascularisation: a report from the Arterial Revascularisation Therapies Study (ARTS). *EuroIntervention.* 2006;2(2):175-80. PMID: 19755257.
90. Anonymous. The ARTS (Arterial Revascularization Therapies Study): Background, goals and methods. *Int J Cardiovasc Intervent.* 1999;2(1):41-50. PMID: 12623386.
91. Gibbons RJ, Miller DD, Liu P, et al. Similarity of ventricular function in patients alive 5 years after randomization to surgery or angioplasty in the BARI trial. *Circulation.* 2001;103(8):1076-82. PMID: 11222469.
92. Anonymous. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol.* 2007;49(15):1600-6. PMID: 17433949.
93. Lombardero MS. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI), by treatment and presence of diabetes. *Cardiovasc Rev Rep.* 2002;23(1):14-18. PMID: 2002025009.
94. Anonymous. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol.* 2000;35(5):1122-9. PMID: 10758950.
95. Hlatky MA, Charles ED, Nobrega F, et al. Initial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol.* 1995;75(9):34C-41C. PMID: 7892821.
96. Rogers WJ, Alderman EL, Chaitman BR, et al. Bypass Angioplasty Revascularization Investigation (BARI): baseline clinical and angiographic data. *Am J Cardiol.* 1995;75(9):9C-17C. PMID: 7892823.
97. Sutton-Tyrrell K, Rihal C, Sellers MA, et al. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol.* 1998;81(4):375-81. PMID: 9485122.
98. Mullany CJ, Mock MB, Brooks MM, et al. Effect of age in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. *Ann Thorac Surg.* 1999;67(2):396-403. PMID: 10197660.
99. Anonymous. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med.* 1996;335(4):217-25. PMID: 8657237.
100. Kapur A, Malik IS, Bagger JP, et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. *Am Heart J.* 2005;149(1):13-9. PMID: 15660030.
101. King SB, 3rd, Lembo NJ, Weintraub WS, et al. Emory Angioplasty Versus Surgery Trial (EAST): design, recruitment, and baseline description of patients. *Am J Cardiol.* 1995;75(9):42C-59C. PMID: 7892822.

102. King SB, 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). *N Engl J Med*. 1994;331(16):1044-50. PMID: 8090163.
103. Zhao XQ, Brown BG, Stewart DK, et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. *Circulation*. 1996;93(11):1954-62. PMID: 8640968.
104. Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). *N Engl J Med*. 1994;331(16):1037-43. PMID: 8090162.
105. Zhang Z, Mahoney EM, Stables RH, et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. *Circulation*. 2003;108(14):1694-700. PMID: 12975252.
106. Stables RH. Design of the 'Stent or Surgery' trial (SoS): a randomized controlled trial to compare coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multi-vessel coronary artery disease. *Semin Interv Cardiol*. 1999;4(4):201-7. PMID: 10738353.
107. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. *Lancet*. 2003;361(9351):13-20. PMID: 12517460.
108. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. *JAMA*. 2005;293(23):2908-17. PMID: 15956636.
109. Hlatky MA, Boothroyd DB, Bravata DM, et al. Addendum to Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Interventions for Multivessel Disease. Comparative Effectiveness Review No. 9 Addendum. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract No. 290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. February 2010. [www.effectivehealthcare.ahrq.gov/products/15/421/CER9%20Addendum%20Final.pdf](http://www.effectivehealthcare.ahrq.gov/products/15/421/CER9%20Addendum%20Final.pdf).
110. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet*. 2009;373(9670):1190-7. PMID: 19303634.
111. Women's Health Research: Progress, Pitfalls, and Promise. Institute of Medicine of the National Academies, Consensus Report. 2010. [www.iom.edu/Reports/2010/Womens-Health-Research-Progress-Pitfalls-and-Promise.aspx](http://www.iom.edu/Reports/2010/Womens-Health-Research-Progress-Pitfalls-and-Promise.aspx).



## Abbreviations

AHRQ	Agency for Healthcare Research and Quality
BMS	bare-metal stent
CABG	coronary artery bypass graft
CAD	coronary artery disease
CI	confidence interval
CVA	cerebrovascular accident
DES	drug-eluting stent
EF	ejection fraction
HCT	Hematocrit
HR	hazard ratio
IABP	intra-aortic balloon pump
ICH	intracranial hemorrhage
IV	Intravenous
KQ	Key Question
MACE	major adverse cardiovascular events
MI	myocardial infarction
NSTEMI	non-ST elevation myocardial infarction
OR	odds ratio
PCI	percutaneous coronary intervention
PTCA	percutaneous transluminal coronary angioplasty
RCT	randomized controlled trial
RR	risk ratio
SOE	strength of evidence
STEMI	ST elevation myocardial infarction
TEP	Technical Expert Panel
TIMI	thrombolysis in myocardial infarction
TMR	transmyocardial revascularization
t-PA	tissue plasminogen activator
UA	unstable angina

## Appendix A. Exact Search Strings

### PubMed® Search Strategy (December 12, 2011)

Set #	Terms
<b>#1</b>	("cardiovascular diseases"[MeSH Terms] OR ("cardiovascular"[All Fields] AND "diseases"[All Fields]) OR "cardiovascular diseases"[All Fields]) OR ("heart diseases"[MeSH Terms] OR ("heart"[All Fields] AND "diseases"[All Fields]) OR "heart diseases"[All Fields]) OR ("heart"[MeSH Terms] OR "heart"[All Fields] OR "coronary"[All Fields]) OR cardiovas*[All fields] OR cardiac*[All fields] OR ("myocardium"[MeSH Terms] OR "myocardium"[All Fields] OR "myocardial"[All Fields]) OR ("acute coronary syndrome"[MeSH Terms] OR ("acute"[All Fields] AND "coronary"[All Fields] AND "syndrome"[All Fields]) OR "acute coronary syndrome"[All Fields]) OR ("myocardial infarction"[MeSH Terms] OR ("myocardial"[All Fields] AND "infarction"[All Fields]) OR "myocardial infarction"[All Fields]) OR ("angina, unstable"[MeSH Terms] OR ("angina"[All Fields] AND "unstable"[All Fields]) OR "unstable angina"[All Fields] OR ("unstable"[All Fields] AND "angina"[All Fields]))
<b>#2</b>	"angioplasty, balloon, coronary"[MeSH Terms] OR ("angioplasty"[All Fields] AND "balloon"[All Fields] AND "coronary"[All Fields]) OR "coronary balloon angioplasty"[All Fields] OR ("percutaneous"[All Fields] AND "transluminal"[All Fields] AND "coronary"[All Fields] AND "angioplasty"[All Fields]) OR "percutaneous transluminal coronary angioplasty"[All Fields] OR "ptca"[All Fields] OR percutaneous coronary intervention[All Fields] OR percutaneous coronary interventional[All Fields] OR percutaneous coronary interventions[All Fields] OR PCI[All Fields] OR stent[All Fields] OR stents[All Fields] OR stent*[All Fields] OR "stents"[MeSH Terms] OR ("balloon"[All Fields] AND "angioplasty"[All Fields]) OR "balloon angioplasty"[All Fields] OR "angioplasty, balloon"[MeSH Terms] OR "balloon dilation"[MeSH Terms] OR ("balloon"[All Fields] AND "dilation"[All Fields]) OR "balloon dilation"[All Fields] OR ("transluminal"[All Fields] AND "angioplasty"[All Fields]) OR "transluminal angioplasty"[All Fields] OR "angioplasty"[MeSH Terms] OR "angioplasty"[All Fields] OR "atherectomy, coronary"[MeSH Terms] OR ("atherectomy"[All Fields] AND "coronary"[All Fields]) OR "coronary atherectomy"[All Fields] OR ("coronary"[All Fields] AND "atherectomy"[All Fields]) OR ("coronary artery bypass"[MeSH Terms] OR ("coronary"[All Fields] AND "artery"[All Fields] AND "bypass"[All Fields]) OR "coronary artery bypass"[All Fields]) OR CABG[All Fields] OR ("coronary artery bypass"[MeSH Terms] OR ("aortocoronary"[All Fields] AND "bypass"[All Fields]) OR "aortocoronary bypass"[All Fields]) OR "coronary revascularization"[All Fields] OR "myocardial revascularization"[All Fields]
<b>#3</b>	"women"[MeSH Terms] OR "women"[All Fields] OR "woman"[All Fields] OR "female"[MeSH Terms] OR "female"[All Fields] OR "females"[All Fields] OR "sex factors"[MeSH Terms] OR ("sex"[All Fields] AND "factors"[All Fields]) OR "sex factors"[All Fields]
<b>#4</b>	randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tiab] OR "clinical trials as topic"[MeSH Terms:noexp] OR randomly[tiab] OR trial[ti]
<b>#5</b>	#1 AND #2 AND #3 AND #4
<b>#6</b>	#5 NOT (Editorial[ptyp] OR Letter[ptyp] OR Case Reports[ptyp]) NOT Animals[Mesh:noexp]
	Limits: Human, English, Publication Date: 2001- Present

## Embase® Search Strategy (December 12, 2011)

Platform: Embase.com

Set #	Terms
#1	'cardiovascular disease'/exp OR 'heart disease'/exp OR 'heart'/exp OR 'acute coronary syndrome'/exp OR 'heart infarction'/exp OR 'unstable angina pectoris'/exp OR 'cardiovascular diseases':ab OR 'heart diseases':ab OR heart:ab OR cardiovasc*:ab OR cardiac*:ab OR coronary:ab OR myocardial:ab OR 'acute coronary syndrome':ab OR 'myocardial infarction':ab OR 'unstable angina':ab OR 'cardiovascular diseases':ti OR 'heart diseases':ti OR heart:ti OR cardiovasc*:ti OR cardiac*:ti OR coronary:ti OR myocardial:ti OR 'acute coronary syndrome':ti OR 'myocardial infarction':ti OR 'unstable angina':ti
#2	'transluminal coronary angioplasty'/exp OR 'percutaneous coronary intervention'/exp OR 'stent'/exp OR 'balloon dilatation'/exp OR 'percutaneous transluminal angioplasty'/exp OR 'atherectomy'/exp OR 'percutaneous transluminal angioplasty':ti OR ptca:ti OR ('percutaneous coronary' NEXT/1 intervention*):ti OR pci:ti OR stent*:ti OR 'balloon angioplasty':ti OR 'balloon dilation':ti OR 'balloon dilatation':ti OR 'transluminal angioplasty':ti OR 'coronary atherectomy':ti OR 'percutaneous transluminal angioplasty':ab OR ptca:ab OR ('percutaneous coronary' NEXT/1 intervention*):ab OR pci:ab OR stent*:ab OR 'balloon angioplasty':ab OR 'balloon dilation':ab OR 'balloon dilatation':ab OR 'transluminal angioplasty':ab OR 'coronary atherectomy':ab OR 'coronary artery bypass graft'/exp OR 'heart muscle revascularization'/exp OR 'coronary artery bypass':ti OR cabg:ti OR 'aortocoronary bypass':ti OR 'coronary revascularization':ti OR 'myocardial revascularization':ti OR 'coronary artery bypass':ab OR cabg:ab OR 'aortocoronary bypass':ab OR 'coronary revascularization':ab OR 'myocardial revascularization':ab OR 'coronary artery recanalization'/exp
#3	'female'/exp OR female OR women OR woman OR females OR 'sex difference'/exp
#4	'randomized controlled trial'/exp OR 'crossover procedure'/exp OR 'double blind procedure'/exp OR 'single blind procedure'/exp OR random* OR factorial* OR crossover* OR cross NEAR/1 over* OR placebo* OR doubl* NEAR/1 blind* OR singl* NEAR/1 blind* OR assign* OR allocat* OR volunteer*
#5	#1 AND #2 AND #3 AND #4
#6	#5 (AND [embase]/lim NOT [medline]/lim)
	Limits: Human, English, Publication Date: 2001- Present

## Cochrane Search Strategy (December 12, 2011)

Platform: Wiley

Databases searched: Cochrane Central Registry of Controlled Trials and Cochrane Database of Systematic Reviews

Set #	Terms
#1	cardiovascular diseases OR heart diseases OR heart OR cardiovas* OR cardiac* OR coronary OR myocardial OR acute coronary syndrome OR myocardial infarction OR unstable angina [in title-abstract-keywords]
#2	percutaneous transluminal coronary angioplasty OR PTCA OR "percutaneous coronary intervention" OR "percutaneous coronary interventions" OR "percutaneous coronary interventional" OR PCI OR Stent* OR stents OR Balloon angioplasty OR Balloon dilatation OR Balloon dilation OR Transluminal angioplasty OR coronary atherectomy OR Coronary Artery Bypass OR CABG OR aortocoronary bypass OR coronary revascularization OR myocardial revascularization [in title-abstract-keywords]
#3	women OR woman OR female OR females OR sex factors [in title-abstract-keywords]
#4	#1 AND #2 AND #3
	Limits: 2001- Present

## Grey Literature Searches

### ClinicalTrials.gov

Search date: 12/16/2011

#### Search #1: PCI vs. CABG

Expert Search String:

( NOT ( “Recruiting” OR “Not yet recruiting” OR “Available” ) ) [OVERALL-STATUS] AND ( heart diseases OR cardiovascular diseases ) [DISEASE] AND ( ( percutaneous transluminal coronary angioplasty OR PTCA OR percutaneous coronary intervention OR PCI OR balloon OR stent ) AND ( coronary artery bypass OR CABG ) ) [TREATMENT]

#### Search #2: CABG vs. Medical Therapy

Expert Search String:

( NOT ( “Recruiting” OR “Not yet recruiting” OR “Available” ) ) [OVERALL-STATUS] AND ( heart diseases OR cardiovascular diseases ) [DISEASE] AND ( ( coronary artery bypass OR CABG ) AND ( medical management OR medical therapy OR OMT OR standard of care OR medical treatment OR standard therapy OR usual care ) ) [TREATMENT]

#### Search #3: PCI vs. Medical Therapy

Expert Search String:

( NOT ( “Recruiting” OR “Not yet recruiting” OR “Available” ) ) [OVERALL-STATUS] AND ( heart diseases OR cardiovascular diseases ) [DISEASE] AND ( ( percutaneous transluminal coronary angioplasty OR PTCA OR percutaneous coronary intervention OR PCI OR balloon OR stent ) AND ( medical management OR medical therapy OR OMT OR standard of care OR medical treatment OR standard therapy OR usual care ) ) [TREATMENT]

#### Processing of results

1. Total number of results: 117
2. Duplicates removed: 10
3. All Status categories other than Completed, Terminated, and Withdrawn removed: 39 removed
4. Final number for screening: 68

### WHO: International Clinical Trials Registry Platform Search Portal

Search date: 12/16/2011

Condition: heart OR cardiovascular OR coronary artery disease OR CAD

Intervention: percutaneous transluminal coronary angioplasty OR PTCA OR percutaneous coronary intervention OR PCI OR balloon OR stent OR coronary artery bypass OR CABG OR coronary revascularization

Processing of results

1. Total number of results: 1157
2. Removed all entries with “Recruiting” status; retained entries with “Not recruiting” status: 253 removed, 904 remaining
3. Removed all entries with NCT designations (covered by a separate search of clinicaltrials.gov with a more refined search strategy): 531 removed, 373 remaining
4. Final number for screening: 373

**ProQuest COS Conference Papers Index**

Search date: 12/12/2011

<b>Set #</b>	<b>Terms</b>
<b>#1</b>	(cardiovascular diseases or heart diseases or heart or cardiovas* or cardiac* or coronary or myocardial or acute coronary syndrome or myocardial infarction or unstable angina) [in all fields + text]
<b>#2</b>	(percutaneous transluminal coronary angioplasty or PTCA or percutaneous coronary intervention* or PCI or Stent* or stents or Balloon angioplasty or Balloon dilatation or Balloon dilation or Transluminal angioplasty or coronary atherectomy or Coronary Artery Bypass or CABG or aortocoronary bypass or coronary revascularization or myocardial revascularization) [in all fields + text]
<b>#3</b>	women OR woman OR female OR females OR sex OR gender [in all fields + text]
<b>#4</b>	#1 AND #2 AND #3 AND #4
	Limits: 2001- Present

# Appendix B. Data Abstraction Elements

## I. Study Characteristics

- Study name and acronym
- Other articles used in this abstraction
- Study dates
- Date enrollment started (Mon and YYYY)
- Date enrollment ended (Mon and YYYY)
- Number of subjects screened/ approached for study participation: Total, Female, Male
- Study site
- Single center, Multicenter, Not reported/Unclear
- Geographic location
- If single center, enter City and State (if US) or City and Country (if outside US). If multicenter, enter number of sites. Enter NR if not reported.
- If multicenter, specify applicable geographic regions
- Funding source: Government, Private foundation, Industry, Not reported, Other.
- Setting: Academic centers, Community hospitals, Outpatient, VA, Not reported/unclear, Other
- Were patients transported from the site of presentation to another location to receive PCI?
- Were patients transported from the site of presentation to another location to receive CABG?
- Qualifications of the study surgeons: Not specified, Minimum case volume (specify), Maximum mortality (specify), Other (specify)
- Qualifications of the study interventional cardiologists: Not specified, Minimum case volume (specify), Maximum mortality (specify), Minimum success rates (specify), Other (specify)
- Qualifications of the sites involved in the trial: Not specified, Minimum case volume (specify), Maximum mortality (specify), Minimum success rates (specify), Other (specify)
- Were guideline-based treatment protocols followed?
- Briefly describe use of guideline-based protocols.
- Length of followup
- Inclusion and exclusion criteria; Copy/paste criteria as reported in the article.
- Clinical presentation: STEMI NSTEMI/ Unstable angina Stable CAD
- Method for interpretation of angiograms: Central laboratory, Local site interpretation, Quantitative angiography, Unclear/ Not reported Other
- Were study patients systematically enrolled in cardiac rehabilitation?
- Does the study report a composite primary endpoint?
- Indicate the components of the composite primary endpoint (check all that apply): Total mortality, Cardiac mortality, Nonfatal myocardial infarction, Stroke, TIA, Unstable angina, Angina/ recurrent symptoms, Angina class, Angina relief, Repeat revascularization, Heart failure, Graft failure, Hospitalization, Length of hospital stay, Bleeding, Quality of life, Cognitive effects, Adverse drug reactions, Radiation exposure, Access site complications, Renal dysfunction, Anaphylaxis, Arrhythmias, Stent thrombosis, Infections, Cost, Employment/ productivity, Other (specify )
- Indicate timing of the components of the composite primary endpoint: Short-term (less than or equal to 30 days), Long-term (greater than 30 days), Mixture of short- and long-term outcomes
- Indicate all short-term (<30 days) primary and secondary endpoints separately reported (i.e. reported singly, rather than only reported as part of a composite primary endpoint): Total

- mortality, Cardiac mortality, Nonfatal myocardial infarction, Stroke, TIA, Unstable angina, Angina/ recurrent symptoms, Angina class, Angina relief, Repeat revascularization, Heart failure, Graft failure, Hospitalization, Length of hospital stay, Bleeding, Quality of life, Cognitive effects, Adverse drug reactions, Radiation exposure, Access site complications, Renal dysfunction, Anaphylaxis, Arrhythmias, Stent thrombosis, Infections, Cost, Employment/ productivity, Other (specify )
- Indicate all long-term (>30 days) primary and secondary endpoints separately reported (i.e. reported singly, rather than only reported as part of a composite primary endpoint): Total mortality, Cardiac mortality, Nonfatal myocardial infarction, Stroke, TIA, Unstable angina, Angina/ recurrent symptoms, Angina class, Angina relief, Repeat revascularization, Heart failure, Graft failure, Hospitalization, Length of hospital stay, Bleeding, Quality of life, Cognitive effects, Adverse drug reactions, Radiation exposure, Access site complications, Renal dysfunction, Anaphylaxis, Arrhythmias, Stent thrombosis, Infections, Cost, Employment/ productivity, Other (specify )
  - Describe how the short- and long-term outcome data is reported (e.g. Kaplan-Meier plots, Cox proportional hazards, hazard ratios, risk ratios, odds ratios, raw numbers, percentages, other methods), including whether p values, confidence intervals, etc. are provided.
  - Include timing of outcomes (e.g. 1 yr, 5 yr)
  - Comments (if needed)

## II. Intervention characteristics

- Briefly indicate which population/intervention combination is reflected by the data abstracted on this instance of the form.
- PCI Procedural Characteristics
  - Describe the PCI intervention
  - Complete the below for Total, Female, and Male
    - Complete revascularization achieved
    - Vessels treated (mean): 1, 2, 3, or Unclear/ Not specified
    - Access site
      - Radial
      - Femoral
      - Unclear/ Not specified
    - Stents used (mean)
      - 0 stents
      - Bare metal stents
        - 1
        - 2
        - 3
        - More than 3
        - Unclear/ Not specified
      - Drug-eluting stents
        - 1
        - 2
        - 3
        - More than 3
        - Unclear/ Not specified
    - Interventional approach
      - Balloon
      - Atherectomy
      - Unclear/ Not specified

- Timing
      - Initial conservative strategy
      - Invasive strategy
      - Unclear/ Not specified
    - If applicable, specify type of bare metal stent used
    - If applicable, specify type of drug-eluting stent used:
  - CABG Procedural Characteristics
    - Describe the CABG intervention:
    - Complete the below for Total, Female, and Male
      - Bypass mode
        - None (beating heart)
        - Normothermic
        - Hypothermic
        - Unclear/ Not specified
      - Cardioplegia type
        - Blood
        - Crystalloid
        - Other
        - Mixed
        - Unclear/ Not specified
      - Incision type
        - Median sternotomy
        - Minimally invasive direct coronary bypass (Midcab)
        - Unclear/ Not specified
      - Grafts used
        - 0 grafts
        - Saphenous vein (mean)
          - 1
          - 2
          - Greater than 2
          - Unclear/ Not specified
        - Mammary arteries (mean)
          - Left internal mammary artery
          - Right internal mammary artery
          - Both mammary arteries
          - Unclear/ Not specified
        - Radial artery (mean)
          - 1
          - 2
          - Unclear/ Not specified
      - Transmyocardial laser revascularization (TMR)
        - Received
        - Not received
        - Unclear/ Not specified
    - If applicable, specify type of crystalloid cardioplegia agent used
    - If applicable, specify type of vein harvest (check all that apply): Endoscopic, Open, Unclear/ Not reported, Other (specify)
    - Mean cardiopulmonary bypass time
    - Mean cross-clamp time



- Were concomitant procedures performed at the time of CABG surgery?
    - If yes, describe the concomitant procedures
- Medical Therapy Intervention Characteristics
  - Describe the medical therapy intervention received by patients in the PCI arm (if applicable)
  - Describe the medical therapy intervention received by patients in the CABG arm (if applicable)
  - Describe the medical therapy intervention received by patients in the OMT arm (if applicable)
  - Medications received in-hospital: record for PCI Subjects, CABG Subjects, and OMT Subjects; If ‘yes’ list drug name(s)/ dosage(s)
    - Acetylsalicylic acid (ASA)
    - Additional antiplatelet agents (e.g. clopidogrel, prasugrel, ticagrelor)
    - Antithrombin drugs (e.g. LMWH, unfractionated heparin, bivalirudin)
    - Glycoprotein IIb/IIIa inhibitors
    - Thrombolytic/ fibrinolytic drugs
    - Statins/ lipid-lowering drugs
    - Beta-blockers
    - ACEIs/ ARBs
    - Calcium channel blockers
    - Nitrates
    - Other #1 (specify)
    - Other #2 (specify)
    - Other #3 (specify)
- Discharge medications
  - Record for PCI Subjects, CABG Subjects, and OMT Subjects; If ‘yes’ list drug name(s)/ dosage(s)
    - Acetylsalicylic acid (ASA)
    - Additional antiplatelet agents (e.g. clopidogrel, prasugrel, ticagrelor)
    - Antithrombin drugs (e.g. LMWH, unfractionated heparin, bivalirudin)
    - Glycoprotein IIb/IIIa inhibitors
    - Thrombolytic/ fibrinolytic drugs
    - Statins/ lipid-lowering drugs
    - Beta-blockers
    - ACEIs/ ARBs
    - Calcium channel blockers
    - Nitrates
    - Other #1 (specify)
    - Other #2 (specify)
    - Other #3 (specify)
- Lifestyle modification
  - Indicate the components of lifestyle modification recommended to patients in the study (check all that apply): Smoking cessation, Diet modification, Exercise, Other (specify)
  - If lifestyle modifications recommended were not consistent across all patients in the study, specify which groups received these recommendations and which did not.
- Therapeutic targets
  - Did the study include consideration of therapeutic target goals?
    - If yes, describe the therapeutic targets considered and whether interventions were adjusted for the purpose of meeting those specific goals.

- Compliance
  - If reported, provide data on in-hospital medication compliance (and lifestyle modification compliance, if available)
  - If reported, provide data on post-discharge medication compliance (and lifestyle modification compliance, if available) at the first followup visit after discharge. Include the time point of this followup visit (including units)
- Comments (if needed)

### III. Outcomes

- Outcomes definitions
  - Authors' definition of procedure-related outcomes
  - Authors' definition of post-CABG MI
  - Authors' definition of post-PCI MI
  - Check all outcomes for which gender-specific data is provided. Include an outcome if (1) data is reported specifically for women, or if (2) data is reported for men that can be used to calculate values for women (Total mortality, Cardiac mortality, Nonfatal myocardial infarction, Stroke, TIA, Unstable angina, Angina/ recurrent symptoms/ refractory angina/ refractory myocardial infarction, Angina class, Angina relief, Repeat revascularization (PCI or CABG), Heart failure, Graft failure, Hospitalization/ Re-hospitalization, Length of hospital stay, Bleeding, Quality of life, Cognitive effects, Adverse drug reactions, Radiation exposure, Access site complications, Renal dysfunction, Anaphylaxis, Arrhythmias, Stent thrombosis, Infections, Cost, Employment/ productivity, Other individual outcome #1 (e.g. CPR, cardioversion, respiratory failure, pulmonary edema) , Other individual outcome #2, Other individual outcome #3.)
  - Comments (if needed)
- Composite outcome data
  - Are one or more composite outcomes reported in such a way that data for women can be abstracted or derived?
  - Is this a Primary or Secondary composite outcome?
  - Refer to the Intervention Characteristics forms completed; indicate which one applies to the outcome data recorded on this form:
  - Indicate the components that make up this composite outcome (check all that apply): Total mortality, Cardiac mortality, Nonfatal myocardial infarction, Stroke, TIA, Unstable angina, Angina/ recurrent symptoms/ refractory angina/ refractory myocardial infarction, Angina class, Angina relief, Repeat revascularization (PCI or CABG), Heart failure, Graft failure, Hospitalization/ Re-hospitalization, Length of hospital stay, Bleeding, Quality of life, Cognitive effects, Adverse drug reactions, Radiation exposure, Access site complications, Renal dysfunction, Anaphylaxis, Arrhythmias, Stent thrombosis, Infections, Cost, Employment/ productivity, Other individual outcome #1 (e.g. CPR, cardioversion, respiratory failure, pulmonary edema) , Other individual outcome #2, Other individual outcome #3.
  - Complete tables to provide data for this outcome/ time point(s).
    - Timing of the outcome data reported in the table: Short term  $\leq$  30 days, Long-term  $>$  30 days,
      - Specify timing of short-term outcome: 30 days, Other (specify)
      - Specify timing of long-term outcome: 6 weeks, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, Other (specify)

- Indicate whether/ how the results reported were adjusted (check all that apply): Results are not adjusted , RCT that did not adjust for any baseline difference, Age, Sex, Race, Comorbidity(ies) (specify), Other (specify all)
        - For each reported group (OMT, PCI, CABG, and/or Mixed Revascularization) record the following for Total, Female, and Male:
          - N for Analysis
          - Result
            - Mean
            - Median
            - Number of patients with outcome
            - % of patients with outcome
            - Relative risk
            - Relative hazard
            - Odds ratio
            - Risk difference
            - Other (specify)
          - Variability
            - Standard Error (SE)
            - Standard Deviation (SD)
            - Other (specify)
          - Confidence Interval (CI) or Interquartile Range (IQR)
            - 95% CI
            - Other %CI
            - IQR
          - p-value between female and male data (within tx group)
          - p-value between tx groups
          - Reference group (for comparisons between tx groups)
  - Comments (if needed)
- Individual outcome data
  - Select the outcome reported: Total mortality, Cardiac mortality, Nonfatal myocardial infarction, Stroke, TIA, Unstable angina, Angina/ recurrent symptoms/ refractory angina/ refractory myocardial infarction, Angina class, Angina relief, Repeat revascularization (PCI or CABG), Heart failure, Graft failure, Hospitalization/ Re-hospitalization, Length of hospital stay, Bleeding, Quality of life, Cognitive effects, Adverse drug reactions, Radiation exposure, Access site complications, Renal dysfunction, Anaphylaxis, Arrhythmias, Stent thrombosis, Infections, Cost, Employment/ productivity, Other individual outcome #1 (e.g. CPR, cardioversion, respiratory failure, pulmonary edema) , Other individual outcome #2, Other individual outcome #3.
  - Complete tables to provide data for this outcome/ time point(s).
    - Timing of the outcome data reported in the table: Short term  $\leq$  30 days, Long-term  $>$  30 days,
      - Specify timing of short-term outcome: 30 days, Other (specify)
      - Specify timing of long-term outcome: 6 weeks, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, Other (specify)
    - Indicate whether/ how the results reported were adjusted (check all that apply): Results are not adjusted , RCT that did not adjust for any baseline difference, Age, Sex, Race, Comorbidity(ies) (specify), Other (specify all)
    - For each reported group (OMT, PCI, CABG, and/or Mixed Revascularization) record the following for Total, Female, and Male:

- N for Analysis
- Result
  - Mean
  - Median
  - Number of patients with outcome
  - % of patients with outcome
  - Relative risk
  - Relative hazard
  - Odds ratio
  - Risk difference
  - Other (specify)
- Variability
  - Standard Error (SE)
  - Standard Deviation (SD)
  - Other (specify)
- Confidence Interval (CI) or Interquartile Range (IQR)
  - 95% CI
  - Other %CI
  - IQR
- p-value between female and male data (within tx group)
- p-value between tx groups
- Reference group (for comparisons between tx groups)
- Comments (if needed)

#### IV. Subgroup Analyses

- Does the article include subgroup analyses reported in a gender-specific way such that data for women can be abstracted or derived for any outcomes of interest?
- For each outcome record for Total, Female, and Male
- Indicate the nature of the subgroup analysis (i.e. the characteristic factor being considered): Age, Race, Other demographic or socioeconomic factor (specify), Diabetes, Chronic kidney disease, Other comorbid disease (specify), Angiographic-specific factor (specify), CABG-specific factor (specify), Hospital characteristic (specify)
- Specify the categories for this subgroup analysis. Columns are provided to capture up to 5 categories. Complete only the number needed to capture the data presented in the study.
  - Define the categories, then complete the tables with as much information as is provided in the study.
  - Provide data for each outcome. Clearly indicate units (number of patients, %, hazard ratio, etc.). Include values for confidence intervals, p values, standard error, standard deviation, etc. when available.
- Comments (if needed):

#### V. Quality Assessment

- Selection Bias
  - Was treatment adequately randomized (e.g. random number table, computer-generated randomization)?
  - Was the allocation of treatment adequately concealed (e.g. pharmacy-controlled randomization or use of sequentially numbered sealed envelopes)?
  - Did the strategy for recruiting participants into the study differ across study groups?
  - Are baseline characteristics similar between groups? If not, did the analysis control for differences?

- Performance Bias
  - Did researchers rule out any impact from a concurrent intervention or an unintended exposure that might bias results?
  - Did variation from the study protocol compromise the conclusions of the study?
- Attrition Bias
  - Was there a high rate of differential or overall attrition?
  - Did attrition result in a difference in group characteristics between baseline (or randomization) and followup?
  - Is the analysis conducted on an intention-to-treat (ITT) basis?
- Detection Bias
  - Were the outcome assessors blinded to the intervention status of participants?
  - Are the inclusion/exclusion criteria measured using valid and reliable measures?
  - Are the inclusion/exclusion criteria implemented consistently across all study participants?
  - Are interventions/exposures assessed using valid and reliable measures?
  - Are interventions/exposures implemented consistently across all study participants?
  - Are primary outcomes assessed using valid and reliable measures?
  - Are primary outcomes implemented consistently across all study participants?
- Reporting Bias
  - Are the potential outcomes pre-specified by the researchers? Are all pre-specified outcomes reported?
- Additional Comments
- Summary Judgment. Assign the study an overall quality rating based on the following definitions:
  - Good (low risk of bias). These studies have the least bias and results are considered valid. A study that adheres mostly to the commonly held concepts of high quality including the following: a formal randomized controlled study; clear description of the population, setting, interventions, and comparison groups; appropriate measurement of outcomes; appropriate statistical and analytic methods and reporting; no reporting errors; low dropout rate; and clear reporting of dropouts.
  - Fair. These studies are susceptible to some bias, but it is not sufficient to invalidate the results. They do not meet all the criteria required for a rating of good quality because they have some deficiencies, but no flaw is likely to cause major bias. The study may be missing information, making it difficult to assess limitations and potential problems.
  - Poor (high risk of bias). These studies have significant flaws that imply biases of various types that may invalidate the results. They have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.

## **VI. Applicability**

- Population (P) (select all that apply)
  - Study population not representative of community patients
  - Study population poorly specified
  - Key characteristics not reported
- Intervention (I) (select all that apply)
  - Monitoring practices or visit frequency not used in typical practice
  - Older versions of an intervention no longer in common use
  - Cointerventions that are likely to modify effectiveness of therapy

- Highly selected intervention team or level of training/proficiency not widely available
- Comparator (C) (select all that apply)
  - Inadequate comparison therapy
- Outcomes (O) (select all that apply)
  - Composite outcomes that mix outcomes of different significance
  - Data not stratified or adjusted for key predictors
  - Only short-term or surrogate outcomes reported
- Timing (T) (n/a)
- Setting (S) (select all that apply)
  - Resources available to providers for diagnosis and treatment of condition vary widely
  - Provider type/specialty varies across settings
  - Comparability of care in international settings unclear
  - Standards of care differ markedly from setting of interest
  - Specialty population or level of care differs from that seen in community
- Comments (if needed)

## Appendix C. List of Included Studies

- Allen KB, Dowling RD, Angell WW, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. *Ann Thorac Surg.* 2004;77(4):1228-34. PMID: 15063241.
- Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. *N Engl J Med.* 1999;341(14):1029-36. PMID: 10502592.
- Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med.* 2003;349(8):733-42. PMID: 12930925.
- Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. *J Am Coll Cardiol.* 1995;26(7):1643-50. PMID: 7594098.
- Anonymous. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. *Thrombolysis in Myocardial Ischemia. Circulation.* 1994;89(4):1545-56. PMID: 8149520.
- Anonymous. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. *Lancet.* 1995;346(8984):1179-84. PMID: 7475656.
- Anonymous. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med.* 1996;335(4):217-25. PMID: 8657237.
- Anonymous. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet.* 1997;350(9076):461-8. PMID: 9274581.
- Anonymous. The ARTS (Arterial Revascularization Therapies Study): Background, goals and methods. *Int J Cardiovasc Intervent.* 1999;2(1):41-50. PMID: 12623386.
- Anonymous. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. *FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet.* 1999;354(9180):708-15. PMID: 10475181.
- Anonymous. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol.* 2000;35(5):1122-9. PMID: 10758950.
- Anonymous. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol.* 2007;49(15):1600-6. PMID: 17433949.
- Boden WE, O'Rourke R A, Teo KK, et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. *Am Heart J.* 2006;151(6):1173-9. PMID: 16781214.
- Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med.* 2007;356(15):1503-16. PMID: 17387127.
- Busk M, Maeng M, Kristensen SD, et al. Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial. *Am J Cardiol.* 2009;104(2):210-5. PMID: 19576349.
- Busk M, Maeng M, Rasmussen K, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. *Eur Heart J.* 2008;29(10):1259-66. PMID: 17956874.
- Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. *Thrombolysis In Myocardial Infarction. Am J Cardiol.* 1998;82(6):731-6. PMID: 9761082.
- Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med.* 2001;344(25):1879-87. PMID: 11419424.

- Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. *Eur Heart J*. 2004;25(18):1641-50. PMID: 15351164.
- Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. *J Am Coll Cardiol*. 2010;55(9):858-64. PMID: 20045278.
- de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. *N Engl J Med*. 2005;353(11):1095-104. PMID: 16162880.
- Di Mario C, Bolognese L, Maillard L, et al. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). *Am Heart J*. 2004;148(3):378-85. PMID: 15389222.
- Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. *Lancet*. 2008;371(9612):559-68. PMID: 18280326.
- Dobrzycki S, Kralisz P, Nowak K, et al. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals. *Eur Heart J*. 2007;28(20):2438-48. PMID: 17884846.
- Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. *Randomized Intervention Trial of unstable Angina*. *Lancet*. 2002;360(9335):743-51. PMID: 12241831.
- Gibbons RJ, Miller DD, Liu P, et al. Similarity of ventricular function in patients alive 5 years after randomization to surgery or angioplasty in the BARI trial. *Circulation*. 2001;103(8):1076-82. PMID: 11222469.
- Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA*. 2002;288(24):3124-9. PMID: 12495392.
- Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). *N Engl J Med*. 1994;331(16):1037-43. PMID: 8090162.
- Hlatky MA, Charles ED, Nobrega F, et al. Initial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol*. 1995;75(9):34C-41C. PMID: 7892821.
- Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med*. 2006;355(23):2395-407. PMID: 17105759.
- Hochman JS, Lamas GA, Knatterud GL, et al. Design and methodology of the Occluded Artery Trial (OAT). *Am Heart J*. 2005;150(4):627-42. PMID: 16209957.
- Hochman JS, Reynolds HR, Dzavik V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. *Circulation*. 2011;124(21):2320-2328. PMID: 22025606.
- Hochman JS, Sleeper LA, Godfrey E, et al. Should we emergently revascularize Occluded Coronaries for cardiogenic shock: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group. *Am Heart J*. 1999;137(2):313-21. PMID: 9924166.
- Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. *JAMA*. 2006;295(21):2511-5. PMID: 16757723.
- Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. *N Engl J Med*. 1999;341(9):625-34. PMID: 10460813.
- Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. *JAMA*. 2001;285(2):190-2. PMID: 11176812.
- Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery



- Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation*. 2010;122(10):949-57. PMID: 20733102.
- Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation*. 2007;115(9):1082-9. PMID: 17339566.
- Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol*. 2004;43(10):1743-51. PMID: 15145093.
- Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). *Circulation*. 1998;98(13):1279-85. PMID: 9751675.
- Kaehler J, Koester R, Billmann W, et al. 13-year follow-up of the German angioplasty bypass surgery investigation. *Eur Heart J*. 2005;26(20):2148-53. PMID: 15975991.
- Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol*. 2010;55(5):432-40. PMID: 20117456.
- Kapur A, Malik IS, Bagger JP, et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. *Am Heart J*. 2005;149(1):13-9. PMID: 15660030.
- King SB, 3rd, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). *J Am Coll Cardiol*. 2000;35(5):1116-21. PMID: 10758949.
- King SB, 3rd, Lembo NJ, Weintraub WS, et al. Emory Angioplasty Versus Surgery Trial (EAST): design, recruitment, and baseline description of patients. *Am J Cardiol*. 1995;75(9):42C-59C. PMID: 7892822.
- King SB, 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). *N Engl J Med*. 1994;331(16):1044-50. PMID: 8090163.
- Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. *Lancet*. 2006;368(9540):998-1004. PMID: 16980115.
- Lagerqvist B, Safstrom K, Stahle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. *J Am Coll Cardiol*. 2001;38(1):41-8. PMID: 11451294.
- Lombardero MS. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI), by treatment and presence of diabetes. *Cardiovasc Rev Rep*. 2002;23(1):14-18. PMID: 2002025009.
- Mancini GB, Bates ER, Maron DJ, et al. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. *Circ Cardiovasc Qual Outcomes*. 2009;2(4):320-7. PMID: 20031857.
- Minai K, Horie H, Takahashi M, et al. Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial. *Am Heart J*. 2002;143(3):497-505. PMID: 11868057.
- Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation*. 2010;121(24):2645-53. PMID: 20530001.
- Mortensen OS, Bjorner JB, Newman B, et al. Gender differences in health-related quality of life following ST-elevation myocardial infarction: women and men do not benefit from primary percutaneous coronary intervention to the same degree. *Eur J Cardiovasc Prev Rehabil*. 2007;14(1):37-43. PMID: 17301625.
- Mullany CJ, Mock MB, Brooks MM, et al. Effect of age in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. *Ann Thorac Surg*. 1999;67(2):396-403. PMID: 10197660.
- Nielsen PH, Maeng M, Busk M, et al. Primary angioplasty versus fibrinolysis in acute myocardial infarction: long-term follow-up in the Danish acute myocardial infarction 2 trial. *Circulation*. 2010;121(13):1484-91. PMID: 20308618.
- Ottervanger JP, Armstrong P, Barnathan ES, et al. Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report

- from GUSTO IV-ACS. *Eur Heart J*. 2004;25(17):1494-501. PMID: 15342168.
- Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. *N Engl J Med*. 2011(18):1718-27. PMID: 21463149
- Rogers WJ, Alderman EL, Chaitman BR, et al. Bypass Angioplasty Revascularization Investigation (BARI): baseline clinical and angiographic data. *Am J Cardiol*. 1995;75(9):9C-17C. PMID: 7892823.
- Serruys PW, Unger F, van Hout BA, et al. The ARTS study (Arterial Revascularization Therapies Study). *Semin Interv Cardiol*. 1999;4(4):209-19. PMID: 10738354.
- Stables RH. Design of the 'Stent or Surgery' trial (SoS): a randomized controlled trial to compare coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multi-vessel coronary artery disease. *Semin Interv Cardiol*. 1999;4(4):201-7. PMID: 10738353.
- Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 1995;75(15):987-92. PMID: 7747700.
- Sutton-Tyrrell K, Rihal C, Sellers MA, et al. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol*. 1998;81(4):375-81. PMID: 9485122.
- Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. *Am Heart J*. 2004;147(1):133-9. PMID: 14691431.
- Vaina S, Voudris V, Morice MC, et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II. *EuroIntervention*. 2009;4(4):492-501. PMID: 19284072.
- van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. *J Am Coll Cardiol*. 2002;39(4):559-64. PMID: 11849851.
- Velazquez EJ, Lee KL, Deja MA, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. *N Engl J Med*. 2011. PMID: 21463150.
- Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. *J Thorac Cardiovasc Surg*. 2007;134(6):1540-7. PMID: 18023680.
- Voudris V, Ong AT, Serruys PW, et al. Sex differences and their impact on clinical outcome after percutaneous or surgical revascularisation: a report from the Arterial Revascularisation Therapies Study (ARTS). *EuroIntervention*. 2006;2(2):175-80. PMID: 19755257.
- Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. *Lancet*. 2000;355(9223):9-16. PMID: 10892758.
- Zhang Z, Mahoney EM, Stables RH, et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. *Circulation*. 2003;108(14):1694-700. PMID: 12975252.
- Zhang Z, Weintraub WS, Mahoney EM, et al. Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). *Am J Cardiol*. 2004;93(4):404-9. PMID: 14969611.
- Zhao XQ, Brown BG, Stewart DK, et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. *Circulation*. 1996;93(11):1954-62. PMID: 8640968.

## Appendix D. Quality and Applicability of Included Studies

**Table D-1. Quality and applicability for RCTs evaluating women with STEMI (KQ 1)**

Study Name	Study Author/Year	Comparator	Quality	Limitations to Applicability
<b>CARESS-in-AMI</b>	Di Mario et al., 2008 <sup>1</sup>	Immediate PCI with fibrinolysis (reteplase) vs. fibrinolysis (reteplase) with rescue PCI	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>DANAMI-2</b>	Andersen et al., 2003 <sup>2</sup>	PCI vs. fibrinolysis (accelerated t-PA)	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>Dobrzycki</b>	Dobrzycki et al., 2007 <sup>3</sup>	Transfer with tirofiban for primary PCI vs. onsite fibrinolysis (streptokinase)	Good	<ul style="list-style-type: none"> <li>• Comparability of care in international settings unclear</li> </ul>
<b>GUSTO II-B</b>	Tamis-Holland et al., 2004 <sup>4</sup>	PCI vs. fibrinolysis (accelerated t-PA)	Good	<ul style="list-style-type: none"> <li>• Comparability of care in international settings unclear</li> </ul>
<b>Minai</b>	Minai et al., 2002 <sup>5</sup>	PCI vs. optimal medical therapy (without fibrinolysis)	Fair	<ul style="list-style-type: none"> <li>• Comparability of care in international settings unclear</li> </ul>
<b>PAMI</b>	Stone et al., 1995 <sup>6</sup>	PCI vs. fibrinolysis (t-PA)	Good	<ul style="list-style-type: none"> <li>• Comparability of care in international settings unclear</li> </ul>
<b>SHOCK</b>	Hochman et al., 2001 <sup>7</sup>	Early invasive revascularization (PCI or CABG within 6 hours) vs. initial medical stabilization (thrombolysis, IABP)	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>

Abbreviations: CABG = coronary artery bypass grafting; PCI = percutaneous coronary revascularization; STEMI = ST elevation myocardial infarction

**Table D-2. Quality and applicability for RCTs evaluating women with UA/NSTEMI (KQ 2)**

Study Name	Study Author/Year	Comparator	Quality	Limitations to Applicability
<b>FRISC II</b>	Lagerqvist et al., 2001 <sup>8</sup>	Early invasive treatment with revascularization vs. initial conservative strategy	Good	<ul style="list-style-type: none"> <li>• Comparability of care in international settings unclear</li> </ul>
<b>GUSTO IV-ACS</b>	Ottervanger et al., 2004 <sup>9</sup>	Early invasive management vs. initial conservative treatment within 30 days.	Good	<ul style="list-style-type: none"> <li>• Older versions of an intervention no longer in common use</li> <li>• Resources available to providers for diagnosis and treatment of condition varied widely</li> <li>• Comparability of care in international settings unclear</li> </ul>
<b>ICTUS</b>	de Winter et al., 2005 <sup>10</sup>	Early invasive therapy with revascularization vs. selective invasive strategy	Good	<ul style="list-style-type: none"> <li>• Comparability of care in international settings unclear</li> </ul>
<b>RITA-2</b>	Anonymous, 1997 <sup>11</sup>	Early invasive therapy with PCI vs. initial conservative	Fair	<ul style="list-style-type: none"> <li>• Provider type/specialty varied across settings</li> <li>• Comparability of care in international settings unclear</li> </ul>
<b>RITA-3</b>	Clayton et al., 2004 <sup>12</sup>	Early invasive with PCI vs. initial conservative	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>TACTICS TIMI-18</b>	Cannon et al., 2001 <sup>13</sup>	Early invasive with PCI vs. initial conservative	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>TIMI III-B</b>	Anonymous, 1994 <sup>14</sup>	Early invasive with PCI vs. initial conservative	Good	<ul style="list-style-type: none"> <li>• Older versions of an intervention no longer in common use</li> </ul>

Abbreviations: CABG = coronary artery bypass grafting; PCI = percutaneous coronary revascularization

**Table D-3. Quality and applicability for RCTs evaluating women with stable angina (KQ 3 Strategy 1)**

Study Name	Study Author/Year	Comparator	Quality	Limitations to Applicability
<b>Allen</b>	Allen et al., 2004 <sup>15</sup>	Surgical revascularization vs. optimal medical therapy	Good	<ul style="list-style-type: none"> <li>• Older versions of an intervention no longer in common use</li> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> </ul>
<b>COURAGE</b>	Boden et al., 2007 <sup>16</sup>	PCI (or CABG if PCI failed) vs. optimal medical therapy	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>MASS II</b>	Hueb et al., 2010 <sup>17</sup>	PCI vs. optimal medical therapy CABG vs. optimal medical therapy	Good	<ul style="list-style-type: none"> <li>• Study population not representative of community patients</li> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> </ul>
<b>OAT</b>	Hochman et al., 2006 <sup>18</sup>	PCI (or CABG if PCI failed) vs. optimal medical therapy	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>STICH</b>	Velazquez et al., 2011 <sup>19</sup>	CABG vs. optimal medical therapy	Good	<ul style="list-style-type: none"> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> <li>• Comparability of care in international settings unclear</li> </ul>

Abbreviations: CABG = coronary artery bypass grafting; PCI = percutaneous coronary revascularization

**Table D-4. Quality and applicability for RCTs evaluating women with stable/unstable angina (KQ 3 Strategy 2)**

Study Name	Study Author/Year	Comparator	Quality	Limitations to Applicability
<b>ARTS I</b>	Vaina et al., 2009 <sup>20</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>BARI</b>	Jacobs et al., 1998 <sup>21</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• Study population not representative of community patients</li> <li>• Older versions of an intervention no longer in common use</li> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> </ul>
<b>CABRI</b>	Anonymous, 1995 <sup>22</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• None</li> </ul>
<b>CARDia</b>	Kapur et al., 2010 <sup>23</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• Key characteristics not reported</li> <li>• Provider type/specialty varied across settings</li> </ul>
<b>EAST</b>	King et al., 2000 <sup>24</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• Study population not representative of community patients</li> <li>• Older versions of an intervention no longer in common use</li> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> </ul>
<b>GABI</b>	Kaehler et al., 2005 <sup>25</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> </ul>
<b>MASS II</b>	Hueb et al., 2010 <sup>17</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• Study population not representative of community patients</li> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> </ul>
<b>PRECOMBAT</b>	Park et al., 2011 <sup>26</sup>	PCI vs. CABG	Good	<ul style="list-style-type: none"> <li>• Comparability of care in international settings unclear</li> </ul>

<b>Study Name</b>	<b>Study Author/Year</b>	<b>Comparator</b>	<b>Quality</b>	<b>Limitations to Applicability</b>
<b>SOS</b>	Zhang et al., 2004 <sup>27</sup>	PCI vs. CABG	Fair	<ul style="list-style-type: none"> <li>• Study population not representative of community patients</li> <li>• Cointerventions that were likely to modify effectiveness of therapy</li> </ul>
<b>SYNTAX</b>	Morice et al., 2010 <sup>28</sup>	PCI vs. CABG	Fair	<ul style="list-style-type: none"> <li>• Data not stratified or adjusted for key predictors</li> <li>• Comparability of care in international settings unclear</li> </ul>

Abbreviations: CABG = coronary artery bypass grafting; PCI = percutaneous coronary revascularization

## References Cited in Appendix D

1. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. *Lancet*. 2008;371(9612):559-68. PMID: 18280326.
2. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med*. 2003;349(8):733-42. PMID: 12930925.
3. Dobrzycki S, Kralisz P, Nowak K, et al. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals. *Eur Heart J*. 2007;28(20):2438-48. PMID: 17884846.
4. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. *Am Heart J*. 2004;147(1):133-9. PMID: 14691431.
5. Minai K, Horie H, Takahashi M, et al. Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial. *Am Heart J*. 2002;143(3):497-505. PMID: 11868057.
6. Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 1995;75(15):987-92. PMID: 7747700.
7. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. *JAMA*. 2001;285(2):190-2. PMID: 11176812.
8. Lagerqvist B, Safstrom K, Stahle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. *J Am Coll Cardiol*. 2001;38(1):41-8. PMID: 11451294.
9. Ottervanger JP, Armstrong P, Barnathan ES, et al. Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. *Eur Heart J*. 2004;25(17):1494-501. PMID: 15342168.
10. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. *N Engl J Med*. 2005;353(11):1095-104. PMID: 16162880.
11. Anonymous. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet*. 1997;350(9076):461-8. PMID: 9274581.
12. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. *Eur Heart J*. 2004;25(18):1641-50. PMID: 15351164.
13. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001;344(25):1879-87. PMID: 11419424.
14. Anonymous. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. *Circulation*. 1994;89(4):1545-56. PMID: 8149520.
15. Allen KB, Dowling RD, Angell WW, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized



- multicenter trial. *Ann Thorac Surg*. 2004;77(4):1228-34. PMID: 15063241.
16. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007;356(15):1503-16. PMID: 17387127.
  17. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation*. 2010;122(10):949-57. PMID: 20733102.
  18. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med*. 2006;355(23):2395-407. PMID: 17105759.
  19. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. *N Engl J Med*. 2011. PMID: 21463150.
  20. Vaina S, Voudris V, Morice MC, et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II. *EuroIntervention*. 2009;4(4):492-501. PMID: 19284072.
  21. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). *Circulation*. 1998;98(13):1279-85. PMID: 9751675.
  22. Anonymous. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. *Lancet*. 1995;346(8984):1179-84. PMID: 7475656.
  23. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol*. 2010;55(5):432-40. PMID: 20117456.
  24. King SB, 3rd, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). *J Am Coll Cardiol*. 2000;35(5):1116-21. PMID: 10758949.
  25. Kaehler J, Koester R, Billmann W, et al. 13-year follow-up of the German angioplasty bypass surgery investigation. *Eur Heart J*. 2005;26(20):2148-53. PMID: 15975991.
  26. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. *N Engl J Med*. 2011(18):1718-27. PMID: 21463149
  27. Zhang Z, Weintraub WS, Mahoney EM, et al. Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). *Am J Cardiol*. 2004;93(4):404-9. PMID: 14969611.
  28. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation*. 2010;121(24):2645-53. PMID: 20530001.

## Appendix E. List of Excluded Studies

All studies listed below were reviewed in their full-text version and excluded. Following each reference, in italics, is the reason for exclusion. Reasons for exclusion signify only the usefulness of the articles for this study and are not intended as criticisms of the articles.

Aaberge L, Aakhus S, Nordstrand K, et al. Myocardial performance after transmyocardial revascularization with CO(2)laser. A dobutamine stress echocardiographic study. *Eur J Echocardiogr.* 2001;2(3):187-96. PMID: 11882452. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aaberge L, Nordstrand K, Dragsund M, et al. Transmyocardial revascularization with CO(2) laser in patients with refractory angina pectoris. *J Am Coll Cardiol.* 2000;35(5):1170-1177. PMID: 10758957. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aaberge L, Rootwelt K, Blomhoff S, et al. Continued symptomatic improvement three to five years after transmyocardial revascularization with CO(2) laser: a late clinical follow-up of the Norwegian Randomized trial with transmyocardial revascularization. *J Am Coll Cardiol.* 2002;39(10):1588-93. PMID: 12020484. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aaberge L, Rootwelt K, Smith HJ, et al. Effects of transmyocardial revascularization on myocardial perfusion and systolic function assessed by nuclear and magnetic resonance imaging methods. *Scand Cardiovasc J.* 2001;35(1):8-13. PMID: 11354578. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aasa M, Dellborg M, Herlitz J, et al. Risk reduction for cardiac events after primary coronary intervention compared with thrombolysis for acute ST-elevation myocardial infarction (five-year results of the Swedish early decision reperfusion strategy [SWEDES] trial). *Am J Cardiol.* 2010;106(12):1685-91. PMID: 21126610. *Exclude - Does not include outcome data reported in a gender-specific fashion*

*for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aasa M, Henriksson M, Dellborg M, et al. Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial. *Am Heart J.* 2010;160(2):322-8. PMID: 20691839. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Abizaid A, Costa MA, Centemero M, et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. *Circulation.* 2001;104(5):533-8. PMID: 11479249. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Acampa W, Petretta M, Spinelli L, et al. Survival benefit after revascularization is independent of left ventricular ejection fraction improvement in patients with previous myocardial infarction and viable myocardium. *Eur J Nucl Med Mol Imaging.* 2005;32(4):430-7. PMID: 15821962. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Adgey J, Fox K, Flather M. *Gusto Iv Acs. Br J Cardiol.* 2000;7(11):663. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Agati L, Funaro S, Madonna M, et al. Does coronary angioplasty after timely thrombolysis improve microvascular perfusion and left ventricular function after acute myocardial infarction? *Am Heart J.* 2007;154(1):151-7. PMID: 17584568. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes*

women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.

Anonymous. Arterial Revascularization Therapies Study (ARTS). Indian Heart J. 2001;53(2):239. PMID: 11428490. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Anonymous. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med. 1997;336(23):1621-8. PMID: 9173270. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Anonymous. Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. Lancet. 1993;341(8845):573-80. PMID: 8094826. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Anonymous. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet. 2002;360(9338):965-70. PMID: 12383664. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Anonymous. Does PCI added to drug therapy improve outcomes in stable CAD? J Fam Pract. 2007;56(7):529. PMID: 17612033. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Anonymous. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation. 1992;86(1):100-10. PMID: 1535568. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Anonymous. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease. A multicenter randomized trial. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. JAMA. 1997;277(9):715-21. PMID: 9042843. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Anonymous. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1997;96(6):1761-9. PMID: 9323059. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Anonymous. Little benefit to revascularization over intensive medical treatment in diabetes mellitus with coronary artery disease. J Natl Med Assoc. 2009;101(9):975-976. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Anonymous. One-year survival following early revascularization for cardiogenic shock (SCHOCK trial). Indian Heart J. 2001;53(2):240. PMID: 11428491. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Anonymous. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet. 2001;358(9286):951-7. PMID: 11583747. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aoki J, Ong AT, Arampatzis CA, et al. Comparison of three-year outcomes after coronary stenting versus coronary artery bypass grafting in patients with multivessel coronary disease, including involvement of the left anterior descending coronary artery proximally (a subanalysis of the arterial revascularization therapies study trial). Am J Cardiol. 2004;94(5):627-31. PMID: 15342295. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aoki J, Ong AT, Hoyer A, et al. Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. *Eur Heart J*. 2005;26(15):1488-93. PMID: 15860519. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. *Eur Heart J*. 2006;27(13):1530-8. PMID: 16757491. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. *JAMA*. 2002;287(15):1943-51. PMID: 11960536. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Baldus S, Köster R, Küchler R, et al. [Percutaneous revascularization of multivessel coronary disease using stents - a multicenter, prospective study]. *Dtsch Med Wochenschr*. 2002;127(11):547-52. PMID: 11894174. *Exclude - Non-English.*

Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. *J Am Coll Cardiol*. 2010;55(11):1067-75. PMID: 20079596. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Barnett PG, Chen S, Boden WE, et al. Cost-effectiveness of a conservative, ischemia-guided management strategy after non-Q-wave myocardial infarction: results of a randomized trial. *Circulation*. 2002;105(6):680-4. PMID: 11839621. *Exclude - Does not include outcomes of interest.*

Bata I, Armstrong PW, Westerhout CM, et al. Time from first medical contact to reperfusion in ST elevation myocardial infarction: a Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. *Can J Cardiol*. 2009;25(8):463-8. PMID: 19668780. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Bell MR, Grill DE, Garratt KN, et al. Long-term outcome of women compared with men after successful coronary angioplasty. *Circulation*. 1995;91(12):2876-81. PMID: 7796495. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Bell MR, Holmes DR, Jr., Berger PB, et al. The changing in-hospital mortality of women undergoing percutaneous transluminal coronary angioplasty. *JAMA*. 1993;269(16):2091-5. PMID: 8468762. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Ben-Gal Y, Moses JW, Mehran R, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *JACC Cardiovasc Interv*. 2010;10(10):1059-67. PMID: 20965465. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Berger PB, Velianou JL, Aslanidou Vlachos H, et al. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). *J Am Coll Cardiol*. 2001;38(5):1440-9. PMID: 11691521. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Berrocal DH, Cohen MG, Spinetta AD, et al. Early reperfusion and late clinical outcomes in patients presenting with acute myocardial infarction randomly assigned to primary percutaneous coronary intervention or streptokinase. *Am Heart J*. 2003;146(6):E22. PMID: 14661011. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes*

women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.

Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. *N Engl J Med.* 1998;338(25):1785-92. PMID: 9632444. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Bohmer E, Arnesen H, Abdelnoor M, et al. The NORwegian study on DIstrict treatment of ST-elevation myocardial infarction (NORDISTEMI). *Scand Cardiovasc J.* 2007;41(1):32-8. PMID: 17365975. *Exclude - Does not include outcomes of interest.*

Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). *J Am Coll Cardiol.* 2010;55(2):102-10. PMID: 19747792. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. *Lancet.* 2002;360(9336):825-9. PMID: 12243916. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. *Eur Heart J.* 2009;30(13):1598-606. PMID: 19429632. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Bonnefoy E, Steg PG, Chabaud S, et al. Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized

clinical trial. *Eur Heart J.* 2005;26(17):1712-8. PMID: 15840623. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. *N Engl J Med.* 2011;364(17):1617-25. PMID: 21463153. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). *Circulation.* 2008;118(4):381-8. PMID: 18606919. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Borden WB, Redberg RF, Mushlin AI, et al. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. *JAMA.* 2011;305(18):1882-9. PMID: 21558519. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Borges JC, Lopes N, Soares PR, et al. Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery. *J Cardiothorac Surg.* 2010;5(91). PMID: 20977758. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Boudriot E, Thiele H, Walther T, et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. *J Am Coll Cardiol.* 2011;57(5):538-45. PMID: 21272743. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Bourassa MG, Kip KE, Jacobs AK, et al. Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery? The Bypass Angioplasty

Revascularization Investigation (BARI). *J Am Coll Cardiol.* 1999;33(6):1627-36. PMID: 10334434. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Brener SJ, Galla JM, Bryant R, 3rd, et al. Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients. *Am J Cardiol.* 2008;101(2):169-72. PMID: 18178401. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. *Circulation.* 2004;109(19):2290-5. PMID: 15117846. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Brener SJ, Murphy SA, Gibson CM, et al. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. *Am J Cardiol.* 2002;90(6):631-3. PMID: 12231091. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Brooks MM, Chung SC, Helmy T, et al. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Circulation.* 2010;122(17):1690-9. PMID: 20937978. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Brooks MM, Jones RH, Bach RG, et al. Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. *Circulation.* 2000;101(23):2682-9. PMID: 10851204. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Buller CE, Rankin JM, Carere RG, et al. Percutaneous coronary intervention in the Occluded Artery Trial: procedural success, hazard, and

outcomes over 5 years. *Am Heart J.* 2009;158(3):408-15. PMID: 19699864. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Buszman P, Tendera M, Bochenek A, et al. A prospective evaluation of early and late results of percutaneous and surgical revascularisation in patients with ischaemic left ventricular dysfunction. *Kardiol Pol.* 2002;56(1):57-61. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Buszman P, Wiernek S, Szymanski R, et al. Percutaneous versus surgical revascularization for multivessel coronary artery disease: a single center 10 year follow-up of SOS trial patients. *Catheter Cardiovasc Interv.* 2009;74(3):420-6. PMID: 19360866. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Buszman PE, Kiesz SR, Bochenek A, et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. *J Am Coll Cardiol.* 2008;51(5):538-45. PMID: 18237682. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Campbell HE, Tait S, Buxton MJ, et al. A UK trial-based cost-utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. *Eur J Cardiothorac Surg.* 2001;20(2):312-8. PMID: 11463549. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Campbell HE, Tait S, Sharples LD, et al. Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris. *Eur J Health Econ.* 2005;6(4):288-97. PMID: 16195897. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Cantor WJ, Burnstein J, Choi R, et al. Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: the TRANSFER-AMI pilot feasibility study. *Can J*

- Cardiol. 2006;22(13):1121-6. PMID: 17102829. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. *N Engl J Med.* 2009;360(26):2705-18. PMID: 19553646. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Cantor WJ, Goodman SG, Cannon CP, et al. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial. *Am Heart J.* 2005;149(2):275-83. PMID: 15846265. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Carrie D, Elbaz M, Puel J, et al. Five-year outcome after coronary angioplasty versus bypass surgery in multivessel coronary artery disease: results from the French Monocentric Study. *Circulation.* 1997;96(9 Suppl):II-1-6. PMID: 9386066. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Carver A, Rafelt S, Gershlick AH, et al. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. *J Am Coll Cardiol.* 2009;54(2):118-26. PMID: 19573727. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Chaitman BR, Hardison RM, Adler D, et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation.* 2009;120(25):2529-40. PMID: 19920001. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Chaitman BR, Rosen AD, Williams DO, et al. Myocardial infarction and cardiac mortality in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. *Circulation.* 1997;96(7):2162-70. PMID: 9337185. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Chauhan MS, Ho KK, Baim DS, et al. Effect of gender on in-hospital and one-year outcomes after contemporary coronary artery stenting. *Am J Cardiol.* 2005;95(1):101-4. PMID: 15619402. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Chen B, Wang W, Zhao H, et al. [Comparison of the clinical efficacy of recombinant tissue-type plasminogen activator thrombolysis with primary coronary stenting in acute myocardial infarction]. *Zhonghua Nei Ke Za Zhi.* 2002(1):21-3. PMID: 11940291. *Exclude - Non-English.*
- Chew DP, Huang Z, Pieper KS, et al. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. *Am Heart J.* 2008;155(2):239-44. PMID: 18215592. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Chung SC, Hlatky MA, Faxon D, et al. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes). *J Am Coll Cardiol.* 2011;58(8):810-9. PMID: 21835316. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Cisowski M, Drzewiecka-Gerber A, Ulczok R, et al. Primary direct stenting versus endoscopic atraumatic coronary artery bypass surgery in patients with proximal stenosis of the left anterior descending coronary artery--a prospective, randomised study. *Kardiol Pol.* 2004;61(9):253-61; discussion 262-4. PMID: 15531937. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Cisowski M, Drzewiecki J, Drzewiecka-Gerber A, et al. Primary stenting versus MIDCAB: preliminary report-comparison of two methods of revascularization in single left anterior descending coronary artery stenosis. *Ann Thorac Surg.* 2002;74(4):S1334-9. PMID: 12400812. *Exclude - Does not include outcome data reported in a gender-*

*specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Claude J, Schindler C, Kuster GM, et al. Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease. Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). *Eur Heart J*. 2004;25(24):2195-203. PMID: 15589636. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Cleland JG, Calvert M, Freemantle N, et al. The Heart Failure Revascularisation Trial (HEART). *Eur J Heart Fail*. 2011;13(2):227-33. PMID: 21156659. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Cohen DJ. CABG and PCI did not differ clinically for angina relief in severe CAD. *Ann Intern Med*. 2011;155(2):JC1-10. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Cohen DJ, Van Hout B, Serruys PW, et al. Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. *N Engl J Med*. 2011;364(11):1016-26. PMID: 21410370. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Courtis J, Rodes-Cabau J, Larose E, et al. Comparison of medical treatment and coronary revascularization in patients with moderate coronary lesions and borderline fractional flow reserve measurements. *Catheter Cardiovasc Interv*. 2008;71(4):541-8. PMID: 18307236. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. *Circulation*. 2004;110(10):1226-30. PMID: 15337693. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Daemen J, Kuck KH, Macaya C, et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. *J Am Coll Cardiol*. 2008;52(24):1957-67. PMID: 19055986. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dagenais GR, Lu J, Faxon DP, et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. *Circulation*. 2011;123(14):1492-500. PMID: 21444887. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dakik HA, Kleiman NS, Farmer JA, et al. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. *Circulation*. 1998;98(19):2017-23. PMID: 9808599. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Damgaard S, Lund JT, Lilleor NB, et al. Comparably improved health-related quality of life after total arterial revascularization versus conventional coronary surgery-Copenhagen arterial revascularization randomized patency and outcome trial. *Eur J Cardiothorac Surg*. 2010. PMID: 20846874. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Damgaard S, Lund JT, Lilleør NB, et al. Comparable three months' outcome of total arterial revascularization versus conventional coronary surgery: Copenhagen Arterial Revascularization Randomized Patency and Outcome trial. *J Thorac Cardiovasc Surg*. 2008;135(5):1069-75. PMID: 18455586. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Damgaard S, Wetterslev J, Lund JT, et al. One-year results of total arterial revascularization vs. conventional coronary surgery: CARRPO trial. *Eur Heart J*. 2009;30(8):1005-11. PMID: 19270315. *Exclude - No data for OMT/PCI/CABG comparison of interest.*



Davis KB, Chaitman B, Ryan T, et al. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS registry study. *Coronary Artery Surgery Study*. *J Am Coll Cardiol*. 1995;25(5):1000-9. PMID: 7897108. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

de Boer MJ, Ottervanger JP, van 't Hof AW, et al. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. *J Am Coll Cardiol*. 2002;39(11):1723-8. PMID: 12039482. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

de Feyter PJ, Serruys PW, Unger F, et al. Bypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina. *Circulation*. 2002;105(20):2367-72. PMID: 12021222. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

De Servi S, Cavallini C, Dellavalle A, et al. Non-ST-elevation acute coronary syndrome in the elderly: treatment strategies and 30-day outcome. *Am Heart J*. 2004;147(5):830-6. PMID: 15131538. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

D'Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. *JACC Cardiovasc Imaging*. 2009;2(9):1060-8. PMID: 19761983. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Denardo SJ, Messerli FH, Gaxiola E, et al. Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). *Am J Cardiol*. 2010;106(4):498-503. PMID: 20691307. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). *Circulation*. 1999;99(5):633-

40. PMID: 9950660. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Devlin G, Reynolds HR, Mark DB, et al. Loss of short-term symptomatic benefit in patients with an occluded infarct artery is unrelated to non-protocol revascularization: results from the Occluded Artery Trial (OAT). *Am Heart J*. 2011;161(1):84-90. PMID: 21167338. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Di Pasquale P, Cannizzaro S, Giambanco F, et al. Immediate versus delayed facilitated percutaneous coronary intervention: a pilot study. *J Cardiovasc Pharmacol*. 2005;46(1):83-8. PMID: 15965359. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Di Pasquale P, Cannizzaro S, Parrinello G, et al. Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings. *J Thromb Thrombolysis*. 2006;21(2):147-57. PMID: 16622610. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Diderholm E, Andren B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. *Am Heart J*. 2002;143(5):760-7. PMID: 12040335. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Diderholm E, Andren B, Frostfeldt G, et al. Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease. *Am J Med*. 2003;115(8):606-12. PMID: 14656612. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Diderholm E, Andren B, Frostfeldt G, et al. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease. *Eur Heart J.* 2002;23(1):41-9. PMID: 11741361. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Diegeler A, Spyranitis N, Matin M, et al. The revival of surgical treatment for isolated proximal high grade LAD lesions by minimally invasive coronary artery bypass grafting. *Eur J Cardiothorac Surg.* 2000;17(5):501-4. PMID: 10814909. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Diegeler A, Thiele H, Falk V, et al. Comparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. *N Engl J Med.* 2002;347(8):561-6. PMID: 12192015. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Diegeler A, Thiele H, Mohr FW, et al. [Comparison of PTCA and stent with minimal invasive bypass surgery for high grade stenosis of the Ramus interventricularis anterior]. *Internistische Praxis.* 2004(4):697-710. *Exclude - Non-English.*

Dieker HJ, van Horssen EV, Hersbach FM, et al. Transport for abciximab facilitated primary angioplasty versus on-site thrombolysis with a liberal rescue policy: the randomised Holland Infarction Study (HIS). *J Thromb Thrombolysis.* 2006;22(1):39-45. PMID: 16786231. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Diercks DB, Owen KP, Kontos MC, et al. Gender differences in time to presentation for myocardial infarction before and after a national women's cardiovascular awareness campaign: a temporal analysis from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation (CRUSADE) and the National Cardiovascular Data Registry Acute

Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (NCDR ACTION Registry-GWTG). *Am Heart J.* 2010;160(1):80-87 e3. PMID: 20598976. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Dijkman LM, Hirsch A, Windhausen F, et al. Cost-effectiveness of early versus selectively invasive strategy in patients with acute coronary syndromes without ST-segment elevation. *Int J Cardiol.* 2009;131(2):204-11. PMID: 18199496. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dong-Bao L, Qi H, Hong-Wei L, et al. Effects of early angioplasty after fibrinolysis on prognosis of patients with ST-segment elevation acute myocardial infarction. *African Journal of Biotechnology.* 2011;10(70):15801-15804. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dragu R, Behar S, Sandach A, et al. Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction? *Am J Cardiol.* 2006;97(8):1142-5. PMID: 16616015. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Drenth DJ, Veeger NJ, Grandjean JG, et al. Isolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? *Eur J Cardiothorac Surg.* 2004;25(4):567-71. PMID: 15037273. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Drenth DJ, Veeger NJ, Middel B, et al. Comparison of late (four years) functional health status between percutaneous transluminal angioplasty intervention and off-pump left internal mammary artery bypass grafting for isolated high-grade narrowing of the proximal left anterior descending coronary artery. *Am J Cardiol.* 2004;94(11):1414-7. PMID: 15566914. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Drenth DJ, Veeger NJ, Winter JB, et al. A prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. *J Am Coll Cardiol*. 2002;40(11):1955-60. PMID: 12475455. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Drenth DJ, Winter JB, Veeger NJ, et al. Minimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months' angiographic and clinical follow-up of a prospective randomized study. *J Thorac Cardiovasc Surg*. 2002;124(1):130-5. PMID: 12091818. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dryja T, Kornacewicz-Jach Z, Goracy J, et al. Treatment of acute ST-segment elevation myocardial infarction in West Pomerania province of Poland. Comparison between primary coronary intervention and thrombolytic therapy. *Kardiol Pol*. 2006;64(6):591-599. PMID: 16810577. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dzavik V, Beanlands DS, Davies RF, et al. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]--a pilot study). *Am J Cardiol*. 1994;73(12):856-61. PMID: 8184807. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dzavik V, Buller CE, Lamas GA, et al. Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial. *Circulation*. 2006;114(23):2449-57. PMID: 17105848. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or*

*older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dzavik V, Carere RG, Mancini GB, et al. Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the Total Occlusion Study of Canada (TOSCA). *Am Heart J*. 2001;142(2):301-8. PMID: 11479470. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. *Eur Heart J*. 2003;24(9):828-37. PMID: 12727150. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Dzavik V, Sleeper LA, Picard MH, et al. Outcome of patients aged  $\geq 75$  years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shock (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization? *Am Heart J*. 2005;149(6):1128-34. PMID: 15976798. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ebbinghaus J, Maier B, Schoeller R, et al. Routine early invasive strategy and in-hospital mortality in women with non-ST-elevation myocardial infarction Results from the Berlin Myocardial Infarction Registry (BMIR). *Int J Cardiol*. 2011. PMID: 21277642. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Echols MR, Mahaffey KW, Banerjee A, et al. Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). *Am J Cardiol*. 2007;99(3):315-21. PMID: 17261389. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Eefting F, Nathoe H, van Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. *Circulation*. 2003;108(23):2870-6. PMID: 14656913. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Eisenberg MJ, Teng FF, Chaudhry MR, et al. Impact of invasive management versus noninvasive management on functional status and quality of life following non-Q-wave myocardial infarction: a randomized clinical trial. *Am Heart J*. 2005;149(5):813-9. PMID: 15894961. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ekstein S, Elami A, Merin G, et al. Balloon angioplasty versus bypass grafting in the era of coronary stenting. *Isr Med Assoc J*. 2002;4(8):583-9. PMID: 12183860. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ellis SG, Mooney MR, George BS, et al. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction. Treatment of Post-Thrombolytic Stenoses (TOPS) Study Group. *Circulation*. 1992;86(5):1400-6. PMID: 1423952. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ellis SG, Roubin GS, King SB, 3rd, et al. In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures. *J Am Coll Cardiol*. 1988;11(2):211-6. PMID: 2963055. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. *JAMA*. 2007;297(18):1985-91. PMID: 17488963. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Farkouh ME, Dangas G, Leon MB, et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. *Am Heart J*. 2008;155(2):215-23. PMID: 18215589. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Farkouh ME, Ramanathan K, Aymong ED, et al. An early revascularization strategy is associated with a survival benefit for diabetic patients in cardiogenic shock after acute myocardial infarction. *Clin Cardiol*. 2006;29(5):204-10. PMID: 16739392. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Favarato D, Hueb W, Gersh BJ, et al. Relative cost comparison of treatments for coronary artery disease: the First Year Follow-Up of MASS II Study. *Circulation*. 2003;108 Suppl 1(II21-3). PMID: 12970202. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Favarato ME, Hueb W, Boden WE, et al. Quality of life in patients with symptomatic multivessel coronary artery disease: a comparative post hoc analyses of medical, angioplasty or surgical strategies-MASS II trial. *Int J Cardiol*. 2007;116(3):364-70. PMID: 16876891. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. *J Am Coll Cardiol*. 1995;25(2):362-9. PMID: 7829789. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. *Lancet*. 2004;364(9439):1045-53. PMID: 15380963. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ferreira-Gonzalez I, Permanyer-Miralda G, Marrugat J, et al. MASCARA (Manejo del Síndrome Coronario Agudo. Registro Actualizado) study. General findings. *Rev Esp Cardiol*. 2008;61(8):803-16.

PMID: 18684363. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS. J Am Coll Cardiol. 1997;29(7):1505-11. PMID: 9180111. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Fosbol EL, Thune JJ, Kelbaek H, et al. Long-term outcome of primary angioplasty compared with fibrinolysis across age groups: a Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI-2) substudy. Am Heart J. 2008;156(2):391-6. PMID: 18657676. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet. 2005;366(9489):914-20. PMID: 16154018. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-15. PMID: 19502645. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Fukunishi M, Nishigaki K, Okubo M, et al. J-SAP study 1-2: outcomes of patients with stable high-risk coronary artery disease receiving medical-preceding therapy in Japan. Circ J. 2006;70(8):1012-6. PMID: 16864934. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gao RL, Han YL, Yang XC, et al. Thrombolytic therapy with rescue percutaneous coronary intervention versus primary percutaneous coronary intervention in patients with acute myocardial infarction: A multicenter randomized clinical trial. Chin Med J (Engl). 2010;123(11):1365-1372. PMID: 20819587 *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Garcia E, Elizaga J, Perez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol. 1999;33(3):605-11. PMID: 10080458. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gaszewska-Zurek E, Zurek P, Ciosek J, et al. Invasive treatment of coronary artery disease in octogenarians. Kardiol Pol. 2005;63(5):488-96; discussion 497-8. PMID: 16362853. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gershlick AH, Stephens-Lloyd A, Hughes S, et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005;353(26):2758-68. PMID: 16382062. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med. 1993;328(10):685-91. PMID: 8433727. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gierlotka M, Gasior M, Wilczek K, et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol.

2011;107(4):501-8. PMID: 21195380. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Goy JJ, Eeckhout E, Burnand B, et al. Coronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. *Lancet*. 1994;343(8911):1449-53. PMID: 7911175. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Goy JJ, Eeckhout E, Moret C, et al. Five-year outcome in patients with isolated proximal left anterior descending coronary artery stenosis treated by angioplasty or left internal mammary artery grafting. A prospective trial. *Circulation*. 1999;99(25):3255-9. PMID: 10385499. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Goy JJ, Kaufmann U, Goy-Eggenberger D, et al. A prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. *Mayo Clin Proc*. 2000;75(11):1116-23. PMID: 11075740. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Goy JJ, Kaufmann U, Hurni M, et al. 10-year follow-up of a prospective randomized trial comparing bare-metal stenting with internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis the SIMA (Stenting versus Internal Mammary Artery grafting) trial. *J Am Coll Cardiol*. 2008;52(10):815-7. PMID: 18755343. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Graham MM, Ghali WA, Faris PD, et al. Survival after coronary revascularization in the elderly. *Circulation*. 2002;105(20):2378-84. PMID: 12021224. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gray TJ, Burns SM, Clarke SC, et al. Percutaneous myocardial laser revascularization in patients with

refractory angina pectoris. *Am J Cardiol*. 2003;91(6):661-6. PMID: 12633794. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. *N Engl J Med*. 1993;328(10):673-9. PMID: 8433725. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Grines CL, Westerhausen DR, Jr., Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. *J Am Coll Cardiol*. 2002;39(11):1713-9. PMID: 12039480. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gruberg L, Mercado N, Milo S, et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: The obesity paradox II? *Am J Cardiol*. 2005;95(4):439-44. PMID: 15695125. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gruberg L, Milo S, Ben Tzvi M, et al. Comparison of bypass surgery and stenting for the treatment of multivessel disease: results from the ARTS trial in Israel. *Isr Med Assoc J*. 2003;5(8):539-42. PMID: 12929288. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes inpatients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). *J Am Coll Cardiol*. 2002;39(5):834-40. PMID: 11869849. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that*

*includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hambrecht R, Walther C, Mobius-Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation*. 2004;109(11):1371-8. PMID: 15007010. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hartigan PM, Giacomini JC, Folland ED, et al. Two- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine. *Am J Cardiol*. 1998;82(12):1445-50. PMID: 9874045. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hassan SA, Hlatky MA, Boothroyd DB, et al. Outcomes of noncardiac surgery after coronary bypass surgery or coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Med*. 2001;110(4):260-6. PMID: 11239843. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. *J Am Coll Cardiol*. 2003;42(7):1161-70. PMID: 14522473. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary artery bypass grafting. Randomised Intervention Treatment of Angina. *Lancet*. 1998;352(9138):1419-25. PMID: 9807988. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Henriques JP, Zijlstra F, van 't Hof AW, et al. Primary percutaneous coronary intervention versus thrombolytic treatment: long term follow up

according to infarct location. *Heart*. 2006;92(1):75-9. PMID: 15831596. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Herz I, Mohr R, Moshkovitz Y, et al. Revascularization of the left anterior descending artery with drug-eluting stents: comparison with arterial off-pump surgery. *Heart Surg Forum*. 2004;7(5):E490-2. PMID: 15799931. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hirsch A, Windhausen F, Tijssen JG, et al. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. *Lancet*. 2007;369(9564):827-35. PMID: 17350451. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hlatky MA, Bacon C, Boothroyd D, et al. Cognitive function 5 years after randomization to coronary angioplasty or coronary artery bypass graft surgery. *Circulation*. 1997;96(9 Suppl):II-11-4; discussion II-15. PMID: 9386068. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hlatky MA, Boothroyd D, Horine S, et al. Employment after coronary angioplasty or coronary bypass surgery in patients employed at the time of revascularization. *Ann Intern Med*. 1998;129(7):543-7. PMID: 9758574. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Hlatky MA, Boothroyd DB, Melsop KA, et al. Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease. *Circulation*. 2004;110(14):1960-6. PMID: 15451795. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hlatky MA, Boothroyd DB, Melsop KA, et al. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the

Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Circulation*. 2009;120(25):2550-8. PMID: 19920002. *Exclude - Does not include outcomes of interest.*

Hlatky MA, Rogers WJ, Johnstone I, et al. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med*. 1997;336(2):92-9. PMID: 8988886. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hochholzer W, Buettner HJ, Trenk D, et al. Percutaneous coronary intervention versus coronary artery bypass grafting as primary revascularization in patients with acute coronary syndrome. *Am J Cardiol*. 2008;102(2):173-9. PMID: 18602516. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hofer S, Doering S, Rumpold G, et al. Determinants of health-related quality of life in patients with coronary artery disease. *Eur J Cardiovasc Prev Rehabil*. 2006;13(3):398-406. PMID: 16926670. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Holmes DR, Jr., Holubkov R, Vlietstra RE, et al. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. *J Am Coll Cardiol*. 1988;12(5):1149-55. PMID: 2971699. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Holmes DR, Jr., Kim LJ, Brooks MM, et al. The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation. *J Thorac Cardiovasc Surg*. 2007;134(1):38-46, 46 e1. PMID: 17599484. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Holper EM, Brooks MM, Kim LJ, et al. Effects of heart failure and diabetes mellitus on long-term mortality after coronary revascularization (from the BARI Trial). *Am J Cardiol*. 2007;100(2):196-202.

PMID: 17631069. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hong SJ, Lim DS, Seo HS, et al. Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. *Catheter Cardiovasc Interv*. 2005;64(1):75-81. PMID: 15619278. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Horie H, Takahashi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. *Circulation*. 1998;98(22):2377-82. PMID: 9832481. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hueb WA, Bellotti G, de Oliveira SA, et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. *J Am Coll Cardiol*. 1995;26(7):1600-5. PMID: 7594092. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Hueb WA, Soares PR, Almeida De Oliveira S, et al. Five-year follow-up of the medicine, angioplasty, or surgery study (MASS): A prospective, randomized trial of medical therapy, balloon angioplasty, or bypass surgery for single proximal left anterior descending coronary artery stenosis. *Circulation*. 1999;100(19 Suppl):II107-13. PMID: 10567287. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Huikeshoven M, van der Sloot JA, Tukkie R, et al. Improved quality of life after XeCl excimer transmyocardial laser revascularization: results of a randomized trial. *Lasers Surg Med*. 2003;33(1):1-7. PMID: 12866115. *Exclude - Does not include outcome data reported in a gender-specific fashion*



for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.

Idorn L, Hofsten DE, Wachtell K, et al. Prevalence and prognostic implications of ST-segment deviations from ambulatory Holter monitoring after ST-segment elevation myocardial infarction treated with either fibrinolysis or primary percutaneous coronary intervention (a Danish Trial in Acute Myocardial Infarction-2 Substudy). *Am J Cardiol.* 2007;100(6):937-43. PMID: 17826373. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Itoh T, Fukami K, Suzuki T, et al. Comparison of long-term prognostic evaluation between pre-intervention thrombolysis and primary coronary intervention: A prospective randomized trial - Five-year results of the IMPORTANT study. *Circ J.* 2010;74(8):1625-1634. PMID: 20571249. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Janzon M, Levin LA, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The Fast Revascularisation during InStability in Coronary artery disease. *Eur Heart J.* 2002;23(1):31-40. PMID: 11741360. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Janzon M, Levin LA, Swahn E. Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial. *Am Heart J.* 2004;148(1):114-21. PMID: 15215800. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Javaid A, Steinberg DH, Buch AN, et al. Outcomes of coronary artery bypass grafting versus percutaneous coronary intervention with drug-eluting stents for patients with multivessel coronary artery disease. *Circulation.* 2007;116(11 Suppl):I200-6. PMID: 17846304. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Jeger RV, Assmann SF, Yehudai L, et al. Causes of death and re-hospitalization in cardiogenic shock. *Acute Card Care.* 2007;9(1):25-33. PMID: 17453536. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Jeger RV, Bonetti PO, Zellweger MJ, et al. Influence of revascularization on long-term outcome in patients > or =75 years of age with diabetes mellitus and angina pectoris. *Am J Cardiol.* 2005;96(2):193-8. PMID: 16018840. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Jeger RV, Harkness SM, Ramanathan K, et al. Emergency revascularization in patients with cardiogenic shock on admission: a report from the SHOCK trial and registry. *Eur Heart J.* 2006;27(6):664-70. PMID: 16423873. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Jeger RV, Lowe AM, Buller CE, et al. Hemodynamic parameters are prognostically important in cardiogenic shock but similar following early revascularization or initial medical stabilization: a report from the SHOCK Trial. *Chest.* 2007;132(6):1794-803. PMID: 17951622. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Jeger RV, Pfisterer ME. Revascularization in patients 75 years or older with diabetes mellitus and angina pectoris. *Cardiol Rev.* 2006;23(1):19-23. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Jeger RV, Tseng CH, Hochman JS, et al. Interhospital transfer for early revascularization in patients with ST-elevation myocardial infarction complicated by cardiogenic shock--a report from the SHould we revascularize Occluded Coronaries for cardiogenic shock? (SHOCK) trial and registry. *Am Heart J.* 2006;152(4):686-92. PMID: 16996836. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Johansen A, Hoiland-Carlsen PF, Christensen HW, et al. Use of myocardial perfusion imaging to predict

the effectiveness of coronary revascularisation in patients with stable angina pectoris. *Eur J Nucl Med Mol Imaging*. 2005;32(12):1363-70. PMID: 15824925. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Johnston N, Jernberg T, Lagerqvist B, et al. Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease. *Am Heart J*. 2006;152(6):1052-8. PMID: 17161052. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kaiser C, Kuster GM, Erne P, et al. Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina--on-treatment analysis of the TIME trial. *Eur Heart J*. 2004;25(12):1036-42. PMID: 15191774. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kapur A, Bartolini D, Finlay MC, et al. The Bypass Angioplasty Revascularization in Type 1 and Type 2 Diabetes Study: 5-year follow-up of revascularization with percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients with multivessel disease. *J Cardiovasc Med (Hagerstown)*. 2010;11(1):26-33. PMID: 19797974. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kasai T, Kajimoto K, Miyauchi K, et al. Propensity analysis of 12 years outcome after bypass graft or balloon angioplasty in patients with multivessel coronary artery disease. *J Cardiol*. 2008;52(3):186-194. PMID: 19027596 *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. *Lancet*. 2002;359(9310):920-5. PMID: 11918909. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes*

*women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kaul P, Armstrong PW, Chang WC, et al. Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. *Circulation*. 2004;110(13):1754-60. PMID: 15381645. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Kaul P, Armstrong PW, Fu Y, et al. Impact of different patterns of invasive care on quality of life outcomes in patients with non-ST elevation acute coronary syndrome: results from the GUSTO-IIb Canada-United States substudy. *Can J Cardiol*. 2004;20(8):760-6. PMID: 15229756. *Exclude - Does not include outcomes of interest.*

Kawecki D, Kubiak G, Orszulik K, et al. Quality of life in patients with severe left ventricle dysfunction due to coronary artery disease. *Central European Journal of Medicine*. 2011;6(6):807-812. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kelsey SF, James M, Holubkov AL, et al. Results of percutaneous transluminal coronary angioplasty in women. 1985-1986 National Heart, Lung, and Blood Institute's Coronary Angioplasty Registry. *Circulation*. 1993;87(3):720-7. PMID: 8443892. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Kempf J, Buysman E, Brixner D. Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a US managed care setting. *American Health and Drug Benefits*. 2011;4(6):355-361. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Kimura T, Morimoto T, Furukawa Y, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. *Circulation*. 2008;118(14 Suppl):S199-209. PMID: 18824755. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

King SB, 3rd. The Emory Angioplasty vs Surgery Trial (EAST). *Semin Interv Cardiol*. 1999;4(4):185-90. PMID: 10738351. *Exclude - Does not include outcome data reported in a gender-specific fashion*

for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.

Kip KE, Alderman EL, Bourassa MG, et al. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. *Circulation*. 2002;105(16):1914-20. PMID: 11997277. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kjaergard H, Nielsen PH, Andreasen JJ, et al. Coronary artery bypass grafting within 30 days after treatment of acute myocardial infarctions with angioplasty or fibrinolysis - a surgical substudy of DANAMI-2. *Scand Cardiovasc J*. 2004;38(3):143-6. PMID: 15223711. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kjaergard HK, Nielsen PH, Andreasen JJ, et al. Coronary artery bypass grafting within the first year after treatment of large acute myocardial infarctions with angioplasty or fibrinolysis. *Scandinavian Cardiovascular Journal*. 2006(1):25-8. PMID: 16448994. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. *J Am Coll Cardiol*. 2002;40(6):1044-50. PMID: 12354426. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kleopatra K, Muth K, Zahn R, et al. Effect of an invasive strategy on in-hospital outcome and one-year mortality in women with non-ST-elevation myocardial infarction. *Int J Cardiol*. 2010. PMID: 20851476. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Kofoed KF, Madsen JK, Grande P, et al. Long-term effects of invasive treatment in patients with a post-

thrombolytic Q-wave myocardial infarction. *Scand Cardiovasc J*. 2010;44(3):146-52. PMID: 20233135. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Konstance RP, Eisenstein EL, Anstrom KJ, et al. Outcomes of second revascularization procedures after stent implantation. *J Med Syst*. 2008;32(2):177-86. PMID: 18461821. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kontny F. Improving outcomes in acute coronary syndromes--the FRISC II trial. *Clin Cardiol*. 2001;24(3 Suppl):I3-7. PMID: 11286312. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Krantz MJ, Haugen SJ, Batal H, et al. Off-site percutaneous coronary intervention reduces hospital length of stay in vulnerable patients with acute myocardial infarction. *Crit Pathw Cardiol*. 2005;4(3):127-130. PMID: 18340197. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Krimly A, Yan RT, Yan AT, et al. Use of Clopidogrel Post-Coronary Artery Bypass Surgery in Canadian Patients With Acute Coronary Syndromes. *Can J Cardiol*. 2011;27(6):711-715. PMID: 21875778. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Kruk M, Buller CE, Tchong JE, et al. Impact of left ventricular ejection fraction on clinical outcomes over five years after infarct-related coronary artery recanalization (from the Occluded Artery Trial [OAT]). *Am J Cardiol*. 2010;105(1):10-6. PMID: 20102883. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kruk M, Kadziela J, Reynolds HR, et al. Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. *JACC Cardiovasc Interv*. 2008;1(5):511-20. PMID: 19194534. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or*

*older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kuch B, Heier M, von Scheidt W, et al. 20-year trends in clinical characteristics, therapy and short-term prognosis in acute myocardial infarction according to presenting electrocardiogram: the MONICA/KORA AMI Registry (1985-2004). *J Intern Med.* 2008;264(3):254-64. PMID: 18397247. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kugelmass AD, Sadanandan S, Lakkis N, et al. Early invasive strategy improves outcomes in patients with acute coronary syndrome with previous coronary artery bypass graft surgery: A report from TACTICS-TIMI 18. *Crit Pathw Cardiol.* 2006(3):167-72. PMID: 18340233. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kukreja N, Serruys PW, De Bruyne B, et al. Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II). *Heart.* 2009;95(13):1061-6. PMID: 19304671. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kunadian B, Sutton AG, Vijayalakshmi K, et al. Early invasive versus conservative treatment in patients with failed fibrinolysis--no late survival benefit: the final analysis of the Middlesbrough Early Revascularisation to Limit Infarction (MERLIN) randomized trial. *Am Heart J.* 2007;153(5):763-71. PMID: 17452151. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kurbaan AS, Bowker TJ, Ilesley CD, et al. The effect of adjusting for baseline risk factors and post revascularisation coronary disease on comparisons between coronary angioplasty and bypass surgery. *Int J Cardiol.* 2001;77(2-3):207-14. PMID: 11182184. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that*

*includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kurbaan AS, Bowker TJ, Ilesley CD, et al. Impact of postangioplasty restenosis on comparisons of outcome between angioplasty and bypass grafting. Coronary Angioplasty versus Bypass Revascularisation Investigation (CABRI) Investigators. *Am J Cardiol.* 1998;82(3):272-6. PMID: 9708652. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kurbaan AS, Bowker TJ, Ilesley CD, et al. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. *Am J Cardiol.* 2001;87(8):947-50; A3. PMID: 11305983. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Kurbaan AS, Bowker TJ, Rickards AF. Trials of angioplasty and surgery: CABRI. *Semin Interv Cardiol.* 1999;4(4):179-84. PMID: 10738350. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Lagerqvist B, Husted S, Kontny F, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. *J Am Coll Cardiol.* 2002;40(11):1902-14. PMID: 12475448. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Lam BK, Gillinov AM, Blackstone EH, et al. Importance of moderate ischemic mitral regurgitation. *Ann Thorac Surg.* 2005;79(2):462-70; discussion 462-70. PMID: 15680815. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Lang IM, Forman SA, Maggioni AP, et al. Causes of death in early MI survivors with persistent infarct artery occlusion: results from the Occluded Artery Trial (OAT). *EuroIntervention.* 2009;5(5):610-8. PMID: 20142183. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Lansky AJ. Outcomes of percutaneous and surgical revascularization in women. *Prog Cardiovasc Dis*. 2004;46(4):305-19. PMID: 14961454. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Lansky AJ, Goto K, Cristea E, et al. Clinical and angiographic predictors of short- and long-term ischemic events in acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. *Circ Cardiovasc Interv*. 2010;4(3):308-16. PMID: 20647564. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Le May MR, Labinaz M, Davies RF, et al. Stenting versus thrombolysis in acute myocardial infarction trial (STAT). *J Am Coll Cardiol*. 2001;37(4):985-91. PMID: 11263625. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Le May MR, Wells GA, Labinaz M, et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study). *J Am Coll Cardiol*. 2005;46(3):417-24. PMID: 16053952. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Lee MS, Jamal F, Kedia G, et al. Comparison of bypass surgery with drug-eluting stents for diabetic patients with multivessel disease. *Int J Cardiol*. 2007;123(1):34-42. PMID: 17292983. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. *J Am Coll Cardiol*. 2006;47(4):864-70. PMID: 16487857. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Legrand VM, Garg S, Serruys PW, et al. Influence of age on the clinical outcomes of coronary revascularisation for the treatment of patients with multivessel de novo coronary artery lesions:

sirolimus-eluting stent vs. coronary artery bypass surgery and bare metal stent, insight from the multicentre randomised Arterial Revascularisation Therapy Study Part I (ARTS-I) and Part II (ARTS-II). *EuroIntervention*. 2011;6(7):838-45. PMID: 21252018. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Legrand VM, Serruys PW, Unger F, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. *Circulation*. 2004;109(9):1114-20. PMID: 14993134. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Legutko J, Dudek D, Chyrchel M, et al. [Safety and effectiveness of pharmacologic versus mechanical stabilization of borderline coronary lesions in patients with acute coronary syndromes]. *Przegl Lek*. 2005;1(1):1-7. PMID: 16053211. *Exclude - Non-English.*

Lehmann R, Fichtlscherer S, SchAchinger V, et al. Favorable long-term survival in patients undergoing multivessel-PCI compared to predicted prognosis of CABG estimated by EuroSCORE: Procedural and clinical determinants of long-term outcome. *J Interv Cardiol*. 2009;22(6):511-519. PMID: 19732282. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Lehmann S, Walther T, Kempfert J, et al. Stentless versus conventional xenograft aortic valve replacement: midterm results of a prospectively randomized trial. *Ann Thorac Surg*. 2007;84(2):467-72. PMID: 17643617. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Lindholm MG, Boesgaard S, Thune JJ, et al. Percutaneous coronary intervention for acute MI does not prevent in-hospital development of cardiogenic shock compared to fibrinolysis. *Eur J Heart Fail*. 2008;10(7):668-74. PMID: 18571985. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Liu YY, Zhou YJ, Wang ZJ, et al. [Comparison between drug eluting stent and coronary artery bypass grafting surgery for the treatment of unprotected left main coronary artery disease in elderly patients]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2009;37(9):769-72. PMID: 20128370. *Exclude - Non-English.*

- Lopes NH, Paulitsch Fda S, Gois AF, et al. Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the Medical, Angioplasty, and bypass Surgery study (MASS). *Eur J Cardiothorac Surg.* 2008;33(3):349-54. PMID: 18249128. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Loponen P, Luther M, Korpilahti K, et al. HRQoL after coronary artery bypass grafting and percutaneous coronary intervention for stable angina. *Scand Cardiovasc J.* 2009;43(2):94-9. PMID: 18819033. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- MacK MJ, Banning AP, Serruys PW, et al. Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. *Ann Thorac Surg.* 2011;92(6):2140-2146. PMID: 21967819. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Mack MJ, Prince SL, Herbert M, et al. Current clinical outcomes of percutaneous coronary intervention and coronary artery bypass grafting. *Ann Thorac Surg.* 2008;86(2):496-503; discussion 503. PMID: 18640323. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Madsen JK, Nielsen TT, Grande P, et al. Revascularization compared to medical treatment in patients with silent vs. symptomatic residual ischemia after thrombolized myocardial infarction--the DANAMI study. *Cardiology.* 2007;108(4):243-51. PMID: 17114878. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Mahmarijan JJ, Dakik HA, Filipchuk NG, et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. *J Am Coll Cardiol.* 2006;48(12):2458-67. PMID: 17174182. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Mahoney EM, Jurkowitz CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. *JAMA.* 2002;288(15):1851-8. PMID: 12377083. *Exclude - Does not include outcomes of interest.*
- Malek LA, Reynolds HR, Forman SA, et al. Late coronary intervention for totally occluded left anterior descending coronary arteries in stable patients after myocardial infarction: Results from the Occluded Artery Trial (OAT). *Am Heart J.* 2009;157(4):724-32. PMID: 19332202. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. *Circulation.* 2005;112(9 Suppl):I371-6. PMID: 16159849. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Mancini GBJ, Bates ER, Maron DJ, et al. Quantitative results of baseline angiography and percutaneous coronary intervention in the courage trial. *Circ Cardiovasc Qual Outcomes.* 2009;2(4):320-327. PMID: 20031857. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Mark DB, Pan W, Clapp-Channing NE, et al. Quality of life after late invasive therapy for occluded arteries. *N Engl J Med.* 2009;360(8):774-83. PMID: 19228620. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Maron DJ, Spertus JA, Mancini GB, et al. Impact of an initial strategy of medical therapy without percutaneous coronary intervention in high-risk patients from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial. *Am J Cardiol.* 2009;104(8):1055-

62. PMID: 19801024. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Martuscelli E, Clementi F, Gallagher MM, et al. Revascularization strategy in patients with multivessel disease and a major vessel chronically occluded; data from the CABRI trial. *Eur J Cardiothorac Surg.* 2008;33(1):4-8. PMID: 17988889. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Matteau A, Dorais M, Rinfret S, et al. Effectiveness of a change in reperfusion strategy to primary percutaneous coronary intervention in a nonselected population. *Can J Cardiol.* 2009;25(8):e279-83. PMID: 19668789. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

McCullough PA, Gibson CM, Dibattiste PM, et al. Timing of angiography and revascularization in acute coronary syndromes: an analysis of the TACTICS-TIMI-18 trial. *J Interv Cardiol.* 2004;17(2):81-6. PMID: 15104769. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

McCullough PA, O'Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial. *J Am Coll Cardiol.* 1998;32(3):596-605. PMID: 9741499. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

McCullough PA, O'Neill WW, Graham M, et al. A time-to-treatment analysis in the medicine versus angiography in thrombolytic exclusion (MATE) trial. *J Interv Cardiol.* 2001;14(4):415-22. PMID: 12053495. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

McKhann GM, Grega MA, Borowicz LM, Jr., et al. Is there cognitive decline 1 year after CABG? Comparison with surgical and nonsurgical controls. *Neurology.* 2005;65(7):991-9. PMID: 16107605. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that*

*includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Mehilli J, Kastrati A, Dirschinger J, et al. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. *JAMA.* 2000;284(14):1799-805. PMID: 11025832. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Meliga E, Orzan F, Chiribiri A, et al. Surgical revascularization in the ischemic heart disease. Long-term results in a series of consecutive patients selected according to the principles. *Minerva Cardioangiol.* 2005;53(2):147-52. PMID: 15986009. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Menon V, Pearte CA, Buller CE, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. *Eur Heart J.* 2009;30(2):183-91. PMID: 19028780. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. *J Thorac Cardiovasc Surg.* 2005;130(2):512-9. PMID: 16077421. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Michalis LK, Stroumbis CS, Pappas K, et al. Treatment of refractory unstable angina in geographically isolated areas without cardiac surgery. Invasive versus conservative strategy (TRUCS study). *Eur Heart J.* 2000;21(23):1954-9. PMID: 11071801. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Moreira AE, Hueb WA, Soares PR, et al. [Comparative study between the therapeutic effects of surgical myocardial revascularization and coronary angioplasty in equivalent ischemic situations: analysis through myocardial scintigraphy with 99mTc-Sestamibi]. *Arq Bras Cardiol.* 2005;72(2):92-9. PMID: 16113846. *Exclude - Does not include outcome data reported in a gender-specific fashion*

*for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Morice MC, Feldman TE, Mack MJ, et al. Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: Fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). *EuroIntervention*. 2011;7(6):670-679. PMID: 21959312. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Morrison DA, Sethi G, Sacks J, et al. A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs. *Control Clin Trials*. 1999;20(6):601-19. PMID: 10588300. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). *J Am Coll Cardiol*. 2001;38(1):143-9. PMID: 11451264. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. *J Am Coll Cardiol*. 2002;40(11):1951-4. PMID: 12475454. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. *JAMA*. 2001;286(19):2405-12. PMID: 11712935. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Nathoe HM, Van Dijk D, Jansen EWL, et al. Off-pump coronary artery bypass surgery compared with stent implantation and on-pump bypass surgery: Clinical outcome and cost-effectiveness at one year. *Neth Heart J*. 2005;13(7 8):259-268. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Nicolau JC, Marin-Neto JA, Giraldez RR, et al. A comparison of percutaneous coronary intervention and surgical revascularization after fibrinolysis for acute myocardial infarction. Insights from the InTIME-2 trial. *Int J Cardiol*. 2007;116(3):383-8. PMID: 17049642. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Nie SP, Ma CS, Lü Q, et al. [Evaluation of early invasive or initially conservative strategies in patients with non-ST-segment elevation acute coronary syndrome at intermediate or high risk]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2005;4(3):307-11. PMID: 15932657. *Exclude - Non-English.*

Nienaber CA, Rousseau H, Eggebrecht H, et al. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. *Circulation*. 2009;120(25):2519-28. PMID: 19996018. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Niles NW, McGrath PD, Malenka D, et al. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. Northern New England Cardiovascular Disease Study Group. *J Am Coll Cardiol*. 2001;37(4):1008-15. PMID: 11263600. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*



- Nishigaki K, Yamazaki T, Kitabatake A, et al. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. *JACC Cardiovasc Interv.* 2008;1(5):469-79. PMID: 19463347. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Nishimi M, Tashiro T. Off-pump coronary artery bypass vs percutaneous coronary intervention. Therapeutic strategies for 3-vessel coronary artery disease: OPCAB vs PCI(PCI-Side). *Circ J.* 2010;74(12):2750-7. PMID: 21084755. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. *J Am Coll Cardiol.* 2004;43(4):585-91. PMID: 14975468. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Nylaende M, Abdelnoor M, Strandén E, et al. The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication. *Eur J Vasc Endovasc Surg.* 2007;33(1):3-12. PMID: 17055756. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Nylaende M, Kroese AJ, Morken B, et al. Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study. *Vasc Med.* 2007;12(4):275-83. PMID: 18048463. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Ochala A, Smolka GA, Wojakowski W, et al. The function of the left ventricle after complete multivessel one-stage percutaneous coronary intervention in patients with acute myocardial infarction. *J Invasive Cardiol.* 2004;16(12):699-702. PMID: 15596873. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- O'Donoghue M, Sabatine MS. Appropriate invasive and conservative treatment approaches for patients with ST-elevation MI. *Curr Treat Options Cardiovasc Med.* 2006;8(1):3-11. PMID: 16401379. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Ohno T, Kinoshita O, Fujita H, et al. Detecting occult coronary artery disease followed by early coronary artery bypass surgery in patients with diabetic retinopathy: report from a diabetic retinocoronary clinic. *J Thorac Cardiovasc Surg.* 2010;139(1):92-7. PMID: 19660392. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Okumura K, Kamiya H, Matsui H, et al. Beneficial effect of quinapril in patients with angiotensin-converting enzyme D allele after coronary stenting. *Atherosclerosis.* 2001;159(2):527-8. PMID: 11730835. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Olson KL, Delate T, Rasmussen J, et al. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management. *Am J Manag Care.* 2009;15(8):497-503. PMID: 19670953. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Orth-Gomer K, Schneiderman N, Wang HX, et al. Stress reduction prolongs life in women with coronary disease: the Stockholm Women's Intervention Trial for Coronary Heart Disease (SWITCHD). *Circ Cardiovasc Qual Outcomes.* 2009;2(1):25-32. PMID: 20031809. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Ostadal P, Alan D, Vejvoda J, et al. Anti-Xa activity of enoxaparin and nadroparin in patients with acute coronary syndrome. *Exp Clin Cardiol.* 2008;13(4):175-178. PMID: 19343162. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Ott I, Malcouvier V, Schomig A, et al. Proteolysis of tissue factor pathway inhibitor-1 by thrombolysis in acute myocardial infarction. *Circulation.* 2002;105(3):279-81. PMID: 11804978. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Ovbiagele B, Campbell S, Faiz A, et al. Relationship between non-specific prescription pill adherence and

- ischemic stroke outcomes. *Cerebrovasc Dis*. 2010;29(2):146-53. PMID: 19955739. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Pache J, Kastrati A, Mehilli J, et al. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. *Am Heart J*. 2004;148(1):e3. PMID: 15215812. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Packer M, Coats AJ, Fowler MB. Carvedilol reduced mortality and hospitalisation in severe chronic heart failure. *Evidence-Based Medicine*. 2001;6(6):173. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Paez KA, Allen JK. Cost-effectiveness of nurse practitioner management of hypercholesterolemia following coronary revascularization. *J Am Acad Nurse Pract*. 2006;18(9):436-44. PMID: 16958775. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Pambianco G, Lombardero M, Bittner V, et al. Control of lipids at baseline in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Prev Cardiol*. 2009;12(1):9-18. PMID: 19301686. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. *N Engl J Med*. 1992;326(1):10-6. PMID: 1345754. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Parisi AF, Hartigan PM, Folland ED. Evaluation of exercise thallium scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease. Findings from the Angioplasty Compared to Medicine (ACME) Study. *J Am Coll Cardiol*. 1997;30(5):1256-63. PMID: 9350924. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Park DW, Yun SC, Lee SW, et al. Long-term mortality after percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass surgery for the treatment of multivessel coronary artery disease. *Circulation*. 2008;117(16):2079-86. PMID: 18413495. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Parodi G, Ndrepepa G, Kastrati A, et al. Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms. *Am Heart J*. 2006;152(6):1133-9. PMID: 17161066. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Parsons E, Newby LK, Bhapkar MV, et al. Postmenopausal hormone use in women with acute coronary syndromes. *J Womens Health (Larchmt)*. 2004;13(8):863-71. PMID: 15671702. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Pater C, Jacobsen CD, Rollag A, et al. Design of a randomized controlled trial of comprehensive rehabilitation in patients with myocardial infarction, stabilized acute coronary syndrome, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting: Akershus comprehensive cardiac rehabilitation trial (the CORE study). *Curr Control Trials Cardiovasc Med*. 2000;1(3):177-183. PMID: 11714435. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Pedersen S, Galatius S, Bech J, et al. 7,528 patients treated with PCI--a Scandinavian real-life scenario. *Cardiology*. 2008;110(2):96-105. PMID: 17971658. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Pedersen S, Galatius S, Mogelvang R, et al. Long-term prognosis in an ST-segment elevation myocardial infarction population treated with routine primary percutaneous coronary intervention: from clinical trial to real-life experience. *Circ Cardiovasc Interv*. 2009;2(5):392-400. PMID: 20031748. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Pedersen TR, Cater NB, Faergeman O, et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). *Am J Cardiol*. 2010;106(3):354-9. PMID: 20643245. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Pell JP, Pell AC, Jeffrey RR, et al. Comparison of survival following coronary artery bypass grafting vs.

percutaneous coronary intervention in diabetic and non-diabetic patients: retrospective cohort study of 6320 procedures. *Diabet Med.* 2004;21(7):790-2. PMID: 15209776. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pereira AC, Lopes NH, Soares PR, et al. Clinical judgment and treatment options in stable multivessel coronary artery disease: results from the one-year follow-up of the MASS II (Medicine, Angioplasty, or Surgery Study II). *J Am Coll Cardiol.* 2006;48(5):948-53. PMID: 16949484. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Pereira AC, Miyakawa AA, Lopes NH, et al. Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. *Thromb Res.* 2007;121(1):25-32. PMID: 17604826. *Exclude - Does not include outcomes of interest.*

Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. *Circulation.* 2003;108(14):1682-7. PMID: 14504182. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Pfisterer M. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME). *Circulation.* 2004;110(10):1213-8. PMID: 15337691. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. *JAMA.* 2003;289(9):1117-23. PMID: 12622581. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pfisterer M, Buser P, Osswald S, et al. Trial of Invasive versus Medical Therapy in the Elderly (TIME): Study protocol and patient outline. *HeartDrug.* 2001;1(3):144-147. *Exclude - Does not*

*include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. *Circulation.* 2003;107(2):279-84. PMID: 12538428. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pijls NH, van Schaardenburgh P, Manoharan G, et al. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. *J Am Coll Cardiol.* 2007;49(21):2105-11. PMID: 17531660. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pilote L, Miller DP, Califf RM, et al. Recurrent ischemia after thrombolysis for acute myocardial infarction. *Am Heart J.* 2001;141(4):559-65. PMID: 11275920. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. *Circulation.* 2006;114(19):2019-25. PMID: 17075010. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pinto DS, Stone GW, Shi C, et al. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. *J Am Coll Cardiol.* 2008;52(22):1758-68. PMID: 19022155. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. *Am J Cardiol.* 2001;87(9):1058-63. PMID: 11348602. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med.* 1999;341(2):70-6. PMID: 10395630. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pocock SJ, Henderson RA, Seed P, et al. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial. *Circulation.* 1996;94(2):135-42. PMID: 8674171. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Pohl T, Giehl W, Reichart B, et al. Retroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. *Catheter Cardiovasc Interv.* 2004;62(3):323-30. PMID: 15224298. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study. *J Am Coll Cardiol.* 2007;49(17):1763-9. PMID: 17466225. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Poole-Wilson PA, Pocock SJ, Fox KA, et al. Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial. *Heart.* 2006;92(10):1473-9. PMID: 16621882. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Poole-Wilson PA, Voko Z, Kirwan BA, et al. Clinical course of isolated stable angina due to coronary heart disease. *Eur Heart J.* 2007;28(16):1928-35. PMID: 17562665. *Exclude -*

*Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Poppe T, Singal B, Cowen M, et al. Is it possible to safely administer early a loading dose of clopidogrel before coronary angiography to patients who are candidates for percutaneous coronary intervention? *Am J Cardiol.* 2009;104(11):1505-10. PMID: 19932783. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Prapas SN, Panagiotopoulos IA, Ayyad MA, et al. Female risk using OPCAB, pi-circuit, and aorta no-touch coronary revascularization. *Heart Surg Forum.* 2009;12(6):E344-8. PMID: 20037100. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Prasad A, Rihal C, Holmes DR, Jr. The COURAGE trial in perspective. *Catheter Cardiovasc Interv.* 2008;72(1):54-9. PMID: 18412271. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Radojkovi, D. D, Perisi, et al. [Influence of the double antiplatelet therapy on patency of the occluded artery after acute myocardial infarction with ST-segment elevation]. *Vojnosanit Pregl.* 2007;72(1):117-21. PMID: 17348463. *Exclude - Non-English.*

Radovanovic D, Erne P, Schilling J, et al. Association of dyslipidemia and concomitant risk factors with in-hospital mortality in acute coronary syndrome in Switzerland: The acute myocardial infarction and unstable angina registry in Switzerland (AMIS Plus). *HeartDrug.* 2005;5(3):131-139. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Raghunathan A, Rapp JH, Littooy F, et al. Postoperative outcomes for patients undergoing elective revascularization for critical limb ischemia and intermittent claudication: a subanalysis of the Coronary Artery Revascularization Prophylaxis (CARP) trial. *J Vasc Surg.* 2006;43(6):1175-82. PMID: 16765234. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rajagopal V, Lincoff AM, Cohen DJ, et al. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. *Am Heart J.* 2006;152(1):149-54. PMID: 16824845.

*Exclude - No data for OMT/PCI/CABG comparison of interest.*

Ramanathan KB, Weiman DS, Sacks J, et al. Percutaneous intervention versus coronary bypass surgery for patients older than 70 years of age with high-risk unstable angina. *Ann Thorac Surg.* 2005;80(4):1340-6. PMID: 16181866. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rana JS, Mannam A, Donnell-Fink L, et al. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. *Am J Cardiol.* 2005;95(12):1456-9. PMID: 15950570. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rao C, Aziz O, Panesar SS, et al. Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. *BMJ.* 2007;334(7594):621. PMID: 17337457. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. *Am J Cardiol.* 2005;96(9):1200-6. PMID: 16253582. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rashba EJ, Lamas GA, Couderc JP, et al. Electrophysiological effects of late percutaneous coronary intervention for infarct-related coronary artery occlusion: the Occluded Artery Trial-Electrophysiological Mechanisms (OAT-EP). *Circulation.* 2009;119(6):779-87. PMID: 19188505. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rasoul S, Ottervanger JP, Timmer JR, et al. One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-insulin-potassium study II. *Int J Cardiol.* 2007;122(1):52-5. PMID: 17223212. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary

intervention. *Eur Heart J.* 2010;31(5):561-572. PMID: 19942600. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rastan AJ, Boudriot E, Falk V, et al. Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study. *Eur J Cardiothorac Surg.* 2008;34(2):376-82; discussion 382-3. PMID: 18579392. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ratner RE, Cannon CP, Gerstein HC, et al. Assessment of the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. *Am Heart J.* 2008;156(6):1074-9. PMID: 19033001. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rauch B, Schiele R, Schneider S, et al. OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction. *Circulation.* 2010;122(21):2152-2159. PMID: 21060071. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rauch B, Schiele R, Schneider S, et al. Highly purified omega-3 fatty acids for secondary prevention of sudden cardiac death after myocardial infarction-aims and methods of the OMEGA-study. *Cardiovasc Drugs Ther.* 2006;20(5):365-75. PMID: 17124558. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Ray KK, Nazer B, Cairns R, et al. Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes. *J Thromb Thrombolysis.* 2010;30(1):10-3. PMID: 20354760. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Reeves BC, Angelini GD, Bryan AJ, et al. A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. *Health Technol Assess.* 2004;8(16):1-43. PMID: 15080865. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes*

women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.

Reeves BC, Angelini GD, Bryan AJ, et al. A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. *Health Technol Assess.* 2004;8(16):iii-38. PMID: 15080865. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Reina A, Colmenero M, Aguayo de Hoyos E, et al. Gender differences in management and outcome of patients with acute myocardial infarction. *Int J Cardiol.* 2007;116(3):389-95. PMID: 16843548. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Reynolds HR, Farkouh ME, Lincoff AM, et al. Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. *Arch Intern Med.* 2007;167(19):2054-60. PMID: 17954798. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Reynolds MR, Neil N, Ho KK, et al. Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience. *Am Heart J.* 2003;145(2):334-42. PMID: 12595853. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ribeiro EE, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. *J Am Coll Cardiol.* 1993;22(2):376-80. PMID: 8335807. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study. *J Am Coll Cardiol.* 1998;32(6):1687-94. PMID: 9822097. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes*

women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.

Riezebos RK, Ronner E, Ter Bals E, et al. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. *Heart.* 2009;95(10):807-12. PMID: 19098058. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rihal CS, Sutton-Tyrrell K, Guo P, et al. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation. *Circulation.* 1999;100(2):171-7. PMID: 10402447. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rinfret S, Kennedy WA, Lachaine J, et al. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen. *JACC Cardiovasc Interv.* 2010;3(10):1011-1019. PMID: 20965458. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rodes-Cabau J, Bertrand OF, Larose E, et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. *Circulation.* 2009;120(20):1978-86. PMID: 19884468. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. *J Am Coll Cardiol.* 2001;37(1):51-8. PMID: 11153772. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rodriguez A, Bouillon F, Perez-Balino N, et al. Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. *J Am Coll Cardiol.* 1993;22(4):1060-

7. PMID: 8409041. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rodriguez A, Mele E, Peyregne E, et al. Three-year follow-up of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). *J Am Coll Cardiol.* 1996;27(5):1178-84. PMID: 8609339. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rodriguez A, Rodriguez Alemparte M, Baldi J, et al. Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. *Heart.* 2003;89(2):184-8. PMID: 12527674. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rodriguez AE, Baldi J, Fernandez Pereira C, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). *J Am Coll Cardiol.* 2005;46(4):582-8. PMID: 16098419. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Roncagli J, Brunelle F, Galinier M, et al. Pre-hospital fibrinolysis followed by angioplasty or primary angioplasty in acute myocardial infarction: the long-term clinical outcome. *J Thromb Thrombolysis.* 2003;15(3):181-8. PMID: 14739627. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ronner E, Boersma E, Akkerhuis KM, et al. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. *Eur Heart J.* 2002;23(3):239-46. PMID: 11792139. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rosengart TK, Sweet J, Finnin EB, et al. Neurocognitive functioning in patients undergoing

coronary artery bypass graft surgery or percutaneous coronary intervention: evidence of impairment before intervention compared with normal controls. *Ann Thorac Surg.* 2005;80(4):1327-34; discussion 1334-5. PMID: 16181864. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rosenon RS, Hislop C, Elliott M, et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. *J Am Coll Cardiol.* 2010;56(14):1079-1088. PMID: 20863951. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Ross AM, Huber K, Zeymer U, et al. The impact of place of enrollment and delay to reperfusion on 90-day post-infarction mortality in the ASSENT-4 PCI trial: assessment of the safety and efficacy of a new treatment strategy with percutaneous coronary intervention. *JACC Cardiovasc Interv.* 2009;2(10):925-30. PMID: 19850250. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rott D, Behar S, Hod H, et al. Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures. *Am Heart J.* 2001;141(2):267-76. PMID: 11174342. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Rouleau J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. *Am J Med.* 2005;118 Suppl 12A(28-35). PMID: 16356805. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Rumsfeld JS, Magid DJ, Plomondon ME, et al. Health-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. *J Am Coll Cardiol.* 2003;41(10):1732-8. PMID: 12767656. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

- Rupprecht HJ, Hamm C, Ischinger T, et al. Angiographic follow-up results of a randomized study on angioplasty versus bypass surgery (GABI trial). GABI Study Group. *Eur Heart J*. 1996;17(8):1192-8. PMID: 8869860. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study. *Curr Med Res Opin*. 2004;20(9):1447-54. PMID: 15383193. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Ryan TJ. Present-day PTCR versus CABG: a randomized comparison with a different focus and a new result. *J Am Coll Cardiol*. 2001;37(1):59-62. PMID: 11153773. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Rymuza H, Kowalik I, Drzewiecki A, et al. Successful primary coronary angioplasty improves early and long-term outcomes in ST segment elevation acute coronary syndromes in patients above 80 years of age. *Kardiol Pol*. 2011;69(4):346-354. PMID: 21523668. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Sabatine MS, Blake GJ, Drazner MH, et al. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. *Circulation*. 2005;111(10):1217-24. PMID: 15769761. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Sabatine MS, Morrow DA, McCabe CH, et al. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. *Am Heart J*. 2006;151(1):25-31. PMID: 16368287. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Sadanandan S, Cannon CP, Gibson CM, et al. A risk score to estimate the likelihood of coronary artery bypass surgery during the index hospitalization among patients with unstable angina and non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol*. 2004;44(4):799-803. PMID: 15312862. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Salem M, Rotevatn S, Stavnes S, et al. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. *Am J Cardiol*. 2004;93(9):1086-91. PMID: 15110197. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Sanborn TA, Sleeper LA, Webb JG, et al. Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. *J Am Coll Cardiol*. 2003;42(8):1373-9. PMID: 14563577. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Sato H, Kinjo K, Ito H, et al. Effect of early use of low-dose pravastatin on major adverse cardiac events in patients with acute myocardial infarction: the OACIS-LIPID Study. *Circ J*. 2008;72(1):17-22. PMID: 18159093. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Saw J, Topol EJ, Steinhubl SR, et al. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. *Am J Cardiol*. 2004;94(5):623-5. PMID: 15342293. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Sawada SG, Dasgupta S, Nguyen J, et al. Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability. *Am J Cardiol*. 2010;106(2):187-92. PMID: 20599001. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Sawhney N, Moses JW, Leon MB, et al. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. *Circulation*. 2004;110(4):374-9. PMID: 15249503. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in



acute myocardial infarction. *J Am Coll Cardiol.* 2003;42(4):634-41. PMID: 12932593. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schettert IT, Pereira AC, Lopes NH, et al. Association between ADAMTS13 polymorphisms and risk of cardiovascular events in chronic coronary disease. *Thromb Res.* 2010;125(1):61-6. PMID: 19427680. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Schettert IT, Pereira AC, Lopes NH, et al. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. *Thromb Res.* 2006;118(6):679-83. PMID: 16405973. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Schinkel AF, Poldermans D, Rizzello V, et al. Impact of diabetes mellitus on prediction of clinical outcome after coronary revascularization by 18F-FDG SPECT in patients with ischemic left ventricular dysfunction. *J Nucl Med.* 2006;47(1):68-73. PMID: 16391189. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Schoenenberger AW, Kobza R, Jamshidi P, et al. Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). *Am J Cardiol.* 2009;104(2):158-63. PMID: 19576339. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. *N Engl J Med.* 2000;343(6):385-91. PMID: 10933737. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schomig A, Mehilli J, Antoniucci D, et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. *JAMA.* 2005;293(23):2865-72. PMID: 15956631. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that*

*includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schomig A, Ndrepepa G, Mehilli J, et al. Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis. *Circulation.* 2003;108(9):1084-8. PMID: 12925458. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schouten O, van Kuijk JP, Flu WJ, et al. Long-term outcome of prophylactic coronary revascularization in cardiac high-risk patients undergoing major vascular surgery (from the randomized DECREASE-V Pilot Study). *Am J Cardiol.* 2009;103(7):897-901. PMID: 19327412. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schroter S, Lamping DL. Responsiveness of the coronary revascularisation outcome questionnaire compared with the SF-36 and Seattle Angina Questionnaire. *Qual Life Res.* 2006;15(6):1069-78. PMID: 16900287. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schwartz L, Kip KE, Alderman E, et al. Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). *Am J Cardiol.* 2009;103(5):632-8. PMID: 19231325. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Schweiger MJ, Cannon CP, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). *Am J Cardiol.* 2001;88(8):831-6. PMID: 11676942. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sciahbasi A, Madonna M, De Vita M, et al. Comparison of immediate vs early invasive strategy in patients with first acute non-ST-elevation myocardial infarction. *Clin Cardiol.* 2010(10):650-5.

PMID: 20960541. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Scott IA, Derhy PH, O'Kane D, et al. Discordance between level of risk and intensity of evidence-based treatment in patients with acute coronary syndromes. *Med J Aust.* 2007;187(3):153-9. PMID: 17680740. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Sculpher MJ, Seed P, Henderson RA, et al. Health service costs of coronary angioplasty and coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. *Lancet.* 1994;344(8927):927-30. PMID: 7934351. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease. *Am J Cardiol.* 2009;104(12):1647-53. PMID: 19962469. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sedlis SP, Morrison DA, Lorin JD, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. *J Am Coll Cardiol.* 2002;40(9):1555-66. PMID: 12427406. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sedlis SP, Ramanathan KB, Morrison DA, et al. Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). *Am J Cardiol.* 2004;94(1):118-20. PMID: 15219521. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Segev A, Fefer P, Strauss BH, et al. Outcome of patients with acute coronary syndromes enrolled in clinical trials. *Coron Artery Dis.* 2009;20(7):473-6. PMID: 19609208. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Sejersten M, Birnbaum Y, Ripa RS, et al. Influences of electrocardiographic ischaemia grades and symptom duration on outcomes in patients with acute myocardial infarction treated with thrombolysis versus primary percutaneous coronary intervention: results from the DANAMI-2 trial. *Heart.* 2006;92(11):1577-82. PMID: 16740918. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sejersten M, Ripa RS, Maynard C, et al. Usefulness of quantitative baseline ST-segment elevation for predicting outcomes after primary coronary angioplasty or fibrinolysis (results from the DANAMI-2 trial). *Am J Cardiol.* 2006;97(5):611-6. PMID: 16490423. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sejersten M, Valeur N, Grande P, et al. Long-term prognostic value of ST-segment resolution in patients treated with fibrinolysis or primary percutaneous coronary intervention results from the DANAMI-2 (DANish trial in acute myocardial infarction-2). *J Am Coll Cardiol.* 2009;54(19):1763-9. PMID: 19874989. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Selker HP, Beshansky JR, Griffith JL. Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction. A multicenter, randomized, controlled, clinical effectiveness trial. *Ann Intern Med.* 2002;137(2):87-95. PMID: 12118963. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Selnes OA, Grega MA, Bailey MM, et al. Cognition 6 years after surgical or medical therapy for coronary artery disease. *Ann Neurol.* 2008;63(5):581-90. PMID: 18481292. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Selnes OA, Grega MA, Borowicz LM, Jr., et al. Cognitive changes with coronary artery disease: a prospective study of coronary artery bypass graft patients and nonsurgical controls. *Ann Thorac Surg.* 2003;75(5):1377-84; discussion 1384-6. PMID: 12735550. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Senior R, Kaul S, Raval U, et al. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. *J Nucl Cardiol.* 2002;9(5):454-62. PMID: 12360125. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. *Eur Heart J.* 1999;20(1):58-69. PMID: 10075142. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Serruys PW, Klein W, Tijssen JP, et al. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial. *Circulation.* 1993;88(4 Pt 1):1588-601. PMID: 8403306. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N Engl J Med.* 2009;360(10):961-72. PMID: 19228612. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. *J Am Coll Cardiol.* 2005;46(4):575-81. PMID: 16098418. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Serruys PW, Onuma Y, Garg S, et al. 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. *J Am Coll Cardiol.* 2010;55(11):1093-101. PMID: 20171036. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI or stable CAD.*

Serruys PW, Rutsch W, Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). *Circulation.* 1991;84(4):1568-80. PMID: 1833088. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Serruys PW, Unger F, Sousa JE. Stents had similar clinical outcomes but more repeated revascularisation than did bypass surgery in multivessel disease. *Evidence-Based Medicine.* 2001;6(6):174. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. *N Engl J Med.* 2001;344(15):1117-24. PMID: 11297702. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Shah SJ, Waters DD, Barter P, et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. *J Am Coll Cardiol.* 2008;51(20):1938-43. PMID: 18482661. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Shavelle DM, Salami A, Abdelkarim M, et al. Rescue percutaneous coronary intervention for failed thrombolysis. *Catheter Cardiovasc Interv.* 2006;67(2):214-20. PMID: 16408298. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. *Circulation.*

2008;117(10):1283-91. PMID: 18268144. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Shaw LJ, Miller DD, Romeis JC, et al. Gender differences in the noninvasive evaluation and management of patients with suspected coronary artery disease. *Ann Intern Med.* 1994;120(7):559-66. PMID: 8116993. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Shelton RJ, Crean AM, Somers K, et al. Real-world outcome from ST elevation myocardial infarction in the very elderly before and after the introduction of a 24/7 primary percutaneous coronary intervention service. *Am Heart J.* 2010;159(6):956-63. PMID: 20569706. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Shen W, Zhang R, Shen Y, et al. Optimal timing of coronary stenting in unstable angina patients. *Chin Med J (Engl).* 2001;114(1):59-61. PMID: 11779437. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Shimada K, Mokuno H, Matsunaga E, et al. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. *Atherosclerosis.* 2004;174(2):343-7. PMID: 15136065. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Shlipak MG, Browner WS, Noguchi H, et al. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction. *Am J Med.* 2001;110(6):425-33. PMID: 11331052. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Shufelt KA, Paradiso-Hardy FL, Papastergiou J, et al. High mortality with ST elevation myocardial infarction in a nontrial setting. *Can J Cardiol.* 2004;20(14):1455-9. PMID: 15614341. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sibbing D, von Beckerath O, von Beckerath N, et al. Plasminogen activator inhibitor-1 4G/5G

polymorphism and efficacy of reperfusion therapy in acute myocardial infarction. *Blood Coagul Fibrinolysis.* 2005;16(7):511-5. PMID: 16175011. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. *J Am Coll Cardiol.* 2001;37(1):81-8. PMID: 11153777. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Silva JC, Rochitte CE, Junior JS, et al. Late coronary artery recanalization effects on left ventricular remodelling and contractility by magnetic resonance imaging. *Eur Heart J.* 2005;26(1):36-43. PMID: 15615797. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Silva PR, Hueb WA, César LA, et al. [Comparative study of the results of coronary artery bypass grafting and angioplasty for myocardial revascularization in patients with equivalent multivessel disease]. *Arq Bras Cardiol.* 2005;84(3):214-21. PMID: 15867994. *Exclude - Non-English.*

Simes RJ, O'Connell RL, Aylward PE, et al. Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. *Am Heart J.* 2010;159(6):988-97. PMID: 20569711. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Singh M, Gersh BJ, McClelland RL, et al. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. *Circulation.* 2004;109(22):2727-31. PMID: 15173022. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Singh M, Gersh BJ, McClelland RL, et al. Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. *J Am Coll Cardiol.* 2005;45(2):198-203. PMID: 15653015. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Singh M, White J, Hasdai D, et al. Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. *J Am Coll Cardiol.* 2007;50(18):1752-8. PMID: 17964038. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Singh M, Williams BA, Gersh BJ, et al. Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the Prevention of Restenosis With Tranilast and its Outcomes (PRESTO) Trial. *J Am Coll Cardiol.* 2006;47(1):34-9. PMID: 16386661. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Singh SM, Alter DA. Is routine early invasive management of non-ST-segment elevation myocardial infarction beneficial in elderly patients? *CMAJ.* 2004;171(9):1046-7. PMID: 15546173. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sinkovic A, Marinsek M, Svensek F. Women and men with unstable angina and/or non-ST-elevation myocardial infarction. *Wien Klin Wochenschr.* 2006;118 Suppl 2(52-7). PMID: 16817045. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Sinkovic A, Pehnek Z. In-hospital mortality and treatment in elderly patients with ST-elevation myocardial infarction. *Journal fur Kardiologie.* 2005;12(11 12):282-284. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sinnaeve PR, Ezekowitz JA, Bogaerts K, et al. Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis. *Eur Heart J.* 2009;30(18):2213-9. PMID: 19586960. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Sleeper LA, Reynolds HR, White HD, et al. A severity scoring system for risk assessment of patients with cardiogenic shock: a report from the SHOCK Trial and Registry. *Am Heart J.* 2010;160(3):443-50. PMID: 20826251. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes*

*women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Soares PR, Hueb WA, Lemos PA, et al. Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II). *Circulation.* 2006;114(1 Suppl):I420-4. PMID: 16820611. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sobolev BG, Levy AR, Kuramoto L, et al. The risk of death associated with delayed coronary artery bypass surgery. *BMC Health Serv Res.* 2006;6(85). PMID: 16822309. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Solodky A, Assali AR, Behar S, et al. Anterior wall myocardial infarction in real world: does reperfusion strategy make any differences? *Catheter Cardiovasc Interv.* 2004;61(1):79-83. PMID: 14696164. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Solomon DH, Stone PH, Glynn RJ, et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. *J Am Coll Cardiol.* 2001;38(4):969-76. PMID: 11583866. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sorajja P, Gersh BJ, Cox DA, et al. Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial. *J Am Coll Cardiol.* 2010;55(14):1416-24. PMID: 20359590. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Spacek R, Widimsky P, Straka Z, et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open

multicenter randomized trial. The VINO Study. *Eur Heart J.* 2002;23(3):230-8. PMID: 11792138. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Spertus JA, Jones PG, Coen M, et al. Transmyocardial CO(2) laser revascularization improves symptoms, function, and quality of life: 12-month results from a randomized controlled trial. *Am J Med.* 2001;111(5):341-8. PMID: 11583635. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. *Circulation.* 2003;108(23):2851-6. PMID: 14623806. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Steg PG, Francois L, Iung B, et al. Long-term clinical outcomes after rescue angioplasty are not different from those of successful thrombolysis for acute myocardial infarction. *Eur Heart J.* 2005;26(18):1831-7. PMID: 15930039. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Steg PG, Kerner A, Mancini GB, et al. Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. *Circulation.* 2010;121(25):2724-30. PMID: 20547926. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Steg PG, Thuaire C, Himbert D, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. *Eur Heart J.* 2004;25(24):2187-94. PMID: 15589635. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Steigen TK, Buller CE, Mancini GB, et al. Myocardial perfusion grade after late infarct artery recanalization is associated with global and regional left ventricular function at one year: analysis from the

Total Occlusion Study of Canada-2. *Circ Cardiovasc Interv.* 2010;3(6):549-55. PMID: 21062997. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Steinhubl SR, Kastrati A, Berger PB. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary interventions and its impact on the apparent safety of antithrombotic drugs. *Am Heart J.* 2007;154(1):3-11. PMID: 17584547. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Stone GW, Teirstein PS, Rubenstein R, et al. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. *J Am Coll Cardiol.* 2002;39(10):1581-7. PMID: 12020483. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Stroupe KT, Morrison DA, Hlatky MA, et al. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. *Circulation.* 2006;114(12):1251-7. PMID: 16966588. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sutton AG, Campbell PG, Graham R, et al. One year results of the Middlesbrough early revascularisation to limit infarction (MERLIN) trial. *Heart.* 2005;91(10):1330-7. PMID: 16162629. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Sutton AG, Campbell PG, Graham R, et al. A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit Infarction (MERLIN) trial. *J Am Coll Cardiol.* 2004;44(2):287-96. PMID: 15261920. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Svensson L, Aasa M, Dellborg M, et al. Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with

abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial. *Am Heart J.* 2006;151(4):798 e1-7. PMID: 16569536. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Swahn E. Invasive strategy among women with Non-ST-Elevation Acute Coronary Syndrome. *ACC Cardiosource Review Journal.* 2007;16(10):29-30. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Szalma I, Kiss A, Kardos L, et al. Piracetam prevents cognitive decline in coronary artery bypass: a randomized trial versus placebo. *Ann Thorac Surg.* 2006;82(4):1430-5. PMID: 16996947. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Szczzech LA, Best PJ, Crowley E, et al. Outcomes of patients with chronic renal insufficiency in the bypass angioplasty revascularization investigation. *Circulation.* 2002;105(19):2253-8. PMID: 12010906. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Szygula-Jurkiewicz B, Zembala M, Wilczek K, et al. Health related quality of life after percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with acute coronary syndromes without ST-segment elevation. 12-Month follow up. *Eur J Cardiothorac Surg.* 2005;29(8):882-6. PMID: 15848330. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Tackett AH, Bailey AL, Foody JM, et al. Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: Insights from the GUSTO-III trial. *Am Heart J.* 2010;160(4):678-684. PMID: 20934562. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Takiuti ME, Hueb W, Hiscock SB, et al. Quality of life after surgical myocardial revascularization, angioplasty or medical treatment. *Arq Bras Cardiol.* 2007;88(5):537-44. PMID: 17589628. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Tamis-Holland J, Lu J, Korytkowski M, et al. Lack of Sex-Based Differences in Outcomes in Patients with Type 2 Diabetes and Coronary Artery Disease Treated with Contemporary Medical Therapy with or without Prompt Revascularization: A Report from BARI 2D. 59th Annual Scientific Session of the American College of Cardiology (ACC 2010). 2010. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

ten Berg JM, Kelder JC, Suttorp MJ, et al. Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study. *J Am Coll Cardiol.* 2001;38(4):1061-9. PMID: 11583883. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Teo KK, Sedlis SP, Boden WE, et al. Optimal medical therapy with or without percutaneous coronary intervention in older patients with stable coronary disease: a pre-specified subset analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) trial. *J Am Coll Cardiol.* 2009;54(14):1303-8. PMID: 19778673. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Teo KK, Sedlis SP, Boden WE, et al. Optimal Medical Therapy With or Without Percutaneous Coronary Intervention in Older Patients With Stable Coronary Disease. A Pre-Specified Subset Analysis of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation) Trial. *J Am Coll Cardiol.* 2009;54(14):1303-1308. PMID: 19778673. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Testa L, Van Gaal WJ, Bhindi R, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. *J Thorac Cardiovasc Surg.* 2008;136(4):884-93. PMID: 18954626. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Thiele H, Engelmann L, Elsner K, et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. *Eur Heart J.* 2005;26(19):1956-63. PMID: 16061501. *Exclude - Does not include outcome data reported in a gender-*

*specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Thiele H, Kappl MJ, Linke A, et al. Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. *Eur Heart J.* 2007;28(12):1433-9. PMID: 17556347. *Exclude - Does not include outcomes of interest.*

Thiele H, Neumann-Schriedewind P, Jacobs S, et al. Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. *J Am Coll Cardiol.* 2009;53(25):2324-31. PMID: 19539141. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Thiele H, Oettel S, Jacobs S, et al. Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: a 5-year follow-up. *Circulation.* 2005;112(22):3445-50. PMID: 16316966. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Thiele H, Scholz M, Engelmann L, et al. ST-segment recovery and prognosis in patients with ST-elevation myocardial infarction reperfused by prehospital combination fibrinolysis, prehospital initiated facilitated percutaneous coronary intervention, or primary percutaneous coronary intervention. *Am J Cardiol.* 2006;98(9):1132-9. PMID: 17056313. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Thomas SB, Sansing VV, Davis A, et al. Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial. *Am J Public Health.* 2010;100 Suppl 1(S269-76. PMID: 20147671. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. *Circulation.* 2005;112(13):2017-21. PMID: 16186438. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study*

*population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Timmer JR, Ottervanger JP, de Boer MJ, et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: results from the Primary Coronary Angioplasty vs Thrombolysis-2 trial. *Arch Intern Med.* 2007;167(13):1353-9. PMID: 17620527. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Timmer JR, Ottervanger JP, Thomas K, et al. Long-term, cause-specific mortality after myocardial infarction in diabetes. *Eur Heart J.* 2004;25(11):926-31. PMID: 15172464. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Tio RA, Tan ES, Jessurun GA, et al. PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. *J Nucl Med.* 2004;45(9):1437-43. PMID: 15347709. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Tjandrawidjaja MC, Fu Y, Goodman SG, et al. The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2. *Eur Heart J.* 2003;24(11):1024-34. PMID: 12788302. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Tornvall P, Johansson M, Herzfeld I, et al. [A controlled trial with prolonged follow up: percutaneous intervention in acute myocardial infarction is equivalent to thrombolytic therapy]. *Läkartidningen.* 200132-33):3397-9. PMID: 11526657. *Exclude - Non-English.*

Tricoci P, Lokhnygina Y, Berdan LG, et al. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. *Circulation.* 2007;116(23):2669-77. PMID: 18025532. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Trzos E, Kurpesa M, Forys J, et al. [Outcomes of primary coronary angioplasty, thrombolysis and pharmacological therapy for the management of acute myocardial infarction in elderly patients]. *Polski Przegląd Kardiologiczny.* 20053):219-26. *Exclude - Non-English.*

Türel B, Gemici K, Baran I, et al. Effects of glucose-insulin-potassium solution added to reperfusion treatment in acute myocardial infarction. *Anadolu Kardiyol Derg.* 20052):90-4. PMID: 15939681.



*Exclude - No data for OMT/PCI/CABG comparison of interest.*

Tygesen H, Wettervik C, Wennerblom B. Intensive home-based exercise training in cardiac rehabilitation increases exercise capacity and heart rate variability. *Int J Cardiol.* 2001;79(2-3):175-82. PMID: 11461739. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Udelson JE, Pearte CA, Kimmelstiel CD, et al. The Occluded Artery Trial (OAT) Viability Ancillary Study (OAT-NUC): influence of infarct zone viability on left ventricular remodeling after percutaneous coronary intervention versus optimal medical therapy alone. *Am Heart J.* 2011;161(3):611-21. PMID: 21392619. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Unger F, Serruys PW, Yacoub MH, et al. Revascularization in multivessel disease: comparison between two-year outcomes of coronary bypass surgery and stenting. *J Thorac Cardiovasc Surg.* 2003;125(4):809-20. PMID: 12698143. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Uriel N, Moravsky G, Blatt A, et al. Acute myocardial infarction with spontaneous reperfusion: clinical characteristics and optimal timing for revascularization. *Isr Med Assoc J.* 2007;9(4):243-6. PMID: 17491214. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Valeur N, Clemmensen P, Grande P, et al. Pre-discharge exercise test for evaluation of patients with complete or incomplete revascularization following primary percutaneous coronary intervention: a DANAMI-2 sub-study. *Cardiology.* 2008;109(3):163-71. PMID: 17726317. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Valeur N, Clemmensen P, Saunamaki K, et al. The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. *Eur Heart J.* 2005;26(2):119-27. PMID: 15618067. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

van der Sloot JA, Huikeshoven M, Tukkie R, et al. Transmyocardial revascularization using an XeCl

excimer laser: results of a randomized trial. *Ann Thorac Surg.* 2004;78(3):875-81; discussion 881-2. PMID: 15337012. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

van Dijk D, Nierich AP, Eefting FD, et al. The Octopus Study: rationale and design of two randomized trials on medical effectiveness, safety, and cost-effectiveness of bypass surgery on the beating heart. *Control Clin Trials.* 2000;21(6):595-609. PMID: 11146152. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

van Domburg RT, Sonnenschein K, Nieuwlaat R, et al. Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction. *J Am Coll Cardiol.* 2005;46(1):15-20. PMID: 15992629. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

van Domburg RT, Takkenberg JJ, Noordzij LJ, et al. Late outcome after stenting or coronary artery bypass surgery for the treatment of multivessel disease: a single-center matched-propensity controlled cohort study. *Ann Thorac Surg.* 2005;79(5):1563-9. PMID: 15854934. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

van Gaal WJ, Arnold JR, Testa L, et al. Myocardial injury following coronary artery surgery versus angioplasty (MICASA): a randomised trial using biochemical markers and cardiac magnetic resonance imaging. *EuroIntervention.* 2011;6(6):703-10. PMID: 21205592. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

van Rees Vellinga TE, Peters RJ, Yusuf S, et al. Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. *Am Heart J.* 2010;160(6):1049-55. PMID: 21146657. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. *Health Qual Life Outcomes.* 2006;4(20). PMID: 16563170. *Exclude - Does not include*

*outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

van 't Hof AW, de Vries ST, Dambrink JH, et al. A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes. Eur Heart J. 2003;24(15):1401-5. PMID: 12909068. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Vanasse A, Courteau J, Niyonsenga T. Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care. BMC Cardiovasc Disord. 2006;6(21). PMID: 16674817. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Venskutonyte L, Malmberg K, Norhammar A, et al. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes. J Intern Med. 2010;268(1):75-82. PMID: 20210844. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart. 1999;82(4):426-31. PMID: 10490554. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Vrachatis AD, Alpert MA, Georgulas VP, et al. Comparative efficacy of primary angioplasty with stent implantation and thrombolysis in restoring basal coronary artery flow in acute ST segment elevation myocardial infarction: quantitative assessment using the corrected TIMI frame count. Angiology. 2001;52(3):161-6. PMID: 11269778. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Wahrborg P. Quality of life after coronary angioplasty or bypass surgery. 1-year follow-up in the Coronary Angioplasty versus Bypass

Revascularization investigation (CABRI) trial. Eur Heart J. 1999;20(9):653-8. PMID: 10208785. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Wahrborg P, Booth JE, Clayton T, et al. Neuropsychological outcome after percutaneous coronary intervention or coronary artery bypass grafting: results from the Stent or Surgery (SoS) Trial. Circulation. 2004;110(22):3411-7. PMID: 15557380. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ward HB, Kelly RF, Thottapurathu L, et al. Coronary artery bypass grafting is superior to percutaneous coronary intervention in prevention of perioperative myocardial infarctions during subsequent vascular surgery. Ann Thorac Surg. 2006;82(3):795-800; discussion 800-1. PMID: 16928485. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Waters D. Comparison of aggressive lipid lowering with Atorvastatin vs. Revascularization Treatments (AVERT) and conventional care for the reduction of ischemic events in patients with stable coronary artery disease. Cardiovasc Rev Rep. 2000;21(1):26-31. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Watkins S, Thiemann D, Coresh J, et al. Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities. Am J Cardiol. 2005;96(10):1349-55. PMID: 16275176. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Webb JG, Lowe AM, Sanborn TA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol. 2003;42(8):1380-6. PMID: 14563578. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Webb JG, Sanborn TA, Sleeper LA, et al. Percutaneous coronary intervention for cardiogenic shock in the SHOCK Trial Registry. Am Heart J. 2001;141(6):964-70. PMID: 11376311. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

- Weintraub WS, Becker ER, Mauldin PD, et al. Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST). *Am J Cardiol.* 2000;86(7):747-52. PMID: 11018194. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Weintraub WS, Boden WE, Zhang Z, et al. Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. *Circ Cardiovasc Qual Outcomes.* 2008;1(1):12-20. PMID: 20031783. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Weintraub WS, Mahoney EM, Zhang Z, et al. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. *Heart.* 2004;90(7):782-8. PMID: 15201249. *Exclude - Does not include outcomes of interest.*
- Weintraub WS, Mauldin PD, Becker E, et al. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). *Circulation.* 1995;92(10):2831-40. PMID: 7586249. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. *N Engl J Med.* 2008;359(7):677-87. PMID: 18703470. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Weintraub WS, Wenger NK, Kosinski AS, et al. Percutaneous transluminal coronary angioplasty in women compared with men. *J Am Coll Cardiol.* 1994;24(1):81-90. PMID: 8006286. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Westerhout CM, Bonnefoy E, Welsh RC, et al. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. *Am Heart J.* 2011;161(2):283-90. PMID: 21315210. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Wexler LF, Blaustein AS, Lavori PW, et al. Non-Q-wave myocardial infarction following thrombolytic therapy: a comparison of outcomes in patients randomized to invasive or conservative post-infarct assessment strategies in the Veterans Affairs non-Q-wave Infarction Strategies In-Hospital (VANQWISH) Trial. *J Am Coll Cardiol.* 2001;37(1):19-25. PMID: 11153737. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Wharton TP, Jr., Grines LL, Turco MA, et al. Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI-No SOS study) versus transfer to surgical centers for primary angioplasty. *J Am Coll Cardiol.* 2004;43(11):1943-50. PMID: 15172395. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- White AJ, Kedia G, Mirocha JM, et al. Comparison of coronary artery bypass surgery and percutaneous drug-eluting stent implantation for treatment of left main coronary artery stenosis. *JACC Cardiovasc Interv.* 2008;1(3):236-45. PMID: 19463306. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial. *Circulation.* 2005;112(13):1992-2001. PMID: 16186436. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Widimsky P, Bilkova D, Penicka M, et al. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years' follow-up of the PRAGUE-2 Trial. *Eur Heart J.* 2007;28(6):679-84. PMID: 17298968. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

- Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. *Eur Heart J*. 2003;24(1):94-104. PMID: 12559941. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. *Eur Heart J*. 2000;21(10):823-31. PMID: 10781354. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. *Eur Heart J*. 2008;29(12):1495-503. PMID: 18441320. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Wijeysundera HC, You JJ, Nallamothu BK, et al. An early invasive strategy versus ischemia-guided management after fibrinolytic therapy for ST-segment elevation myocardial infarction: a meta-analysis of contemporary randomized controlled trials. *Am Heart J*. 2008;156(3):564-572, 572 e1-2. PMID: 18760142. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Winchester DE, Wen X, Xie L, et al. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. *J Am Coll Cardiol*. 2010;56(14):1099-109. PMID: 20825761. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Windhausen F, Hirsch A, Tijssen JG, et al. ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non-ST-elevation acute coronary syndromes A substudy of the Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) Trial. *J Electrocardiol*. 2007;40(5):408-15. PMID: 17604045. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*
- Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. *Circulation*. 2007;116(14):1540-8. PMID: 17848615. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Wong A, Mak KH, Chan C, et al. Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study. *Catheter Cardiovasc Interv*. 2004;62(4):445-52. PMID: 15274152. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. *Circulation*. 2002;106(2):202-7. PMID: 12105159. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Wong JA, Goodman SG, Yan RT, et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. *Eur Heart J*. 2009;30(5):549-57. PMID: 19201761. *Exclude - No data for OMT/PCI/CABG comparison of interest.*
- Wong SC, Sleeper LA, Monrad ES, et al. Absence of gender differences in clinical outcomes in patients with cardiogenic shock complicating acute myocardial infarction. A report from the SHOCK Trial Registry. *J Am Coll Cardiol*. 2001;38(5):1395-401. PMID: 11691514. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*
- Yamagata K, Kataoka Y, Kokubu N, et al. A 3-year clinical outcome after percutaneous coronary intervention using sirolimus-eluting stent and off-pump coronary artery bypass grafting for the treatment of diabetic patients with multivessel disease. *Circ J*. 2010;74(4):671-8. PMID: 20154406. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Yan AT, Yan RT, Cantor WJ, et al. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: Insights from the Trial of Routine ANgioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). *Eur Heart J*. 2011;32(16):1994-2002. PMID: 21307037. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Yan AT, Yan RT, Tan M, et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. *Arch Intern Med*. 2007;167(10):1009-16. PMID: 17533203. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Yan AT, Yan RT, Tan M, et al. Long-term prognostic value and therapeutic implications of continuous ST-segment monitoring in acute coronary syndrome. *Am Heart J*. 2007;153(4):500-6. PMID: 17383285. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Yan Q, Changsheng M, Shaoping N, et al. Percutaneous treatment with drug-eluting stent vs bypass surgery in patients suffering from chronic stable angina with multivessel disease involving significant proximal stenosis in left anterior descending artery. *Circ J*. 2009;73(10):1848-55. PMID: 19713656. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Yang SS, Li WM, Yin LL, et al. [Chronic effects of percutaneous transmyocardial laser revascularization in patients with refractory angina]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2007;39(1):51-4. PMID: 17386166. *Exclude - Non-English.*

Yang X, Alexander KP, Chen AY, et al. The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. *J Am Coll Cardiol*. 2005;46(8):1490-5. PMID: 16226173. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Yang YM, Zhu J, Tan HQ, et al. [Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases]. *Zhonghua Yi Xue Za Zhi*. 2005;87(2):2176-82. PMID: 16321179. *Exclude - Non-English.*

Yin L, Li GP, Liu T, et al. [Role of probucol in preventing contrast induced acute kidney injury after coronary interventional procedure: a randomized trial]. *Zhonghua Xin Xue Guan Bing Za Zhi*. 2009;41(3):385-8. PMID: 19781209. *Exclude - Non-English.*

Yip HK, Wu CJ, Chang HW, et al. Comparison of primary angioplasty and conservative treatment on short- and long-term outcome in octogenarian or older patients with acute myocardial infarction. *Jpn Heart J*. 2002;43(5):463-74. PMID: 12452304. *Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Yousef ZR, Redwood SR, Bucknall CA, et al. Late intervention after anterior myocardial infarction: effects on left ventricular size, function, quality of life, and exercise tolerance: results of the Open Artery Trial (TOAT Study). *J Am Coll Cardiol*. 2002;40(5):869-76. PMID: 12225709. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Yuval R, Halon DA, Lewis BS. Perceived disability and lifestyle modification following hospitalization for non-ST elevation versus ST elevation acute coronary syndromes: the patients' point of view. *Eur J Cardiovasc Nurs*. 2007;6(4):287-92. PMID: 17449324. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Zachorski M, Dziuk M, Pietrzykowski J, et al. [Left ventricular function in gated single photon emission computed tomography (GSPET) in patients with myocardial infarction subjected to thrombolysis or primary PTCA]. *Pol Merkur Lekarski*. 2005;10(6):376-9. PMID: 16161914. *Exclude - Non-English.*

Zeymer U, Gitt A, Junger C, et al. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction. *Thromb Haemost*. 2008;99(1):150-4. PMID: 18217147. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Zeymer U, Gitt A, Junger C, et al. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice. *Am J Cardiol*. 2006;98(1):19-22. PMID: 16784913. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Zeymer U, Schroder R, Machnig T, et al. Primary percutaneous transluminal coronary angioplasty accelerates early myocardial reperfusion compared to thrombolytic therapy in patients with acute

myocardial infarction. *Am Heart J.* 2003;146(4):686-91. PMID: 14564324. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. *J Am Coll Cardiol.* 2001;38(6):1644-50. PMID: 11704395. *Exclude - No data for OMT/PCI/CABG comparison of interest.*

Zeymer U, Uebis R, Vogt A, et al. Randomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte. *Circulation.* 2003;108(11):1324-8. PMID: 12939210. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zhang Q, Zhang RY, Zhang JS, et al. Outcomes of primary percutaneous coronary intervention for acute ST-elevation myocardial infarction in patients aged over 75 years. *Chin Med J (Engl).* 2006;119(14):1151-6. PMID: 16863605. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zhang Z, Kolm P, Boden WE, et al. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina. *Circ Cardiovasc Qual Outcomes.* 2011;4(2):172-82. PMID: 21304091. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zhang Z, Mahoney EM, Spertus JA, et al. The impact of age on outcomes after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: one-year results from the Stent or Surgery (SoS) trial. *Am Heart J.* 2006;152(6):1153-60. PMID: 17161069. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or*

*older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zhang Z, Spertus JA, Mahoney EM, et al. The impact of acute coronary syndrome on clinical, economic, and cardiac-specific health status after coronary artery bypass surgery versus stent-assisted percutaneous coronary intervention: 1-year results from the stent or surgery (SoS) trial. *Am Heart J.* 2005;150(1):175-81. PMID: 16084166. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zhao XQ, Kosinski AS, Barnhart HX, et al. Prediction of native coronary artery disease progression following PTCA or CABG in the Emory Angioplasty Versus Surgery Trial. *Med Sci Monit.* 2003;9(2):CR48-54. PMID: 12601286. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Ziegelstein RC, Hilbe JM, French WJ, et al. Magnesium use in the treatment of acute myocardial infarction in the United States (observations from the Second National Registry of Myocardial Infarction). *Am J Cardiol.* 2001;87(1):7-10. PMID: 11137825. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zijlstra F, Beukema WP, van 't Hof AW, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. *J Am Coll Cardiol.* 1997;29(5):908-12. PMID: 9120174. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. *N Engl J Med.* 1993;328(10):680-4. PMID: 8433726. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zijlstra F, Hoorntje JC, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med.* 1999;341(19):1413-9. PMID:

10547403. *Exclude - Does not include outcome data reported in a gender-specific fashion for a study population that includes women 18 or older with angiographically proven CAD w/ STEMI, NSTEMI, or stable CAD.*

Zijlstra F, Patel A, Jones M, et al. Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. *Eur Heart J.* 2002;23(7):550-7. PMID: 11922645.

*Exclude - Study type is not RCT, prospective or retrospective observational study, or registry.*

Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. *Am J Cardiol.* 2002;90(5):533-6. PMID: 12208418.

*Exclude - No data for OMT/PCI/CABG comparison of interest.*

## Appendix F. Summary Tables for Sex-Specific Clinical Outcomes

Table F-1. Summary of RCTs reporting clinical outcomes for STEMI (KQ 1)

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>CARESS-in-AMI</b> <b>Di Mario et al., 2008<sup>1</sup></b>  and  <b>Di Mario et al., 2004<sup>2</sup></b>	STEMI	Fibrinolysis (reteplase) plus immediate PCI vs. fibrinolysis (reteplase) plus rescue PCI	Total: 600 Women: 128 (21%)	<u>1) Composite outcome</u> (total mortality/reinfarction/refractory MI within 30 days) HR (95%CI) Women: 0.4 (0.12 to 1.31) Men: 0.39 (0.18 to 0.85) Overall: 0.40 (0.21 to 0.76)  <u>2) Cumulative event rate</u> (total mortality/reinfarction/refractory MI within 30 days) Women: 6.2 vs. 14.5 Men: 3.9 vs. 9.7 Overall: 4.4 vs. 10.7	Good



Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<p><b>DANAMI-2</b> <b>Andersen et al., 2003<sup>3</sup></b></p> <p><b>and</b></p> <p><b>Mortensen et al., 2007<sup>4</sup></b> <b>Nielsen et al., 2010<sup>5</sup></b> <b>Busk et al., 2009<sup>6</sup></b> <b>Busk et al., 2008<sup>7</sup></b></p>	STEMI	Primary PCI vs. fibrinolysis (accelerated t-PA)	Total: 1,572 Women: 417 (27%)	<p><u>1) Composite outcome</u> (total mortality/nonfatal MI/stroke) <b>30 days OR (95% CI)</b> Women: 0.47 (0.27 to 0.81) Men: 0.59 (0.39 to 0.90) Overall: 0.55 (0.39 to 0.76)</p> <p><b>3 years HR (95% CI)</b> Women: 0.62 (0.42 to 0.90) Men: 0.81 (0.63 to 1.04) Overall: 0.74 (0.60 to 0.92)</p> <p><b>Median 7.8 years HR (95% CI)</b> Women: 0.73 (0.53 to 0.99) Men: 0.80 (0.66 to 0.97) Overall: 0.78 (0.66 to 0.92)</p> <p><u>2) Angina</u> (angina/recurrent symptoms/refractory angina/refractory MI) <b>30 days</b> Women: 25.3% vs. 30.7% Men: 18.8% vs. 26.4%</p> <p><b>1 year</b> Women: 18.5% vs. 21.3% Men: 15.5% vs. 17.6%</p> <p><u>3) General health SF-36</u> <b>30 days</b> Women: 62 vs. 61.1 Men: 69.2 vs. 65.1</p> <p><b>1 year</b> Women: 61.5 vs. 66.4 Men: 68.2 vs. 63.1</p>	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>Dobrzycki et al., 2007<sup>8</sup></b>	STEMI	Fibrinolysis (streptokinase) onsite vs. tirofiban plus transfer for primary PCI	Total: 401 Women: 105 (26%)	<p><u>1) Composite outcome (total mortality/nonfatal MI/stroke):</u>  <b>30 days RR (95% CI)</b>  Women: 2.04 (0.85 to 4.90)  Men: 1.79 (0.85 to 3.79)  Overall: 1.95 (1.1 to 3.45)</p> <p><b>1 year</b>  Women: 2.48 (1.06 to 5.79)  Men: 1.61 (0.92 to 2.85)  Overall: 1.88 (1.18 to 3.00)</p> <p><u>2) Total mortality</u>  <b>30 days RR (95% CI)</b>  Women: 2.19 (0.73 to 6.53)  Men: 1.41 (0.50 to 3.96)  Overall: 1.81 (0.86 to 3.82)</p> <p><b>1 year</b>  Women: 2.41 (0.82 to 7.07)  Men: 1.48 (0.68 to 3.22)  Overall: 1.79 (0.96 to 3.35)</p>	Good
<b>GUSTO II-B Tamis-Holland et al., 2004<sup>9</sup></b>	STEMI	PCI vs. fibrinolysis (accelerated t-PA)	Total: 1,137 Women: 260 (23%)	<p><u>1) Composite outcome (30-day):</u>  (total mortality/nonfatal MI/nonfatal disabling stroke) OR (95% CI)  Women: 0.685 (0.36 to 1.32)  Men: 0.562 (0.35 to 0.91)  Overall: 0.67 (0.47 to 0.97)</p> <p><u>2) Total mortality (30-day)</u>  Women: 10.9% vs. 11.6%  Men: 4% vs. 5.8%</p> <p><u>3) Nonfatal MI (30-day):</u>  Women: 6.5% vs. 6.6%  Men: 3.8% vs. 6.4%</p> <p><u>4) Nonfatal disabling stroke (30-day):</u>  Women: 0 vs. 2.5%  Men: 0.2% vs. 0.4%</p>	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>Minai et al., 2002<sup>10</sup></b>	STEMI age ≥ 80 years	PCI vs. conservative/supportive medical therapy (without fibrinolysis)	Total: 120 Women: 60 (50%)	<p><u>Composite outcome</u> (total mortality/heart failure/repeat MI/stroke) <b>3 years</b> 46 of the PCI subjects vs. 31 of the no PCI subjects; p = 0.06</p> <p>Multivariate analysis was done to look at factors associated with the composite endpoint in the overall study (i.e., not treatment specific) and found that male gender was NOT a factor significantly associated with outcome in the overall population.</p>	Fair
<b>PAMI Stone et al., 1995<sup>11</sup></b>	STEMI	PCI vs. fibrinolysis (t-PA)	Total: 395 Women: 107 (27%)	<p><u>1) In-hospital death or reinfarction</u> Women: 6% vs. 17.5%; p = 0.07 Men: 4.8% vs. 9.8%; p = 0.11 Overall: 5.1% vs. 12%; p=0.02</p> <p><u>2) In-hospital total mortality</u> Women: 4.0% vs. 14%; p = 0.07 Men: 2.1% vs. 3.5%; p = 0.46</p> <p><u>3) In-hospital nonfatal MI</u> Women: 2.0% vs. 3.5%; p = 0.64 Men: 2.8% vs. 7.7%; p = 0.06</p> <p><u>4) In-hospital recurrent ischemia</u> Women: 16% vs. 28.1%; p = 0.14 Men: 8.2% vs. 28%; p = 0.001</p> <p><u>5) In-hospital stroke</u> Women: 0 vs. 5.3%; p = 0.10 Men: 0 vs. 2.8%; (p = 0.04</p> <p><u>6) Length of stay</u> Women: 7.8 ± 3.4 days vs. 8.5 ± 4.1 days; p = 0.34 Men: 7.4 ± 3.3 days vs. 8.3 ± 4.8 days; p = 0.05</p>	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>SHOCK</b> <b>Hochman et al., 2001</b> <sup>12</sup>  <b>and</b>  <b>Hochman et al., 2006</b> <sup>13</sup> <b>Hochman et al., 1999</b> <sup>14</sup> <b>Hochman et al., 1999</b> <sup>15</sup>	STEMI	Early revascularization (PCI or CABG within 6 hours) vs. initial medical stabilization (thrombolysis, IABP)	Total: 302 Women: 97 (32%)	Relative risk (95% CI) for death at 1 year with early revascularization vs. initial medical stabilization: 0.72 (0.54 to 0.95)  There was no interaction between treatment effect and sex.	Good

Abbreviations: BMS = bare metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; CI = confidence interval; DES = drug-eluting stent; HR = hazard ratio; IABP = intra-aortic balloon pump; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial; RR = relative risk; UA = unstable angina

**Table F-2. Summary of RCTs reporting clinical outcomes for UA/NSTEMI (KQ 2)**

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<p><b>FRISC II</b> Lagerqvist et al., 2001<sup>16</sup></p> <p>and</p> <p>Lagerqvist et al., 2006<sup>17</sup> Wallentin et al., 2000<sup>18</sup> Anonymous, 1999<sup>19</sup></p>	<p>UA/NSTEMI</p>	<p>Early invasive treatment with revascularization vs. initial conservative strategy</p>	<p>Total: 2,457 Women: 749 (30%)</p>	<p><u>Primary endpoint</u> (death/MI or both) <b>6 months</b> RR (95% CI) Invasive vs. conservative Women: 1.26 (0.80 to 1.97) Men: 0.64 (0.49 to 0.84) Overall: 0.78 (0.62 to 0.98); p = 0.031</p> <p><b>1 year</b> Women: 12.4% vs. 10.5%; p = not significant Men: 9.6% vs. 15.8%; p &lt; 0.001 Overall: 0.74 (0.60 to 0.92); p = 0.005 Interaction by sex: p = 0.008 (significant) OR (95% CI) 0.91 (0.68 to 1.22) for effect of women on primary endpoint adjusted for treatment group</p> <p>Women did not benefit from early invasive strategy partly because of higher mortality related to CABG.</p> <p><b>5 years</b> OR (95% CI) Women: 1.12 (0.83 to 1.50) Men: 0.70 (0.59 to 0.86) Overall: 0.81 (0.69 to 0.95); p = 0.009 Interaction by sex p = 0.010 (significant)</p>	<p>Good</p>
<p><b>GUSTO IV-ACS</b> Ottervanger et al., 2004<sup>20</sup></p>	<p>NSTEMI  Acute coronary syndrome</p>	<p>Revascularization within 30 days (early invasive) vs. initial conservative strategy</p>	<p>Total: 7,800 Women: 2896 (37%)</p>	<p><u>Death, 1 year</u> Women: adjusted HR (95% CI) 0.53 (0.28 to 1.00) Men: adjusted HR (95% CI) 0.55 (0.35 to 0.85) Overall: adjusted RR (95% CI) 0.53 (0.37 to 0.77)</p>	<p>Good</p>

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>ICTUS</b> <b>de Winter et al., 2005<sup>21</sup></b>  <b>and</b>  <b>Damman et al., 2010<sup>22</sup></b>	NSTEMI-acute coronary syndrome	Early invasive therapy with revascularization vs. selective invasive strategy (initial conservative)	Total: 1,200 Women: 320 (27%)	<p><u>1) Death/MI/rehospitalization for angina</u>  <b>1 year</b>            Early invasive vs. selective            Total: RR (95% CI) 1.07 (0.87 to 1.33); p = 0.33            No significant difference among sex groups</p> <p><u>2) Death/spontaneous MI</u>  <b>5 years HR (95% CI)</b>            Women: 0.87 (0.53 to 1.43); p = 0.59            Men: 1.22 (0.87 to 1.71); p = 0.24            Overall: 1.10 (0.83 to 1.45); p = 0.52</p>	Good
<b>RITA-2</b> <b>Anonymous, 1997<sup>23</sup></b>	UA/stable CAD (no recent MI)	Early invasive therapy with PCI (PTCA) vs. initial conservative	Total: 1,018 Women: 183 (8%)	<p><u>1) Death/MI</u>  <b>Median followup of 2.7 years</b>            PTCA vs. optimal medical therapy            Total: RR (95% CI) 1.92 (1.08 to 3.41); p = 0.02            No significant interaction by sex</p> <p><u>2) Secondary outcomes</u>  <b>Angina grade 2+ at 6 months</b>            Women: 22.8% vs. 39.8%            Men: 20.5% vs. 31.4%</p> <p><u>3) Exercise time</u>  <b>6 months mean (SE)</b>            Women: 6.72 (0.25) vs. 6.52 (0.26);            Men: 9.34 (0.13) vs. 8.90 (0.15)</p>	Fair



Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
RITA-3 (continued)				<p><b>High risk</b> Women: 11.7% vs. 8.2% Men: 10.3% vs. 17.9%</p> <p>Women in moderate- or high-risk TIMI groups had higher event rate in early invasive arm</p> <p>Men in moderate- or high-risk TIMI groups had benefit from early invasive therapy</p>	
<p><b>TACTICS TIMI-18</b> <b>Cannon et al., 2001<sup>26</sup></b></p> <p><b>and</b></p> <p><b>Glaser et al., 2002<sup>27</sup></b> <b>Cannon et al., 1998<sup>28</sup></b></p>	UA./NSTEMI	Early invasive (PCI) vs. initial conservative	Total: 2,220 Women: 757 (34%)	<p><u>1) Primary endpoint</u> (death/MI/rehospitalization for acute coronary syndrome) Early invasive vs. initial conservative <b>6 months</b> Adjusted OR (95% CI) Women: 0.72 (0.47 to 1.11) Men: 0.64 (0.47 to 0.88) Overall: 0.78 (0.62 to 0.97)</p> <p><u>2) Secondary outcomes</u> (death/MI) Early invasive vs. initial conservative <b>6 months</b> Adjusted OR (95% CI) Women: 0.45 (0.24 to 0.88) Men: 0.68 (0.43 to 1.05) Overall: 0.74 (0.54 to 1.00); p &lt; 0.05</p> <p><u>3) Death</u> Early invasive vs. initial conservative <b>6 months</b> Adjusted OR (95% CI) Women: 0.94 (0.37 to 2.44) Men: 0.75 (0.36 to 1.56)</p> <p>Women less likely to undergo CABG even after adjustment for 3-vessel and left main disease</p>	Good



Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>TIMI III-B</b> <b>Anonymous, 1994<sup>29</sup></b>  <b>and</b>  <b>Anderson et al., 1995<sup>30</sup></b>	UA/NSTEMI	Early invasive vs. initial conservative	Total: 1,425 Women: 497 (35%)	<u>1) Primary endpoint</u> (death/MI/failed symptom-limited exercise treadmill test) <b>6 weeks</b> Overall: 16.2% vs. 18.1%; p = 0.33  <u>2) Secondary outcomes</u> (death/MI) Early invasive vs. initial conservative <b>6 weeks</b> Women: 6.1% vs. 8.9%; p = 0.24 Men: 7.8% vs. 7.3%; p = 0.73  <b>1 year</b> Women: 9.7% vs. 15.4%; p = 0.06 Men: 11.3% vs. 10.6%; p = 0.68 Overall: 10.8% vs. 12.2%; p = 0.42 No interaction by sex	Good

Abbreviations: CABG = coronary artery bypass graft; CAD = coronary artery disease; CI = confidence interval; HR = hazard ratio; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial; RR = risk ratio; SD = standard deviation; SE = standard error; t-PA = tissue plasminogen activator; UA = unstable angina

**Table F-3. Summary of RCTs reporting clinical outcomes for stable angina (KQ 3 Strategy 1—revascularization vs. optimal medical therapy)**

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<p><b>Allen et al., 2004<sup>31</sup></b>  and  <b>Allen et al., 1999<sup>32</sup></b></p>	Stable angina	Surgical revascularization (CABG with transmyocardial revascularization) vs. optimal medical therapy	Total: 222 Women: 61 (27%)	<p>1) <u>Death</u> <b>5.7 years</b> (SD 0.8) Men: OR (95% CI) 1.4 (0.4 to 5.0); p = 0.63</p> <p>2) <u>Angina relief</u> <b>5.7 years</b> (SD 0.8) Men: OR (95% CI) 1.1 (0.7 to 1.8); p = 0.41</p>	Good
<p><b>COURAGE</b> <b>Boden et al., 2007<sup>33</sup></b>  and  <b>Mancini et al., 2009<sup>34</sup></b> <b>Boden et al., 2006<sup>35</sup></b></p>	Stable angina	PCI (type not specified) or CABG if PCI failed vs. optimal medical therapy	Total: 2,287 Women: 338 (15%)	<p>1) <u>Death/MI</u> <b>4.6 years (median followup)</b> PCI vs. optimal medical therapy: Women: 18% vs. 26% Men: 19% vs. 18% p = 0.03</p> <p>Women: HR (95% CI) 0.65 (0.40 to 1.06) Men: HR (95% CI) 1.15 (0.93 to 1.42) Overall: HR (95%CI) 1.05 (0.87 to 1.27)</p>	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>MASS II</b> <b>Hueb et al., 2010<sup>36</sup></b>  <b>and</b>  <b>Hueb et al., 2004<sup>37</sup></b> <b>Hueb et al., 2007<sup>38</sup></b>	Stable angina with multiple-vessel CAD	PCI vs. Optimal medical therapy  CABG vs. optimal medical therapy	Total: 611 Women: 196 (32%)	<u>Primary endpoint</u> (death/MI/angina requiring mechanical revascularization) <b>10 years</b> Adjusted HR (95% CI)  Women: Optimal medical therapy vs. PCI: 1.57 (1.01 to 2.46); p = 0.047(favoring PCI)  CABG vs. optimal medical therapy: 0.43 (0.26 to 0.72); p = 0.001  Men: Optimal medical therapy vs. PCI: 1.13 (0.84 to 1.53); p = 0.410  CABG vs. optimal medical therapy: 0.43 (0.31 to 0.60); p = 0.001  Overall: PCI vs. optimal medical therapy: 0.79 (0.62- 1.01) CABG vs. optimal medical therapy: 0.43 (0.32 to 0.58) p < 0.001	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>OAT</b> <b>Hochman et al., 2006</b> <sup>39</sup>  <b>and</b>  <b>Hochman et al., 2005</b> <sup>40</sup> <b>Hochman et al., 2011</b> <sup>41</sup>	Stable angina	PCI (or CABG if PCI failed) vs. optimal medical therapy	Total: 2,166 Women: 476 (22%)	<u>Primary endpoint</u> (death/MI/heart failure) <b>4 years</b> PCI vs. optimal medical therapy: Women: 18.3% vs. 22.9% Men: 16.8% vs. 13.5% p = 0.13  Women: HR < 1.0 (favoring PCI, but not significant) Men: HR > 1.0 (favoring optimal medical therapy, but not significant) Overall: HR 0.43 (0.32 to 0.56)  <b>7 years</b> PCI vs. optimal medical therapy: Women: 25.5% vs. 28.6%; HR 0.89 (0.62 to 1.28) Men: 21.3% vs. 21.3%; HR 1.11 (0.89 to 1.39) p = 0.31	Good
<b>STICH</b> <b>Velazquez et al., 2011</b> <sup>42</sup>  <b>and</b>  <b>Velazquez et al., 2007</b> <sup>43</sup>	Stable angina	CABG vs. optimal medical therapy	Total: 1,212 Women: 148 (12%)	<u>Death</u> <b>5 years</b> HR (95% CI) Women: 0.75 (0.42 to 1.31) Men: 0.87 (0.72 to 1.06) Overall: 0.86 (0.72 to 1.04) p = 0.61	Good

Abbreviations: BMS = bare metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; CI = confidence interval; DES = drug-eluting stent; HR = hazard ratio; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial; SD = standard deviation; UA = unstable angina

**Table F-4. Summary of RCTs reporting clinical outcomes for stable/unstable angina (KQ 3 Strategy 2–PCI vs. CABG)**

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<p><b>ARTS I</b>  <b>Vaina et al., 2009<sup>44</sup></b></p> <p><b>and</b></p> <p><b>van den Brand, et al., 2002<sup>45</sup></b>  <b>Serruys et al., 1999<sup>46</sup></b>  <b>Voudris et al., 2006<sup>47</sup></b>  <b>Anonymous, 1999<sup>48</sup></b></p>	<p>Unstable angina</p>	<p>PCI (BMS) vs. CABG</p>	<p>Total: 1,205                      Women: 283 (23%)</p>	<p><u>1) Composite outcome</u>                      (death/CVA/MI/CABG/repeat PCI)</p> <p><b>30 days</b>                      Women: PCI 13.0% vs. CABG 8.3%                      Men: PCI 8.0% vs. CABG 5.7%</p> <p><b>1 year</b>                      Women: PCI 29.0% vs. CABG 14.5%                      Men: PCI 25.8% vs. CABG 10.7%</p> <p><b>3 years</b>                      Women: PCI 35.5% vs. CABG 19.3%                      Men: PCI 33.5% vs. CABG 15.1%</p> <p><u>2) Composite death/CVA</u></p> <p><b>30 days</b>                      Women: PCI 4.3% vs. CABG 4.8%                      Men: PCI 1.9% vs. CABG 1.5%</p> <p><b>1 year</b>                      Women: PCI 8.0% vs. CABG 7.6%                      Men: PCI 3.5% vs. CABG 3.5%</p> <p><b>3 years</b>                      Women: PCI 10.9% vs. CABG 9.7%                      Men: PCI 5.8% vs. 5.9%</p>	<p>Good</p>

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
ARTS I (continued)				<p><u>3) Composite death/MI/CVA</u>  <b>30 days</b>  Women: PCI 7.2% vs. 6.9%  Men: PCI 4.5% vs. 5.0%</p> <p><b>1 year</b>  Women: PCI 11.6% vs. 11.0%  Men: PCI 8.9% vs. CABG 7.0%</p> <p><b>3 years</b>  Women: PCI 14.5% vs. CABG 14.5%  Men: PCI 12.3% vs. CABG 9.6%</p> <p><u>4) Death—5 years</u>  PCI: women 7.4% vs. men 9.0%; p = 0.29  CABG: women 7.2% vs. men 10.1%; p = 0.48</p> <p>PCI: OR (95% CI) 1.1 (0.5 to 2.8); p = 0.86  CABG: OR (95% CI) 1.4 (0.5 to 4.1); p = 0.54</p> <p><u>5) MI—5 years</u>  PCI: OR (95% CI) 1.4 (0.7 to 3.2); p = 0.44  CABG: OR (95%CI) 0.6 (0.3 to 1.3); p = 0.17</p> <p><u>6) CVA—5 years</u>  PCI: OR (95% CI) 0.8 (0.3 to 2.2); p = 0.58  CABG: OR (95%CI) 0.6 (0.3 to 1.9); p = 0.39</p> <p><u>7) Revascularization—5 years</u>  PCI: OR (95% CI) 1.0 (0.6 to 1.5); p = 0.92  CABG: OR (95%CI ) 0.7 (0.4 to 1.4); p = 0.32</p>	
ARTS I (continued)				<p><u>8) Composite death/MI/CVA</u>  Men vs. women  PCI: OR (95% CI) 1.2 (0.7 to 1.2); p = 0.57  CABG: OR (95%CI) 0.8 (0.5 to 1.5); p = 0.57</p> <p><u>9) Composite MI/CVA/PTCA</u>  Men vs. women  PCI : OR (95% CI) 0.9 (0.6 to 1.4); p = 0.77  CABG : OR (95% CI) 0.8 (0.5 to 1.3); p = 0.38</p>	

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
ARTS I (continued)				<p><u>10) In-hospital outcomes</u>  PCI: OR 95% CI 0.6 (0.3 to 1.2); p = 0.14  CABG: OR 95%CI 1.8 (0.7 to 6.2); p = 0.29</p> <p><u>11) In-hospital MI</u>  PCI: OR 95% CI 0.7 (0.2 to 2.6); p = 0.58  CABG: OR 95%CI 1.2 (0.4 to 4.3); p = 0.72</p> <p><u>12) In-hospital CVA</u>  PCI: OR 95% CI 0.6 (0.1 to 12.5); p = 0.65  CABG: OR 95%CI 1.8 (0.3 to 34.9); p = 0.57</p> <p><u>13) Quality of life—3 years</u>  Euro-QoL summary:  PCI: Men 86 ± 16 vs. women 83 ± 19  P = 0.08</p> <p>CABG: Men 86 ± 20 vs. women 82 ± 20  P = 0.02</p> <p><u>14) Composite outcome</u>  (death/CVA/MI/CABG/repeat CABG)  <b>5 years</b>  Men vs. women  PCI: OR (95%CI) 0.9 (0.6 to 1.4); p = 0.77  CABG: OR (95%CI) 0.8 (0.5 to 1.3) p = 0.38</p>	

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
ARTS I (continued)				<p>15) <u>Individual outcomes</u>  <b>30 days</b>  Death:  Women: PCI 2.9% vs. CABG 4.1%  Men: PCI 1.3% vs. CABG 0.4%</p> <p>CVA:  Women: PCI 2.2% vs. CABG 0.7%  Men: PCI 0.6% vs. CABG 1.1%</p> <p>MI:  Women: PCI 3.6% vs. CABG 4.1%  Men: PCI 3.2% vs. CABG 3.7%</p> <p>Revascularization:  Women: PCI 7.2% vs. CABG 1.4%  Men: PCI 5.2% vs. CABG 0.7%</p> <p>Major cardiovascular adverse event- free survival:  Women: PCI 87.0% vs. CABG 91.7%  Men: PCI 92.0% vs. CABG 94.3%</p>	



Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
ARTS I (continued)				<p><b>1 year</b></p> <p>Death: Women: PCI 5.8% vs. CABG 6.2% Men: PCI 1.7% vs. CABG 1.5%</p> <p>CVA: Women: PCI 2.9% vs. CABG 2.1% Men: PCI 1.7% vs. CABG 2.0%</p> <p>MI: Women: PCI 5.1% vs. CABG 5.5% Men: PCI 6.1% vs. CABG 3.7%</p> <p>Revascularization: Women: PCI 20.3% vs. CABG 4.1% Men: PCI 21.2% vs. CABG 4.2%</p> <p>Major cardiovascular adverse event- free survival: Women: PCI 71.0% vs. CABG 85.5% Men: PCI 74.2% vs. CABG 89.3%</p>	
ARTS I (continued)				<p><b>3 years</b></p> <p>Death: Women: PCI 7.2% vs. CABG 6.9% Men: PCI 3.0% vs. CABG 3.5%</p> <p>CVA: Women: PCI 4.3% vs. CABG 4.1% Men: PCI 3.0% vs. CABG 2.8%</p> <p>MI: Women: PCI 5.8% vs. CABG 7.6% Men: PCI 7.1% vs. CABG 4.2%</p> <p>Revascularization: Women: PCI 24.6% vs. CABG 6.2% Men: PCI 26.8% vs. CABG 6.6%</p> <p>Major cardiovascular adverse event- free survival: Women: PCI 64.5% vs. CABG 80.7% Men: PCI 66.5% vs. CABG 84.9%</p>	

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<p><b>BARI</b> <b>Jacobs et al., 1998</b><sup>49</sup></p> <p><b>and</b></p> <p><b>Gibbons et al., 2001</b><sup>50</sup> <b>Anonymous, 2007</b><sup>51</sup> <b>Lombardero et al., 2002</b><sup>52</sup> <b>Anonymous, 2000</b><sup>53</sup> <b>Hlatky et al., 1995</b><sup>54</sup> <b>Rogers et al., 1995</b><sup>55</sup> <b>Sutton-Tyrrell et al., 1998</b><sup>56</sup> <b>Mullany et al., 1999</b><sup>57</sup> <b>Anonymous, 1996</b><sup>58</sup></p>	<p>Stable/unstable angina</p> <p>Diabetics</p>	<p>PCI (type not specified) vs. CABG</p>	<p>Total: 915 Women: 249 (27%)</p>	<p><u>1) 5-year cumulative survival rate</u> Women: PCI 86.3% vs. CABG 89.3% Men: PCI 86% vs. CABG 89%</p> <p>Survival free of MI: Women: PCI 74% vs. CABG 76%</p> <p>In-hospital death: PCI 1.1% vs. CABG 1.3% Women: PCI 0.8% vs. CABG 1.3% Men: PCI 1.2% vs. CABG 1.4%</p> <p>Q-waves MI: Women : PCI 1.2% vs. CABG 4.7% Men : PCI 2.4% vs. CABG 4.6%</p> <p>Congestive heart failure: Women: PCI 4.8% vs. CABG 9.8% Men: PCI 1.4% vs. CABG 1.8%</p> <p><u>2) 7-year survival rate</u> Women: PCI 79.2% vs. CABG 82.6% Men: PCI 81.6% vs. CABG 85.1%</p>	<p>Good</p>
<p><b>BARI (continued)</b></p>				<p><u>3) 10-year survival rate</u> Women: PCI 70.2% vs. CABG 67.8% Men: PCI 71.3% vs. CABG 75.5%</p> <p><u>4) 4-year angina status</u> Women: PCI 23.3% vs. CABG 18.8% Men: PCI 19.7% vs. CABG 13.2%</p> <p>At 5 years, anginal status was not significantly different between men and women</p> <p><u>5) Repeat revascularization</u> CABG: Women RR 1.74 p = 0.043 PCI: Women RR 0.74 p = 0.011</p> <p>Women were less likely than men to undergo repeat revascularization with an initial strategy of CABG compared with PTCA (11.2% vs. 51.9%, respectively; p &lt; 0.001)</p>	

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>CABRI</b> <b>Anonymous, 1995</b> <sup>59</sup>	Stable/unstable angina with multiple-vessel disease	PCI (PTCA) vs. CABG	Total: 1,054 Women: 234 (22%)	<p><u>1) Primary endpoint of mortality, 1 year</u> PTCA 3.9% vs. CABG 2.7% RR 95%CI 1.42 (0.731 to 2.74); p = 0.297</p> <p>Women had higher risk of 1-year mortality RR (95% CI) 2.07 (1.07 to 4.01); p=0.031</p> <p><u>2) Angina, 1 year</u> PTCA 13.9% vs. CABG 10.1% RR (95% CI) 1.54 (1.09 to 2.16) Women: 3.12 (1.41 to 6.54) p = 0.002 Men: 1.25 (0.85 to 1.85); p = 0.256</p> <p><u>3) Crude absolute risk of angina, 1 year</u> PTCA Women: 0.214 Men: 0.131</p> <p>CABG Women: 0.069 Men: 0.104</p>	Good
<b>CARDia</b> <b>Kapur et al., 2010</b> <sup>60</sup>  <b>and</b>  <b>Kapur et al., 2005</b> <sup>61</sup>	UA/NSTEMI  Stable angina  Diabetic  Multiple-vessel disease or complex single lesion	PCI (BMS or DES) vs. CABG	Total: 510 Women: 132 (26%)	<p><u>1) Primary endpoint, 1 year</u> (death/MI/stroke) HR (95%CI) Women: 2.13 (0.68 to 6.68) Men: 1.07 (0.59 to 1.93) Overall: 1.25 (0.75 to 2.09)</p> <p><u>2) Secondary endpoint, 1 year</u> (death/MI/stroke/repeat revascularization) HR (95%CI) Women: 2.4 (0.87 to 6.61) Men: 1.62 (0.95 to 2.74) Overall: 1.77 (1.11 to 2.09)</p>	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>EAST</b> <b>King et al., 2000</b> <sup>62</sup>  <b>and</b>  <b>King et al., 1995</b> <sup>63</sup> <b>King et al., 1994</b> <sup>64</sup> <b>Zhao et al., 1996</b> <sup>65</sup>	Stable angina with multiple-vessel disease	PCI (type not specified) vs. CABG	Total: 392 Women: 103 (26%)	<u>Single outcome survival</u> <b>3 years</b> CABG 93.8% vs. PTCA 92.9%  <b>8 years</b> CABG 82.7% vs. PTCA 79.3%  Comparisons were made for other baseline variables including sex, and no survival differences by treatment assignment were seen	Good
<b>GABI</b> <b>Kaehler et al., 2005</b> <sup>66</sup>  <b>and</b>  <b>Hamm et al., 1994</b> <sup>67</sup>	Stable angina	PCI (type not specified) vs. CABG	Total: 359 Women: 66 (18%)	<u>Death</u> <b>13 years</b> No significant sex differences in hazard ratio for death	Good
<b>MASS II</b> <b>Hueb et al., 2010</b> <sup>36</sup>  <b>and</b>  <b>Hueb et al., 2004</b> <sup>37</sup> <b>Hueb et al., 2007</b> <sup>38</sup>	Stable angina with multiple-vessel coronary artery disease	PCI (type not specified) vs. CABG	Total: 611 Women: 196 (32%)	<u>Primary endpoint</u> (death/MI/angina requiring mechanical revascularization) <b>10 years</b> Adjusted HR (95% CI)  Women: CABG vs. PCI: 0.68 (0.40 to 1.15); p = 0.015  Men: CABG vs. PCI: 0.49 (0.34 to 0.69); p = 0.001  Overall: CABG vs. PCI: 0.53 (0.39 to 0.72); p < 0.001	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>PRECOMBAT</b> <b>Park et al., 2011<sup>68</sup></b>	Stable/unstable angina	PCI (DES) vs. CABG	Total: 600 Women: 141 (24%)	<p>1) <u>Composite endpoint, 1 year</u>            (death/MI/stroke/ischemia-driven target-vessel            revascularization)            PCI 8.7% vs. CABG 6.7%</p> <p>2) <u>Composite endpoint, 2 years</u>            PCI 12.2% vs. CABG 8.1%            HR (95% CI) 1.50 (0.90 to 2.52); p = 0.12</p> <p>Women: PCI 13.9% vs. CABG 11.7 %            HR (95% CI) 1.22 (0.48 to 3.08); p = 0.68            Men: PCI 11.7% vs. CABG 7.0%            HR (95%CI) 1.65 (0.88 to 3.07); p = 0.12            Overall : HR 1.50 (0.90 to 2.52)</p>	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Outcomes	Quality
<b>SOS</b> <b>Zhang et al., 2004</b> <sup>69</sup>  <b>and</b> <b>Zhang et al., 2003</b> <sup>70</sup> <b>Stables et al., 1999</b> <sup>71</sup>	Stable angina	PCI (BMS) vs. CABG	Total: 908 Women: 206 (23%)	<b>1) Quality of life</b> (adjusted relative difference of CABG vs. PCI) <b>6 months</b> Women: 39.3 Men: 18.3  <b>1 year</b> Women: 0.6 Men: 15.3  <b>2) Angina frequency</b> (adjusted relative difference of CABG vs. PCI) <b>6 months</b> Women: 43.2 Men: 31.3  <b>1 year</b> Women: 11.1 Men: 19.7  <b>3) Physical limitation</b> (adjusted relative difference of CABG vs. PCI) <b>6 months</b> Women: 11.6 Men: 54.7  <b>1 year</b> Women: 1.6 Men: 50.6	Fair
<b>SYNTAX</b> <b>Morice et al., 2010</b> <sup>72</sup>	Triple-vessel or left main coronary artery disease	PCI (type not specified) vs. CABG	Total: 705 Women: 185 (26%)	<b>1) Primary endpoint , 1 year</b> (death/MI/stroke/repeat revascularization) CABG vs. PCI 13.6% vs. 15.8% OR (95% CI) 2.1 (-3.2 to 7.4); p = 0.44  <b>2) Predictors of 1-year major adverse cardiovascular events</b> OR (95% CI) Women: 0.50 (0.27 to 0.91); p = 0.02	Fair

Abbreviations: BMS = bare metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; CI = confidence interval; CVA = cerebrovascular accident; DES = drug-eluting stent; HR = hazard ratio; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial; UA = unstable angina

## References Cited in Appendix F

1. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. *Lancet*. 2008;371(9612):559-68. PMID: 18280326.
2. Di Mario C, Bolognese L, Maillard L, et al. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). *Am Heart J*. 2004;148(3):378-85. PMID: 15389222.
3. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med*. 2003;349(8):733-42. PMID: 12930925.
4. Mortensen OS, Bjorner JB, Newman B, et al. Gender differences in health-related quality of life following ST-elevation myocardial infarction: women and men do not benefit from primary percutaneous coronary intervention to the same degree. *Eur J Cardiovasc Prev Rehabil*. 2007;14(1):37-43. PMID: 17301625.
5. Nielsen PH, Maeng M, Busk M, et al. Primary angioplasty versus fibrinolysis in acute myocardial infarction: long-term follow-up in the Danish acute myocardial infarction 2 trial. *Circulation*. 2010;121(13):1484-91. PMID: 20308618.
6. Busk M, Maeng M, Kristensen SD, et al. Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial. *Am J Cardiol*. 2009;104(2):210-5. PMID: 19576349.
7. Busk M, Maeng M, Rasmussen K, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up. *Eur Heart J*. 2008;29(10):1259-66. PMID: 17956874.
8. Dobrzycki S, Kralisz P, Nowak K, et al. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals. *Eur Heart J*. 2007;28(20):2438-48. PMID: 17884846.
9. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. *Am Heart J*. 2004;147(1):133-9. PMID: 14691431.
10. Minai K, Horie H, Takahashi M, et al. Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial. *Am Heart J*. 2002;143(3):497-505. PMID: 11868057.
11. Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 1995;75(15):987-92. PMID: 7747700.
12. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. *JAMA*. 2001;285(2):190-2. PMID: 11176812.
13. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. *JAMA*. 2006;295(21):2511-5. PMID: 16757723.
14. Hochman JS, Sleeper LA, Godfrey E, et al. SHould we emergently revascularize Occluded Coronaries for cardiogenic shockK: an international randomized trial of emergency PTCA/CABG-trial design. The SHOCK Trial Study Group. *Am Heart J*. 1999;137(2):313-21. PMID: 9924166.
15. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for

- Cardiogenic Shock. *N Engl J Med*. 1999;341(9):625-34. PMID: 10460813.
16. Lagerqvist B, Safstrom K, Stahle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. *J Am Coll Cardiol*. 2001;38(1):41-8. PMID: 11451294.
  17. Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. *Lancet*. 2006;368(9540):998-1004. PMID: 16980115.
  18. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. *Lancet*. 2000;355(9223):9-16. PMID: 10892758.
  19. Anonymous. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. *Lancet*. 1999;354(9180):708-15. PMID: 10475181.
  20. Ottervanger JP, Armstrong P, Barnathan ES, et al. Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. *Eur Heart J*. 2004;25(17):1494-501. PMID: 15342168.
  21. de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. *N Engl J Med*. 2005;353(11):1095-104. PMID: 16162880.
  22. Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. *J Am Coll Cardiol*. 2010;55(9):858-64. PMID: 20045278.
  23. Anonymous. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. *Lancet*. 1997;350(9076):461-8. PMID: 9274581.
  24. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. *Eur Heart J*. 2004;25(18):1641-50. PMID: 15351164.
  25. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. *Randomized Intervention Trial of unstable Angina*. *Lancet*. 2002;360(9335):743-51. PMID: 12241831.
  26. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001;344(25):1879-87. PMID: 11419424.
  27. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA*. 2002;288(24):3124-9. PMID: 12495392.
  28. Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. *Am J Cardiol*. 1998;82(6):731-6. PMID: 9761082.
  29. Anonymous. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. *Circulation*. 1994;89(4):1545-56. PMID: 8149520.
  30. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative



- strategies in unstable angina and non-Q wave myocardial infarction. *J Am Coll Cardiol*. 1995;26(7):1643-50. PMID: 7594098.
31. Allen KB, Dowling RD, Angell WW, et al. Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. *Ann Thorac Surg*. 2004;77(4):1228-34. PMID: 15063241.
  32. Allen KB, Dowling RD, Fudge TL, et al. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. *N Engl J Med*. 1999;341(14):1029-36. PMID: 10502592.
  33. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. *N Engl J Med*. 2007;356(15):1503-16. PMID: 17387127.
  34. Mancini GB, Bates ER, Maron DJ, et al. Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial. *Circ Cardiovasc Qual Outcomes*. 2009;2(4):320-7. PMID: 20031857.
  35. Boden WE, O'Rourke R A, Teo KK, et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. *Am Heart J*. 2006;151(6):1173-9. PMID: 16781214.
  36. Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation*. 2010;122(10):949-57. PMID: 20733102.
  37. Hueb W, Soares PR, Gersh BJ, et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. *J Am Coll Cardiol*. 2004;43(10):1743-51. PMID: 15145093.
  38. Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation*. 2007;115(9):1082-9. PMID: 17339566.
  39. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. *N Engl J Med*. 2006;355(23):2395-407. PMID: 17105759.
  40. Hochman JS, Lamas GA, Knatterud GL, et al. Design and methodology of the Occluded Artery Trial (OAT). *Am Heart J*. 2005;150(4):627-42. PMID: 16209957.
  41. Hochman JS, Reynolds HR, Dzavik V, et al. Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. *Circulation*. 2011;124(21):2320-2328. PMID: 22025606.
  42. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. *N Engl J Med*. 2011. PMID: 21463150.
  43. Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. *J Thorac Cardiovasc Surg*. 2007;134(6):1540-7. PMID: 18023680.
  44. Vaina S, Voudris V, Morice MC, et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II. *EuroIntervention*. 2009;4(4):492-501. PMID: 19284072.
  45. van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. *J Am Coll Cardiol*. 2002;39(4):559-64. PMID: 11849851.
  46. Serruys PW, Unger F, van Hout BA, et al. The ARTS study (Arterial Revascularization Therapies Study). *Semin Interv Cardiol*. 1999;4(4):209-19. PMID: 10738354.
  47. Voudris V, Ong AT, Serruys PW, et al. Sex differences and their impact on clinical outcome after percutaneous or surgical revascularisation: a report from the Arterial Revascularisation Therapies Study (ARTS). *EuroIntervention*. 2006;2(2):175-80. PMID: 19755257.
  48. Anonymous. The ARTS (Arterial Revascularization Therapies Study): Background, goals and methods. *Int J Cardiovasc Intervent*. 1999;2(1):41-50. PMID: 12623386.

49. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). *Circulation*. 1998;98(13):1279-85. PMID: 9751675.
50. Gibbons RJ, Miller DD, Liu P, et al. Similarity of ventricular function in patients alive 5 years after randomization to surgery or angioplasty in the BARI trial. *Circulation*. 2001;103(8):1076-82. PMID: 11222469.
51. Anonymous. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol*. 2007;49(15):1600-6. PMID: 17433949.
52. Lombardero MS. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI), by treatment and presence of diabetes. *Cardiovasc Rev Rep*. 2002;23(1):14-18. PMID: 2002025009.
53. Anonymous. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol*. 2000;35(5):1122-9. PMID: 10758950.
54. Hlatky MA, Charles ED, Nobrega F, et al. Initial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol*. 1995;75(9):34C-41C. PMID: 7892821.
55. Rogers WJ, Alderman EL, Chaitman BR, et al. Bypass Angioplasty Revascularization Investigation (BARI): baseline clinical and angiographic data. *Am J Cardiol*. 1995;75(9):9C-17C. PMID: 7892823.
56. Sutton-Tyrrell K, Rihal C, Sellers MA, et al. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol*. 1998;81(4):375-81. PMID: 9485122.
57. Mullany CJ, Mock MB, Brooks MM, et al. Effect of age in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. *Ann Thorac Surg*. 1999;67(2):396-403. PMID: 10197660.
58. Anonymous. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med*. 1996;335(4):217-25. PMID: 8657237.
59. Anonymous. First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. *Lancet*. 1995;346(8984):1179-84. PMID: 7475656.
60. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol*. 2010;55(5):432-40. PMID: 20117456.
61. Kapur A, Malik IS, Bagger JP, et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. *Am Heart J*. 2005;149(1):13-9. PMID: 15660030.
62. King SB, 3rd, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST). *J Am Coll Cardiol*. 2000;35(5):1116-21. PMID: 10758949.
63. King SB, 3rd, Lembo NJ, Weintraub WS, et al. Emory Angioplasty Versus Surgery Trial (EAST): design, recruitment, and baseline description of patients. *Am J Cardiol*. 1995;75(9):42C-59C. PMID: 7892822.
64. King SB, 3rd, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). *N Engl J Med*. 1994;331(16):1044-50. PMID: 8090163.
65. Zhao XQ, Brown BG, Stewart DK, et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coronary angioplasty with bypass surgery. *Circulation*. 1996;93(11):1954-62. PMID: 8640968.
66. Kaehler J, Koester R, Billmann W, et al. 13-year follow-up of the German angioplasty bypass surgery investigation. *Eur Heart J*. 2005;26(20):2148-53. PMID: 15975991.
67. Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty

- compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). *N Engl J Med*. 1994;331(16):1037-43. PMID: 8090162.
68. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. *N Engl J Med*. 2011(18):1718-27. PMID: 21463149
69. Zhang Z, Weintraub WS, Mahoney EM, et al. Relative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). *Am J Cardiol*. 2004;93(4):404-9. PMID: 14969611.
70. Zhang Z, Mahoney EM, Stables RH, et al. Disease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. *Circulation*. 2003;108(14):1694-700. PMID: 12975252.
71. Stables RH. Design of the 'Stent or Surgery' trial (SoS): a randomized controlled trial to compare coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multi-vessel coronary artery disease. *Semin Interv Cardiol*. 1999;4(4):201-7. PMID: 10738353.
72. Morice MC, Serruys PW, Kappetein AP, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation*. 2010;121(24):2645-53. PMID: 20530001.

## Appendix G. Summary Table for Modifiers of Effectiveness

Table G-1. Summary of RCTs reporting modifiers of effectiveness (subgroup analyses)

Study Author/Year Related Articles	Population	Comparison	# Subjects	Subgroup Analyses	Quality
<b>BARI</b> <b>Jacobs et al., 1998<sup>1</sup></b>  <b>and</b>  <b>Gibbons et al., 2007<sup>2</sup></b> <b>Anonymous, 2007<sup>3</sup></b> <b>Lombardero et al., 2002<sup>4</sup></b> <b>Anonymous, 2000<sup>5</sup></b> <b>Hlatky et al., 1995<sup>6</sup></b> <b>Rogers et al., 1995<sup>7</sup></b> <b>Sutton-Tyrrell et al., 1998<sup>8</sup></b> <b>Mullany et al., 1999<sup>9</sup></b> <b>Anonymous, 1996<sup>10</sup></b>	Stable/unstable angina  Diabetics	PCI vs. CABG	Total: 915 Women: 249 (27%)	<u>7-year survival rates</u> Women: PCI 61.0% vs. CABG 74.3% Men: PCI 51.5% vs. CABG 77.9%	Good
<b>Minai et al., 2002<sup>11</sup></b>	STEMI age ≥ 80 years	PCI vs conservative/supportive therapy	Total: 120 Women: 60 (50%)	No difference in composite outcome (death/congestive heart failure/repeat MI/cerebrovascular accident at 3 years between treatment groups).	Fair
<b>PAMI</b> <b>Stone et al., 1995<sup>12</sup></b>	STEMI	PCI vs. fibrinolysis (t- PA)	Total: 395 Women: 107 (27%)	<u>In-hospital mortality</u> Women aged <65: 0% vs. 4%; p = 0.42 Women aged ≥65: 5.9% vs. 21.9%; p = 0.58  Men aged <65: 0.9% vs. 0%; p = 0.74 Men aged ≥65: 5.6% vs. 10.4%; p = 0.42	Good

Study Author/Year Related Articles	Population	Comparison	# Subjects	Subgroup Analyses	Quality
<b>RITA-3</b> <b>Clayton et al., 2004</b> <sup>13</sup>  <b>and</b>  <b>Fox et al., 2002</b> <sup>14</sup>	UA/NSTEMI	Early invasive (PCI) vs. initial conservative	Total: 1,810 Women: 682 (38%)	<p>Lower TIMI risk scores, both men and women had similar event rates in early invasive vs. initial conservative treatment arms.</p> <p>In those with moderate to high risk, men had lower event rates in intervention arm compared with conservative arm while women had higher event rates in the intervention arm.</p> <p>Moderate risk (women) Invasive: 13.4% Conservative: 3.4%</p> <p>High risk (women) Invasive: 11.7% Conservative: 8.2%</p> <p>Moderate risk (men) Invasive: 5.4% Conservative: 9.4%</p> <p>High risk (men) Invasive: 10.3% Conservative: 17.9%</p> <p>No benefit of intervention was seen in any BMI group for women.</p>	Good
<b>TACTICS TIMI-18</b> <b>Cannon et al., 2001</b> <sup>15</sup>  <b>and</b>  <b>Glaser et al., 2002</b> <sup>16</sup> <b>Cannon et al., 1998</b> <sup>17</sup>	UA/NSTEMI	Early invasive (PCI) vs. initial conservative	Total: 2,220 Women: 757 (34%)	<p><u>Primary endpoint</u> (death/MI/rehospitalization for acute coronary syndrome by risk)</p> <p>Women with intermediate (3–4) and high (5–7) TIMI risk scores did not have significantly different outcomes in early invasive vs. initial conservative group.</p> <p>OR (95% CI) 0.72 (0.45 to 1.16) vs. 0.56 (0.23 to 1.32)</p>	Good

Abbreviations: BMS = bare metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; CI = confidence interval; DES = drug-eluting stent; HCT = hematocrit; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial; TIMI = thrombolysis in myocardial infarction; t-PA = tissue plasminogen activator; UA = unstable angina

## References Cited in Appendix G

1. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the bypass angioplasty revascularization investigation (BARI). *Circulation*. 1998;98(13):1279-85. PMID: 9751675.
2. Gibbons RJ, Miller DD, Liu P, et al. Similarity of ventricular function in patients alive 5 years after randomization to surgery or angioplasty in the BARI trial. *Circulation*. 2001;103(8):1076-82. PMID: 11222469.
3. Anonymous. The final 10-year follow-up results from the BARI randomized trial. *J Am Coll Cardiol*. 2007;49(15):1600-6. PMID: 17433949.
4. Lombardero MS. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI), by treatment and presence of diabetes. *Cardiovasc Rev Rep*. 2002;23(1):14-18. PMID: 2002025009.
5. Anonymous. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. *J Am Coll Cardiol*. 2000;35(5):1122-9. PMID: 10758950.
6. Hlatky MA, Charles ED, Nobrega F, et al. Initial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol*. 1995;75(9):34C-41C. PMID: 7892821.
7. Rogers WJ, Alderman EL, Chaitman BR, et al. Bypass Angioplasty Revascularization Investigation (BARI): baseline clinical and angiographic data. *Am J Cardiol*. 1995;75(9):9C-17C. PMID: 7892823.
8. Sutton-Tyrrell K, Rihal C, Sellers MA, et al. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol*. 1998;81(4):375-81. PMID: 9485122.
9. Mullany CJ, Mock MB, Brooks MM, et al. Effect of age in the Bypass Angioplasty Revascularization Investigation (BARI) randomized trial. *Ann Thorac Surg*. 1999;67(2):396-403. PMID: 10197660.
10. Anonymous. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. *N Engl J Med*. 1996;335(4):217-25. PMID: 8657237.
11. Minai K, Horie H, Takahashi M, et al. Long-term outcome of primary percutaneous transluminal coronary angioplasty for low-risk acute myocardial infarction in patients older than 80 years: a single-center, open, randomized trial. *Am Heart J*. 2002;143(3):497-505. PMID: 11868057.
12. Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 1995;75(15):987-92. PMID: 7747700.
13. Clayton TC, Pocock SJ, Henderson RA, et al. Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial. *Eur Heart J*. 2004;25(18):1641-50. PMID: 15351164.
14. Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. *Randomized Intervention Trial of unstable Angina*. *Lancet*. 2002;360(9335):743-51. PMID: 12241831.
15. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001;344(25):1879-87. PMID: 11419424.

16. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA*. 2002;288(24):3124-9. PMID: 12495392.
17. Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. *Am J Cardiol*. 1998;82(6):731-6. PMID: 9761082.

## Appendix H. Summary Table for Safety Concerns

Table H-1. Summary of RCTs reporting safety concerns (harms)

Study Author/Year Related Articles	Population	Comparison	# Subjects	Harms	Quality
<b>ARTS I</b> <b>Vaina et al., 2009<sup>1</sup></b>  <b>and</b>  <b>van den Brand, et al., 2002<sup>2</sup></b> <b>Serruys et al., 1999<sup>3</sup></b> <b>Voudris et al., 2006<sup>4</sup></b> <b>Anonymous, 1999<sup>5</sup></b>	UA/NSTEMI	PCI vs. CABG	Total: 1,205 Women: 283 (23%)	<u>Major bleeding</u> PCI (men vs. women): OR (95% CI) 29.4 (5.3 to 500); p = 0.001  CABG (men vs. women): OR (95%CI) 1.5 (0.4 to 10.1); p = 0.58	Good
<b>GUSTO II-B</b> <b>Tamis-Holland et al., 2004<sup>6</sup></b>	STEMI	PCI vs. fibrinolysis (accelerated t-PA)	Total: 1,137 Women: 260 (23%)	<u>Intracranial hemorrhage</u> Women PCI: 0 Optimal medical therapy: 4.1% Men PCI: 0 Optimal medical therapy: 0.7%	Good
<b>PAMI</b> <b>Stone et al., 1995<sup>7</sup></b>	STEMI	PCI vs. fibrinolysis (t-PA)	Total: 395 Women: 107 (27%)	<u>Nadir HCT (PCI vs. fibrinolysis)</u> Women: 30 ± 5% vs. 33 ± 5%; p = 0.002 Men: 35 ± 6% vs. 35 ± 6%; p = 0.17  <u>Requirement for blood transfusion (PCI vs. fibrinolysis)</u> Women: 18% vs. 8.8%; p = 0.16 Men: 9.7% vs. 8.4%; p = 0.71	Good
<b>TACTICS TIMI-18</b> <b>Cannon et al., 2001<sup>8</sup></b>  <b>and</b>  <b>Glaser et al., 2002<sup>9</sup></b> <b>Cannon et al., 1998<sup>10</sup></b>	UA/NSTEMI	Early invasive vs. initial conservative	Total: 2,220 Women: 757 (34%)	Bleeding in women undergoing PTCA was higher compared to men; adjusted OR (95% CI) 3.6 (1.6 to 8.3).  Bleeding related to CABG was similar in women and men (12.6% vs. 15%). Occurrence of stroke at 30 days related to CABG also was similar in women and men (2.1% vs. 1.5%).	Good

Abbreviations: BMS = bare metal stent; CABG = coronary artery bypass graft; CAD = coronary artery disease; CI = confidence interval; DES = drug-eluting stent; HCT = hematocrit; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RCT = randomized controlled trial; t-PA = tissue plasminogen activator; UA = unstable angina



## References Cited in Appendix H

1. Vaina S, Voudris V, Morice MC, et al. Effect of gender differences on early and mid-term clinical outcome after percutaneous or surgical coronary revascularisation in patients with multivessel coronary artery disease: insights from ARTS I and ARTS II. *EuroIntervention*. 2009;4(4):492-501. PMID: 19284072.
2. van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. *J Am Coll Cardiol*. 2002;39(4):559-64. PMID: 11849851.
3. Serruys PW, Unger F, van Hout BA, et al. The ARTS study (Arterial Revascularization Therapies Study). *Semin Interv Cardiol*. 1999;4(4):209-19. PMID: 10738354.
4. Voudris V, Ong AT, Serruys PW, et al. Sex differences and their impact on clinical outcome after percutaneous or surgical revascularisation: a report from the Arterial Revascularisation Therapies Study (ARTS). *EuroIntervention*. 2006;2(2):175-80. PMID: 19755257.
5. Anonymous. The ARTS (Arterial Revascularization Therapies Study): Background, goals and methods. *Int J Cardiovasc Intervent*. 1999;2(1):41-50. PMID: 12623386.
6. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. *Am Heart J*. 2004;147(1):133-9. PMID: 14691431.
7. Stone GW, Grines CL, Browne KF, et al. Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol*. 1995;75(15):987-92. PMID: 7747700.
8. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. *N Engl J Med*. 2001;344(25):1879-87. PMID: 11419424.
9. Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. *JAMA*. 2002;288(24):3124-9. PMID: 12495392.
10. Cannon CP, Weintraub WS, Demopoulos LA, et al. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. *Am J Cardiol*. 1998;82(6):731-6. PMID: 9761082.